<SEC-DOCUMENT>0001171843-25-005533.txt : 20250821
<SEC-HEADER>0001171843-25-005533.hdr.sgml : 20250821
<ACCEPTANCE-DATETIME>20250821073024
ACCESSION NUMBER:		0001171843-25-005533
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20250804
FILED AS OF DATE:		20250821
DATE AS OF CHANGE:		20250821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brainsway Ltd.
		CENTRAL INDEX KEY:			0001505065
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35165
		FILM NUMBER:		251238377

	BUSINESS ADDRESS:	
		STREET 1:		16 HARTUM STREET RAD TOWER, 14TH FLOOR
		STREET 2:		Har HaHotzvim
		CITY:			Jerusalem
		STATE:			L3
		ZIP:			9777516
		BUSINESS PHONE:		972 2 581-3140

	MAIL ADDRESS:	
		STREET 1:		16 HARTUM STREET RAD TOWER, 14TH FLOOR
		STREET 2:		Har HaHotzvim
		CITY:			Jerusalem
		STATE:			L3
		ZIP:			9777516
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_080425.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<div align="center"><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="border-top: Black 2.5pt solid; font-size: 1pt; border-bottom: Black 1.1pt solid; width: 100%">&#160;</DIV></DIV><P ALIGN="CENTER" STYLE="font-size: 14pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 2054</B></P>

<P STYLE="font-size: 14pt; text-align: center"><B>Form 6-K</B></P><P STYLE="text-align: center"><STRONG></STRONG></P><P STYLE="text-align: center"><STRONG>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</STRONG></P><P STYLE="text-align: center"><STRONG></STRONG><STRONG>For the month of August 2025</STRONG></P><P STYLE="text-align: center">Commission File Number: <STRONG>001-35165</STRONG></P><P STYLE="text-align: center"><FONT STYLE="font-size: 12pt"><B>BRAINSWAY
LTD.<BR>
</B></FONT>(Translation of registrant's name into English)</P><P STYLE="text-align: center"><!--16 Hartum Street RAD Tower, 14th Floor <br>Har HaHotzvim--><B>16
Hartum Street RAD Tower, 14th Floor <BR>
Har HaHotzvim<BR>
Jerusalem, 9777516, Israel</B></P>

<P STYLE="text-align: center"><B>(+972-2) 582-4030<BR>
</B>(Address and telephone number of Registrant&#8217;s principal executive office)</P></DIV><P>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<BR>
Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</P><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#160;</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#160;</p>--><P>This
Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission
on April 22, 2019 (Registration No. 333- 230979) and the Company's Registration Statements on Form F-3 filed with the Securities and
Exchange Commission on July 22, 2024 (Registration No. 333-280934) and on April 22, 2025 (Registration No. 333-286672).<P STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><STRONG>&nbsp;</STRONG></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><STRONG></STRONG></FONT></P>

<P STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><STRONG>EXHIBIT INDEX</STRONG></FONT></P><P STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&#160;</FONT><TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt"><TR><TD STYLE="vertical-align: bottom; text-decoration: underline; width: 12%"><FONT STYLE="font-size: 10pt"><STRONG>Exhibit Number</STRONG></FONT></TD><TD STYLE="vertical-align: bottom; text-decoration: underline; width: 88%"><FONT STYLE="font-size: 10pt"><STRONG>Description</STRONG></FONT></TD></TR><TR><TD><FONT STYLE="font-size: 10pt"></FONT></TD><TD><FONT STYLE="font-size: 10pt">&#160;</FONT></TD></TR><TR><TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD><TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-size: 10pt">Press
                                            Release dated August 21, 2025</FONT></A></TD></TR><TR>
<TD STYLE="vertical-align: top"><A HREF="exh_992.htm">99.2</A></TD><TD STYLE="vertical-align: top"><A HREF="exh_992.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTMENT
                                         AGREEMENT</FONT></A></TD></TR>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              <TR>
<TD STYLE="vertical-align: top"><A HREF="exh_993.htm">99.3</A></TD><TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="exh_993.htm">CALL
                                            OPTION AGREEMENT</A></FONT></TD></TR>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              <TR>
<TD STYLE="vertical-align: top"><A HREF="exh_994.htm">99.4</A></TD><TD STYLE="vertical-align: top"><A HREF="exh_994.htm">Amended and Restated Articles of <FONT STYLE="font-size: 10pt">Association</FONT></A></TD></TR>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              <TR>
<TD STYLE="vertical-align: top"><A HREF="exh_995.htm">99.5</A></TD><TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="exh_995.htm">SECOND
                                            AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</A></FONT></TD></TR>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              <TR>
<TD STYLE="vertical-align: top">&nbsp;</TD><TD STYLE="vertical-align: top">&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </TABLE>




<P>&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P><P STYLE="text-align: center"><STRONG>SIGNATURES</STRONG></P><P>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: center; width: 50%"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;BRAINSWAY LTD.&nbsp;&nbsp;&nbsp;</U></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: center">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date: August 21, 2025</TD>
  <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: center"><U>&nbsp;&nbsp;&nbsp;/s/ Hadar Levy&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: center">Hadar Levy </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: center">Chief Executive Officer</TD></TR>
</TABLE>

<P>&nbsp;</P><P><FONT>&#160;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0; background-color: white">BrainsWay Targets Expansion
of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0; background-color: white"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>This investment marks BrainsWay&rsquo;s entrance into the market for
mental health therapies that can be administered outside of a clinic, including at home </I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>Neurolief&rsquo;s breakthrough Proliv<FONT STYLE="font-size: 10pt">&trade;</FONT>Rx
device is pending Premarket Approval from the U.S. FDA, and if granted, will become the first FDA-cleared medical device for MDD treatment
that can be delivered outside of the clinic </I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>BURLINGTON, Mass. and JERUSALEM, Israel, August 21, 2025</B> -- BrainsWay Ltd. (NASDAQ &amp; TASE: BWAY) (&ldquo;BrainsWay&rdquo; or the &ldquo;Company&rdquo;), a global
leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has closed an initial
strategic investment by means of a $5 million convertible loan to, along with an option to acquire, Neurolief Ltd.
(&ldquo;Neurolief&rdquo;), developer of the world&rsquo;s first wearable, non-invasive, multi-channel brain neuromodulation platform
that is designed for use at home. Neurolief&rsquo;s technology has demonstrated positive clinical outcomes and includes a
proprietary therapy for treatment-resistant major depressive disorder (MDD) and migraine. The Agreement also includes additional
possible milestone-based funding.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&ldquo;We are very excited with this strategic investment in Neurolief. Upon an FDA approval,
we believe this technology will significantly expand our addressable market, enabling care for patients who cannot easily access clinics
and empowering medical professionals to extend treatment beyond traditional settings. This aligns with our strategic goal of accelerating
access to and awareness of innovative mental health treatments, especially offerings that we believe are complementary to mental health
professionals using our Deep TMS therapy,&rdquo; said Hadar Levy, BrainsWay&rsquo;s Chief Executive Officer. &ldquo;The BrainsWay team
has rapidly expanded sales of the Deep TMS&trade; system, supported by scaling of our commercial platform and customer network. We are
excited by the opportunity to leverage our platform and explore potential synergies between our two companies, as Neurolief brings its
at-home neuromodulation systems to the market through mental health professionals.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Neurolief is a pioneering neuromodulation company dedicated to developing innovative solutions
for mental health and neurological disorders. Neurolief's Relivion<SUP>&reg;</SUP>MG therapy is currently approved in the U.S., Europe
and Japan for the treatment of migraine, and it is awaiting Premarket Approval from the U.S. FDA for its Proliv<FONT STYLE="font-size: 10pt"><SUP>TM</SUP></FONT>Rx
therapy addressing Major Depressive Disorder (MDD) in treatment resistant patients. If approved, Neurolief will be the first medical device
company to offer an FDA-cleared MDD treatment that can be delivered outside of the clinic.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"><IMG SRC="logo.jpg" ALT="">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">MDD is a leading cause of disability globally, with millions of people affected. The situation
is especially dire for those patients who fail to respond to traditional treatments, facing prolonged suffering, higher healthcare costs,
and a heightened risk of comorbid conditions such as substance abuse and suicide. Despite the global impact of MDD, there is a critical
gap in accessible, effective therapies, particularly for these patients. Proliv&trade;Rx is designed to bridge this gap by offering a
revolutionary, non-invasive brain neuromodulation therapy that can be administered at a mental health clinic or a patient&rsquo;s home.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&ldquo;This strategic investment by BrainsWay is a strong validation of our science, our team,
and our vision,&rdquo; stated Scott Drees, Neurolief's Chief Executive Officer. &ldquo;This partnership enhances our ability to reach
the patients who need our therapy most. BrainsWay&rsquo;s market presence, deep expertise, and established commercial platform can complement
our innovation and momentum. Together, we aim to reshape the treatment landscape for depression and expand access to evidence-based, effective
care.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Beyond the initial $5 million convertible loan, the agreement provides for potential additional
milestone-based funding to Neurolief, including a second tranche of up to a $6 million convertible loan upon FDA approval of Neurolief&rsquo;s
Proliv Rx system for MDD treatment, and a third tranche consisting of up to a $5 million equity investment upon Neurolief achieving an
agreed-upon revenue milestone. BrainsWay has also been granted a &ldquo;call option&rdquo; to acquire all outstanding equity interests
in Neurolief during clearly defined exercise windows, at a price based on the greater of a specified enterprise value or a revenue multiple,
with the values varying depending on timing of exercise.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Through this multi-phased transaction, BrainsWay aims to expand its long-term total addressable
market.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>About BrainsWay</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental
health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS&trade;)
platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications
backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including
reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The
Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical
trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the
United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and
information about BrainsWay, please visit www.brainsway.com.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>About Neurolief</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Neurolief is a pioneering neuromodulation company committed to developing breakthrough therapies
for mental health and neurological disorders. The company has developed the world&rsquo;s first wearable, non-invasive, multi-channel
brain neuromodulation system, that is designed for use at home, engineered to simultaneously stimulate key neural pathways in the head
in order to modulate brain regions involved in regulation of mood and pain. Neurolief's technology is currently FDA-cleared and CE-marked
for the treatment of migraine, and the company is actively seeking regulatory approvals for Proliv<FONT STYLE="font-size: 10pt">&trade;</FONT>Rx,
its flagship product for the treatment of Major Depressive Disorder. If granted, Neurolief will be the first medical device company to
offer an FDA-approved MDD treatment that can be delivered outside of the clinic. Learn more at: <FONT STYLE="color: Black">www.neurolief.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"><IMG SRC="logo.jpg" ALT="">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Forward-Looking Statement</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;targets,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential&rdquo;
or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their
implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results
or conclusions from scientific research and clinical studies &ndash; especially preliminary data which remains subject to peer-review
&ndash; do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be
interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements: the failure to realize anticipated synergies and other benefits
of the proposed transaction; the failure of our investments in management services organizations and/or other clinic-related entities
to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market
requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals
by regulatory agencies on the Company&rsquo;s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge
is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to
develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the
Company&rsquo;s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes
in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or
delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including
internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and
introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially
from those contemplated in such forward-looking statements.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Any forward-looking statement in this press release speaks only as of the date of this press
release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks
and uncertainties affecting the Company is contained under the heading &ldquo;Risk Factors&rdquo; in the Company&rsquo;s filings with
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"><IMG SRC="logo.jpg" ALT="">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Contacts: </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>BrainsWay:</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Ido Marom<BR>
Chief Financial Officer<BR>
Ido.Marom@BrainsWay.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>Investors:</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Brian Ritchie<BR>
LifeSci Advisors<BR>
<FONT STYLE="color: Black">britchie@lifesciadvisors.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="border-bottom: Black 4pt solid; margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exh_992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-decoration: none"><B></B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INVESTMENT
AGREEMENT</U> </B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">THIS
INVESTMENT AGREEMENT </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;<B>Agreement</B>&rdquo;) is made and entered into effective as of the 18th day of August, 2025, by and among Neurolief
Ltd., a company organized under the laws of the State of Israel having its principal offices at 12 Giborei Israel, Netanya, Israel,
4250412 (the &ldquo;<B>Company</B>&rdquo;) and Brainsway Ltd., a company organized under the laws of the State of Israel having its
principal offices at 16 Hartum Street, RAD Tower, Jerusalem, 9777516, Israel (the &ldquo;<B>Investor</B>&rdquo;), and together with
the Company, the &ldquo;<B>Parties</B>&rdquo; and each, a &ldquo;<B>Party</B>&rdquo;).</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RECITALS</U></B>:</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">WHEREAS</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the Board of Directors of the Company (the &ldquo;<B>Board</B>&rdquo;) has determined that it is in the best interests of the Company
to raise additional capital in an aggregate amount of up to $16M, to be extended in up to three installments (each: an &ldquo;<B>Installment</B>&rdquo;),
the first two of which, by means of convertible loans all as further provided herein; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Investor wishes to effectuate the initial investment in the Company of the first Installment, by way of a convertible loan, in the
principal amount of US$5,000,000 in consideration of the grant of the rights in this Agreement to the Investor, upon and subject to the
terms and conditions hereof; and</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the satisfaction of certain milestones, the Investor undertakes to make certain additional investments in the Company in an
aggregate amount of up to $11M, in two further Installments, on the terms and subject to the conditions provided herein; and</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
as a further material inducement for the Investor&rsquo;s undertakings herein, the Investor wishes to be granted certain rights (such
rights, collectively, the &ldquo;<B>Call Option</B>&rdquo;) to acquire all of the outstanding equity interests of the Company, subject
to the terms and conditions of this Agreement and the Call Option Agreement (as defined herein). The Company acknowledges and agrees
that such Call Option is a significant factor in the Investor&rsquo;s decision to enter into this Agreement and provide financing to
the Company and the Investor acknowledges and agrees that the grant of the Call Option to it by the Company is a valuable economic right
afforded to the Investor by the Company in order to receive such financing; and</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
as a further material inducement for the Investor&rsquo;s undertakings herein, in order to grant the Investor certain governance rights
prior to the conversion of the Principal Amount (as defined herein), the Company has agreed to create and issue to the Investor, at the
Closing, one (1) share of a newly designated class of Special Shares (the &ldquo;<B>Special Share</B>&rdquo;), which shall carry no economic
rights but shall entitle the holder to appoint director(s) to the Board of Directors, to certain special consent rights, and the right
to receive its nominal value upon liquidation of the Company, all as set forth in the Amended Articles; and</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">WHEREAS, the Company is a party: (i) to that certain
Second Amended and Restated Convertible Bridge Loan Agreement dated on or around February 2025 in an aggregate principal amount of approximately
$4.895M (plus an additional approximately $89,579 deemed convertible loans thereunder from the Company&rsquo;s CFO and CEO in in lieu
of deferred salary through September 30, 2024 the <B>&ldquo;First Company CLA Salary Deferral&rdquo;</B>) (collectively: the &ldquo;<B>First
Company CLA</B>&rdquo;); and (ii) that certain Convertible Bridge Loan Agreement dated on or around February 2025 in an aggregate principal
amount not to exceed $3.776M (which amount includes approximately $87,499 (the <B>&ldquo;Second Company Salary CLA Deferral&rdquo;</B>)
deemed convertible loans thereunder from the Company&rsquo;s CFO and CEO in in lieu of deferred salary from October 1, 2024 through Closing)
(collectively, the &ldquo;<B>Second Company CLA</B>&rdquo;, and together with the First Company CLA, the &ldquo;<B>Existing Company CLAs</B>&rdquo;;
all lenders which are parties to the Existing Company CLAs shall herein be collectively referred to as the &ldquo;<B>Existing Company
CLA Lenders</B>&rdquo;);</P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
at the Closing (and contingent thereupon), the First Company CLA (but without any interest accrued thereon which shall be forgiven) shall
be converted into such number of Series B-2 Preferred Shares of the Company as reflected in the Capitalization Table (as defined below)
(it being clarified that all of such shares underlying the foregoing conversion shall be included in the Fully Diluted Basis (as defined
below) for purposes of calculation of the Conversion Price (as defined below) which shall have the rights, privileges and preferences
as set forth in the Amended Articles (as defined below) (the &ldquo;<B>First Company CLA Conversion</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">WHEREAS,
(i) pursuant to the Existing Company CLA Amendments (defined below) up to $3.776M of principal amount (including the Second Company CLA
Salary Deferral) shall rank pari passu with Loan Amount, including with respect to creditor and repayment rights, and upon conversion
(as further reflected in the Capitalization Table on a pro-forma basis following the Closing), and (ii) any amount of principal actually
advanced under the Second Company CLA by the Closing Date, in excess of $3.776M (if any) (the <B>&ldquo;Second Company CLA Surplus Subordinated
Amount&rdquo;</B>), shall be treated as follows: (i) any and all shares of the Company underlying the conversion of the Second Company
CLA Surplus Subordinated Amount shall be included in the Fully Diluted Basis (as defined below) for purposes of calculation of the Conversion
Price (as defined below) (it being clarified however, that nothing in the foregoing shall be deemed to imply the actual conversion thereof,
which conversion terms (including timing) shall be determined according to the terms of the Second Company CLA, as amended), all as further
reflected in the Capitalization Table (as defined below), and (ii) any repayment thereof shall be subordinate and subject to the prior
and full repayment of the Loan Amount as further provided in the Existing Company CLA Amendments (as defined below);</FONT></P>


<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">NOW,
THEREFORE</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, in consideration of the foregoing recitals
and the mutual promises, representations, warranties and covenants hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Agreement
                                            to Make and Accept the Convertible Loan and Subsequent Investments</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<U>Convertible Loan</U>. Subject to and in accordance with the terms and conditions of this Agreement, at the Closing (as defined below),
the Investor shall provide to the Company, and the Company shall accept from the Investor, a convertible loan in the principal amount
of <FONT STYLE="font-weight: normal">US$5,000,000 </FONT>(the &ldquo;<B>Initial Principal Amount</B>&rdquo;).</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<U>Interest</U>. The Initial Principal Amount will bear interest on the outstanding balance at a simple rate per annum equal to the minimal
rate permitted by Section 3(j)(<I>&ldquo;yud&rdquo;</I>) of the Israeli Income Tax Ordinance, 5721-1961 (and any rules and regulations
promulgated thereof) (the &ldquo;<B>Interest</B>&rdquo;). The Initial Principal Amount, and all Interest accrued thereon and the VAT
payable on such Interest, are collectively referred to as the &ldquo;<B>Initial Loan Amount</B>&rdquo;.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.
<U>Repayment</U>. Unless previously converted or repaid pursuant to the terms of this Agreement, the outstanding Initial Loan Amount
shall become due and payable to the Investor on the date that is the three-year anniversary of the Closing Date (the <B>&ldquo;Maturity
Date&rdquo;</B>); provided that it shall not be a breach of this Agreement as long as the Company completes the repayment of the Initial
Loan Amount in full within 1 (one) year following the Maturity Date (the &ldquo;<B>Repayment Grace Period</B>&rdquo;), and further provided,
that the Investor may, at the request of the Company and subject to its sole discretion, defer the Maturity Date to the Call Option Termination
Date (as defined in the Call Option Agreement), by giving the Company notice in writing at any time prior to the Maturity Date. At any
time prior to the Maturity Date (as and if deferred), the Investor will inform the Company by written notice if upon the Maturity Date,
if it elects for the outstanding Initial Loan Amount to be repaid, or alternatively to have the Initial Principal Amount converted into
shares as provided herein (in which case the accrued Interest thereon shall be deemed waived by the Investor and therefore shall be neither
converted nor repaid); provided, however that in the event that no such written notice is timely given, then the Investor shall be deemed
to have elected the outstanding Loan Amount to be repaid in accordance with the provisions of this Agreement. If it elects it to be repaid,
the Company may obtain additional debt or equity financing to repay the outstanding Initial Loan Amount, without any restriction on the
part of the Investor, and the Call Option shall expire immediately upon the repayment in full of the outstanding Loan Amount to the Investor.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4.
<U>Issuance of Special Share</U>. Subject to the Closing taking place, the Company shall issue to the Investor the Special Share. The
Special Share shall have such rights, preferences and privileges as set forth in the Amended Articles.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5.
<U>Use of Proceeds</U>. The Company will use the Initial Principal Amount substantially in accordance with the budget following the Closing
attached hereto as <U>Exhibit A</U> (the &ldquo;<B>Budget</B>&rdquo;), as may be amended from time to time Board subject to the procedures
set forth in the Amended Articles.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6.
<U>[Reserved].</U></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7.
<U>Subordination and Amendment of Existing Company CLAs</U>. A condition to Closing shall be that Existing Company CLA Lenders, constituting
the requisite majority necessary to effectuate an amendment to the Existing Company CLAs, execute and deliver an amendment to each of
the Existing Company CLAs in substantially the form as set forth in <U>Schedule 2.2.1.8(A) and (B)</U>) (the &ldquo;<B>Existing Company
CLAs Amendments</B>&rdquo;) confirming, <I>inter alia</I>, (i) effectuation of the First Company CLA Conversion immediately prior to
the Closing (and contingent thereupon), (ii) that any payments with respect to the Second Company CLA Surplus Subordinated Amount (if
any) shall be subordinated to the full repayment of the Loan Amount (as defined below), that the maturity date under the Second Company
CLA shall be the Maturity Date under this Agreement, that interest accrued on the Second Company CLA with respect to the period commencing
on the Closing Date and onwards, shall accrue at the same rate as provided in Section 1.2 of this Agreement (it being clarified that
any interest accrued
on the Second Company CLA during the period commencing on the respective dates of funding of all amounts constituting the Second Company
CLA through the Closing Date shall remain unchanged as set forth in the Existing Company CLAs Amendment), and that the Event of Default
under the Second Company CLA shall be substantially identical to the corresponding provisions of this Agreement.</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.
<U>Additional Future Investments</U>. Subject to the Closing having occurred, and contingent upon the Company meeting certain milestones
described below, the Investor undertakes to provide additional funding at two subsequent closings (the &ldquo;<B>Second Closing</B>&rdquo;
and the &ldquo;<B>Third Closing</B>&rdquo;, each of which may be referred to as a &ldquo;<B>Subsequent Closing</B>&rdquo; and collectively
the &ldquo;<B>Subsequent Closings</B>&rdquo;), as further provided in this Section 1.8.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.1.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Second Investment</U>. At the Second Closing, and (in addition to the conditions set forth in <U>Section &#8206;2.4</U>), conditioned
upon FDA Approval (defined below) (the &ldquo;<B>Second Investment Milestone</B>&rdquo;), the Investor shall provide to the Company,
a convertible loan in the principal amount of up to <FONT STYLE="font-weight: normal">US$6,000,000, </FONT>as specified in the Company&rsquo;s
Investment Request (as defined below, where the exact portion of the Second Principal Amount to be provided shall be determined by the
Board (such principal amount actually extended to the Company by the Investor per the Company&rsquo;s request, shall be referred to herein:
the &ldquo;<B>Second Principal Amount</B>&rdquo;). The Second Principal Amount will bear Interest on the outstanding balance from the
date of its disbursement to the Company, at the same rate as set forth in Section 1.2 above per annum. The Second Principal Amount, and
all Interest and VAT accrued thereon, are collectively referred to as the &ldquo;<B>Second Loan Amount</B>&rdquo;, and collectively with
the Initial Loan Amount, which is outstanding, the &ldquo;<B>Loan Amount</B>&rdquo;. The Second Principal Amount and the Initial Principal
Amount are collectively referred to as the &ldquo;<B>Principal Amount</B>&rdquo;. Unless previously converted or repaid pursuant to the
terms of this Agreement, the Second Loan Amount shall become due and payable to the Investor on the Maturity Date (as and if deferred
in accordance with Section 1.3, and subject to the Repayment Grace Period set forth therein). At any time prior to the Maturity Date,
the Investor will inform the Company by written notice if upon the Maturity Date, it elects for the outstanding Second Loan Amount to
be repaid, or alternatively to have the Second Principal Amount converted into shares as provided herein (in which case the accrued Interest
thereon shall be deemed waived by the Investor and therefore shall be neither converted nor repaid); provided, however that in the event
that no such written notice is timely given, then the Investor shall be deemed to have elected the outstanding Loan Amount to be repaid
in accordance with the provisions of this Agreement. If it elects it to be repaid, the Company may obtain additional debt or equity financing
to repay the outstanding Second Loan Amount, without any restriction on the part of the Investor, and the Call Option shall expire as
of immediately upon the repayment in full of the outstanding Loan Amount to the Investor. <B>&ldquo;FDA Approval&rdquo;</B> means: receipt
by the Company of an Approval Order from the U.S. Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;) for the Proliv Rx neurostimulation
system for depression, which shall include approval as an adjunctive tool for management or treatment, or use for medication resistant
or treatment-refractory depression, for use at home, and may include post approval obligations provided that it does not include any
condition that would prevent commercial sale of the product in the United States.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.8.2.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Third Investment</U>. Subject to the Second Closing having occurred and the investment of the Second Principal Amount, at the Third
Closing, and (in addition to the conditions set forth in <U>Section &#8206;2.4</U>), conditioned upon Company having achieved twelve
month revenues of US$10,000,000, calculated on a trailing 12-month basis based on a reviewed (by the Company&rsquo;s auditors, in accordance
with US GAAP) statement(s) of the Company&rsquo;s revenues for the applicable 12 calendar month period (the &ldquo;<B>Third Investment
Milestone</B>&rdquo;)<I>,</I> the Investor shall (subject to satisfaction of the conditions to a Subsequent Closing set forth in Section
2.4 below) pay to the Company the Third Investment Amount, in consideration for which the Company shall allot to the Investor Series
S-3 Preferred Shares of the Company (the Preferred S-3 Shares, and together with the Preferred S-1 Shares and Preferred S-2 Shares, as
defined below, the <B>&ldquo;Preferred S Shares&rdquo;</B>), which shall have the rights, preferences and privileges set forth in <U>Amended
Articles</U>, for the aggregate purchase price specified in the Company&rsquo;s Investment Request, such amount not to exceed US$5,000,000
(the &ldquo;<B>Third Investment Amount</B>&rdquo;) (where the exact portion of the Third Investment Amount to be provided shall be determined
by the Board). The price per share of the Preferred S-3 Shares (the &ldquo;<B>Third Investment PPS</B>&rdquo;) shall reflect a pre-money
Company valuation, as of the Closing Date, on a Fully Diluted Basis, of $55,000,000, assuming the investment and conversion of the Principal
Amount and the Second Company CLA; and the number of Preferred S-3 Shares to be issued and allotted to Investor (the &ldquo;<B>Third
Closing Shares</B>&rdquo;)) shall be the result obtained by dividing the Third Investment Amount by the Third Investment PPS; all as
further reflected in the Capitalization Table. The current Capitalization Table simulation assumes the investment of the maximum Principal
Amount (i.e., $11M) prior to investment of the Third Investment Amount, in which case, the Third Investment PPS shall be $2.82 (and if
and to the extent the Second Principal Amount actually invested is lower than $6M, at the request of the Company, then the Capitalization
Table shall be adjusted accordingly so to reflect the actual Principal Amount that was invested).</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.3.&nbsp;&nbsp;&nbsp;&nbsp;
The amounts actually called by the Company in respect of the Second Principal Amount and the Third Investment Amount shall each be determined
by the Board in its reasonable discretion, considering the Company&rsquo;s capital needs, business plan, and other relevant factors.
</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.4.&nbsp;&nbsp;&nbsp;&nbsp;
In order to minimize the potential for any dispute regarding the determination of the Company&rsquo;s revenues for the purpose of determining
the Third Investment Milestone, the Parties agree to the following:&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.4.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company&rsquo;s revenues will be calculated in accordance with US GAAP, as consistently applied
                                            by the Company in accordance with past practice;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.4.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
                                            decision of the Board, following the date upon which the Company first generates revenues
                                            in any calendar quarter of at least $250,000, the Company&rsquo;s quarterly financial statements
                                            which shall be delivered to the Investor and the other entitled shareholders pursuant to
                                            the IRA (as defined below) on a quarterly basis shall be financial statements reviewed by
                                            the Company&rsquo;s auditors (<B>&ldquo;Quarterly Reviewed FS&rdquo;).</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.4.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
                                            Investor&rsquo;s receipt of any Quarterly Reviewed FS from the Company, the Investor shall
                                            have the right, to be exercised within 14 business days following the delivery date thereof,
                                            to review, inter alia, the Company&rsquo;s revenues with the Company&rsquo;s CFO and ensure
                                            that they are reflected in accordance with the abovementioned accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.4.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenues
                                            of the Company as set forth in any Quarterly Reviewed FS which were (i) approved by the Board,
                                            with the affirmative vote or written consent of a director appointed by the Investor, or
                                            (ii) not subject to any outstanding contest that was previously raised by the Investor pursuant
                                            to the procedure set forth in Section 1.8.4.3 shall have the presumption of being correct
                                            for purposes of determining whether the Third Investment Milestone has been achieved, unless
                                            such revenues has been adjusted in the course of the preparation of the Audited Financial
                                            Statements of the Company, in which case the revenues as adjusted shall have the presumption
                                            of being correct for purposes of determining whether the Third Investment Milestone has been
                                            achieved.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.5.&nbsp;&nbsp;&nbsp;&nbsp;
The Company shall provide the Investor with written notice promptly upon it becoming aware of the achievement of each of the Second Investment
Milestone and the Third Investment Milestone (each, a &ldquo;<B>Milestone</B>&rdquo; and a &ldquo;<B>Milestone Notice</B>&rdquo;, respectively),
together with the documentary evidence reasonably necessary to demonstrate that the applicable Milestone has been reached. Together with
such notice, or in a separate notice to be given no later than 30 days after the date when the applicable Milestone was reached, the
Company may issue a request (&ldquo;<B>Investment Request</B>&rdquo;) for the Second Principal Amount or the Third Investment Amount,
as the case may be.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.8.6.&nbsp;&nbsp;&nbsp;&nbsp;
The Investor shall have 10 business days following the delivery of each Milestone Notice (as applicable with respect to each Milestone,
the &ldquo;<B>Review Period</B>&rdquo;) to review such Milestone Notice and any additional information and documents received from the
Company and to either: (a) inform the Company of its position as to the attainment of the Milestone by the Company, or (b) request additional
information and documents from the Company as may be reasonably required for the Investor in order to confirm the satisfaction of the
Milestone. If such additional information has been requested by the Investor, the Review Period shall be extended for 10 additional business
days following the delivery to the Investor of all such additional information and documentation. In case the Investor does not agree
that the Company has achieved such Milestone (the &ldquo;<B>Dispute</B>&rdquo;), the Investor shall inform the Company in writing, within
the Review Period, of its conclusion which such written notice shall include the reason for such Dispute (the &ldquo;<B>Objection Notice</B>&rdquo;)
and the Investor and the Company will promptly commence discussions to resolve such Dispute. If the Investor does not deliver an Objection
Notice within the applicable Review Period (as extended, if and as applicable), then the Investor shall be deemed to have agreed with
the Milestone Notice. If within 3 business days following the commencement of such discussions, the Investor and the Company have not
resolved such Dispute, then either the Investor or the Company may submit for resolution of the Dispute to an independent expert consultant
(the &ldquo;<B>Expert</B>&rdquo;). The Expert shall be appointed by mutual agreement of the Company&rsquo;s chairman and the Investor&rsquo;s
Chief Executive Officer and shall serve as an arbitrator to resolve the items in Dispute. If the Parties cannot agree on the appointment
of the Expert within 5 business days, the appointment shall be an individual recommended by the Company&rsquo;s US regulatory counsel
for the Second Investment Milestone, and the Company&rsquo;s auditor for the Third Investment Milestone (in each case with meeting the
necessary requirements and qualifications set forth in this Section 1.8.6).&nbsp;The Expert shall hold the relevant expertise and experience.
Accordingly, the Parties contemplate the appointment of an independent regulatory consultant with at least seven (7) years&rsquo; direct
experience in FDA medical-device submissions (including De Novo and PMA pathways) and who has no current or former association with the
Company in case of dispute regarding completion of the Second Investment Milestone, or appointment of an accounting firm associated with
one of the &ldquo;Big 4&rdquo; international accounting firms, that has no current or former association with the Company or the Investor
in case of dispute regarding completion of the Third Investment Milestone. The Expert will provide its final determination within 14
days after the date of its appointment in case of the Second Investment Milestone or 30 days after the date of its appointment in case
of the Third Investment Milestone. This provision for arbitration shall be specifically enforceable by the Parties, and the determination
of the Expert in accordance with the provisions hereof shall be final and binding upon the Company and the Investor with no right of
appeal therefrom (save for manifest error) This arbitration clause shall be treated as an arbitration contract between the parties for
all intents and purposes and the provisions of the Israeli Arbitration Law of 1968 shall be applied to the arbitration proceedings and
the Expert, unless the parties expressly agree to the contrary. The Expert shall not be bound by procedural rules. The costs of the Expert
and any legal expenses borne in connection therewith shall be borne by the Party against whom the Dispute is determined.</FONT></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.7.&nbsp;&nbsp;&nbsp;&nbsp;
Subject to the satisfaction of the conditions to the Subsequent Closings pursuant to Section 2.4 below, upon completion of the Review
Period (and, if applicable, the Expert determination under Section 1.8.6), each of the Subsequent Closings shall take place as follows:
(A) If no Objection Notice is delivered during the Review Period (as extended), the applicable Subsequent Closing shall take place within
7 business days after the expiration of the Review Period (as and if extended in accordance with Section 1.8.6 above); and (B) If a Dispute
is raised and referred to an Expert, then, upon and subject to receipt of the Expert&rsquo;s final determination that the applicable
Milestone was achieved, the applicable Subsequent Closing shall take place within 7 business days after such determination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.8.&nbsp;&nbsp;&nbsp;&nbsp;
If, notwithstanding the satisfaction of all the conditions to the applicable Subsequent Closing, the Investor fails to duly comply with
its obligations herein and fund the Second Principal Amount or the Third Investment Amount by the applicable date designated therefor
according to this Agreement (each, a &ldquo;<B>Default</B>&rdquo;), the Company shall immediately notify the Investor of such Default
and in the event that such Default is not remedied within 21 days from the date of delivery of the notice by the Company, then the Investor
shall constitute a &ldquo;Defaulting Investor&rdquo; (a &ldquo;<B>Defaulting Investor</B>&rdquo;) for the purpose of this Agreement,
the Amended Articles and the Call Option Agreement. In case the Investor is a Defaulting Investor, and as a sole and exclusive remedy
for the Company, the following provisions shall apply: (a) the Investor&rsquo;s Call Option and the right of the Investor to appoint
any director to the Company&rsquo;s (or any of its subsidiaries) Board of Directors pursuant to the Amended Articles, shall be automatically
extinguished and of no further force and effect; (b) so long as the Second Company CLA remains outstanding and is not converted, the
outstanding Principal Amount shall remain outstanding (and shall not be converted without the Company&rsquo;s prior consent), shall become
due and repayable by the later date of: (i) the Maturity Date plus the Repayment Grace Period (i.e., the fourth year anniversary of the
Closing Date), or (ii) 12 months from the date upon which the Investor is as a Defaulting Investor; and may be prepaid at any time. In
such case, the rights, privileges and preferences of the Special Share pertaining to the Investor (including its veto rights) shall be
automatically amended as specified in the Amended Articles in reference to a case of a Defaulting Investor; (c) upon conversion of the
Second Company CLA into shares of the Company an amount equal to the greater of $5,000,0000 or 50% of the outstanding Principal Amount
(if any) (without any accrued interest which shall be deemed waived (i.e., neither converted nor paid) shall be automatically and concurrently
converted into Conversion Shares (as defined below) based on the applicable a Conversion Price (which shall be
the First Conversion Price (defined below) if Default is with respect to the Second Principal Amount, and the Second Conversion Price
(defined below) if Default is with respect to the Third Principal Amount), and shall have such rights, privileges and preferences as
specified in the Amended Articles, specifically in reference to a case of a Defaulting Investor, and following such conversion, any portion
of the outstanding Principal Amount not so converted and the Interest accrued thereupon, shall remain outstanding under the terms of
this Section 1.8.8 and may be converted at any time at the option of the Investor at the Third Investment PPS (without any accrued interest
which shall be deemed waived (i.e., neither converted nor paid); and (d) any other provisions in the Amended Articles relating to a Defaulting
Investor shall apply.</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8.9.&nbsp;&nbsp;&nbsp;&nbsp;
Nothing in this <U>Section 1.8</U> (other than in case of Default) shall supersede or limit the Investor&rsquo;s Call Option rights set
forth in <U>Section &#8206;4</U>. The Call Option may be exercised (subject to its own terms) during the Call Option Period (as defined
in the Call Option Agreement) regardless of whether the Second Closing or Third Closing has occurred, except as otherwise expressly stated
in this Agreement or the Call Option Agreement (e.g., Non-Exercise Period or if the Investor has elected not to invest despite the satisfaction
of the applicable Milestone due to the occurrence of a Material Adverse Change as per Section 2.4.6.2).</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Closing,
                                            Delivery and Payment</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.
<U>Closing</U>. The closing of the payment and receipt of the Initial Principal Amount and the grant of the Call Option (the &ldquo;<B>Closing</B>&rdquo;)
shall take place via an electronic closing through exchange of separate counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument, on or around the date which is 14 days following the date hereof
or at such other time as the Company and the Investor mutually agree (the date of the closing being herein referred to as the &ldquo;<B>Closing
Date</B>&rdquo;).</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.
<U>Deliveries and Transactions at the Closing</U>. At the Closing, the following transactions shall occur, which transactions shall be
deemed to take place simultaneously and no transaction shall be deemed to have been completed or any document delivered until all such
transactions have been completed and all required documents delivered:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.&nbsp;&nbsp;&nbsp;&nbsp;
The Company shall deliver to the Investor the following documents:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Shareholders Resolutions</U>. Duly executed resolutions of the shareholders of the Company (which may be in the form of a written
resolution or minutes of a general meeting and in any event shall include the requisite approvals as required under the Current Articles),
substantially in the form attached as <B><U>Schedule 2.2.1.1</U></B> hereto, pursuant to which the shareholders of the Company shall
have, inter alia, approved all transactions contemplated hereby and taken all necessary corporate actions related to such transactions,
including but not limited to: </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of immediately prior to the Closing: (A) increasing and modifying the authorized share capital of the Company to create and authorize
the Special Share for the issuance to the Investor, and the creation of the Preferred S Shares, (B) approving the replacement, no later
than immediately prior to the Closing, of the Current Articles (as defined below) with the Amended and Restated Articles of Association,
in the form attached hereto
as <B><U>Schedule 2.2.1.1.1</U></B> (the &ldquo;<B>Amended Articles</B>&rdquo;); (C) approving the execution, delivery and performance
by the Company of this Agreement, the Existing Company CLA Amendments (and all transaction contemplated thereby, including without limitation,
the First Company CLA Conversion), the IRA and all documents, agreements, certificates, and instruments furnished pursuant or ancillary
hereto or thereto (collectively with the Amended Articles, the &ldquo;<B>Ancillary Documents</B>&rdquo;, and collectively with this Agreement,
the &ldquo;<B>Transaction Documents</B>&rdquo;); and (D) changing the composition of the Board as of the Closing and each Subsequent
Closing; and</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
[Reserved]. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
[Reserved]. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Board Resolutions</U>. Duly executed unanimous resolutions of the Board (which may be in the form of a written resolution or minutes
of the board of directors), substantially in the form attached as <B><U>Schedule 2.2.1.2</U></B> hereto, pursuant to which the Board
shall have, inter alia, approved all transactions contemplated hereby and taken all necessary corporate actions related to such transactions,
including but not limited to, (A) approving the execution, delivery and performance by the Company of this Agreement and each Ancillary
Document requiring such, (B) approving the issuance of the Special Share to the Investor, and (C) approving the issuance to the Investor
of the Conversion Shares upon conversion of the Principal Amount, and the Third Closing Shares at the Third Closing (the &ldquo;<B>Aggregate
Shares</B>&rdquo;, and together with the Call Option, and the Ordinary Shares which may be issued upon conversion of the Aggregate Shares,
collectively, the &ldquo;<B>Securities</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Share Certificate</U>. Validly executed share certificate evidencing the registration of the Special Share in the name of the Investor,
in the form attached hereto as <B><U>Schedule 2.2.1.3</U></B> in the name of the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Shareholders Register</U>. A copy, duly certified by an officer of the Company and dated as of the Closing, of the Company's shareholders
register, in the form of <B><U>Schedule 2.2.1.4</U></B> attached hereto (the &ldquo;<B>Shareholders Register</B>&rdquo;), which shall
also reflect the registration by the Company of the issuance of the Special Share to the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Waivers;
Confirmation of Holdings</U>. Unless included in the shareholders resolutions, the Company shall deliver to the Investor a written
consent in the form attached hereto as <B><U>Schedule 2.2.1.5</U></B>, signed by the Preferred B Majority (as defined under the
Amended Articles) pursuant to which (i) any and all preemptive rights, rights of first refusal, or any other rights by virtue of
which such shareholder (or any permitted transferee or assignee) may be entitled to purchase or receive securities of the Company
(&ldquo;<B>Participation Rights</B>&rdquo;) with respect to the transactions contemplated by this Agreement, including the issuance
of any Shares upon the conversion of the Principal Amount, have been waived or excluded<I>;</I> and (ii) any and all anti-dilution
rights to which such shareholder (or any permitted transferee or assignee) may be entitled under the Current Articles or under any
other instrument have been waived or excluded; and (iii) with respect to the holders of at least 85% of the Company&rsquo;s issued
and outstanding share capital on a Fully-Diluted Basis, represents that its shareholdings as set forth in the Capitalization Table
accurately reflects its holdings of the securities
of the Company, both prior to and following the Closing, on a Fully-Diluted Basis (where confirmation to this effect in the Call Option
Agreement shall satisfy this condition). </FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compliance Certificate</U>. A certificate, duly executed by the Chief Executive Officer of the Company, dated as of the Closing, in
the form attached hereto as <B><U>Schedule 2.2.1.6</U></B> (the &ldquo;<B>Compliance Certificate</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Existing Company CLA Amendments</U>. The Company shall deliver to the Investor the Existing Company CLA Amendments, in the form attached
hereto as <B><U>Schedule 2.2.1.8</U></B>, duly executed by the requisite majority of lenders under the Existing Company CLAs necessary
in order to effectuate the Existing Company CLA Amendments and the conversion of the First Company CLA. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Payment of Initial Principal Amount</U>. The Investor shall cause the transfer to the Company of the Initial Principal Amount by wire
transfer in accordance with written instructions of the Company attached hereto as <B><U>Schedule 2.2.2</U></B>. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.3.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Investors' Rights Agreement</U>. The Amended and Restated Investors' Rights Agreement attached hereto as <B><U>Schedule 2.2.3</U></B>
(the &ldquo;<B>Investors' Rights Agreement</B>&rdquo; or &ldquo;<B>IRA</B>&rdquo;) shall have been executed by each of the Company, the
Investor and the other existing shareholders necessary in order to effectuate the Investors&rsquo; Rights Agreement. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.4.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnification Agreements</U>. The Company shall have executed the indemnification agreements with each of the Company&rsquo;s directors
(including the director designated by the Investor), in the form attached hereto as <B><U>Schedule 2.2.4</U></B>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.5.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Call Option Agreement</U>. The Call Option Agreement (as defined in <U>Section &#8206;4</U> below) shall have been executed by the
Company, shareholders of the Company holding at least 85% of the Company&rsquo;s issued and outstanding shares, including the holders
of a majority of each class of shares of the Company, and the Investor. </FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.
<U>Transactions and Deliveries at Subsequent Closings</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1.&nbsp;&nbsp;&nbsp;&nbsp;
At the Second Closing, the following transactions shall occur, which transactions shall be deemed to take place simultaneously and no
transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed and all
required documents delivered: The Company shall (i) if and to the extent legally required with respect to any shares newly issued following
the Closing and prior to the Second Closing, deliver to the Investor a waiver of Participation Rights in the same or substantially similar
form as provided at the Closing, as applicable to the Second Closing with respect to any shares or convertible securities, options or
warrants issued following the Closing, (ii) deliver to the Investor an Officer Certificate duly executed by the CEO of the Company confirming
to the Investor that no Material Adverse Change (as defined below) shall have occurred and remains outstanding prior to such date, substantially
in the form attached hereto as <B><U>Schedule 2.3.1 </U></B>(the &ldquo;<B>Officer Certificate</B>&rdquo;). The Investor shall cause
the transfer to the Company of the Second Principal Amount by wire transfer in accordance with written instructions of the Company.</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Material
Adverse Change&rdquo;</B> shall mean (i) as of the Closing and each Subsequent Closing, any change, event or effect that is materially
adverse to the business, results of operations, assets, liabilities, or financial condition of the Company, taken as a whole, or that
prevents or could reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement or performance
by any the Company of any material obligations under this Agreement; and (ii) as of the Second Closing or Third Closing, respectively,
any adverse change (a <B>&ldquo;R&amp;W Material Adverse Change&rdquo;</B>) to any of the Company&rsquo;s representations and warranties
constituting MAC Representations (as defined below) which meets the materiality criteria specified therein, and remains outstanding as
of the Second Closing or Third Closing (as applicable), and, if curable, was not rectified by the Company within 30 days of notice thereof.
The &ldquo;<B>MAC Representations</B>&rsquo;&rdquo; mean: (x) with respect to each of the Second Closing and the Third Closing: (x) (a)
5.14 (Intellectual Property) &ndash; in the context of any patent infringement claim against the Company, which has been accepted, is
subject to ongoing settlement negotiations with the Company, or where such claim has been filed against the Company in any court or arbitration
forum, and (b) 5.16 (Litigation) - in the context of any outstanding claim in the amount of at least $2.5M, that is accepted, is subject
to ongoing settlement negotiations with the Company, or where such claim has been filed against the Company in any court or arbitration
forum ; and (y) with respect to the Third Closing &ndash; also 5.20 (Regulatory Matters) &ndash; in the context of: revocation, suspension
or withdrawal of the FDA Approval below, even if such failure of a MAC Representation does not, in and of itself, meet the criteria set
forth in clause (i) of this definition; provided, however, that any effect to the extent resulting or arising from any of the following
shall not be considered when determining whether a Material Adverse Change under clause (i) shall have occurred: (a) any change or development
in general economic conditions in the industries or markets or countries in which the Company operates, (b) any change in financing,
banking or securities markets generally, (c) any act of god (including earthquakes, fires, floods and natural catastrophes) or act of
war, armed hostilities or terrorism, change in political environment or any worsening thereof or actions taken in response thereto, and
(d) any changes in law or the interpretation thereof; provided that any of the foregoing effects stated in clauses (a) through (d) shall
be excluded only to the extent they do not have a disproportionate effect on the Company compared to other similarly situated companies
in the same industry or market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2.&nbsp;&nbsp;&nbsp;&nbsp;
At the Third Closing, the following transactions shall occur, which transactions shall be deemed to take place simultaneously and no
transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed and all
required documents delivered: The Company shall (i) issue and allot the Third Closing Shares and the Conversion Shares; (ii) deliver
to the Investor a validly executed share certificate covering the Third Closing Shares and the Conversion Shares; (iii) register the
allotment of the portion of the Third Closing Shares purchased by the Investor, and the Conversion Shares issued upon conversion of the
Principal Amount, in its Shareholders Register and deliver a copy thereof to the Investor; (iv) deliver to the Investor an Officer Certificate
in the same form as provided at the Second Closing, as applicable to the Third Closing; and (v) the Investor shall transfer the Third
Investment Amount, for the Third Closing Shares being purchased to the Company by wire transfer in accordance with written instructions
of the Company. Promptly following the Third Closing, the Company shall file the applicable reports with the Israeli Companies Registrar
regarding the issuance of the Third Closing Shares.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.
<U>Conditions to the Closing and the Subsequent Closings of the Investor</U>. The obligations of the Investor to transfer the Investor&rsquo;s
Initial Principal Amount at the Closing, and to transfer the
Investor Second Principal Amount, and the Third Investment Amount, as applicable, at the Subsequent Closings, are subject to the fulfilment
at or before the Closing, and the applicable Subsequent Closing (where indicated), of the following conditions precedent, any one or
more of which may be waived in whole or in part by the Investor:</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Warranties</U>. The representations and warranties made by the Company in this Agreement shall have been true
and correct when made, and shall be true and correct in all material respects as of the Closing Date. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Covenants</U>. All covenants, agreements, and conditions contained in this Agreement to be performed or complied with by the Company
prior to or at the Closing or the applicable Subsequent Closing, shall have been performed or complied with by the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Consents, etc.</U> The Company shall have secured all permits, consents and authorizations that shall be necessary or required lawfully
to consummate this Agreement and to issue the Special Share, the Third Closing Shares, and the other securities herein contemplated to
the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Documents</U>. All of the documents to be delivered by the Company at the Closing pursuant to this <U>Section &#8206;2</U>
shall have been delivered to the Investor. All other applicable actions and transactions set forth in this <U>Section &#8206;2</U> shall
have been completed on or prior to the Closing, and prior to each Subsequent Closing, as applicable.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.5.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Proceedings and Documents</U>. All corporate and other proceedings in connection with the transactions contemplated by this Agreement
shall be reasonably satisfactory in substance and form to the Investor, and the Investor shall have received all such counterpart originals
or certified or other copies of such documents as the Investor or its counsel may reasonably request.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.6.&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Material Adverse Change</U>.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.6.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of the Closing and as of each Subsequent Closing, (i) there shall have been no Material Adverse
                                            Change as of such closing following the date of this Agreement and (ii) the Investor shall
                                            have received the Company's written confirmation thereof in the Officer Certificate. In the
                                            event the Investor claims that the condition set forth in Section 2.4.6 has not been satisfied
                                            (notwithstanding the Officer Certificate provided pursuant to Section 2.4.6.1(ii) was provided
                                            by the Company (as evidenced by the applicable Officer Certificate), the Investor shall promptly
                                            provide notice to the Company within 5 business days of the delivery of such Officer Certificate
                                            of its refusal to fund at the Subsequent Closing (as applicable) with a written explanation
                                            substantiating the basis for such refusal.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.6.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If
                                            the Subsequent Closing is not consummated by reason of non- satisfaction of the condition
                                            set forth in this Section 2.4.6, the Call Option shall immediately and automatically be
                                            deemed extinguished and of no further force and effect as of the date of the applicable Officer's
                                            Certificate, the Investor shall not be entitled to make any further investments under this
                                            <FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement, and the Company shall
                                            at any time be entitled to repay the outstanding Loan Amount.</FONT></FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.7.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Updating Disclosure Schedule</U>. At least ten (10) business days prior to each Subsequent Closing, the Company shall deliver to the
Investor an updated Schedule of Exceptions solely referencing and updating matters that require disclosure in order not to render any
representation or warranty in the MAC Representations untrue or incorrect as of the date of such Subsequent Closing. For the avoidance
of doubt, the provision of such updated disclosures shall not, in and of itself, preclude the Investor from claiming, in its reasonable
discretion, that any matter disclosed therein constitutes or gives rise to an R&amp;W Material Adverse Change. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.8.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Milestones</U>. The respective Milestone for such Subsequent Closing shall have been achieved, as determined under this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.9.&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Injunction</U>. No injunction, judgment, order, decree, statute, law, ordinance, rule or regulation, entered, enacted, promulgated,
enforced or issued by any court or other authority of competent jurisdiction or other similar legal restraint or prohibition preventing,
enjoining, restraining, prohibiting or making illegal the consummation of the Agreement or any of the transactions contemplated by the
Agreement, shall be in effect.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.
<U>Conditions to the Closing and the Subsequent Closings of the Company</U>. The obligations of the Company to accept the Principal Loan
Amount and the Third Investment Amount and issue the securities contemplated herein to the Investor at the Closing and the Subsequent
Closings, as applicable, are subject to the fulfilment at or before the Closing, and the applicable Subsequent Closing, of the following
conditions precedent, any one or more of which may be waived in whole or in part by the Company:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.1.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Warranties</U>. The representations and warranties made by the Investor in this Agreement shall have been true
and correct when made, and shall be true and correct in all respects as of the Closing, and as of the Subsequent Closing(s).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.2.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Payment</U>. The Investor shall pay to the Company the Initial Principal Amount, the Second Principal Amount or the Third Investment
Amount, as applicable. For avoidance of doubt, it is clarified that if the Investor is in Default in respect of the Second Closing, and
such Default is not fully remedied as set forth in Section 1.8.7, then the Investor shall not be entitled to invest the Third Investment
Amount and purchase the Third Investment Shares at the Third Closing. Furthermore, it is clarified that a condition of the Company for
the consummation of the Third Closing is the occurrence of the Second Closing, such that, in no event will Investor be entitled to invest
the Third Investment Amount, if the Second Closing was not consummated (regardless of the reasoning therefor) and the Second Principal
Amount not extended to the Company at the Second Closing. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.3.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Performance</U>. The Investor shall have performed and complied with all other agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by it prior to or at the Closing or the applicable Subsequent Closing,
including the execution of each Ancillary Document requiring its execution.</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.4.&nbsp;&nbsp;&nbsp;&nbsp;
 <U>No Injunction</U>. No injunction, judgment, order, decree, statute, law, ordinance, rule or regulation, entered, enacted, promulgated,
enforced or issued by any court or other authority of competent jurisdiction or other similar legal restraint or prohibition preventing,
enjoining, restraining, prohibiting or making illegal the consummation of the Agreement or any of the transactions contemplated by the
Agreement, shall be in effect. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Conversion</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.
<U>Definitions</U>. As used herein:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1.&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Conversion Price</B>&rdquo; means, (A) in respect of the Initial Principal Amount, a price per share of US$2.26 (subject to
appropriate adjustment in the event of any share dividend, share split, combination or other similar recapitalization with respect to
the applicable Conversion Shares) reflecting a pre-money valuation of US$30,000,000 (thirty million USD) as of the Closing on a Fully
Diluted Basis (the <B>&ldquo;First Conversion Price&rdquo;</B>); and (B) in respect of the Second Principal Amount a price per share
of US$2.64 (subject to appropriate adjustment in the event of any share dividend, share split, combination or other similar recapitalization
with respect to the applicable Conversion Shares) reflecting a pre-money valuation of US$45,000,000 (forty five million USD) as of the
Closing, on a Fully Diluted Basis (the <B>&ldquo;Second Conversion Price&rdquo;</B>), assuming the conversion of the Initial Principal
Amount and the Second Company CLA; in each case as further reflected in the Capitalization Table. &#9;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2.&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Conversion Shares</B>&rdquo; means (i) with respect to the Initial Principal Amount &ndash; Series S-1 Preferred Shares of
the Company (&ldquo;<B>Preferred S-1 Shares</B>&rdquo;), and (ii) with respect to the Second Principal Amount &ndash; Series S-2 Preferred
Shares of the Company (&ldquo;<B>Preferred S-2 Shares</B>&rdquo;), in each case having the respective rights, preferences and privileges
as set forth in the Amended Articles.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3.&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Exit Event</B>&rdquo; means a Deemed Liquidation (as defined in the Amended Articles) or an IPO (as defined in the Articles),
excluding an acquisition of the Company by the Investor (or any of its affiliates) (i.e., through the exercise of the Call Option or
otherwise).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4.&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Fully Diluted Basis</B>&rdquo; means, the total number of shares of the Company&rsquo;s outstanding share capital (on an as-converted
basis, assuming the implementation of all applicable anti-dilution protections and rights) plus all shares issuable upon the exercise
of outstanding options, warrants, or other convertible securities (including the shares issuable upon conversion of the First Company
CLAs, but not the Second Company CLAs), whether or not such options, warrants, or other rights are vested or exercisable; all as of the
Closing Date, as reflected in the Capitalization Table.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.
<U>Conversion upon the Third Investment</U>. To the extent that any part of the Loan Amount has not been repaid or converted pursuant
to the terms of this Agreement, in the event of the Third Closing, the entire outstanding balance of the Principal Amount (without any
accrued Interest, which, in such event, shall then be deemed waived (i.e. neither converted nor payable) concurrently with the conversion
and shall convert into Conversion Shares at the applicable Conversion Price simultaneously with the Third Closing.</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.
<U>Conversion upon Exercise of Call Option</U>. To the extent that any part of the Loan Amount has not been repaid or converted pursuant
to the terms of this Agreement, in the event that the Investor elects to exercise the Call Option (as defined in <U>Section &#8206;4.1</U>),
the entire outstanding balance of the Principal Amount (without any accrued Interest, which, in such event, shall then be deemed waived
(i.e. neither converted nor payable concurrently with the conversion) shall convert into Conversion Shares at the applicable Conversion
Price with effect as of immediately prior to the consummation of the transactions contemplated by the Call Option Agreement (as defined
in Section &#8206;4.1).</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4.
<U>Optional Conversion</U>. Unless previously converted or repaid, and unless otherwise expressly indicated otherwise under this Agreement
(e.g., in the event Investor is a Defaulting Investor), the Investor shall at any time be entitled, upon providing the Company with written
notice, to immediately convert the entire then outstanding Principal Amount (without any accrued Interest, which, in such event, shall
then be deemed waived (i.e. neither converted nor payable) concurrently with the conversion)into Conversion Shares at the applicable
Conversion Price. Upon receiving the written instructions of the Investor in accordance with the provisions of this <U>Section 3.5</U>,
the Company shall take all the necessary steps required to effectuate the conversion as described herein, and filing the necessary documents
to the Israeli Registrar of Companies, all within fourteen (14) days upon receiving Investor&rsquo;s notice.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5.
<U>Conversion upon an Exit Event</U>. Unless previously converted or repaid, in the event of the consummation of an Exit Event, immediately
prior to the closing of the Exit Event, the entire outstanding Principal Amount (without any accrued Interest, which, in such event,
shall then be deemed waived (i.e., neither converted nor payable) concurrently with the conversion) shall be automatically converted,
at the applicable Conversion Price, into Conversion Shares. Upon receiving the written instructions of the Investor in accordance with
the provisions of this <U>Section 3.5</U>, instructing the Company to convert the entire Principal Amount into Conversion Shares, then
the Company shall take all the necessary steps required to effectuate the conversion as described herein, and filing the necessary documents
to the Israeli Registrar of Companies, all within fourteen (14) days upon receiving the Investor&rsquo;s notice.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.
<U>Automatic Conversion </U>&ndash; Defaulting Investor. The outstanding Principal Amount (if any) (without any accrued interest which
shall be deemed waived (i.e., neither converted nor paid) shall be automatically converted in accordance with and subject to the provisions
of Section 1.8.7.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7.
<U>Notice</U>. For as long as the Loan Amount has not been converted or repaid, the Company shall deliver prior written notice to the
Investor of any contemplated Exit Event, as promptly as possible, but in any event at least thirty (30) days prior to the closing of
such transaction.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8.
<U>Automatic Conversion of Second Company CLAs</U>. Immediately prior to, but subject to, the conversion of the outstanding Principal
Amount by the Investor, the Second Company CLAs shall be converted according to the terms set forth in the Existing Company CLA Amendments
and consistent with this Agreement.</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Investor&rsquo;s Call Option</U></B></FONT></P>




<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
<U>Grant of Call Option</U>. A condition to the Closing shall be the execution and delivery, effective as of the Closing, of the definitive
Call Option Agreement (in the form attached hereto as <B><U>Exhibit C</U></B> (the &ldquo;<B>Call Option Agreement</B>&rdquo;)) to purchase
all of the Option Purchased Securities (as defined therein directly or indirectly through an affiliate of the Investor, free and clear
of any encumbrances, all subject to and in accordance with the terms of the Call Option Agreement.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
<U>[Reserved]</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Warranties of the Company</U></B>. The Company hereby represents and warrants to the Investor, and acknowledges that the Investor
is entering into this Agreement in reliance thereon, that, except as set forth on the Schedule of Exceptions attached as <B><U>Schedule
5</U></B> to this Agreement, which exceptions shall explicitly reference the representations hereunder to which they relate thereby qualifying
only such Company representation or such other Company representations which are readily apparent to be relevant, and shall be deemed
to be representations and warranties as if made hereunder, the following representations are true and complete on the date hereof and
shall remain true and complete as of the date of the Closing (except to the extent such representations and warranties refer to a specific
date, in which case the Company makes such representations and warranties as of such date), it being noted that, with the exception of
the representations in <U>Sections &#8206;5.1</U>, <U>&#8206;5.3</U>, &#8206;<U>5.5</U>, &#8206;<U>5.6</U> and &#8206;<U>5.8</U>, the
representations in this <U>Section &#8206;5</U> shall be read as if made also with respect to each Subsidiary (as defined below).</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.
<U>Organization</U>. The Company is a private company, duly organized and validly existing under the laws of the State of Israel, and
has full corporate power and authority to own, lease and operate its properties and assets and to conduct its business as now being conducted
and as proposed to be conducted. A true and correct copy of the Articles of Association of the Company in effect prior to the Closing
and prior to the adoption of the Amended Articles (the &ldquo;<B>Current Articles</B>&rdquo;) was delivered to counsel to the Investor.
The Company has not taken any action or failed to take any action, which action or failure would preclude or prevent the Company from
conducting its business after the Closing in the manner heretofore conducted.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.
<U>General Compliance with Instruments and Law</U>. The Company is not in violation or default (a)&nbsp;under the Current Articles, or
(b) under any material contract, note, indenture, mortgage, lease, purchase order or other instrument, document or agreement to which
the Company is a party, or (c)&nbsp;with respect to any law, statute, ordinance, regulation, order, writ, injunction, decree, or judgment
of any court or any governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign (any of the foregoing,
a &ldquo;<B>Law</B>&rdquo;). The Company has not received notice regarding any violation of, conflict with, or failure to comply with,
any Law. Without derogating from the generality of the foregoing, the Company is not registered under the status and has not been declared
by the Registrar as a &ldquo;violating company&rdquo; within the meaning of Section 362A of the Israeli Companies Law, and it has not
received any notice or warning (in writing or otherwise) concerning any intention of the Registrar to register and/or declare the Company
as a &ldquo;violating company&rdquo;.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.
<U>Authorization and Approvals Related to the Transaction; No Breach</U>.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.1.&nbsp;&nbsp;&nbsp;&nbsp;
 <U>Authorization and Approvals Related to the Transaction</U>. The Company has full power and authority to execute and deliver the Transaction
Documents and to consummate the transactions and to perform its obligations contemplated thereby. All corporate action on the part of
the Company, its shareholders and directors necessary for the authorization, execution, delivery, and performance of all of the Company's
obligations under the Transaction Documents and for the authorization, issuance and allotment of the Securities has been taken or will
be taken prior to the Closing and each Subsequent Closing as applicable. The Transaction Documents, when executed and delivered by or
on behalf of the Company, shall be duly and validly authorized, executed and delivered by the Company, and shall constitute the valid
and legally binding obligations of the Company, legally enforceable against the Company in accordance with their respective terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement
of creditors&rsquo; rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief,
or other equitable remedies.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.2.&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Breach</U>. The execution, delivery and performance by the Company of the Transaction Documents shall not conflict with, or result
in a breach, violation or default (or event which with the giving of notice or lapse of time, or both, would become a default) of, any
of the terms, conditions and provisions of: (i)&nbsp;the Current Articles or the Amended Articles, (ii)&nbsp;any judgment, order, injunction,
decree, or ruling of any court or Governmental Entity (as defined below), domestic or foreign, (iii)&nbsp;any agreement, contract, lease,
license or commitment to which the Company is a party or by which it is bound, or to which any of its properties is subject, nor shall
it result in the imposition of any Lien (as defined below) upon such assets, (iv) any Law applicable to the Company. Such execution,
delivery, compliance and consummation, will not (a)&nbsp;give to others any rights, including rights of prior notice, termination, cancellation
or acceleration, in or with respect to any material agreement, contract or commitment referred to in this paragraph, or (b)&nbsp;otherwise
require the prior notice to, or consent or approval of, any person or entity (including without limitation any Governmental Entity),
which prior notice, consent or approval has not heretofore been delivered or obtained. &ldquo;<B>Governmental Entity</B>&rdquo;, or &ldquo;<B>Government
Entity</B>&rdquo; means any supra-national, national, federal, provincial, state, regional, municipal or local government (including
any sub-division, ministry, tribunal, court, body, bureau, agency, public or other authority or instrumentality, department, administrative
agency, commission or other authority thereof) or private body exercising any regulatory, taxing, customs, importing or quasi-governmental
authority, including but not limited to state-owned or state-controlled entities or enterprises, in each case having jurisdiction or
authority.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4.
<U>Corporate Records</U>. The minute books of the Company contain accurate and complete copies, in all material respects, of the minutes
of every meeting (and all written consents in lieu of meetings) of the Company's shareholders and the Board (and any committee thereof).
There are no applications or filing outstanding which would reasonably be expected to adversely affect such documents or the corporate
status of the Company (except where such applications or filings can be remediated with minimal cost and effort). No material resolutions
(including, for the avoidance of any doubt, resolutions regarding the grant of options, issuance of shares or any other securities) have
been passed, enacted, consented to or adopted by the Board (or any committee thereof) or shareholders of the Company, except for those
contained in such minute books. The corporate records of the Company have been maintained in accordance with all applicable statutory
requirements.</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5.
<U>Subsidiaries</U>. Except as set forth in <U>Section 5.5 of the Schedule of Exceptions,</U> the Company does not own or control any
equity security or other interest of any other corporation, limited partnership or other business entity (&ldquo;<B>Subsidiary</B>&rdquo;).
Each Subsidiary listed in <U>Section 5.5 of the Schedule of Exceptions</U> (A) is duly organized and validly existing under the Laws
of the state of its incorporation, is active and has paid all is fees, and has full corporate power and authority to own, lease and operate
its properties and assets and to conduct its business as now being conducted and as proposed to be conducted; and (B) is a wholly-owned
(directly or indirectly) subsidiary of the Company and no third party, directly or indirectly, owns or has any rights with respect to,
any equity security or other interest whatsoever in any of the Subsidiaries. The Company is not a participant in any joint venture, partnership
or similar arrangement.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.
<U>Capitalization</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.1.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Share Capital</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Immediately prior to the Closing, the authorized share capital of the Company shall consist of NIS 200,000 divided into: (a) 13,800,000
Ordinary Shares, par value NIS 0.01 each - (i) 2,318,094 of which shall be issued and outstanding; (ii) 1,500,220 of which have been
reserved for issuance to employees, consultants, officers, or directors of the Company pursuant to the ESOP and 595,360 of which shall
be available for future issuances of options thereunder; (b) 1,400,000 Series A Shares, par value NIS 0.01 each, 1,060,179 of which are
issued and outstanding, and 100,000 Series A-1 Shares, par value NIS 0.01 each, 41,849 of which are issued and outstanding; (c) 2,500,000
Series B Shares, par value NIS 0.01 each, 1,363,540 of which are issued and outstanding, and (d) 2,200,000 Series B-1 Shares, par value
NIS 0.01 each, 2,128,133 of which are issued and outstanding.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Simultaneous with the Closing and as of immediately thereafter, the authorized share capital of the Company shall consist of NIS 391,648
divided into: (a) 21,062,619 Ordinary Shares, par value NIS 0.01 each: (i) 2,488,454 of which shall be issued and outstanding; (ii) 1,500,220
of which have been reserved for issuance to employees, consultants, officers, or directors of the Company pursuant to the ESOP and 595,360
of which shall be available for future issuances of options thereunder; (b) 1,400,000 Series A Shares, par value NIS 0.01 each, 948,581
of which are issued and outstanding; (c) 100,000 Series A-1 Shares, par value NIS 0.01 each, 41,849 of which are issued and outstanding;
(d) 2,500,000 Series B Shares, par value NIS 0.01 each, 1,363,540 of which are issued and outstanding; (e) 2,200,000 Series B-1 Shares,
par value NIS 0.01 each, 2,069,371 of which are issued and outstanding; (f) 1,621,000 Series B-2 Shares, par value NIS 0.01 each, 1,620,156
of which are issued and outstanding; (g) 1,000,000 Series B-3 Preferred Shares par value NIS 0.01 each, none of which are issued and
outstanding; (h) 3,042,000 Series B-4 Preferred Shares par value NIS 0.01 each, none of which are issued and outstanding; (i) 2,212,524
Series S-1 Preferred Shares par value NIS 0.01 each none of which are issued and outstanding; (j) 2,271,458 Series S-2 Preferred Shares
par value NIS 0.01 each none of which are issued and outstanding; (k) 1,755,219 Series S-3 Preferred Shares par value NIS 0.01 each none
of which are issued and outstanding; and (f) one Special Share, par value NIS 0.01, which is issued and outstanding. </FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.2.&nbsp;&nbsp;&nbsp;&nbsp;
 <B><U>Exhibit B</U></B> attached hereto (the &ldquo;<B>Capitalization Table</B>&rdquo;) accurately and completely reflects the Company's
capitalization on a Fully Diluted Basis, setting forth the number and class or series of shares held by each of the Company's shareholders
(all of which are the lawful owners, beneficially and of record, of all of the issued and outstanding share capital of the Company and
of all rights thereto) and holders of options to purchase shares of the Company, and the number of reserved and granted or promised options,
warrants, and all other rights to subscribe for, purchase or acquire from the Company any share capital of the Company, immediately prior
to, and immediately following, the Closing assuming the investment of the entire Initial Principal Amount, Second Principal Amount and
Third Investment Amount. All issued and outstanding shares were upon their issuance duly authorized and validly issued, fully paid up,
non-assessable, and issued in accordance with applicable securities Laws and no party has any Lien on such shares or anti-dilution rights
with respect to such prior issuances.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.3.&nbsp;&nbsp;&nbsp;&nbsp;
Simultaneously with the Closing, the number of ESOP Shares issuable under the ESOP shall be 2,095,850 of which 1,500,220 ESOP Shares
will have been allocated under the Company&rsquo;s ESOP Plan and of which 595,630 shall constitute Free ESOP Shares which remain free
for future allocation thereunder and shall represent the Free ESOP Percentage. No employee, officer, director or consultant has options
or any other securities that provide for accelerated vesting upon a change of control transaction or termination of employment or service
or any other event. The Company has not adjusted or amended the exercise price of any share options previously awarded, whether through
amendment, cancellation, replacement grant, re-pricing, or any other means. <U>Schedule 5.6.3 of the Schedule of Exceptions</U> sets
forth for each outstanding or promised option or equity award: (i) the name of the holder thereof; (ii) the exercise price, (iii) the
vesting commencement date and vesting schedule (and any acceleration terms, if any); (iii) whether each such option or award was granted
and is subject to tax pursuant to Section 3(i) or Section 102 of the Israeli Income Tax Ordinance [New Version], 1961 (and specifying
the subsection of Section 102) or tax regimes of other jurisdictions.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.4.&nbsp;&nbsp;&nbsp;&nbsp;
Other than as set forth on the Capitalization Table, and except as may be granted pursuant to this Agreement and the Ancillary Documents,
there are no share capital, anti-dilution rights or preemptive rights (except in each case under the Company's Current Articles), convertible
securities, outstanding warrants, options or other rights or promises to subscribe for, purchase or acquire from the Company or, to the
Company's knowledge, from security holders of the Company, any share capital or other securities of the Company, and there are no undertakings,
promises, commitments, written or oral, contracts or binding commitments of the Company providing for the issuance of, or the granting
of rights to acquire from the Company or, to the Company's knowledge, from security holders of the Company, any share capital or other
securities of the Company or under which the Company is, or may become, obligated to issue any of its securities or, to the Company's
knowledge, any of the Company's security holders is obligated to transfer any of its securities in the Company. Except as set forth in
<U>Section 5.6.4 of the Schedule of Exceptions</U>, there are no agreements or other arrangements that provide for acceleration or other
changes in the vesting provision or other terms of any options and/or warrants as the result of any merger, sale of shares of the Company,
change in control or other similar transaction involving the Company or as a result of the transactions contemplated under this Agreement,
or upon termination of employment or service of any holder thereof or upon any other event.</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.5.&nbsp;&nbsp;&nbsp;&nbsp;
 Except as required pursuant to the Investors' Rights Agreement, the Company is not under any obligation, and has not granted any rights,
to register any of the Company's presently outstanding securities or any of its securities that may hereafter be issued, and to the Company's
best knowledge no shareholder of the Company has entered into any agreement with respect to the voting or transfer of equity securities
of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.6.&nbsp;&nbsp;&nbsp;&nbsp;
Since its incorporation, there has been no declaration or payment by the Company of dividends, or any distribution by the Company of
any assets of any kind to any of its shareholders in redemption of or as the purchase price for any of the Company's securities. The
Company is not under any obligations (contingent or otherwise) to purchase, redeem or otherwise acquire any shares of its share capital
or any interest therein or to pay any dividend or make any other distribution in respect thereof. There are no outstanding or authorized
share appreciation rights, phantom shares, or similar rights with respect to the Company or to the Company&rsquo;s knowledge with respect
to a shareholder of the Company. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6.7.&nbsp;&nbsp;&nbsp;&nbsp;
The rights, preferences and privileges of the Securities are as stated in the Amended Articles and Investors' Rights Agreement (as each
may be amended pursuant to the provisions hereof). When issued in compliance with the provisions of this Agreement and the Amended Articles,
the Securities will be (i) validly issued, fully paid and non-assessable, (ii) issued in compliance with all applicable securities Laws,
and (iii) free of any mortgage, pledge, lien, royalty obligations, conditional sale agreement, security agreement, encumbrance or other
charge (collectively, &ldquo;<B>Liens</B>&rdquo;), subject to any restrictions on transfer under applicable securities Laws, the Amended
Articles and the other Ancillary Documents. </FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7.
<U>Governmental Consents and Filings</U>. Except for routine filings with the Registrar regarding the issuances of securities as contemplated
hereby, no consent, approval, order, or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state or local Governmental Entity (including but not limited to the IIA) is required on the part of the Company in connection
with the consummation of the transactions contemplated by this Agreement and the Ancillary Documents.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8.
<U>Offering Valid</U>. The offer, sale, issuance and delivery of the Securities under this Agreement will be exempt from the registration
and prospectus requirements of the Israeli securities Laws, and will have been registered or qualified (or are exempt from registration
and qualification) under the registration, permit or qualification requirements of all the applicable securities Laws of Israel. Without
derogating from the generality of the foregoing, the Company has taken or will, prior to Closing, take all action necessary to be taken
to ensure compliance with Section 15A of the Israeli Securities Law, 5728-1968, and that there were less than 35 offerees, in the aggregate,
excluding qualified investors as defined in such law, to whom the Company and any of its respective representatives made an offering
of any securities of the Company in the past twelve months.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.
<U>Agreements</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.1.&nbsp;&nbsp;&nbsp;&nbsp;
Except for this Agreement and (as of the Closing) the Ancillary Documents, and except as set forth in <U>Section 5.9 of the Schedule
of Exceptions</U>, there are no agreements, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or
decrees in force to which the Company is a party or by which it or any of its property is bound that involve or may involve (i) obligations
(contingent or otherwise) of, or payments to, the Company
in excess of $50,000 each or in the aggregate, (ii) the license of any patent, copyright, trade secret or other proprietary right or
Intellectual Property to or from the Company, (iii) provisions restricting or affecting the development, manufacture or distribution
of the Company&rsquo;s products or services, (iv) indemnification by the Company with respect to infringements of proprietary rights,
(v) restrictions or limitations on the Company&rsquo;s right to do business or compete in any area or any field with any person, firm
or company, (vi) the sale or purchase of goods or services, (vii) the leasing of any real property or (viii) any other agreement material
to the Company (collectively, the &ldquo;<B>Material Agreements</B>&rdquo;). Except as set forth in <U>Section 5.9.1 of the Schedule
of Exceptions</U>, the Company is not and has never been a party to, as a contractor or subcontractor, and is not making and has never
made, any bid or proposal with respect to, any contract with any government or Governmental Entity.</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9.2.&nbsp;&nbsp;&nbsp;&nbsp;
True and correct copies of all of the Material Agreements (and a summary description of any oral agreements) have been made available
to the Investor. The Company is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation and has not
otherwise agreed to become directly or contingently liable for any obligation of any person, firm or corporation, nor is any person,
firm or corporation a guarantor of any indebtedness of the Company. The Company is not party to and is not bound by any contract, agreement
or instrument, or subject to any restriction under its governing documents that adversely affects its business as now conducted or as
presently proposed to be conducted, its properties and assets or its financial condition. Each Material Agreement is a legal, valid and
binding agreement of the Company, enforceable by or against the Company in accordance with its terms, and in full force and effect, and
each Material Agreement is, to the Company&rsquo;s knowledge, a valid and binding agreement of the other parties thereto. The Company
has no knowledge of the invalidity of or grounds for rescission of any Material Agreement, or of any intention to terminate any such
agreements, and to the Company&rsquo;s knowledge no third party is in default under any such agreement and there is no Lien over all
or any part of any such agreement. To the Company&rsquo;s knowledge, the Material Agreements will continue to be legal, valid, binding,
enforceable, and in full force and effect on identical terms following the consummation of the transactions contemplated hereby. The
Company is in compliance in all material respects with the provisions of the Material Agreements, and the Company has no reason to believe
that it will not be able to fulfil fully and in a timely manner all of its obligations under the Material Agreements.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Obligations to Related Parties</U>. Except as set forth in <U>Section 5.10 of the Schedule of Exceptions</U>, no officer, director,
or shareholder of the Company (nor any affiliate of such person or entity) has or has had (a) any direct or indirect interest in any
person or entity which is affiliated with or has a business relationship with the Company, or (b) a beneficial interest in any material
contract or agreement to which the Company is a party or by which it may be bound or affected, except for normal compensation for services
performed as employees, duly approved by the Board of Directors or shareholders of the Company in accordance with applicable Law. Except
as set forth in <U>Section 5.10 of the Schedule of Exceptions</U>, no employee, shareholder, officer, or director of the Company is indebted
to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them. Each related-party
transaction set forth in <U>Section 5.10 of the Schedule of Exceptions</U> was duly approved by the appropriate organ(s) of the Company
and is on arm&rsquo;s-length terms, and neither the Company nor any other party is in material breach or default thereunder. To the Company&rsquo;s
knowledge, none of the Company&rsquo;s directors, officers, employees, or service providers owns any material interest in any entity
that competes with the Company.
Except as set forth in the Current Articles, no shareholder of the Company (or any other party) has been granted veto or other consent
or special voting rights with respect to any action or resolution of the Company.</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Financial Statements; Indebtedness.</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.1.&nbsp;&nbsp;
A true copy of (i) the audited consolidated financial statements of the Company dated as of December 31, 2023 and (ii) the unaudited
but reviewed consolidated balance sheets, trial balance, and profit and loss accounts of the Company as of December 31, 2024, is attached
to <U>5.11 of the Schedule of Exceptions</U> (the &ldquo;<B>Financial Statements</B>&rdquo;). In addition, a list of each material payment
(exceeding US$ 20,000) which has been paid by the Company since December 31, 2024 (the &ldquo;<B>Financials Date</B>&rdquo;) is listed
separately in <U>Section 5.11 of the Schedule of Exceptions</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.2.&nbsp;&nbsp;
The Financial Statements have been prepared in accordance with generally accepted accounting principles in Israel (&ldquo;<B>GAAP</B>&rdquo;)
applied on a consistent basis throughout the periods indicated. The Financial Statements fairly present in all material respects the
financial condition and operating results of the Company as of the dates, and for the periods, indicated therein. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11.3.&nbsp;&nbsp;
As of the Closing, the Company has no material obligations, debts or liabilities, whether accrued, absolute or contingent, other than
the obligations, debts and liabilities (i) disclosed in the Financial Statements;(ii) disclosed in <U>Section 5.11.3 of the Schedule
of Exceptions</U>; or (iii) obligations incurred in the ordinary course of business since the date of the Financial Statements and not
individually or in the aggregate material. Without derogating from the generality of the foregoing: (i) the Company is not a guarantor
of any debt or obligation of another, nor has the Company given any indemnification, loan, security or otherwise agreed to become directly
or contingently liable for any obligation of any person, and no person has given any guarantee of, indemnity for, or security for, any
obligation of the Company; (ii) the Company does not have any debt for borrowed funds or pursuant to credit arrangements; and (iii) the
Company has not undertaken to make and is not a party to any agreement providing for, any carve-out mechanism, bonus arrangement or any
other obligation by the Company to make any payments to existing shareholders, service providers, employees or other third parties, in
connection with an M&amp;A Event or an IPO (as such terms are defined in the Amended Articles). Except as set forth in Section 5.11.3
of the Schedule of Exceptions, the Company has no monetary obligations, debts or liabilities, whether accrued, absolute or contingent
towards any of the Founders (as such term is defined in the Amended Articles).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Changes</U>. Since the Financials Date, there has not been, except as set forth in <U>Section 5.12 of the Schedule of Exceptions</U>:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.1.&nbsp;&nbsp;
Any Material Adverse Change; </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.2.&nbsp;&nbsp;
Any resignation or termination of any executive officer, key employee or group of employees of the Company; </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.3.&nbsp;&nbsp;
Any material damage, destruction or loss, whether or not covered by insurance, with respect to the properties and assets of the Company;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.4.&nbsp;&nbsp;
 Any waiver or compromise by the Company of a valuable right or of a material debt owed to it;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.5.&nbsp;&nbsp;
Any loans, advances or capital contributions made by the Company to any shareholder, employee, executive officer or director of the Company,
other than advances made in the ordinary course of business; </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.6.&nbsp;&nbsp;
Any material change in any compensation arrangement or agreement with any employee, executive officer, director or shareholder; </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.7.&nbsp;&nbsp;
Any declaration or payment of any dividend or other distribution of the assets of the Company;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.8.&nbsp;&nbsp;
Any labour organization activity related to the Company;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.9.&nbsp;&nbsp;
Any debt incurred, assumed or guaranteed by the Company, or any Lien incurred, created or assumed on any of the Company's assets or properties,
except those for immaterial amounts and for current liabilities incurred in the ordinary course of business;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.10.&nbsp;Any sale, mortgage, pledge, transfer, lease, license or other assignment of any Company Intellectual Property, except for licenses in
the ordinary course of business;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.11.&nbsp;The execution of any agreement that would be classified as a Material Agreement, or any material change to any Material Agreement or
to the Company's governing documents; </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.12.&nbsp;Any total or material partial loss of the business of any substantial or material customers or suppliers of the Company;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.13.&nbsp;Any sale, mortgage, pledge, transfer, lease or other assignment of any of its material tangible assets outside of the ordinary course
of business;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.14.&nbsp;Any change in the accounting methods used by the Company; or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12.15.&nbsp;Any arrangement or commitment by the Company to do any of the acts described in the foregoing list.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Real and Personal Property</U>. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.1.&nbsp;&nbsp;
<U>Real Property</U>. Except as set forth in <U>Section 5.13.1 of the Schedule of Exceptions</U>, the Company does not own or lease any
real property.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.2.&nbsp;&nbsp;
<U>Personal Property</U>. Except as set forth in <U>Section 5.13.2 of the Schedule of Exceptions</U>, the Company does not own or lease
any personal property.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13.3.&nbsp;&nbsp;
<U>Sufficiency and Condition of Property</U>. Except as set forth on <U>Section 5.13.3 of the Schedule of Exceptions</U>, the Company
owns, or otherwise has (and is in compliance with) the valid leasehold interest providing sufficient and legally enforceable rights to
use, all of the property and assets necessary or otherwise material to the conduct of its respective business as conducted immediately
prior to the date hereof and the Closing Date, free and clear of any Liens,
other than (i) statutory Liens for current taxes not yet due or payable or for future taxes or other governmental or regulatory assessments
which are not delinquent, and in each case, for which appropriate reserves have been maintained in accordance with IFRS; (ii) mechanic's,
carrier's, worker's, material man's, warehouse man's, supplier's, vendor's Liens; or (iii) similar statutory Liens arising or incurred
in the ordinary course of business with respect to liabilities that are not yet due and payable or being contested in good faith (collectively
&ldquo;<B>Permitted Liens</B>&rdquo;). Such property and assets are sufficient for the continued operation of the business of the Company
as currently conducted and as currently proposed by the Company to be conducted at the Closing. The Company has good and valid title
to all assets reflected on the Financial Statements, free and clear of all Liens. Except as set forth on <U>Section 5.13.3 of the Schedule
of Exceptions</U>, such assets are in good operating condition and repair, are suitable for their use and have been reasonably maintained
consistent with standards generally followed in the industry. No tangible asset owned by the Company is shared by the Company with any
other person and the Company does not depend upon or require for its business any tangible assets, facilities or services owned or supplied
by any related party.</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Intellectual Property</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.1.&nbsp;&nbsp;
<U>General</U>. The Company owns or has (as is in compliance with) the exclusive, irrevocable, unrestricted, worldwide, perpetual, and
(to the extent relevant) assignable right to use, pursuant to a written license, sublicense, or other agreement, free and clear of any
Lien, third-party rights, commissions, and royalties, all Intellectual Property currently used or necessary for the operation of the
business of the Company as presently conducted and as presently proposed to be conducted (collectively, &ldquo;<B>Company Intellectual
Property</B>&rdquo;). Except for readily and commercially available off-the-shelf software (acquired on standard terms), no other third-party
Intellectual Property of any kind is required by the Company to conduct its business, as presently conducted and as presently proposed
to be conducted. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.2.&nbsp;&nbsp;
<U>No Infringement</U>. (A) To its knowledge, the Company has not interfered with, infringed upon, misappropriated, or otherwise come
into conflict with any Intellectual Property rights of any third party, nor is the Company <U>aware of any facts or circumstances that
would reasonably be expected to cause </U>the conduct of its business (and the use of the Company Intellectual Property), as presently
conducted and as presently proposed to be conducted, to interfere with, infringe upon, misappropriate, or otherwise come into conflict
with any Intellectual Property rights of any third party; (B) the Company has never received any charge, complaint, claim, demand, or
notice alleging any such interference, infringement, misappropriation, or violation (including any claim that the Company must license
or refrain from using any Intellectual Property of any third party), and, to the Company&rsquo;s knowledge, there is no basis for any
such claim; (C) to the Company&rsquo;s knowledge, no third party has interfered with, infringed upon, misappropriated, or otherwise come
into conflict with any Company Intellectual Property; and (D) neither the Company nor, to the Company&rsquo;s knowledge, any officer,
director, employee, or consultant has received any communication alleging that the Company&rsquo;s use of the Company Intellectual Property,
or conduct of its business, violates any Intellectual Property rights of a third party.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.3.&nbsp;&nbsp;
<U>Ownership of IP</U>. <U>Section 5.14.3 of the Schedule of Exceptions</U> identifies each: (i) patent, trademark, copyright, domain
name, or registration which has been issued to the Company with respect to any of the Company Intellectual Property; (ii) pending patent,
trademark, or copyright application or application for registration which the Company has made
with respect to any of the Company Intellectual Property; (iii) trade name or unregistered trademark used by the Company; and (iv) license,
agreement, or other permission the Company has received from any third party with respect to any Intellectual Property (other than off-the-shelf
software), or granted to any third party with respect to any of the Company Intellectual Property. The Company has made available to
the Investor correct and complete copies of all such patents, copyrights, trademarks, registrations, applications, licenses, agreements,
and permissions (as amended to date) and has made available correct and complete copies of all other written documentation evidencing
ownership and prosecution (if applicable) of each such item. Except as set forth in <U>Section 5.14.3 of the Schedule of Exceptions</U>,
(i) the Company possesses all right, title, and interest in and to each item of Company Intellectual Property, free and clear of any
Security Interest, Lien, license, royalty, commission, or similar arrangement; (ii) no item of Company Intellectual Property is subject
to any outstanding injunction, judgment, order, decree, ruling, or charge; (iii) no action, suit, proceeding, hearing, investigation,
charge, complaint, claim, or demand is pending or, to the Company&rsquo;s knowledge, threatened in writing, that challenges in a material
manner the legality, validity, enforceability, use, or ownership of the Company Intellectual Property; (iv) the Company has not agreed
to indemnify any person for or against any interference, infringement, misappropriation, or other conflict with respect to any Company
Intellectual Property; and (v) the Company has not granted, and there are no outstanding, any options, licenses, or agreements of any
kind relating to the Company Intellectual Property, nor is the Company bound by or a party to any option, license, or agreement of any
kind with respect to any Company Intellectual Property.</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.4.&nbsp;&nbsp;
<U>Founders</U>. All Intellectual Property developed by each Founder prior to the incorporation of the Company and relating to the Company&rsquo;s
business (as conducted and as proposed to be conducted) (the &ldquo;<B>Founder IP</B>&rdquo;) was duly assigned by such Founder to the
Company at or following the Company&rsquo;s incorporation, free and clear of any Security Interest. To the Company&rsquo;s knowledge,
all declarations and documents required by the relevant authorities in order to register such assignments were duly submitted. Neither
the Founders nor, to the Company&rsquo;s knowledge, any other party has any interest in or rights to any of the Founder IP. <U>Section
5.14.4 of the Schedule of Exceptions</U> sets forth any concurrent employment or third-party consulting relationship the Founder had
during the period in which the Founder IP was developed; any such relationship did not result in any third-party claim to the Founder
IP.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.5.&nbsp;&nbsp;
<U>Service Providers</U>. All current and former Service Providers of the Company (including employees, consultants, contractors, and
similar) have expressly and irrevocably waived the right and/or any claim to receive compensation (in addition to the compensation paid
to them under their respective employment, service, or consulting agreements) in connection with &ldquo;Service Inventions&rdquo; under
Section 134 of the Israeli Patent Law of 1967, or any other similar provision under applicable Laws of any jurisdiction.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.6.&nbsp;&nbsp;
<U>Protection of IP Rights and Trade Secrets</U>. The Company takes all actions that are reasonable and customary in its industry to
maintain and protect each item of Company Intellectual Property. The Company has complied in all material respects with the requirements
of, and has filed all material documentation required by, all applicable patent and trademark offices (or equivalent authorities) in
which its patent or trademark applications were filed. All material confidential information of the Company (and all third-party confidential
information disclosed to the Company under a duty of confidentiality) is continuously maintained in confidence by the Company through
the use of reasonable precautions to protect and prevent its
disclosure to unauthorized parties. All payments due prior to the date of this Agreement to any authority for maintaining the effectiveness
or validity of such patents (or applications) have been fully and timely paid in the jurisdictions the Company has selected as necessary
to conduct its business as currently conducted.</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.7.&nbsp;&nbsp;
<U>Open Source Materials</U>. <U>Section 5.14.7 of the Schedule of Exceptions identifies open source software used by the Company. </U>The
Company has not embedded or used any open source, copyleft, or community-source code, or any code that is subject to a similar licensing
or distribution model (including libraries or code licensed under the General Public License (GPL), Lesser General Public License (LGPL),
or similar license arrangement) (&ldquo;<B>Open Source Materials</B>&rdquo;) in any of its products (whether generally available or in
development) in a manner that would: (i) require disclosure or distribution in source code form of any Company product; (ii) require
the licensing of any product of the Company for the purpose of making derivative works; (iii) impose any restriction on the consideration
to be charged for the distribution of any product of the Company; (iv) create, or purport to create, obligations for the Company with
respect to any of the Company Intellectual Property; or (v) impose any other material limitation, restriction, or condition on the Company&rsquo;s
right to use or distribute any Company Intellectual Property.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14.8.&nbsp;&nbsp;
<U>Government Funding</U>. Except as set forth in <U>Section 5.14.8 of the Schedule of Exceptions</U>, no Israeli or foreign government
funding (including from the Israel Innovation Authority), no facilities of an Israeli or foreign university or government-owned institution,
college, or other educational institution or research centre, and no funding from any third party were used in the development of any
Company Intellectual Property. To the Company&rsquo;s knowledge, no current or former employee, consultant, or independent contractor
of the Company who was involved in, or who contributed to, the creation or development of any Company Intellectual Property, has performed
services for or was an employee of any Governmental Entity or government-owned institution while also performing services for the Company
during the period in which such Company Intellectual Property was invented, created, or developed. The Company has not received any written
notice of a claim by any such entity or institution to any rights in the Company Intellectual Property. Neither the Company, any of the
Founders nor any of the Company employees or service providers have used facilities or resources of a university, college, other educational
institution, multinational, bi-national or international organization, research grants or research centre in the development of the Company
Intellectual Property.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Product
Warranty, Liability; Corrective Action</U>. Except as set forth in <U>Section 5.15 of the Schedule of Exceptions</U>, with respect
to any product sold, developed, manufactured, licensed, leased or delivered by the Company (collectively, the &ldquo;<B>Company
Products</B>&rdquo;) the Company provides no guaranty, warranty or other indemnity beyond the applicable terms and conditions of
sale granted by the Company in the ordinary course of business or beyond obligations under applicable Law. Except as set forth in <U>Section
5.15 of the Schedule of Exceptions</U>, (a)&nbsp;no third party (including any Governmental Entity or customer) has given written
notice to the Company that any Company Product is unsafe or fails to meet any product warranty or any standards promulgated by Law,
by any Governmental Entity or contract applicable to such customer, which claim resulted in a material liability to the Company, and
(b)&nbsp;the Company has no material liability arising out of any defect in, or breach of warranty with respect to, any Company
Products or arising out of any material product liability, damages or injury to individuals or property in connection with the
distribution, ownership, possession or
use of any Company Products. Except as set forth in <U>Section 5.15 of the Schedule of Exceptions</U>, each Company Product conforms
and has been in conformity, in each case, in all material respects, with the respective specifications for such Company Product, the
applicable contractual commitments with respect to such Company Product and the Laws applicable to such Company Product. Except as set
forth in <U>Section 5.15 of the Schedule of Exceptions</U>, no Company Product has been the subject of a recall, withdrawal, suspension,
seizure or discontinuance (other than for commercial or other business reasons not arising in connection with any actual or alleged defect
or violation of warranty, contract or applicable Law) by the Company (whether voluntarily or otherwise), and none of such actions are
under consideration by the Company with respect to any such products. Except as set forth in <U>Section 5.15 of the Schedule of Exceptions</U>,
the Company has not committed any act, and there has been no omission by the Company, that has resulted or, to the best knowledge of
the Company, would reasonably be expected to result, in any material product liability or material liability for breach of warranty (whether
covered by insurance or not) on the part of any of the Company, with respect to Company Products.</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Litigation</U>. There is no claim, suit, litigation, arbitration, mediation, proceeding, or investigation pending or, to the Company&rsquo;s
knowledge (including where there is written notice of a threat), threatened against the Company or any of its properties or assets or
against any officer, director, or key employee of the Company in his or her capacity as such (including, without limitation, (i) any
claim relating to alleged material defects in, or for the repair or replacement of, any of the Company Products or the failure of any
such Company Product to meet its specifications, applicable contractual commitments, or relevant Laws, and (ii) any claim involving the
prior employment of any of the Company&rsquo;s employees, their use in connection with the Company&rsquo;s business of any information
or techniques allegedly proprietary to a former employer, or their obligations under any agreement with a former employer), nor is there
any action or claim that questions the validity or would hinder the enforceability of this Agreement or any of the Ancillary Documents
or the transactions contemplated hereby or thereby. To the Company&rsquo;s knowledge, there is no event or condition on the basis of
which any such claim, suit, litigation, proceeding, or investigation might properly be instituted. The Company is not subject to the
provisions of any order, writ, injunction, judgment, or decree of any Governmental Entity, nor is there any action or suit by the Company
now pending or threatened against others, and the Company does not intend to initiate any such action or suit.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Tax</U>. The Company has filed or has obtained presently effective extensions with respect to all Israeli and foreign tax returns
which are required to be filed by it, such returns are complete and accurate and all taxes shown thereon to be due have been timely paid.
Income tax returns of the Company have not been audited by any tax authority. The Company has not made any elections under applicable
Laws (other than elections that related solely to methods of accounting, depreciation or amortization) that have an adverse effect on
the Company, its financial condition, its business as presently conducted or any of its properties or assets. The Company is not currently
liable for any tax (whether income tax, capital gains tax, or otherwise) that became due and was not duly paid.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B><U>Employees</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18.1.&nbsp;&nbsp;
<U>Section 5.18.1 of the Schedule of Exceptions</U> sets forth a list of (I) all current employees, consultants and independent contractors
of the Company, together with each such person's
position, initial date of engagement, salary, and any other compensation payable to such person (including, without limitation, compensation
payable pursuant to bonus, deferred compensation or commission arrangements), and (II) each contract, commitment, arrangement, whether
oral or written, relating to the employment of, or the performance of services by, any employee, consultant, or independent contractor.
The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any written or oral, express
or implied, contract, commitment or arrangement with any labour union, and no labour union has requested or sought to represent any of
the employees, representatives or agents of the Company. There is no strike or other labour dispute involving the Company pending, or
to the best of the Company's knowledge, threatened, nor is the Company aware of any labour organization activity involving their employees.
Except as set forth in <U>Section 5.18.1 of the Schedule of Exceptions</U>, the employment of each officer and employee of the Company
is terminable at the will of the Company, subject to a prior notice not exceeding 30 days, without any additional obligation or payment.
The Company has complied in all material respects with all applicable equal employment opportunity, health and safety, and other Laws,
policies, procedures and arrangements related to employment.</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18.2.&nbsp;&nbsp;
Notwithstanding the generality of the foregoing, (i) the engagement with the Company of all of the Company's employees is &ldquo;at will&rdquo;
subject to the termination notice provisions included in their employment agreements or applicable Law; (ii) the Company's obligations
to provide severance pay and pension to its employees under applicable Law are fully funded or accrued on the Financial Statements; (iii)
the Company has no knowledge of any circumstance that could give rise to any valid claim by a current or former employee for compensation
on termination of employment (beyond the statutory severance pay to which employees are entitled); (iv) all amounts that the Company
is legally or contractually required either to deduct, transfer, withhold or pay, from its employees' salaries have been duly deducted,
transferred, withheld and paid, and Company does not have any outstanding obligation to make any such deduction, transfer, withholding
or payment (including without limitation with respect to those employees engaged by the Company at any time as consultants or independent
contractors); and (v) the Company is in compliance in all material respects with all applicable legal requirements and contracts relating
to employment, employment practices, wages, bonuses and other compensation matters and terms and conditions of employment related to
its employees. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18.3.&nbsp;&nbsp;
The Company has made provision in the Financial Statements, and at all times since the dates thereof, in accordance with GAAP for its
employees on account of wages, severance pay, pension funds, redemption of annual leave or otherwise, whether required by Law or pursuant
to an agreement, with respect to the period until the date hereof. The Company is not subject to, nor do any of its employees benefit
from, any collective bargaining agreement, other than by way of any applicable employment Laws and extension orders (<I>tzavei harchava</I>)
applicable to companies in the Company's field of business or applicable to all employers in Israel.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18.4.&nbsp;&nbsp;
Other than the ESOP and standard payments for educational funds (<I>Keren Hishtalmut</I>), managers' insurance schemes and for pension
funds, the Company does not maintain or contribute to any employee benefit plan, pension plan, share option, bonus or incentive plan,
severance pay policy or agreement, deferred compensation agreement, or any similar plan or agreement.</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18.5.&nbsp;&nbsp;
 To the knowledge of the Company, no employee of the Company, nor any consultant with whom the Company has contracted, is in violation
of any term of any employment contract, proprietary information agreement or any other agreement relating to his engagement by the Company,
including but not limited to the right of any such individual to be employed by, or to contract with, the Company because of the nature
of the business conducted by the Company; and the continued employment by the Company of its present employees, and the performance of
the Company's contracts with its independent contractors, will not result in any such violation. The Company has not received notice
alleging that any such violation has occurred. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18.6.&nbsp;&nbsp;
No employee of the Company has been granted the right to continued employment by the Company or to any material compensation following
termination of employment with the Company. To the Company's best knowledge, no executive officer, key employee or group of employees
intends to terminate his, her or their employment with the Company. The Company does not have a present intention to terminate the employment
of any executive officer, key employee or group of employees. Other than as set forth on <U>Section 5.18.6 of the Schedule of Exceptions</U>,
each former key employee whose employment was terminated by the Company has entered into an agreement with the Company providing for
the full release of any claims against the Company or any related party arising out of such employment. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Permits</U>. Attached as <U>Section 5.19 of the Schedule of Exceptions</U> is a list of all of the franchises, permits, licenses,
regulatory approvals, and any similar authority necessary for the conduct of the Company&rsquo;s business as now being conducted and
as presently proposed to be conducted, the lack of which could adversely affect the business, properties, prospects or financial condition
of the Company (&ldquo;<B>Permits</B>&rdquo;). Except as set forth in <U>Section 5.19 of the Schedule of Exceptions</U>, the Company
has obtained all such Permits, has maintained them in full force and effect, and is not aware of any circumstances that could lead to
their rescindment. The Company is not in default under any such Permits.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Regulatory Matters</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20.1.&nbsp;&nbsp;
The Company has conducted all activities relating to the research, development, testing, manufacturing, labelling, storage, distribution,
marketing, and sale of Company Products in compliance in all material respects with all applicable Health Care Laws and the requirements
of any Governmental Entity (including the FDA)<B>,</B> the Israeli Ministry of Health, and any relevant European regulatory authority).
Neither the Company, nor, to the Company&rsquo;s knowledge, any third party acting on the Company&rsquo;s behalf, has received any written
notice, warning letter, untitled letter, inspectional observation, or other communication from any Governmental Entity or institutional
review board alleging a material lack of compliance with any Health Care Law or any Company Product registration, approval, authorization,
license, or other material permit required to exploit (meaning develop, manufacture, distribute, market, or sell) any Product (&ldquo;<B>Product
Registration</B>&rdquo;). Each Product Registration is valid, in full force and effect, and owned or controlled by the Company. There
is no information or event that the Company is aware of that, would reasonably be expected to lead any Governmental Entity to withdraw,
suspend, or materially limit any Product Registration. In this Agreement, <B>&ldquo;Health Care Laws&rdquo;</B> means all applicable
Laws, rules, regulations, and requirements (including those administered by the FDA, the Israeli Ministry of Health, European regulatory
authorities, or other Governmental Authorities) that govern or relate
to the development, manufacture, testing, labelling, marketing, sale, or reimbursement of products intended for human use, including
any applicable anti-kickback, fraud and abuse, privacy, data protection, clinical trial, good manufacturing practice, and product clearance
or approval Laws.</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20.2.&nbsp;&nbsp;
No Action (including any investigation, suit, or proceeding) is pending or, to the Company&rsquo;s knowledge, threatened against the
Company, or, to the Company&rsquo;s knowledge, any third party acting on the Company&rsquo;s behalf, relating to any actual or alleged
violation of any Health Care Law. The Company has not received any written communication indicating that any Company Product has been
or may be recalled, withdrawn, suspended, or discontinued (voluntarily or otherwise), nor is the Company subject to any outstanding order,
writ, injunction, judgment, or decree of any Governmental Entity relating to the Company Products. To the Company&rsquo;s knowledge,
none of the clinical investigators, contract research organizations, or other service providers involved in the development, manufacture,
or clinical testing of any Company Product has been disqualified, restricted, or otherwise sanctioned by the FDA, the Israeli Ministry
of Health, any European regulatory authority, or any other applicable Governmental Entity. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20.3.&nbsp;&nbsp;
All studies, tests and preclinical and clinical trials conducted by or on behalf of the Company were and, if still pending, are, in all
material respects, being conducted in accordance with experimental protocols, procedures and controls pursuant to accepted professional
scientific standards, applicable Laws for products or product candidates comparable to those being developed by the Company and all applicable
Laws and all franchises, grants, authorizations, licenses, permits, easements, consents, certificates and orders of any Governmental
Entity or self-regulatory body required for the conduct of such trials. The descriptions of, protocols for, and data and other results
of, the studies, tests, development, and trials conducted by or on behalf of the Company that have been furnished or made available to
the Investor are accurate and complete. The Company is not aware of any studies, tests, development or trials the results of which reasonably
call into question the results of the studies, tests, development and trials conducted by or on behalf of the Company, and the Company
has not received any notices or correspondence from any Governmental Entity or any institutional review board or comparable authority
requiring the termination, suspension or material modification of any studies, tests, preclinical development or clinical trials conducted
by or on behalf of the Company. The Company has not received any notices or correspondence from any Governmental Entity requiring the
termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of
the Company. <U>Section 5.20.3 of the Schedule of Exceptions</U> lists the clinical and pre-clinical studies conducted by the Company
prior to the date hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20.4.&nbsp;&nbsp;
The applications, notifications, submissions, data, and other information provided by or on behalf of the Company to any Governmental
Entity in connection with obtaining or maintaining Product Registrations were, at the time of submission, true, accurate, and complete
in all material respects and did not contain any material untrue statement or omit any material fact necessary to make the statements
made not misleading. Neither the Company, nor, to the Company&rsquo;s knowledge, any officer, director, employee, or agent of the Company,
has committed any act or made any statement that could reasonably be expected to result in criminal or civil liability or lead any Governmental
Entity to impose sanctions, exclusions, suspensions, debarments, or penalties related to any Health Care Law.</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20.5.&nbsp;&nbsp;
 The Company has made available to the Investor (a) true, correct, and complete copies of all material filings, correspondence, and communications
with any applicable Governmental Entity regarding the Products, (b) all material data, information, reports, protocols, and analyses
relating to the safety, efficacy, or regulatory status of the Products, and (c) its current development plans for the Products, including
any planned submissions to the FDA, Israeli Ministry of Health, EU regulatory bodies, or other Governmental Entities for Product Registrations.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Privacy and Data Protection</U>. In connection with its collection, storage, cross-border transfer, and use of any individually identifiable
information (&ldquo;<B>Personal Information</B>&rdquo;), including personal data under the Israeli Protection of Privacy Law, 1981, the
General Data Protection Regulation (Regulation (EU) 2016/679), the Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;),
and any other applicable privacy or data protection Laws, including Laws of any other jurisdictions in which the Company collects or
processes Personal Information (collectively, &ldquo;<B>Privacy Laws</B>&rdquo;), the Company has at all times taken the measures required
by, and is in compliance in all material respects with, the Privacy Laws, its own privacy policies, and any contractual requirements
binding on the Company. The Company has implemented and maintains reasonable and legally required physical, technical, organizational,
and administrative safeguards to protect Personal Information against loss, unauthorized access, misuse, or modification, including appropriate
written agreements with all vendors or data processors handling Personal Information on the Company&rsquo;s behalf. To the Company&rsquo;s
knowledge, no unauthorized access to, or other misuse of, Personal Information or the Company&rsquo;s information technology systems
has occurred, and the Company has not received any notice (nor is any action pending or, to its knowledge, threatened) from any Governmental
Entity or private party alleging noncompliance with any Privacy Law. The Company has complied with all applicable data breach notification
requirements, and any consents required under the Privacy Laws for the collection, processing, transfer, and other use of Personal Information
have been validly obtained. The Company has not sold or shared Personal Information in violation of any Privacy Law. To the Company&rsquo;s
knowledge, no event or condition exists that would reasonably be expected to require the Company to alter or cease any current or planned
use of Personal Information under any Privacy Law, nor does the Company have any contractual or legal obligations that prevent it from
collecting or using Personal Information in the manner it currently does or as contemplated in its business plans.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B><U>Anti-Corruption and Sanctions</U>. The Company is not engaging in any activity or conduct that would constitute an offense under
any ABC Laws or any Sanctions, and, unless permitted by the relevant Governmental Entity, has not conducted any business dealings with
a Sanctioned Party. The Company is itself not a Sanctioned Party and is not the subject of any pending or threatened investigation, inquiry,
or proceeding by any Governmental Entity concerning non-compliance with ABC Laws or Sanctions. The Company shall (i) comply fully with
all ABC Laws and Sanctions; (ii) not directly or indirectly pay, offer, promise, or authorize the provision of money or anything of value
to a Government Official, intending to influence that official to obtain or retain business or an improper advantage, or otherwise secure
unlawful personal gain; and (iii) unless permitted by the relevant Governmental Entity, refrain from conducting direct or indirect business
dealings with any Sanctioned Party or any party located in, organized within, or operating from a sanctioned country or territory. For
purposes of this Agreement, (a) &ldquo;<B>ABC Laws</B>&rdquo; includes anti-corruption and anti-bribery Laws such as the U.S. Foreign
Corrupt Practices Act of 1977, the U.K. Bribery Act 2010, and the applicable sections of
the Israeli Penal Law 1977, each as amended; (b) &ldquo;<B>Government Official</B>&rdquo; means an employee, officer, or representative
of, or anyone acting in an official capacity for, a Governmental Entity, political party, or supra-national organization; (c) &ldquo;<B>Sanctioned
Party</B>&rdquo; refers to any person who is subject to sanctions (including those on restricted-party lists maintained by the U.S.,
U.N., Switzerland, the EU, or the U.K.) or located in a comprehensively sanctioned country; and (d) &ldquo;<B>Sanctions</B>&rdquo; means
U.S. or other sanctions imposed by the U.S., the United Nations, Israel, the EU, or the U.K.</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Insurance</U>. <U>Section 5.23 of the Schedule of Exceptions</U> contains a list of all insurance policies issued to or for the benefit
of the Company, which policies contain coverage in amounts which to the Company's best knowledge are customary in the Company's industry
and are reasonable under the circumstances. All such policies are in full force and effect, and there is no claim by the Company pending
under any of such policies. All due premiums payable under all such policies have been paid; the Company is otherwise in compliance with
the terms and conditions of all such policies; and the Company is not aware of any circumstances reasonably likely to give rise to any
claim under any of such policies. The Company has not, to the best of its knowledge, taken any action, or omitted to take any action,
which would be reasonably likely to render any such insurance policy void or voidable. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governmental Funding, Programs, etc</U>. Except as set forth in <U>Section 5.24 of the Schedule of Exceptions</U>, the Company has
not received, and there are no outstanding applications for, any grants, incentives, benefits (including tax benefits) and subsidies
from any Governmental Entity or any agency thereof or any international or bilateral fund, institute or organization or public entities
or authorities, including, from the Investment Centre of the Ministry of Economy and Industry of the State of Israel or the National
Authority for Technological Innovation (previously known as the Office of the Chief Scientist of Israel&rsquo;s Ministry of Economy),
nor is the Company an &ldquo;approved enterprise&rdquo;, &ldquo;benefited enterprise&rdquo; or &ldquo;preferred enterprise&rdquo; within
the meaning of the Israeli Encouragement of Capital Investments Law, 1959. The Company was and is in compliance, in all material respects,
with the terms and conditions of any such grants or benefits. Except as set forth in <U>Section 5.24 of the Schedule of Exceptions</U>,
there are no outstanding obligations of the Company to make any payment or other royalties under such grants or benefits. Except as set
forth in <U>Section 5.24 of the Schedule of Exceptions</U>, no royalties, interest, or other payments are payable or will be payable
by the Company as a result of such grants or benefits, and the consummation of the transactions contemplated hereby will not affect the
continued qualification for such grants or benefits, the terms or duration thereof or require any reimbursement, repayment, refund or
cancellation of any previously claimed or received grants or benefits.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Registration Rights</U>. Except for the Investors' Rights Agreement as and from the Closing, the Company is not under any obligation
to register for trading on any securities exchange, any of its currently outstanding securities or any of its other securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Broker's Fees</U>. Other than as set forth in <U>Section 5.26 of the Schedule of Exceptions</U>, no agent, broker, investment banker,
person or firm acting on behalf of or under the authority of the Company is or will be entitled to any broker's or finder's fee or any
other commission directly or indirectly in connection with the transactions contemplated herein. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Directors and Office Holders</U>. The directors of the Company immediately following the Closing shall be as set forth in <B><U>Exhibit
D</U></B>, attached hereto. Other than as set forth in
<U>Section 5.26 of the Schedule of Exceptions,</U> each officer of the Company is currently devoting one hundred percent (100%) of his
or her business time to the conduct of the business of the Company. To the Company's knowledge, no officer of the Company is planning
to work less than full-time at the Company in the future.</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Disclosure</U>. The Company's representations and warranties made or contained in this Agreement, when considered in conjunction with
the disclosures expressly included in the Schedule of Exceptions, do not contain any untrue statement of a material fact and do not omit
to state a material fact required to be stated therein or necessary in order prevent any such representation or warranty from being misleading
in light of the circumstances in which they were made or delivered. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Representations and Warranties of the Investor</U></B>. The Investor hereby represents and warrants to the Company that as of the
date hereof, as of the Closing, and acknowledges that the Company is entering into this Agreement in reliance thereon:</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.
<U>Requisite Power and Authority</U>. The Investor is duly organized and validly existing under the Laws of the State of Israel and has
all necessary power and authority to execute and deliver this Agreement and the Ancillary Documents to which it is a party and to carry
out their provisions. Upon their execution and delivery, this Agreement and the Ancillary Documents to which such Investor is a party
will be valid and binding obligations of Investor, enforceable in accordance with their respective terms, except (a)&nbsp;as limited
by applicable bankruptcy, insolvency, reorganization, moratorium or other Laws of general application affecting enforcement of creditors'
rights and (b)&nbsp;as limited by general principles of equity that restrict the availability of equitable remedies.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.
<U>Investment Experience</U>. The Investor is an investor in securities of companies in the development stage and acknowledges that it
can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable
of evaluating the merits and risks of the investment in the Company.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.
<U>No Registration</U>. The Investor acknowledges that none of the securities which it is acquiring hereunder have been registered on
any stock exchange or under the securities Laws of any jurisdiction.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.
<U>Brokers</U>. No agent, broker, investment banker, person or firm acting in a similar capacity on behalf of or under the authority
of the Investor is or will be entitled to any brokerage or finders&rsquo; fees or agents&rsquo; commissions or any similar fee, directly
or indirectly, in connection herewith.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.
<U>No Public Market</U>. The Investor understands that no public market now exists for its shares purchased hereunder and these have
not been registered under the U.S. Securities Act of 1933, as amended or the rules or regulations promulgated thereunder (the &ldquo;<B>Securities
Act</B>&rdquo;), and that the Company has made no assurances that a public market will ever exist for the shares purchased hereunder.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6.
<U>Full Access to Information</U>. Without derogating from the Investor&rsquo;s reliance on the Company&rsquo;s representations and warranties
under Section 5 above, and without limiting the scope thereof, the Investor has had opportunity to inquire and receive information relating
to the
Company and it has had an opportunity to ask questions and receive answers from the Company regarding the business, properties, prospects
and financial condition of the Company in order to evaluate the financial risk inherent in making the investment hereunder, and deciding
whether to purchase its shares.</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<B><U>Reserved.]</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Default</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.
<U>Repayment upon an Event of Default</U>. The Loan Amount shall become due and immediately repayable by the Company in full to the Investor,
upon the first to occur of the following events (each, an &ldquo;<B>Event of Default</B>&rdquo;), unless waived in writing by the Investor:
(i) the execution by the Company of a general assignment for the benefit of creditors; (ii) the filing by or against the Company of any
petition in bankruptcy or liquidation proceedings of the Company or any petition for relief under the provisions of any Law for the relief
of debtors, and the continuation of such petition without dismissal for a period of forty-five (45) days or more; (iii) the appointment
of a receiver, a trustee or a special manager to take possession of a portion of the property or assets of the Company and the continuation
of such appointment without dismissal for a period of forty-five (45) days or more; (iv) the commencement by the Company of any liquidation
proceedings, or the adoption of a winding up resolution by the Company, or the calling by the Company of a meeting of creditors for the
purpose of entering into a scheme or arrangement with them or any resolution in favour of any of the foregoing by the Board of Directors
or shareholders of the Company; or (v) the cessation of conduct of all or substantially all of the Company&rsquo;s business affairs for
a consecutive period of more than sixty (60) days.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.
<U>Notice.</U> The Company undertakes to notify the Investor in writing promptly and in any case no later than within two working days,
upon becoming aware of the occurrence of any Event of Default.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Post-Closing
                                            Covenants</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.&#8239;
<U>Survival of Representations and Warranties; Indemnification</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.1.&nbsp;&nbsp;&nbsp;&nbsp;
Each representation and warranty herein is deemed to be made on the date of this Agreement and at the Closing and shall survive and remain
in full force and effect after the Closing; provided however, that the survival of all representations and warranties of the Company
shall be limited to a period ending upon the earlier of (i) lapse of 3 (three) years from the Closing or (ii) the closing of a Deemed
Liquidation event (including without limitation, through an exercise of the Call Option); and provided further, however, that notwithstanding
the aforesaid, the survival of those representations and warranties contained in <U>Section &#8206;5.1</U> (Organization), <U>Section
&#8206;5.3</U> (Authorization and Approvals Related to the Transaction; No Breach), <U>Section &#8206;5.6</U> (Capitalization), <U>Section
&#8206;5.14</U> (Intellectual Property), <U>Section &#8206;5.17</U> (Tax), <U>Section &#8206;5.20</U> (Regulatory Matters) and <U>Section
&#8206;5.21</U> (Privacy and Data Protection) shall survive for a period of 5 (five) years from the Closing (in each case, a &ldquo;<B>Survival
Period</B>&rdquo;). </FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.2.&nbsp;&nbsp;&nbsp;&nbsp;
 The Company hereby agrees to hold harmless and indemnify the Investor and its executive officers, directors, employees, shareholders,
agents and representatives (together with the Investor, the &ldquo;<B>Indemnitees</B>&rdquo;, and each an &ldquo;<B>Indemnitee</B>&rdquo;)
against any and all damages, liabilities, losses, costs and expenses (including reasonable attorneys' fees and expenses), whether or
not arising out of third-party claims (<B>&ldquo;Losses&rdquo;</B>), based upon, or arising out of, or relating to, (i) any breach by
the Company of any representation or warranty or other statement contained in this Agreement which occurs within the applicable Survival
Period (&ldquo;<B>Representation Indemnifiable Claims</B>&rdquo;), or (ii) any breach of any covenant or agreement contained in this
Agreement, and which, if reasonably susceptible to being cured, remains uncured for 30 days following receipt of written notice thereof
(&ldquo;<B>Covenant Indemnifiable Claims</B>&rdquo;; and collectively with Representation Indemnifiable Claims, &ldquo;<B>Company Indemnifiable
Claims</B>&rdquo;); provided that, with respect to Company Indemnifiable Claims, in no event shall the Company be liable for any indirect,
consequential, punitive, or special damages, including loss of profits or loss of business opportunities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In the event that an Indemnitee shall sustain or incur any Losses in respect of which indemnification may be sought by it pursuant hereto,
such Indemnitee shall assert a claim for indemnification (a &ldquo;<B>Claim</B>&rdquo;) by giving written notice thereof, which shall
describe in reasonable detail the facts and circumstances upon which the asserted claim for indemnification is based, to the Company
and shall thereafter keep the Company reasonably informed with respect thereto; <I>provided</I>, that a failure of the Indemnitee to
give the Company prompt notice as provided herein shall not relieve the Company of any of its obligations hereunder, except in the case
where the Company, is actually and materially prejudiced by such failure, in which case, the Company will be relieved from its indemnification
obligations hereunder but only to the extent of the damages caused to it due to such failure. In connection with a third-party claim,
the Company shall promptly assume the defense of the Claim with counsel reasonably satisfactory to the Indemnitee, and the fees and expenses
of such counsel shall be borne by the Company. The Indemnitee will cooperate with the Company in the defense of any Claim for which the
Company assumes the defense, at the Company&rsquo;s reasonable cost and expense. In the event that counsel retained by the Company to
defend a Claim also represents the Company in any other matter giving rise to a conflict of interest with respect to such Claim, the
Indemnitee shall have the right to select separate counsel to assume the defense, and the fees and expenses of such separate counsel
shall be borne by the Company. In any event, the Indemnitee shall have the right to participate in the defense of any third-party Claim
with counsel of its choosing at its own expense. The Company will not agree, without the consent of the Indemnitee (which shall not be
unreasonably withheld, conditioned or delayed), to any settlement that (i) includes any admission of fault or wrongdoing by the Indemnitee,
or (ii) imposes any non-monetary obligations or restrictions on the Indemnitee, or (iii) would result in a monetary liability to the
Indemnitee.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.4.&nbsp;&nbsp;&nbsp;&nbsp;
The monetary amount of the indemnification hereunder shall be limited to the aggregate outstanding principal actually advanced by
the Investor under the Initial Principal Amount, the Second Principal Amount and any portion of the Third Investment Amount funded
as of the date of the applicable Claim less any amount of damages previously paid to the Indemnitee by the Company under this
indemnity clause, and any amount of the Initial Principal Amount or Second Principal Amount previously repaid to the Investor;
provided, however, that any such repayments shall not reduce the monetary cap applicable to indemnification for Losses arising from
the defence of Third Party Claims. No claim or claims shall be brought unless the aggregate amount of such claim exceeds fifty
thousand U.S. Dollars ($50,000),
provided that in case of a claim in excess of the aforesaid threshold, the claim can be submitted for the entire amount of such loss.
Subject to <U>Section &#8206;9.2</U> below, the indemnification provided by the Company pursuant to this <U>Section &#8206;9.1</U> shall
be the exclusive remedy available to the Indemnitees against the Company in connection with any Company Indemnifiable Claim, except in
the case of gross negligence or fraudulent, bad faith, or wilful misrepresentation or breach (in which cases the limitations under this
<U>Section &#8206;9.1.4</U> shall not apply). Notwithstanding the foregoing or anything else in this Section 9, the Investor shall be
entitled to specific performance of any of the covenants, obligations, or undertakings of the Company under this Agreement and to such
other injunction or other equitable relief as may be granted by a court of competent jurisdiction.</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.5.&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding anything to the contrary herein, no Indemnitee shall be entitled to recover from the Company more than once for the same
Loss, even if such Loss gives rise to more than one claim for indemnification under this Agreement or involves more than one Indemnitee.
For the avoidance of doubt, separate and distinct Losses incurred by different Indemnitees (even if arising from the same Company Indemnifiable
Claim) shall each be recoverable by the respective Indemnitee.&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.
<U>Capitalization Adjustments</U>. If at any time following the Closing, the Capitalization Table is found to have been not reflective
of all the issued and outstanding share capital of the Company as of the Closing on a Fully-diluted Basis, then at the Investor&rsquo;s
election (in lieu of indemnification remedy under Section 9.1 above), the Company shall issue to the Investor upon conversion of the
Principal Amount (and contingent thereon), or thereafter if such discovery is made after the conversion, the number of additional Conversion
Shares, for no additional consideration, that would have been required in order for the Investor to maintain its shareholding percentage
in the Company on a fully-diluted basis as of the Closing, as set forth in the Capitalization Table, and the Capitalization Table shall
be updated accordingly. This provision shall expire upon the earlier of: (i) the lapse of the applicable statute of limitations, and
(ii) immediately prior to the consummation of a Deemed Liquidation event (including without limitation, through an exercise of the Call
Option).</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.
<U>Evidence of Filing &ndash; Share Issuances</U>. The Company shall file with the Israeli Registrar of Companies the Amended Articles
and the issuance of the Special Share immediately following the Closing. All notices that were to be filed with the Israeli Registrar
of Companies according to applicable Law in connection with this Agreement shall be immediately filed following the Closing and each
Subsequent Closing subject to receipt from the Investor of the data and documents required for such filings.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.
<U>Data Protection Officer</U>. Within 60 days following the Closing the Company agrees to seek external counsel advice with respect
to the necessary to appoint a data protection officer and to comply with such advice.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.
&#8239;&#8239;<U>Governing Law</U>. This Agreement shall be governed, construed and interpreted in accordance with the Laws of the State of Israel,
without giving effect to principles of conflicts of Law or choice of Law that would cause the substantive Laws of any other jurisdiction
to apply.</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.&#8239;&nbsp; <U>Jurisdiction</U>. The competent courts in Jerusalem shall have sole and exclusive jurisdiction over all matters relating to this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.&nbsp;&#8239;
<U>Amendment and Waiver</U>. Any provision of this Agreement may be amended and the observance thereof may be waived (either generally
or in a particular instance and either retroactively or prospectively), only (a) by the written consent of the Company and the Investor;
or (b) in the case of a waiver only, by the written consent of the Investor or the Company, as applicable. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.&#8239;
&#8239;<U>Entire Agreement</U>. This Agreement (including the preamble hereof), the Exhibits and Schedules hereto, and the other Ancillary Documents
constitute the entire agreement among the Parties relative to the specific subject matter hereof and thereof. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.&nbsp;&#8239;
<U>Notices</U>. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a)&nbsp;upon
personal delivery to the party to be notified; (b)&nbsp;when sent by email with confirmation of transmission if sent during normal business
hours of the recipient, if not, then on the next business day; (c)&nbsp;ten (10) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (d)&nbsp;two business days after deposit with an internationally-recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent out as set forth below:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; padding-right: -1.95pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</FONT></TD>
    <TD STYLE="width: 78%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neurolief
    Ltd.</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12
    Giborei Israel, Netanya, Israel, 4250412</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Chief Executive Officer</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    scott.drees@neurolief.com</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy (which shall not constitute service of process) to:</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amit,
    Polak, Matalon &amp; Co.</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18
    Raoul Wallenberg St.</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building
    D</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6th
    floor<BR>
    Tel Aviv 6971915</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    James Raanan, Adv.</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    jamesr@apm.law</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BrainsWay
    Ltd______________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16
    Hartum St, Har Hotzvim, Jerusalem 9777516, Israel</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
    +972-2-5812517</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Menachem C. Klein. Esq.,</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP,
    General Counsel and Corporate Secretary Office</FONT></P>
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    MKlein@brainsway.com</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; padding-right: -1.95pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    a copy (which shall not constitute service of process) to:</FONT></TD>
    <TD STYLE="width: 78%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S.
    Friedman, Abramson &amp;Co______________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azrieli
    Town, 146 Menachem Begin Road, Tel Aviv, Israel</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
    +972-3-6931930</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Sarit Molcho and Simon Synett__________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
    saritm@sfa.law;simons@sfa.law___________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6.&nbsp;
&#8239;<U>Severability</U>. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement,
which shall remain enforceable, to the fullest extent permitted by Law. Furthermore, to the fullest extent possible, the provisions of
this Agreement (including, without limitation, the portion of this Agreement containing any provision held to be invalid, illegal or
unenforceable that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested
by the provision held invalid, illegal or unenforceable. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.&#8239;&nbsp;
<U>Expenses</U>. Each Party shall pay all costs and expenses that it incurs with respect to this Agreement; provided however that, the
Company shall pay to the Investor (or its designee), subject to and upon the consummation of the Closing, the legal and accounting fees
and other expenses in respect of the due diligence process and execution and closing of this transaction as incurred by the Investor,
in an aggregate amount not to exceed $35,000 plus (ii) VAT on such amount. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8.&#8239;&#8239;&nbsp;<U>Counterparts</U>. This Agreement may be executed in two or more counterparts (including counterparts transmitted by electronic mail
in PDF format), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9.&nbsp;&#8239;&#8239;<U>Successors and Assigns</U>. The provisions hereof shall inure to the benefit of, and be binding upon, the successors and assigns of
the parties hereto. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations, or&nbsp;liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement. None of the rights, privileges, or obligations set forth in, arising under, or created
by this Agreement may be assigned by the Investor or transferred without the prior consent in writing of the Company, with the exceptions
of permitted assignments contemplated in Section 12.10 of the Call Option Agreement which shall apply mutatis mutandis. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10.&#8239;<U>Titles and Subtitles</U>. The titles of the sections and subsections of this Agreement are for convenience of reference only and are
not to be considered in construing this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11.
<U>Further Assurances</U>. Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably
be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.
Without derogating from the generality of the foregoing, in the event of a readjustment of the Investor&rsquo;s Pro Rata Portion (as
defined in the Call Option Agreement and in connection with the exercise of the Call Option), the term Fully Diluted (and hence the Conversion
Price and the Third Investment PPS) will be adjusted accordingly, and the Parties agree to take such actions as are necessary to ensure
that the Investor will hold the correct number of shares in connection therewith, or to otherwise modify contractually modify the Investor&rsquo;s
Pro Rata Portion accordingly. </FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</I></B></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[EXECUTION
PAGE TO INVESTMENT AGREEMENT]</I></B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Investment Agreement as of the date set forth in the first paragraph hereof.</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0 0 0 77.25pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neurolief
    Ltd.</B></FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name: ____________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brainsway
    Ltd.</B></FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name: ____________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 11.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 2pt; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 2pt; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>exh_993.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit
99.3</B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0pt 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>CALL
OPTION AGREEMENT</B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>THIS
CALL OPTION AGREEMENT</B> (the <B>&ldquo;Agreement&rdquo;</B>) is made and entered into this 18th day of August, 2025 by and among BrainsWay
Ltd., an Israeli public company (the <B>&ldquo;Buyer&rdquo;</B> or the <B>&ldquo;Investor&rdquo;</B>), Neurolief Ltd., a company organized
under the laws of the State of Israel (the &ldquo;<B>Company</B>&rdquo;), and the persons listed in <B><U>Schedule A</U></B> hereto,
as may be amended and/or supplemented from time to time in accordance herewith (the <B>&ldquo;Grantors&rdquo; </B>or the <B>&ldquo;Sellers&rdquo;)
</B>and Behir Sabban, Adv. as the Sellers&rsquo; Representative, and together with the Grantors, the Company and the Buyer, the <B>&ldquo;Parties&rdquo;</B>
and each, a <B>&ldquo;Party&rdquo;</B>).</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: 0.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>RECITALS</U></B>:</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: 0.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>WHEREAS</B>,<B>&#9;</B>
concurrently with the execution of this Agreement, the Investor and the Company have entered into that certain Investment Agreement dated
as of even date herewith (the <B>&ldquo;Investment Agreement&rdquo;</B>), providing for funding of the Company by the Buyer, in an aggregate
amount of up to $16M, to be extended in up to three installments, all subject to the terms and conditions of the Investment Agreement.
All Capitalized Terms not otherwise defined herein shall have the meaning ascribed to them in the Investment Agreement;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>WHEREAS</B>,
&#9;as a material inducement for the Investor&rsquo;s undertakings pursuant to the Investment Agreement, the Investor wishes to be granted
an option to acquire all (100%) of the outstanding equity interests in the Company (not held by the Investor or its Affiliates), and
the Sellers agree to grant the same to the Investor, all subject to the terms and conditions of this Agreement;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; color: Black"><B>NOW,
THEREFORE</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">, the Parties, intending
to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>The
                                            Call Option</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Grant of Option</U>. Subject to the terms and conditions of this Agreement, effective upon the consummation of the Closing of the
Investment Agreement (and contingent thereupon) (the &ldquo;<B>Call Option Commencement Date</B>&rdquo;), the Grantors hereby grant to
the Investor an option during the Call Option Period (as defined below) (the &ldquo;<B>Call Option</B>&rdquo;) to purchase all of the
Option Purchased Securities (as defined below), free and clear of any Encumbrances (&ldquo;<B>Free and Clear</B>&rdquo;). <B>&ldquo;Encumbrances&rdquo;</B>
means any mortgage, pledge, lien, charge, option, right of first refusal, right of first offer, pre-emptive right, security interest,
encumbrance, claim, restriction (including any restriction on the right to vote, sell, or otherwise transfer a security), or other third-party
right, whether arising under the Amended Articles, by agreement, by operation of law or otherwise.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Right to Exercise</U>. The Call Option may be exercised at any time, commencing as of the Call Option Commencement Date and up to
and including the Call Option Termination Date (as defined below) (the &ldquo;<B>Call Option Period</B>&rdquo;); provided that, if the
Call Option is not exercised before the Call Option Pause Date, the Investor shall not be entitled to exercise the Call Option during
the Call Option Non-Exercise Period (except pursuant to Article 143 of the Amended Articles, if applicable). Upon the expiration of the
Non-Exercise Period, the Investor may exercise the Call Option at any time until and including the Call Option Termination Date. &ldquo;<B>Call
Option Pause Date</B>&rdquo; means the date that is twelve (12) months following the Second Closing under the Investment Agreement; &ldquo;<B>Call
Option Non-Exercise Period</B>&rdquo; means the period commencing on the Call Option Pause Date and ending on the second anniversary
thereof; and &ldquo;<B>Call Option Expiry Date</B>&rdquo; means the date that is six (6) months following the lapse of the Call Option
Non-Exercise Period. In the event that an Exercise Notice is not delivered in accordance with the terms hereof on or prior to the <FONT STYLE="line-height: 115%">Call
Option Termination Date, this Agreement shall terminate and have no further force or effect, and none of the parties shall have any rights,
liabilities or obligations hereunder. For the avoidance of doubt, as long as an Exercise Notice is duly delivered in accordance with
the terms hereof prior to 12:00 AM (Israel time) on the Call Option Pause Date or prior to 11:59 PM and 59 seconds (Israel time) of the
Call Option Termination Date (as applicable), the Option Closing may occur after such date(s) in accordance with Section 2 below; and,
wherever reference is made in this Agreement to exercise of the Call Option by a particular date, such exercise shall be deemed to occur
upon delivery of an Exercise Notice in accordance with the terms hereof.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="line-height: 115%">&nbsp;</FONT></FONT></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 0pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise Price</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Certain
Defined Terms</U>. In this Agreement, the capitalized terms below shall have the meaning ascribed to them (even if defined in the investment
agreement):</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Adjustment Escrow Amount</B>&rdquo; <B></B>shall mean as set forth in Section 3A below.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Affiliate</B>&rdquo; of a specified Person means a Person that directly or indirectly through one or more intermediaries, controls
or is controlled by, or is under common control with, the Person specified. The term &ldquo;control&rdquo; means the holding, directly
or indirectly, of more than 50% of the equity and voting power of a Person or the right to appoint a majority of its board of directors
or other equivalent body shall be considered &ldquo;control&rdquo;. The terms &ldquo;controlling&rdquo; and &ldquo;controlled by&rdquo;
have correlative meanings to the foregoing.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Amit Dar Bonus</B>&rdquo; means the Exit Success Bonus payable to Amit Dar pursuant to his Amendment to Employment Agreement
with the Company dated May 4, 2023.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Baseline Options and Warrants</B>&rdquo; means (i) options granted or reserved for grant to the Company&rsquo;s employees,
consultants and advisors to purchase 2,095,580 shares of nominal value NIS0.01 of the Company, (ii) warrants to purchase 41,489 1 Preferred
A-1 Shares of nominal value NIS0.01 of the Company, and (iii) warrants to purchase 35,647 Preferred B-1 Shares, 1,078,825 Preferred
B Shares, and 1,492,963 Preferred B-4 Shares, all of nominal value NIS0.01 of the Company; all deemed to be outstanding under the Baseline
Pre-money Capitalization.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Baseline Pre-money Capitalization</B>&rdquo; <B></B>means the Company&rsquo;s issued and outstanding share capital on a fully
diluted basis as set forth in the Capitalization Table as of the immediately prior to the Closing (as defined in the Investment Agreement).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Business Day</B>&rdquo; <B></B>means any day other than a Friday, Saturday or official public holiday in Israel or a day on
which banks in Israel are authorized or required by law to be closed.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Capitalization Table</B>&rdquo; means the Capitalization Table set forth in the Investment Agreement (it being clarified that
such Capitalization Table includes a proforma of the investment of the entire Principal Amount and Third Investment Amount (as defined
therein), and to the extent different amounts are invested by Investor, then the Capitalization Table shall be adjusted accordingly.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Carveout Bonus Payments</B>&rdquo; means those bonus payments approved under the bonus plan (the &ldquo;<B>2025 Bonus Plan</B>&rdquo;)
by the board of directors of the Company on or around July 21, 2025, as the <I>&ldquo;Exit Carveout&rdquo;</I>, to be made to employees
of the Company on the Option Closing Date (but not including those bonuses referenced in the 2025 Bonus Plan and defined below as Company
Milestone Bonuses).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Company&rsquo;s Equity Value</B>&rdquo; means (i) the Company&rsquo;s Enterprise Value (as defined below), minus (ii) Aggregate
Debt (as defined below) and plus Aggregate Cash (as defined below), calculated as of the Option Closing Date in accordance with this
Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.10.&nbsp;&nbsp;
&ldquo;<B>Company Exit Bonuses</B>&rdquo; <B></B>means the aggregate of the Carveout Bonus Payments and the Amit Dar Bonus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.11.&nbsp;&nbsp;
&ldquo;<B>Company Milestone Bonuses</B>&rdquo; <B></B>means the bonus payments payable on the Option Closing Date to employees pursuant
to the 2025 Bonus Plan in respect of achievement of certain milestones, which payments may only be made from freely available cash held
by the Company (and, with respect to the portion of such bonuses payable on the Option Closing, the cash held by the Company as of immediately
prior to the Option Closing); provided, that in the event that the Company has insufficient available cash to satisfy the Company Milestone
Bonuses, any resulting shortfall in such payments shall not be payable at all and the Company shall have no outstanding obligations in
connection therewith.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.12.&nbsp;&nbsp;
 &ldquo;<B>Company Options</B>&rdquo; shall mean all issued and outstanding options, whether vested or unvested, to acquire shares of
the Company, as of the Option Closing Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.13.&nbsp;&nbsp;
&ldquo;<B>Governmental Authority</B>&rdquo; means the government of any nation, state, city, locality or other political subdivision
of any of them or any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to
any government.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.14.<B>&nbsp;&nbsp;
</B>&ldquo;<B>Investor Participation Amount</B>&rdquo; <B></B>means an amount representing Investor&rsquo;s participation in Company Exit
Bonuses, equal to the lower of $1,000,000 and 25% of the Company Exit Bonuses.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.15.&nbsp;&nbsp;
&ldquo;<B>Investor&rsquo;s Pro Rata Portion</B>&rdquo; means the amount equal to the product of (i) the Company&rsquo;s Equity Value,
multiplied by (ii) the percentage of Shares held by the Investor (including by any of its Affiliates) (as set forth in the Capitalization
Table), on a Fully Diluted As-Converted Basis as of the Option Closing Date; provided, however, that for purposes of calculating the
Fully Diluted As-Converted Basis: (i) all convertible loans, SAFEs, and any other convertible notes then outstanding and that are convertible/exercisable
pursuant to their terms, shall be taken into account, as if exercised or converted, and (ii) outstanding options and warrants that are
not Vested Company Options or Vested Warrants, immediately prior to the Option Closing and therefore expire pursuant to the provision
of Section &#8206;1.3.6 below for no consideration, shall be disregarded and deemed not to have been issued (&ldquo;<B>Fully Diluted
As-Converted Basis</B>&rdquo;). Without derogating from the foregoing, the number of Shares held by the Investor at the Option Closing
for the purpose of determining the Investor&rsquo;s Pro Rata Portion, shall also be subject to readjustment (if required) as follows:
upon expiration, cancellation or termination of any unexercised Baseline Options and Warrants which were originally included in the Baseline
Pre-money Capitalization, for purposes of determining the applicable Conversion Price, the Third Investment PPS and the number of Conversion
Shares and Third Investment Shares (all such capitalized terms as defined in the Investment Agreement) issued based thereon, shall be
deemed readjusted to reflect the result that would have been obtained had such unexercised Baseline Options and Warrants never been part
of the Baseline Pre-money Capitalization (an example of which is attached as <U>Exhibit E</U> hereto).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.16.&nbsp;&nbsp;
&ldquo;<B>Minimum Call Option EV</B>&rdquo; <B></B>means the First Minimum Call Option EV or Second Minimum Call Option EV (each as defined
below).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.17.&nbsp;&nbsp;
&ldquo;<B>Non-Signing Shareholders</B>&rdquo; <B></B>means shareholders of the Company that have not signed this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.18.&nbsp;&nbsp;
&ldquo;<B>Non-Signing Shareholders&rsquo; Pro Rata Portion</B>&rdquo; means the amount equal to the product of (i) the Company&rsquo;s
Equity Value, multiplied by (ii) the percentage of Shares held, on a Fully Diluted As-Converted Basis as of immediately prior to the
Option Closing, by those shareholders of the Company whose Shares are not transferred to the Investor at the Option Closing in accordance
with Section &#8206;5.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.19.&nbsp;&nbsp;
&ldquo;<B>Option Purchased Securities</B>&rdquo; means (i) all Shares (as defined in the Amended Articles, as may be amended from time
to time (including any future type of shares created or authorized by the Option Closing Date) (the &ldquo;<B>Shares</B>&rdquo;), including,
for the avoidance of doubt, Preferred Shares, and all warrants that are vested and in-the-money as of the Option Closing, in each case
held directly or indirectly by the Grantors or their respective Permitted Transferees (as defined in the Amended Articles), whether currently
held or acquired prior to the Option Closing, (ii) any Vested Company Options, and (iii) the Shares of any Non-Signing Shareholders which
are transferred pursuant to effectuation of the provisions of Section 5 below.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.20.&nbsp;&nbsp;
&ldquo;<B>Company&rsquo;s Enterprise Value</B>&rdquo; means the agreed enterprise value of the Company, as determined below:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.20.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
                                            the Call Option is exercised at any time prior to the Call Option Pause Date, the greater
                                            of: (A) USD 65,000,000 (the &ldquo;<B>First Minimum Call Option EV</B>&rdquo;) or (B) 4.5
                                            times the Determining Revenues (as defined below).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.20.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
                                            the Call Option is exercised at any time following the expiration of the Non-Exercise Period,
                                            the greater of: (A) USD 90,000,000 (the &ldquo;<B>Second Minimum Call Option EV</B>&rdquo;)
                                            or (B) 4.5 times the Determining Revenues.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.21.&nbsp;&nbsp;
&ldquo;<B>Consideration Recipients</B>&rdquo; shall mean the Sellers (and if and as applicable, the Non-Signing Shareholders whose Shares
are transferred to the Investor and the holders of Vested Company Options and Vested Warrants (each of the Consideration Recipients shall
be referred to individually as a &ldquo;<B>Consideration Recipient</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.22.&nbsp;&nbsp;
&ldquo;<B>Consideration</B>&rdquo; shall mean the Exercise Price whether paid entirely in cash or partially in cash and partially in
the form of Equity Consideration pursuant to the provisions of this Agreement,</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.23.&nbsp;&nbsp;
&ldquo;<B>Determining Revenues</B>&rdquo; means the Company&rsquo;s annualized revenues on a trailing six-month basis as reflected in
the Company&rsquo;s reviewed financial statements prepared in accordance with GAAP (defined below) for the six (6) most recent calendar
months immediately preceding the exercise of the Call Option.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.24.&nbsp;&nbsp;
&ldquo;<B>Aggregate Debt</B>&rdquo; means, as of and including the Option Closing Date, the sum (without duplication) of (i) all indebtedness
for borrowed money of the Company or any of its subsidiaries (including, for the avoidance of doubt, outstanding principal, accrued interest,
and any prepayment penalties or premiums), (ii) all amounts owed by the Company or any of its subsidiaries under capital lease obligations,
(iii) any drawn amounts under lines of credit or similar facilities of the Company or any of its subsidiaries, (iv) all unpaid dividends
declared and not paid to the shareholders prior to the Option Closing, (iv) all obligations of the Company or any of its subsidiaries
under interest rate, currency, or commodity hedging or derivative contracts (to the extent such contracts are out-of-the-money to the
Company or any of its subsidiaries), and (v) any other indebtedness of the Company or any of its subsidiaries evidenced by notes, bonds,
debentures, or similar instruments. For avoidance of doubt (i) any financing provided to the Company by means of convertible loans, SAFEs
or other convertible debt securities, by the Company&rsquo;s shareholders and/or any of their affiliates, which remains outstanding and
not converted immediately prior to the Option Closing, shall be considered as indebtedness for purpose of the definition of Aggregate
Debt.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.25.&nbsp;&nbsp;
&ldquo;<B>Aggregate Cash</B>&rdquo; means, as of and including the Option Closing Date, the aggregate amount of unrestricted and freely
available cash and cash equivalents held by the Company and its subsidiaries (excluding any restricted cash, pledged accounts, or amounts
subject to third-party claims, liens, or other Encumbrances).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.26.&nbsp;&nbsp;
&ldquo;<B>Paying Agent</B>&rdquo; means ESOP Management &amp; Trust Services Ltd.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.27.&nbsp;&nbsp;
&ldquo;<B>Paying Agent &amp; Escrow Agreement</B>&rdquo; means the agreement by and among the Buyer, the Representative and the Paying
Agent, in customary form to be finalized by the Investor, the Representative and the Paying Agent within 90 days of the Closing (or two
separate agreements to the extent required by the Paying Agent).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.28.&nbsp;&nbsp;
&ldquo;<B>Payment Schedule</B>&rdquo; means the payment schedule to be delivered by the Company to the Buyer at least 3 Business days
prior to the Option Closing, setting forth the name of each Seller, the number of Shares held thereby, the portion of the Exercise Price
payable at the Option Closing presented in US dollars payable to each Consideration Recipient, the contribution of each Consideration
Recipient to the Adjustment Escrow Amount and to the Representative Expense Amount, and if applicable, the distribution of the Equity
Consideration and the allocation and recipients thereof, and the amount of the Net Debt/Cash Position. The payment Schedule shall be
certified by the Company&rsquo;s CFO as true and correct.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.29.&nbsp;&nbsp;
&ldquo;<B>Person</B>&rdquo; means any individual, corporation, partnership, limited liability company, limited liability partnership,
firm, joint venture, association, joint stock company, trust, unincorporated organization, Governmental Authority or other entity.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.30.<B>&nbsp;&nbsp;
</B>&ldquo;<B>Net Debt/Cash Position</B>&rdquo; means the net balance of the Aggregate Debt and Aggregate Cash.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.31.&nbsp;&nbsp;
&ldquo;<B>Representative Expense Amount</B>&rdquo; shall mean an amount to be deducted from the Call Option Exercise Price, as determined
by the Majority Sellers and the Representative and deposited with the Representative to be used for expenses as set forth in the Payment
Schedule.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.32.&nbsp;&nbsp;
&ldquo;<B>Section 102 Option</B>&rdquo; means any Company Option that was granted pursuant to Section 102 of the ITO.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.33.&nbsp;&nbsp;
<B>&ldquo;Section&nbsp;102 Shares</B>&rdquo; means any Ordinary Shares of Company issued upon exercise of a Section&nbsp;102 Option.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.34.&nbsp;&nbsp;
&ldquo;<B>Section 102 Trustee</B>&rdquo; shall mean a trustee appointed by the Company and approved by the ITA to act as a trustee for
the purposes of Section 102 of the ITO (&ldquo;<B>Section 102</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.35.&nbsp;&nbsp;
&ldquo;<B>Vested Company Option</B>&rdquo; means any Company Option (or portion thereof) that (i) is not an Unvested Company Option,
(ii) is &ldquo;in-the-money&rdquo; as of immediately prior to the Option Closing and that (iii) the holder thereof signed a joinder to
this Agreement in the form attached as <U>Exhibit A</U> (the &ldquo;<B>Optionee/ Warrantholder Joinder</B>&rdquo;), or with respect to
holders of Vested Company Options, alternatively, to the extent any such holders do not sign the Optionee Joinder, then a pre-requisite
condition for such holder to receive its respective Consideration would include the delivery of the Optionee Joinder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.36.&nbsp;&nbsp;
&ldquo;<B>Unvested Company Option</B>&rdquo; shall mean any Company Option (or portion thereof) that is unvested as of immediately prior
to the Option Closing and does not vest at the Option Closing (including, for the avoidance of doubt, through acceleration by its terms
as of the Option Closing) as well as vested Company Options that are not &ldquo;in the money&rdquo; as of the Option Closing Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.1.37.&nbsp;&nbsp;
&ldquo;<B>ITO</B>&rdquo; <B></B>shall mean the Israeli Income Tax Ordinance and any regulations and decrees promulgated pursuant thereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Call Option Exercise Price</U>. The Call Option purchase price for the Option Purchased Securities (the &ldquo;<B>Exercise Price</B>&rdquo;)
shall be equal to (i) the Company&rsquo;s Equity Value, minus (ii) the Investor&rsquo;s Pro Rata Portion, plus (iii) the Investor Participation
Amount, and further minus, if applicable (iv) the Non-Signing Shareholders&rsquo; Pro Rata Portion, and shall be subject to further adjustment
in accordance with Section &#8206;2 below.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Partial Payment in Shares</U>. The Investor may elect in the Exercise Notice (as defined below) to satisfy up to twenty-five percent
(25%) of the Exercise Price through the issuance to the Grantors of newly issued, publicly traded ordinary shares of the Investor (the
&ldquo;<B>Equity Consideration</B>&rdquo;), provided that: (i) the aggregate value of such consideration in kind does not exceed ten
percent (10%) of the Investor&rsquo;s total market capitalization at the time of issuance<I>; </I>(ii) the value of the Investor&rsquo;s
ordinary shares shall be determined based on the volume-weighted average closing price (VWAP) over the thirty (30) trading days immediately
preceding the Option Closing Date (as defined below); (iii) the ADSs representing the ordinary shares of the Investor are listed and
actively traded on the Nasdaq Global Market, with an average daily trading volume of at least 60,500 ADSs over the thirty (30) trading
days preceding the Option Closing Date; and (iv) the Investor remains in compliance with all applicable Nasdaq listing requirements and
is not subject to any delisting procedures or material compliance at the time of issuance. Any payment made by means of Equity Consideration
shall be subject to Buyer&rsquo;s compliance with Section 7.8 and 11.1 hereof. To the extent that the Exercise Price includes Equity
Consideration, the allocation of the Exercise Price by means of cash and Equity Consideration between the Consideration Recipients shall
be determined as set forth in the Payment Schedule.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Manner of Exercise</U>. The Call Option may be exercised by the Investor only once, and only with respect to all (and not less than
all) of the Option Purchased Securities by delivering written irrevocable notice to such effect to the Representative (with a copy to
the Company (who shall forward the Exercise Notice to all Sellers)) (the &ldquo;<B>Exercise Notice</B>&rdquo;). If the Investor elects
to make a partial payment in shares pursuant to Section &#8206;1.3.3, the Exercise Notice shall include such election and set forth the
number of shares to be issued and the calculation used to determine such amount.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Treatment of outstanding Company Options and Warrants</U></B>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;
<U>Treatment of Warrants</U>. Immediately prior to the Option Closing, each outstanding Warrant that is (i) vested (including, for the
avoidance of doubt, through acceleration by its terms as of the Option Closing) (ii) is &ldquo;in-the-money&rdquo; and (iii) the holder
thereof has signed the Optionee/ Warrantholder Joinder (&ldquo;<B>Vested Warrants</B>&rdquo;), shall be exercised whether by paying the
exercise price of each such Warrant, by each holder thereof or by cashless exercise, such that such Warrants shall be terminated and
cancelled as of the Option Closing,
and, in exchange of such exercise and/or cashless exercise, each holder thereof shall be entitled to receive, a portion of the Consideration
hereunder equal to the amount set forth opposite such holder of Vested Warrants&rsquo; name in the Payment Schedule as further detailed
in this Agreement. <FONT STYLE="line-height: 115%">Each outstanding Warrant that is not a Vested Warrant immediately prior to the Option
Closing, shall be terminated and extinguished as of immediately prior to the Option Closing and contingent thereupon.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;
Treatment of Vested Company Options. The Company shall cause each Vested Company Option, immediately prior to the Option Closing, to
be exercised into ordinary shares of the Company, whether by paying the exercise price of each such Vested Company Option, by each holder
thereof or by cashless exercise, such that that the then outstanding Vested Options shall be terminated and cancelled as of the Option
Closing, and, in consideration of such exercise and/or cashless exercise, each holder thereof shall be entitled to receive, a portion
of the Consideration hereunder equal to the amount set forth opposite such holder of Vested Company Options&rsquo; name in the Payment
Schedule as further detailed in this Agreement.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;
Treatment of Unvested Company Options. Company shall take all action necessary to cause all Unvested Company Options and the Company&rsquo;s
current existing share incentive plan to be terminated and cancelled at the Option Closing.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)&nbsp;&nbsp;
Notwithstanding anything to the contrary, any Consideration payable hereunder shall be transferred by the Buyer, at the Option Closing
to the Paying Agent who shall act with respect to the Consideration in accordance with the provisions of the Paying Agent. Without derogation
from the generality of the above, it is agreed that the Consideration (if any) payable upon the exercise of a Vested Company Option granted
under Section 102 or in respect of a share held by the Section 102 Trustee following the exercise of a Vested Company Option granted
under Section 102 shall be delivered in accordance with the Israeli Options Tax Ruling, to the Section 102 Trustee and held in trust
by the Section 102 Trustee pursuant to the applicable provisions of Section 102 and the Israeli Options Tax Ruling. Such Consideration
shall be released by the Section 102 Trustee, in accordance with applicable law, the Israeli Options Tax Ruling, and the trust documents
governing the trust held by the Section 102 Trustee.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Withholding</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each of the Investor, Investor&rsquo;s agent, including the Paying Agent (each, a &ldquo;<B>Payor</B>&rdquo;) shall be entitled to deduct
and withhold from the Consideration if applicable, such amounts as it is required to deduct and withhold with respect to the payment
of such Consideration under the Income Tax Ordinance (New Version), 5721&ndash;1961 at the applicable rate for such withholding. To the
extent any amounts were so deducted or withheld, such withheld amounts shall be timely remitted by the relevant Payor, to the applicable
Governmental Authority and the Payor shall promptly provide the applicable payment recipient a written confirmation of the payment details
and the amount so withheld as well as any other reasonable evidence of said withholding.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding the foregoing, with respect to Israeli Tax, if the Paying Agent provides the Investor with an undertaking prior to
the Option Closing Date as required under Section 6.2.4.3 of the Income Tax Circular 19/2018 (Transaction for Sale of Rights in a
Corporation that includes Consideration that will be transferred to the Seller at Future Dates), any consideration paid pursuant to
this Agreement on the Option Closing Date shall be retained by the Paying Agent for a period of up to 180 days from the Option
Closing Date (or, with respect to any other payment of Consideration payable or otherwise deliverable following the Option Closing
Date, for a period of 90 days following such payment or delivery date), or a shorter period of time if requested in writing by a
Person in respect of such Person&rsquo;s portion of the Consideration) (respectively, the &ldquo;<B>Withholding Drop
Date</B>&rdquo;), during which time the Paying Agent shall not withhold any Israeli Tax on such Consideration paid except as
provided below, and during which time such Person may obtain a Valid Certificate regarding the deduction or withholding of Israeli
Tax from any Consideration paid to such Person hereunder. If such Person delivers a Valid Certificate (as defined below) to the
Paying Agent no later than three (3) Business Days prior to the Withholding Drop Date, the deduction and withholding of any Israeli
Taxes shall be made in accordance with the provisions of such Valid Certificate and the balance of the payment that is not withheld
shall be paid to such Person. If a Person (i) does not provide the Investor or the Paying Agent with a Valid Certificate by no later
than three (3) Business Days before the Withholding Drop Date or (ii) submits a written request to the Investor or the Paying Agent
to release its portion of the Consideration paid to the Paying Agent pursuant to this Agreement prior to the Withholding Drop Date
and fails to submit a Valid Certificate at or before such time, then the amount of Israeli Tax to be withheld from such
Person&rsquo;s portion of the consideration paid pursuant to this Agreement shall be calculated according to the applicable
withholding rate as reasonably determined by the Paying Agent in accordance with the Income Tax Ordinance which amount shall be
calculated in NIS based on the US:NIS exchange rate known on the date the payment is actually made to such recipient. The amount so
withheld shall be timely delivered or caused to be delivered to the ITA by the Paying Agent, and the Paying Agent shall promptly pay
to any such Person the balance of the payment due to such Person that is not so withheld (and, for the avoidance of doubt, in the
case of subclause (ii), the Consideration shall be released to such Person promptly following the receipt of such request without
the need to wait until the lapse of the 180 days (or 90 days from any later payment date)). To the extent that amounts are so
withheld by the Paying Agent, the Paying Agent shall provide the applicable Person with formal documentation evidencing such
withholding and payment.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A &ldquo;<B>Valid Certificate</B>&rdquo; shall mean a valid and applicable certificate or ruling issued by the Israeli Tax Authority
(the <B>&ldquo;ITA&rdquo;</B>) stating that no withholding (or reduced withholding) of Israeli Tax is required with respect to such Person,
or providing for other instructions regarding the payment due to such Person. The Parties agree that, a valid certificate of exemption
from withholding pursuant to Israeli Income Tax Regulations (Withholding from Payments for Services or Assets), 5737-1977, issued by
the ITA will be deemed a Valid Certificate, provided that such certificate shall not be valid for transfers outside Israel or for payments
not made in cash. The parties further agree that the Israeli Options Tax Ruling, the Interim Options Tax Ruling and the 104H Tax Ruling
shall be deemed a Valid Certificate. For the avoidance of doubt, if a Valid Certificate was not obtained, the Payor, when a payment of
the Consideration is made shall withhold tax in accordance with the withholding tax rates stipulated in the Israeli Income Tax Regulations
(Withholding from Payments for Services or Assets), 5737-1977.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In the event that any Payor receives a written demand from the ITA to withhold any amount out of the amount in respect of any Person
hereunder and transfer it to the ITA, the Payor (i) shall notify such Person of such matter promptly after receipt of such written demand,
and provide such payee with reasonable time (but in no event less than 14 days unless otherwise required by the ITA or any applicable
Tax Law) to attempt to delay such requirement or extend the period for complying with such requirement as evidenced by a written certificate,
ruling or confirmation from the ITA, and (ii) to the extent that any such certificate, ruling or confirmation is not timely provided
by such Person to the Investor and the relevant Payor, transfer to the ITA any amount so demanded, including any interest, indexation
and fines required by the ITA in respect thereof, and such amounts shall be treated for all purposes of this Agreement as having been
delivered and paid to such Person and the Payor shall timely provide the Person with a written confirmation of such tax withholding.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.6.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Israeli Tax Rulings</U>. The Parties shall work together and cooperate in good faith so to take such actions, if and as required by
the Representative (on behalf of Grantors) so to minimize tax implications for the Grantors. In furtherance of the foregoing, the Parties
contemplate that as soon as reasonably practicable following delivery by Buyer of an Exercise Notice, Buyer and the Company shall jointly
instruct their respective Israeli counsels to prepare and file with the ITA an application for the following tax rulings, all as and
if required by the Company and/or the Representative (on behalf of Grantors):</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;
If the Option Purchased Securities include any Section 102 Options and/or Section 102 Shares, and the mandatory holding period therefor
pursuant to Section 102 has not elapsed with respect to some, or all of the Section 102 Options and/or Section 102 Shares, a ruling that
confirms that payment of the Exercise Price in consideration therefor: (i) shall not result in an immediate taxable event for the Person
entitled to such options and shares, (ii) shall be taxed at capital gains rates or any other preferential tax rate, as may be agreed
with the ITA, and, if applicable (iii) shall not affect the length of the holding period required with respect to such options and shares
under the Section 102, which ruling may be subject to such terms regularly associated with such ruling (the &ldquo;<B>Israeli Options
Tax Ruling</B>&rdquo;), and/or an interim tax ruling from the ITA (if applicable) confirming, among other things, that the Investor and
anyone acting on its behalf shall be exempt from Israeli withholding Tax in relation to any payments made to the Paying Agent, Section
102 Trustee and/or anyone on their behalf (&quot;Interim Options Tax Ruling&quot;); Notwithstanding anything to the contrary herein,
in the event that such Israeli Options Tax Ruling and/or Interim Options Tax Ruling are obtained, Israeli Tax withholding with respect
to holders of Section 102 Options and/or Section 102 Shares shall be as determined in the Israeli Options Tax Ruling, or the Options
Interim Tax Ruling, as applicable; and </FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;
If the Exercise Price includes payment by means of Equity Consideration, then at the request of any Sellers, to be delivered through
the Representative, the Company, through its legal and accounting representatives will approach the ITA with an application for a ruling
(the &ldquo;<B>104H Tax Ruling</B>&rdquo;) permitting any such Seller, who elects to become a party to such a tax ruling (each, an &ldquo;<B>Electing
Holder</B>&rdquo;), to defer any applicable Israeli Tax with respect to any Equity Consideration that such Electing Holder will receive
pursuant to this Agreement until the date set forth in Section 104H of the Israel Tax Ordinance. Buyer shall reasonably cooperate with
the Company, the Electing Holders and their Israeli counsel with respect to the preparation and filing of such application and in the
preparation of any written or oral submissions that may be necessary, proper or advisable to obtain the 104H Tax Ruling; provided that
the 104H Tax Ruling shall not impose any material restrictions or obligations other than restrictions applicable under the Israel Tax
Ordinance, on Buyer, or the Company without the written consent of Buyer (such consent not to be unreasonably withheld, conditioned or
delayed).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company shall use commercially reasonable efforts to promptly take, or cause to be taken, all actions and to do, or cause
to be done, all things necessary, proper or advisable under applicable law to obtain the 104H Tax Ruling, as promptly as practicable.
For the avoidance of doubt, the Electing Holders, the Company and its and their respective legal and accounting representatives shall
not make any application to the ITA with respect to any matter relating to the 104H Tax Ruling, without granting Buyer&rsquo;s Israel
legal counsel the opportunity to review, comment on and approve the draft application in advance (which approval shall not be unreasonably
withheld, delayed or conditioned), and the Electing Holders, the Company and its and their respective legal and accounting representatives
will inform Buyer&rsquo;s Israel legal counsel in advance of the content of, and enable Buyer&rsquo;s Israel legal counsel to participate
in, all material discussions and meetings with the ITA relating thereto. To the extent that Buyer&rsquo;s Israel legal counsel elects
not to participate in any such meeting or discussion, the Electing Holders, the Company and its and their respective legal and accounting
representatives shall provide Buyer&rsquo;s Israel legal counsel with an update of the discussions or meetings held with the ITA. The
text of the applications for, filing relating to, and the final text of the 104H Tax Ruling, shall be subject to the prior written confirmation
of Buyer or its Israel legal counsel, not to be unreasonably withheld, conditioned or delayed. Notwithstanding anything to the contrary
in this Agreement, if the 104H Tax Ruling shall be received and delivered to the Paying Agent prior to the applicable withholding date,
and no later than five Business Days prior to the Withholding Drop Date, in form and substance reasonably acceptable to Buyer, then the
provisions of the 104H Tax Ruling, shall apply and all applicable withholding procedures with respect to any Electing Holders shall be
made in accordance with Section 104H of the Israel Tax Ordinance, and the provisions of the 104H Tax Ruling . All expenses related to
the issuance of the 104H Ruling shall be borne by the Company.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Option
                                            Closing.</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Option Closing</U>. Subject to the satisfaction (or waiver, to the extent permissible) of the conditions to closing set forth herein,
the consummation of the purchase and sale of the Option Purchased Securities (the &ldquo;<B>Option Closing</B>&rdquo;) shall take place
remotely via the electronic exchange of documents and signatures, on the date set forth in the Exercise Notice, which shall be no later
than thirty (30) Business Days following delivery of the Exercise Notice (the &ldquo;<B>Option Closing Date</B>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Transactions at the Option Closing.</U> At the Option Closing, and subject to the terms and conditions of this Agreement, the following
transactions shall take place simultaneously, and no transaction shall be deemed to have occurred until all such transactions have been
completed:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Investor (or its Affiliate, on its behalf) shall deliver by wire transfer of immediately available funds to the Paying Agent for
further distribution to the Consideration Recipients in accordance with the Payment Schedule and the Paying Agent &amp; Escrow Agreement:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if the entire Exercise Price is to be paid in cash, an amount in cash equal to the Exercise Price (determined in accordance with the
Estimated Closing Statement, as defined below) less the Adjustment Escrow Amount; or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if the Investor elects partial payment in Equity Consideration pursuant to Section &#8206;1.3.3, ninety seven and one half percent (97.5%)
of the cash portion of the Exercise Price, together with ninety seven and one half percent (97.5%) of the shares comprising the Equity
Consideration;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pursuant to Sections 2.2.2 and 2.2.3 the Investor (or its Affiliate, on its behalf) shall deliver to the Paying Agent:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 if the entire Exercise Price is to be paid in cash, an amount in cash equal to the Adjustment Escrow Amount by wire transfer of immediately
available funds; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if the Investor elects partial payment in Equity Consideration pursuant to Section &#8206;1.3.3, two and one half percent (2.5%) of the
cash portion of the Exercise Price, and 2.5% of the shares comprising the Equity Consideration (the <B>&ldquo;Deposited Shares&rdquo;</B>),
into the Adjustment Escrow Account established pursuant to the Paying Agent &amp; Escrow Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Investor shall deliver to the Representative and the Paying Agent, a copy of the Paying Agent &amp; Escrow Agreement duly executed
by the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Sellers and/or the Company, as applicable, shall deliver to the Investor:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
an updated shareholder register of the Company, in the form attached hereto as <U>Exhibit B</U> evidencing that the Investor is the sole
registered holder of all issued and outstanding Shares of the Company (other than the Shares of the Non-Signing Shareholders which are
not transferred to the Investor at the Option Closing, if any) as of immediately following the Option Closing Date;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
duly executed share transfer deeds from each Grantor in favor of the Investor, in the form attached hereto as <U>Exhibit C</U> together
with corresponding share certificates (to the extent certificated), or affidavit of lost share certificate, and any other documents reasonably
required to effect the legal and beneficial transfer of the Option Purchased Securities, Free and Clear;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
a copy of the Paying Agent &amp; Escrow Agreement duly executed by the Sellers; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
written resignations (or, where applicable, evidence of removal in accordance with the Amended Articles) of each director of the Company
who was not nominated by the Investor, effective as of the Option Closing, in the form attached hereto as <U>Exhibit D</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 46.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="line-height: 115%"><B><U>Adjustment to Exercise Price</U></B></FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Estimated Closing Statement</U>. No later than five (5) Business Days prior to the Option Closing Date, the Company shall deliver
to the Investor a written statement (the &ldquo;<B>Estimated Closing Statement</B>&rdquo;), setting forth the Company&rsquo;s good-faith
estimates of (i) the Determining Revenues, (ii) the Net Debt/Cash Position, (iii) the Company Exit Bonuses, in each case calculated as
of the Option Closing Date and in accordance with the definitions set forth in this Agreement, and (iv) the resulting calculation of
the Exercise Price to be paid at the Option Closing. The Estimated Closing Statement shall be prepared in accordance with US generally
acceptable accounting principles, using the same accounting principles, practices, procedures, and policies used to prepare the Company&rsquo;s
annual audited financial statements last published prior to the date of the Exercise Notice (the <B>&ldquo;Accounting Principles&rdquo;
</B>or <B>&ldquo;GAAP&rdquo;</B>). In the event the Company believes that the Company Enterprise Value would not be greater than the
applicable Minimum Call Option EV it shall so notify the Investor, and in such event, the Company shall not be required to provide a
calculation of Determining Revenues, and the Determining Revenues shall not be subject to further review or reference by any Party, including
in connection with any Draft Closing Statement or any Objection Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Determination of Final Closing Statement</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As soon as reasonably practicable and no later than 90 days after the Option Closing Date (the &ldquo;<B>Draft Closing Statement
Deadline</B>&rdquo;), the Investor shall deliver to the Representative a written statement (the &ldquo;<B>Draft Closing
Statement</B>&rdquo;) setting forth Buyer&rsquo;s calculation of (i) the actual Determining Revenues (if relevant) and Net Debt/Cash
Position as of the Option Closing Date, and (ii) the resulting calculation of the Adjusted Exercise Price, or an acceptance
statement of the Estimated Closing Statement (the &ldquo;<B>Buyer Acceptance Statement</B>&rdquo;). The Closing Statement shall be
prepared in accordance with definitions used herein and the Accounting Principles.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Review and Objections</U>. Promptly upon delivery of the Draft Closing Statement, the Investor shall provide the Representative and
its representatives with reasonable access to the working papers and supporting materials used in its preparation and applicable personnel
of the Company. The Representative shall have 30 Business Days following receipt of the Draft Closing Statement (the &ldquo;<B>Examination
Period</B>&rdquo;) to review and either accept the Draft Closing Statement (the &ldquo;<B>Acceptance Notice</B>&rdquo;) or deliver to
the Investor a written notice of objections (an &ldquo;<B>Objection Notice</B>&rdquo;) describing in reasonable detail the items disputed
and the grounds for such dispute. Failure to deliver an Objection Notice within the Examination Period shall constitute the Representative&rsquo;s
acceptance of the Draft Closing Statement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Resolution of Disputes</U>. If an Objection Notice is timely delivered, the Investor and the Representative shall attempt in good
faith to resolve the disputed items. If they are unable to resolve all disputed items within fifteen (15) Business Days following delivery
of the Objection Notice, either Party may refer the remaining unresolved items (and only those) set forth in the Objection Notice (the
&ldquo;<B>Unresolved Objections</B>&rdquo;) to one of the Big Four accounting firms in Israel or such other independent accounting firm,
as agreed between the Investor and the Representative (the &ldquo;<B>Independent Accountant</B>&rdquo;). Each of Buyer and the Representative
shall promptly, but in no event later than twenty (20) Business Days following the referral of the Unresolved Objections to the Independent
Accountant, prepare a written statement describing their respective positions with respect to the Unresolved Objections, which, together
with the relevant documents, will be submitted to the Independent Accountant for review and final determination (&ldquo;<B>Written Statement</B>&rdquo;).
Following submission of any Unresolved Objections to the Independent Accountant, Buyer and the Representative shall furnish the Independent
Accountant with such information and documents as the Independent Accountant may reasonably request in order to resolve the Unresolved
Objections. For the avoidance of doubt, the review of the Independent Accountant will be limited to the Unresolved Objections. The Independent
Accountant shall determine its calculation of the Unresolved Objections in accordance with the definitions set forth in this Agreement
and the Accounting Principles and may not deviate from the positions taken by each party&rsquo;s Written Statement. Within ten (10) days
after the date of receipt of the last Written Statement, the Independent Accountant shall make a determination as to the resolution of
the Unresolved Objections and shall issue a written ruling of such resolution, which shall include an illustration of all adjustments
(which for the avoidance of doubt shall only be related to the Unresolved Objections) to the Draft Closing Statement based on any resolutions
to objections agreed upon by Buyer and the Representative and pursuant to the Independent Accountant&rsquo;s resolution of the Unresolved
Objections. The Independent Accountant shall make a determination only as to the Unresolved Objections and shall not decide any specific
items not under dispute and its determination as to the Unresolved Objections shall be within the range of values assigned to each such
disputed item in the Draft Closing Statement and the Objection Notice, respectively.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Independent Accountant shall act as an expert (not an arbitrator), shall be instructed to resolve only those matters in dispute
in accordance with GAAP and the principles set forth herein, and shall render its decision as promptly as practicable. The Final
Closing Statement shall be conclusive, non-appealable and binding upon Buyer and the Representative, absent manifest error or
fraud. Buyer and the Representative agree that the procedure set forth in this <U>Section <FONT STYLE="line-height: 115%">&#8206;3.2</FONT></U><FONT STYLE="line-height: 115%">
for resolving disputes with respect to the Draft Closing Statement shall be the sole and exclusive method for resolving such
disputes and the Final Closing Statement will be final, conclusive and binding on the parties; <I>provided</I>, that this provision
shall not prohibit either Buyer or the Representative from instituting litigation to enforce the ruling of the Independent
Accountant.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="line-height: 115%">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The fees, costs and expenses of the Independent Accountant shall be allocated to and borne by Buyer and the Representative, on behalf
of the Consideration Recipients, based on the inverse of the percentage that the Independent Accountant&rsquo;s determination (before
such allocation)&nbsp;bears to the total amount of the total Unresolved Objections originally submitted to the Independent Accountant.
For example, should the Unresolved Objections total $1,000 and the Independent Accountant awards $600 in favor of the Representative&rsquo;s
position, sixty percent (60%) of the costs of its review would be borne by Buyer and forty percent (40%) of the costs would be borne
by the Representative (on behalf of Consideration Recipients).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Final Adjustment and Payments</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
                                            the Adjusted Exercise Price, as determined in the Final Closing Statement (as defined below),
                                            exceeds the Closing Purchase Price (as defined below), the Investor shall, no later than
                                            seven (7) Business Days following the final determination of the Adjusted Exercise Price:
                                            (i) promptly instruct the Paying Agent to release and disburse the Adjustment Escrow Amount
                                            (including the Deposited Shares, if any) to the Consideration Recipients in accordance with
                                            the allocation provided in the Payment Schedule and subject to the provisions of the Paying
                                            Agent &amp; Escrow Agreement, and (ii) pay to the Paying Agent by wire transfer of immediately
                                            available funds the amount of such excess for further distribution to the Consideration Recipients
                                            in accordance with the allocation provided in the Payment Schedule and subject to the provisions
                                            of the Paying Agent &amp; Escrow Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
                                            the Adjusted Exercise Price is less than the Closing Purchase Price, then: (A) to the extent
                                            the difference is less than or equal to the Adjustment Escrow Amount, the Representative
                                            shall promptly instruct the Paying Agent to disburse to the Investor an amount equal to such
                                            difference (which shall be allocated ratably between the respective cash and Deposited Shares
                                            comprising the Adjustment Escrow Amount), and to release any remaining balance of the Adjustment
                                            Escrow Amount and the Deposited Shares (if any) to the Consideration Recipients in accordance
                                            with the allocation provided in the Payment Schedule and subject to the provisions of the
                                            Paying Agent &amp; Escrow Agreement; and (b) to the extent the difference exceeds the Adjustment
                                            Escrow Amount, the Representative shall promptly instruct the Paying Agent to release the
                                            entire Adjustment Escrow Amount and the Deposited Shares (if any) to the Investor or in accordance
                                            with its instructions, and the Consideration Recipients shall, severally and not jointly,
                                            each in accordance with its pro rata percentage of the Consideration as set forth in the
                                            Payment Schedule, within five (5) Business Days of such instruction, pay to the Investor
                                            the remaining shortfall, on a dollar-for-dollar basis, by wire transfer of immediately available
                                            funds to an account designated by the Investor. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
                                            the purposes of this Section &#8206;3.2, <B>&ldquo;Final Closing Statement&rdquo;</B> means
                                            and refers to: (i) the Estimated Closing Statement delivered by the Company to the extent
                                            Buyer provides a Buyer Acceptance Statement or fails to provide either a Buyer Acceptance
                                            Statement or a Draft Closing Statement by the Draft Closing Statement Deadline, (ii) the
                                            Draft Closing Statement delivered by Buyer if the Representative delivers to Buyer an Acceptance
                                            Notice or fails to deliver an Objection Notice by the lapse of the Examination Period; or
                                            (iii) the Draft Closing Statement as adjusted pursuant to the agreement between the Representative
                                            and the Investor and/or the Independent Accountant&rsquo;s resolution of the Unresolved Objections;
                                            <B>&ldquo;Adjusted Exercise Price&rdquo;</B> means the Exercise Price as determined in the
                                            Final Closing Statement; and <B>&ldquo;Closing Purchase Price&rdquo;</B> means the aggregate
                                            Exercise Price paid at the Option Closing, including (i) any amount paid to the Representative
                                            ((including by deposit with the Paying Agent) for the benefit of the Sellers), and (ii) the
                                            Adjustment Escrow Amount deposited with the Paying Agent in accordance with Section &#8206;3.A.
                                            (including both cash and, if applicable, the value of any shares issued pursuant to Section
                                            &#8206;1.3.3).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 46.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
                                            post-closing adjustment payments made under this Section 3.3 shall be treated as adjustments
                                            to the Exercise Price for all tax purposes.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Company Exit Bonuses.</U> To the extent the Company Exit Bonuses are not paid by the Paying Agent from the Closing Purchase Price,
any amount of the Company Exit Bonuses directly paid or furnished by the Company to employees of the Company in cash or Deposited Shares,
will be reduced from the cash or Deposited Shares to be transferred to the Paying Agent pursuant to Section 2.2.1 or 2.2.2 above, and
the dollar amount represented thereby shall be deemed as a payment of an equivalent amount of the Exercise Price. Where such payments
are made directly by the Company, the Company may withhold two and a half percent (2.5%) of the applicable amount of Company Exit Bonuses
so paid or payable, to be treated as a part of the Adjustment Escrow Amount due pursuant to Section 3.A. below, such amount to be treated
in accordance with the terms of the Paying Agent &amp; Escrow Agreement, mutatis mutandis.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Treatment of Company Milestone Bonuses.</U> Company Milestone Bonuses, to the extent paid, will be accounted for by reducing the Company&rsquo;s
Aggregate Cash as of the Option Closing Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Treatment of Consideration between Consideration Recipients.</U> As between the Consideration Recipients, for purpose of the allocation
of Consideration between Consideration Recipients, the provisions of Articles 8.1.1.2 through 8.1.1.6 of the Amended Articles shall apply
(thereby treating the acquisition by the Investor of the then outstanding equity interests of the Company hereunder as a Deemed Liquidation),
where in such case the Distributable Proceeds (as defined in the Amended Articles) shall be deemed net of any Company Exit Bonuses that
are paid.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>3.A.
Escrow. </U></B>At the Option Closing, the Investor shall deposit into a separate escrow account maintained by the Paying Agent an amount
equal to two and a half percent (2.5%) of the Exercise Price calculated based on the Estimated Closing Statement (the &ldquo;<B>Adjustment
Escrow Amount</B>&rdquo;) for the purpose of satisfying any downward adjustment to the Exercise Price in favor of the Investor due to
the calculation of Determining Revenues and/or Net Debt/Cash Position (as determined in accordance with the terms of this Agreement).
The Adjustment Escrow Account shall be governed by the Paying Agent &amp; Escrow Agreement.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>The
                                            Representative</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each of the Sellers hereby irrevocably appoints Behir Sabban, Adv, of Sabban Law Offices (together with any successor appointed pursuant
to this Section, the &ldquo;<B>Representative</B>&rdquo;) as its sole representative, attorney-in-fact and agent with full power of substitution
to act in the name, place and stead of the Sellers with respect to this Agreement and the Paying Agent &amp; Escrow Agreement and to
take any and all actions and make any decisions required or permitted to be taken by the Representative under this Agreement or the Paying
Agent &amp; Escrow Agreement, including (a) receiving and giving notices and communications, (b) authorizing delivery of payments (including
from the Adjustment Escrow Account) to the Sellers or to the Investor as appropriate, (c) agreeing to, negotiating, entering into settlements
and compromises of, and otherwise administering and resolving disputes relating to the Adjustment Escrow Amount or the determination
of the Exercise Price, and (d) engaging attorneys, accountants or other advisors as the Representative determines necessary or desirable.
The Sellers acknowledge that the Representative is legal counsel to KT Squared, LLC, and nothing in his role as Representative, shall
preclude him from continuing to advise KT Squared, LLC in that capacity.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Sellers acknowledge and agree that the Investor shall be entitled to rely on any action or decision of the Representative as being
binding on all of the Sellers, and shall have no responsibility to determine whether the Representative is acting in accordance with
the instructions of the Sellers. All decisions and actions by the Representative, including any agreement between the Representative
and the Investor relating to the determination of the Exercise Price or the disbursement of the Adjustment Escrow Amount, shall be binding
upon all Sellers as if expressly confirmed and ratified in writing by each of them.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each Seller hereby irrevocably constitutes and appoints the Representative, with full power of substitution, as its true and lawful proxy
and attorney-in-fact (the &ldquo;<B>Voting Proxy</B>&rdquo;), to vote all of such Seller&rsquo;s Shares and to exercise all rights, powers
and privileges of such Seller with respect to such Shares (including the right to act by written consent) in accordance with the provisions
of this Agreement and the transactions contemplated hereby, including without limitation in connection with any Company Acquisition (as
defined below) or other resolution or action required to be approved by the Sellers or shareholders of the Company in order to effectuate
the Option Closing. Each Seller agrees to take such further actions and to execute such further instruments as may be reasonably necessary
to effectuate the foregoing. The grant of the Voting Proxy is coupled with an interest, shall be irrevocable and shall survive the death,
incapacity, bankruptcy or liquidation of the Seller.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Representative (through deposit with the Paying Agent) shall be the sole party entitled to receive payment of the Exercise Price
on behalf of the Sellers. The Investor shall have no responsibility or liability whatsoever for the allocation, apportionment, or delivery
of any amount received by the Representative to any Seller, and no Seller shall have any claim against the Investor in connection with
any such distribution.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Representative may resign at any time, and may be removed for any reason or no reason by the vote or written consent of a
majority in interest (the &quot;<B>Majority Sellers</B>&quot;) of the Sellers according to each Sellers' pro rata share of all
Shares held by the Sellers <B>(&ldquo;Seller&rsquo;s Pro-rata Share&rdquo;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">) <FONT STYLE="line-height: 115%">;&nbsp;<I>provided,
however</I>, in no event shall Representative be removed without the Majority Sellers having first appointed a new </FONT>Representative
who shall assume such duties immediately upon the removal of Representative. In the event of the death, incapacity, resignation, or
removal of Representative, a new Representative shall be appointed by the vote or written consent of the Majority Sellers, and if
such appointment is not made within 30 days the Representative shall be KT Squared, LLC, until a successor Representative is
appointed. Notice of such vote or a copy of the written consent appointing such new Representative shall be sent to Buyer, such
appointment to be effective upon the later of the date indicated in such consent or the date such notice is received by
Buyer;&nbsp;<I>provided,&nbsp;</I>that until such notice is received, Buyer shall be entitled to rely on the decisions and actions
of the prior Representative as described&nbsp;above. If the Representative is dissolved, liquidated, ceases to exist, is declared
bankrupt, enters into receivership or administration, resigns, or is otherwise unable or unwilling to act then the Majority Sellers
may, by written notice to the Investor, appoint a successor Representative and if such appointment is not made within 30 days the
Representative shall be KT Squared, LLC, until a successor Representative is appointed. Any such appointment shall be effective upon
the delivery to the Investor of written notice of the appointment, together with a written acceptance of such appointment by the
successor Representative. The removal of a Representative shall not be effective until such a successor has been duly appointed and
accepted the role in writing.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Representative may rely upon any document or communication believed to be genuine and may assume any Person purporting to act on
behalf of a Seller has been duly authorized. The Representative shall not be liable to the Sellers for actions taken pursuant to this
Agreement or the Paying Agent &amp; Escrow Agreement/any Transaction Document, except to the extent such actions shall have been determined
by a court of competent jurisdiction to have constituted gross negligence or involved fraud, intentional misconduct or bad faith (it
being understood that any act done or omitted pursuant to the advice of counsel, accountants and other professionals and experts retained
by Representative shall be conclusive evidence of good faith). The Sellers shall severally and not jointly (in accordance with each Seller&rsquo;s
pro-rata share of the Consideration (less the amount of any Company Exit Bonuses paid or deducted therefrom)), indemnify and hold harmless
Representative from and against, compensate it for, reimburse it for, and pay any and all losses, liabilities, claims, actions, damages,
and expenses, including attorneys' fees and disbursements, arising out of and in connection with its activities as Representative under
this Agreement and the Paying Agent &amp; Escrow Agreement/any Transaction Document (the &quot;<B>Representative Losses</B>&quot;), in
each case as such Representative Loss is suffered or incurred;&nbsp;<I>provided</I>, that in the event it is finally adjudicated that
a Representative Loss or any portion thereof was primarily caused by the gross negligence, fraud, intentional misconduct or bad faith
of Representative, Representative shall reimburse the Sellers the amount of such indemnified Representative Loss attributable to such
gross negligence, fraud, intentional misconduct, or bad faith. The Representative Losses shall be satisfied: (i) first from the Representative
Expense Amount; and (ii) to the extent the amount of the Representative Losses exceeds amounts available to Representative from the Representative
Expense Amount, from the Sellers, severally and not jointly (in accordance with each Seller&rsquo;s pro-rata share of the Consideration
(less the amount of any Company Exit Bonuses paid or deducted therefrom)). As soon as practicable after the date on which the final obligation
of Representative under this Agreement and the Paying Agent &amp; Escrow Agreement/any Transaction Document have been discharged or such
other date as Representative deems appropriate, any remaining Representative Expense shall be released to the Consideration Recipients
on a pro-rata basis between them (based on the portion of the Consideration each such Consideration Recipient is entitled to receive).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Sellers shall jointly bear the Representative&rsquo;s costs and expenses (including professional advisor fees) incurred in
connection with the performance of its duties under this Agreement, which may be paid directly from any amounts otherwise payable to
Sellers, including from the Adjustment Escrow Account, and to the extent such amounts or not available or are insufficient, shall be
paid by the Consideration Recipients on a pro-rata basis between them (based on the portion of the Consideration each such
Consideration Recipient is entitled to receive). The Representative may withhold from, or cause to be deducted from, any amounts
payable to the Sellers any amounts required to fund such expenses on a pro rata basis.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Representative may act through one or more individuals or officers as it may designate from time to time in writing to the Investor.
The Investor shall be entitled to rely upon the actions or signatures of any such designated individual as though they were taken or
given by the Representative itself. Without limiting the foregoing, Behir Sabban, Adv., and such other Persons as may be designated in
writing by the Representative, are hereby authorized to act on behalf of the Representative, and the Investor may rely on any such act
or deed as the valid act or deed of the Representative.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Treatment
                                            of Non-Signing Shareholders</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Investor shall be obligated, upon exercise of the Call Option, to purchase all of the Option Purchased Securities which include all
Shares held by the Grantors who are party to this Agreement and Vested Company Options, and the Shares held by Non-Signing Shareholders
that are transferred pursuant to a Company Acquisition.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Subject to the following sentence, the Investor shall have sole discretion as to whether to acquire all (but not less than all) the Shares
held by any or all Non-Signing Shareholders at the Option Closing. Without limiting the generality of the foregoing, the Investor may,
and upon the demand of the Majority Sellers, shall, elect to pursue such acquisition (i) through the exercise of drag-along rights pursuant
to the Amended Articles or (ii) by causing the acquisition of all outstanding Shares of the Company by way of a reverse triangular merger
under the Companies Law 5759&ndash;1999; <I>provided</I> that the foregoing shall not require the Representative, acting on behalf of
the Sellers, to agree to any change in form that will result in a reduction in the amount of Consideration payable in the aggregate to
the Sellers (each, a &quot;<B>Company Acquisition</B>&quot;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Sellers, in their capacity as shareholders of the Company, hereby irrevocably agree to vote (or cause to be voted) all Shares
with respect to which such Sellers presently own or have voting power, and all Shares with respect to which such shareholders in the
future acquire ownership or voting power (including through the exercise or conversion of any securities), at any meeting of the
shareholders of the Company (including any class meetings), and in any action by written consent of the shareholders of the Company
(or any class thereof), (i) in favor of the approval, consent, and ratification of the Company Acquisition by Buyer as contemplated
by this Agreement, including, but not limited to, the exercise of any of shareholder&rsquo;s rights under the Company&rsquo;s
constitutional documents to require all holders of Company share capital to sell such shares pursuant to an Acquisition, and (ii)
against any action that would impede, interfere, or discourage any such Acquisition by Buyer, would facilitate an acquisition or
change of control of the Company, in any manner, by a party other than Buyer. To the extent inconsistent with the foregoing
provisions of this Section 5.3, each of the Sellers hereby irrevocably revokes any and all previous proxies with respect to any
Shares that such shareholder owns or has the right to vote. Each Seller hereby irrevocably agrees not to demand, and hereby
irrevocably waives, any and all rights to obtain payment of the fair value of its securities as afforded by statute, if any, or
otherwise arising in connection with the approval, execution and delivery of this Agreement by such Seller and consummation of the
transactions contemplated hereby and the approval execution and delivery of any agreement in connection with the exercise by Buyer
of the Acquisition, including with respect to consummation of the transactions contemplated thereby. Each Grantor irrevocably
agrees, and irrevocably instructs the Representative to, vote in favor of, consent to, and otherwise take all actions reasonably
requested by the Investor in order to effectuate any Company Acquisition, including any resolutions of the Board or shareholders of
the Company required to approve or implement such transaction. Each such Grantor further agrees, and irrevocably instructs the
Representative to execute any documentation reasonably requested by the Investor in connection with the foregoing, in form and
substance reasonably satisfactory to the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If the Shares held by Non-Signing Shareholders are not purchased by Investor in accordance with the terms of this Agreement, such Shares
shall remain outstanding and held by such shareholders, and no special rights, privileges or obligations shall attach to such Shares
or to such shareholders by virtue of the Investor&rsquo;s exercise of the Call Option or this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Investor shall have no responsibility or liability of any kind to any Non-Signing Shareholder in connection with the exercise of
the Call Option, including without limitation the amount, structure, or allocation of consideration paid or not paid to such shareholders.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If, in connection with any Company Acquisition, any shareholder of the Company (other than the Grantors) validly asserts statutory appraisal
rights or any similar rights under applicable law (a &ldquo;<B>Dissenting Shareholder</B>&rdquo;), and as a result thereof the Investor
or the Company is required to pay to any such Dissenting Shareholder an amount in excess of the Exercise Price payable under this Agreement
(including, for the avoidance of doubt, any interest, expenses, legal fees, or other costs), then: (a) the Grantors hereby irrevocably
waive any claim for an upward adjustment to the Exercise Price or any other payment from the Investor in respect of any such appraisal
rights or amounts paid to a Dissenting Shareholder; (b) the Investor shall be entitled to offset and deduct from the Exercise Price (including
amounts payable to the Representative or any Grantor under the Adjustment Escrow Amount) any costs, expenses, payments or liabilities
incurred or suffered in connection with the resolution or settlement of such appraisal or dissenters&rsquo; rights, including but not
limited to legal fees, expert costs, court-awarded amounts or settlement payments; and (c) the Representative shall, upon the Investor&rsquo;s
instruction and without any requirement for further Seller consent, instruct the Paying Agent to release from the Adjustment Escrow Amount
any such amounts owed to the Investor pursuant to clause (b), and any remaining balance in the Adjustment Escrow Account shall be distributed
in accordance with Section 3.2.6.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Representations
                                            and Warranties of the Grantors</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Each
Grantor, severally and not jointly, and solely with respect to itself, hereby represents and warrants to the Investor, as of the date
hereof and as of the Option Closing Date, as follows (provided that representations relating to accredited investor status shall apply
only to those Grantors who are accredited investors):</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Authorization;
Capacity; No Conflicts</U>. Each Grantor has full power, capacity and authority to execute and deliver this Agreement and to perform
its obligations hereunder. If such Grantor is not an individual, it is duly organized, validly existing and in good standing under
the laws of its jurisdiction of organization and has all requisite corporate or equivalent power and authority to enter into this
Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by such
Grantor and constitutes a valid and binding obligation of such Grantor, enforceable against it in accordance with its terms, subject
to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors&rsquo;
rights generally and to general principles of equity. The execution, delivery and performance of this Agreement and the consummation
of the transactions contemplated hereby will not result in any breach or violation of, or default under, (a) any law applicable to
such Grantor, (b) any judgment, order or decree of any governmental authority binding on such Grantor, or (c) any agreement,
contract or instrument to which such Grantor is a party or by which it or its assets are bound.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Title to Option Purchased Securities</U>. Such Grantor is the sole legal and beneficial owner of the Option Purchased Securities set
forth opposite its name in <U>Schedule &#8206;A</U>, free and clear of any Encumbrances (including, for the avoidance of doubt, any transfer
restrictions under the Articles or under applicable law, save for those that will be released or waived at or prior to the Option Closing
in accordance with this Agreement). Upon delivery of the share transfer deeds at the Option Closing in accordance with this Agreement,
the Investor will acquire full legal and beneficial title to such Option Purchased Securities, Free and Clear.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Other Rights</U>. Except as set forth in the Amended Articles, such Grantor is not a party to, or bound by, any option, warrant,
call, subscription agreement, voting trust, proxy, pledge agreement, rights of first refusal, co-sale rights, or any other contract,
agreement or understanding (whether written or oral) that requires or permits the sale, transfer, pledge, assignment or other disposition
of any Option Purchased Securities (or any interest therein) to any Person other than the Investor, or that could require such Grantor
to vote or transfer any Option Purchased Securities in any particular manner.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Proceedings</U>. There is no action, suit, proceeding, claim, arbitration, investigation or other legal proceeding pending or,
to the knowledge of such Grantor, threatened against such Grantor with respect to the Option Purchased Securities or the transactions
contemplated by this Agreement, nor is there any judgment, order or decree outstanding against such Grantor that would affect such Grantor&rsquo;s
performance hereunder or the transfer of the Option Purchased Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Finder&rsquo;s Fees</U>. No Person or entity is entitled to any brokerage, financial advisory, finder&rsquo;s or similar fee or
commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of such Grantor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Solely to the extent that the payment of the Exercise Price includes Equity Consideration, then the following representations shall apply
as of the Option Closing:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.6.1.&nbsp;&nbsp;&nbsp;&nbsp;
Purchase Entirely for Own Account. The Shares composing the Equity Consideration (the &ldquo;<B>Purchased Securities</B>&rdquo;) will
be acquired for investment for the Seller's own account, not as a nominee or agent, and not with a view to the resale or distribution
of any part thereof, and the Seller has no present intention of selling, granting any participation in, or otherwise distributing the
same. The Seller does not presently have any contract, undertaking, agreement or arrangement to sell, transfer or grant participation
rights to any person with respect to any of the Purchased Securities. The Seller has not been formed for the specific purpose of acquiring
the Purchased Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.6.2.&nbsp;&nbsp;&nbsp;&nbsp;
Investment Experience; Accredited Investor; Non-U.S. Person. Each Grantor is a sophisticated, experienced investor in securities of
companies in similar stage as the Buyer acknowledges that it is able to fend for itself, can bear the economic risk of its
investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating and
understanding the merits and risks of the investment in the Purchased Securities. Each Grantor is either (i) an accredited investor
as defined in Rule 501(a) of Regulation D promulgated under the Securities Act, (ii) a Non U.S. Person as defined under Regulation S
promulgated under the Securities Act. To the extent that a Grantor is a non U.S. Person, such Grantor (x) is not acquiring Purchased
Securities for the account or benefit of any U.S. Person, (y) is not, at the time of execution of this Agreement, and will not be,
at the time of the Option Closing, in the United States and (z) is not a &ldquo;distributor&rdquo; (as defined in Regulation S
promulgated under the Securities Act).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.6.3.&nbsp;&nbsp;&nbsp;&nbsp;
Restricted Securities. The Purchased Securities have not been and will not be registered under the Securities Act or any state securities
laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless
an exemption from such registration requirements is available. Seller is aware that, except as set forth in Section 11.1 below, the Company
is under no obligation to effect any such registration or to file for or comply with any exemption from registration. The sale and issuance
of the Purchased Securities have not been registered under the Securities Act by reason of a specific exemption from registration which
depends upon, among other things, the accuracy of the Seller's representations as expressed herein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.6.4.&nbsp;&nbsp;&nbsp;&nbsp;
Legends. The Purchased Securities may be notated with the following or a similar legend as well as other legends as may be required by
applicable securities laws: &ldquo;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE
BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO TRANSFER OF SUCH SHARES
MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.&rdquo;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Representations
                                            and Warranties of the Investor</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Investor hereby represents and warrants to the Company and the Grantors, as of the date hereof and as of the Option Closing Date, as
follows:</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Organization; Authority</U>. The Investor is duly organized, validly existing and in good standing under the laws of the State of
Israel and has all requisite corporate or equivalent power and authority to enter into this Agreement and to perform its obligations
hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by the Investor of this Agreement
and the consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate or similar
action. This Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable against it in accordance with its
terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors&rsquo;
rights generally and to general principles of equity.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Conflict</U>. The execution, delivery and performance of this Agreement by the Investor and the consummation of the transactions
contemplated hereby do not and will not (a) violate the organizational documents of the Investor, (b) conflict with or result in a breach
of, or constitute a default under, any contract, agreement or instrument to which the Investor is a party or by which it is bound, or
(c) violate any applicable law, judgment or order of any governmental authority binding on the Investor, except in each case as would
not materially impair the Investor&rsquo;s ability to perform its obligations under this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 <U>Consents and Approvals</U>. No filing with, and no permit, order, authorization, registration, declaration, consent or approval of,
any public or governmental body or authority is necessary for the execution, delivery and consummation by the Investor of the transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Finder&rsquo;s Fees.</U> No Person or entity is entitled to any brokerage, financial advisory, finder&rsquo;s or similar fee or
commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Investor.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Public Market</U>. The Investor understands that the Option Purchased Securities have not been registered under any applicable
securities law and no public market now exists for any of the securities issued by the Company and that the Company has made no assurances
that a public market will ever exist for the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Available Funds</U>. The Investor shall have as of immediately prior to the Option Closing sufficient funds to pay any amounts payable
hereunder to be paid on such date in order to consummate any and all transactions contemplated hereby.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Equity Consideration Additional Reps</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Solely
to the extent that the payment of the Exercise Price includes Equity Consideration, then the following representations shall apply as
of the Option Closing:</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.0pt"></TD><TD STYLE="width: 25.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.7.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Buyer
                                            SEC Documents; Financial Statements; and Valid Issuance</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
With respect to the period commencing as of the date hereof, Buyer has timely filed all forms, reports and documents required under the
Exchange Act to be filed with the SEC (the &ldquo;<B>Buyer SEC Documents</B>&rdquo;). Each of the Buyer SEC Documents, and all documents
incorporated therein by reference, complied in all material respects with all applicable requirements of the Exchange Act and the rules
and regulations promulgated thereunder, each as in effect on the dates such forms, reports, and documents were filed, and no such statement
or report contained an untrue statement of a material fact or omitted to state any material fact necessary to make the statements made
therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Buyer has not, in the twelve (12) months preceding the date hereof, received notice from the NASDAQ Global Select Market to the effect
that Buyer is not in compliance with the listing or maintenance requirements of such trading market. Buyer is in compliance in all material
respects with all such listing and maintenance requirements and the consummation of the transactions contemplated by this Agreement do
not violate any rules or regulations of the NASDAQ Global Select Market.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Valid Issuance</U>. The Purchased Securities to be issued pursuant to this Agreement will, when issued in accordance with the provisions
of this Agreement, be validly issued, fully paid and nonassessable, and will not be subject to pre-emptive rights, rights of first refusal
or other restrictions on transfer, other than restrictions which apply by virtue of applicable legal requirements.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Certain
                                            Covenants of the Company and the Grantors</U></B>. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Issuance
of Shares</U>. The Company undertakes and covenants (and the Grantors undertake to apply all of their voting power in the Company to
cause the Company to comply with such undertakings and covenants) that, from the date hereof until the <FONT STYLE="line-height: 115%">Call
Option Termination Date, any issuance of Shares or of any convertible, exercisable or exchangeable securities (including options,
warrants, or other instruments exercisable, convertible or exchangeable for Shares), by the Company shall be expressly conditioned
upon the recipient of such Shares or other securities becoming a party to this Agreement by executing and delivering a joinder or
counterpart hereto in form and substance satisfactory to the Investor, thereby becoming subject to the terms and conditions of this
Agreement as a &ldquo;Grantor&rdquo; with respect to the Shares so issued or issuable upon conversion, exchange or exercise of such
other securities. The Company shall not register, and the Grantors shall not approve or otherwise permit, any such issuance unless
and until such joinder has been duly executed and delivered to the Investor.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="line-height: 115%">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Transfers</U>. Each Grantor severally and not jointly, further covenants that, except as may be required to give effect to the
transactions contemplated hereby or with the prior written consent of the Investor (and subject to the conditions determined by it),
it shall not, directly or indirectly, sell, assign, transfer, pledge, encumber, hypothecate or otherwise dispose of any of its Shares
or any interest therein, nor create any Encumbrance thereon, nor enter into any agreement to do any of the foregoing, prior to the earlier
of the Option Closing or 11:59 PM and 59 seconds (Israel time) on the Call Option Termination Date, if no Exercise Notice has been provided
by the Investor prior to such time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Further Assurances</U>. The Company, the Grantors, the Representative and the Investor shall take, or cause to be taken, all actions
and do, or cause to be done, all things necessary or desirable to consummate and make effective the transactions contemplated by this
Agreement. At the Option Closing, the Grantors shall, at the request of the Investor and without further consideration, execute and deliver
further instruments of transfer and assignment and take such other action as the Investor may reasonably require to more effectively
transfer and assign to the Investor the Option Purchased Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Power of Attorney</U>. Without derogating from the Sellers&rsquo; and the Representative&rsquo;s obligations set forth herein, the
Grantors hereby appoints the Representative as its attorney in fact, with full power and authority to act on behalf of each Grantor such
that in the event that any Grantor fails to transfer any of the Option Shares pursuant to this Agreement, Representative shall be the
attorney of such Grantor with full power to execute, complete and deliver, in the name and on behalf of such Grantor transfers of the
Option Purchased Securities to the Investor against payment of the Exercise Price to such Grantor in the manner provided for in this
Agreement. Notwithstanding any resignation of the Representative, the power of attorney provided in this Section 8.4 shall remain in
effect and may not be transferred to any successor Representative without the written consent of the Investor, which consent shall not
be unreasonably withheld. Upon payment of the Exercise Price to such Grantor in the manner provided for in this Agreement, the Investor
shall be deemed to have obtained a good discharge for such payment. The Representative shall have no liability to any Grantor or third
party for actions taken pursuant to this power of attorney, and each Grantor hereby agrees to indemnify and hold harmless the Representative
from any claims, losses, or expenses arising from the Representative&rsquo;s exercise of this power of attorney, except in cases of the
Representative&rsquo;s gross negligence or willful misconduct as finally adjudicated by a court.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">8.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><U>Release</U>.
                                            Each Grantor</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">,
                                            on its own behalf and on behalf of its respective Affiliates,
                                            representatives, heirs, successors and assigns (collectively, the &ldquo;<B>Grantor Releasing
                                            Parties</B>&rdquo;), hereby absolutely, unconditionally and irrevocably releases and forever
                                            discharges the Company and its present and former Affiliates, successors and assigns, and
                                            their respective representatives, shareholders, members and partners (collectively, the &ldquo;<B>Company
                                            Released Parties</B>&rdquo;), with effect as of the Option Closing (and conditioned upon
the consummation thereof), from any and all claims, causes of action, legal proceedings, liabilities, losses, costs, reimbursements,
damages (whether for compensatory, special, incidental or punitive damages, equitable relief or otherwise), demands, recoveries, indemnities
and obligations of any kind, whether in law, equity or otherwise, whether known or unknown, whether concealed or hidden, whether disclosed
or undisclosed, whether contingent or absolute, whether liquidated or unliquidated, whether foreseeable or unforeseeable, whether foreseen
or unforeseen, whether anticipated or unanticipated, whether suspected or unsuspected and whether arising by operation of law or otherwise,
which such Grantor Releasing Parties ever have had, or ever may have in the future, against the Company Released Parties and which are
based on acts, events or omissions occurring up to and including the Option Closing (the &ldquo;<B>Released Claims</B>&rdquo;). Released
Claims include, without limitation, any claims relating to or arising from preemptive rights, rights of first offer, rights of first
refusal, co-sale rights, over-allotment rights or other participation rights or timely notice thereof that any Grantor may have had under
(i) the Company&rsquo;s Articles of Association (as amended from time to time), (ii) any other agreement, document or instrument, (iii)
any other understanding or arrangement with the Company, or (iv) any applicable law. Each Grantor, on behalf of itself and the Grantor
Releasing Parties, acknowledges that it may hereafter discover facts in addition to or different from those which it now knows or believes
to be true with respect to the subject matter of the Released Claims, but intends to and, by operation of this Agreement, shall have
fully, finally and forever settled and released any and all Released Claims, without regard to the subsequent discovery or existence
of such different or additional facts. <FONT STYLE="line-height: 115%">Without derogating from the foregoing, it is hereby expressly
stated the Released Claims shall not include: (i) any right of a Grantor under this Agreement or any related Agreement, including any
rights to payments pursuant to this Agreement or the transactions contemplated hereby, (ii) any rights to continuing indemnification
under (A) any indemnification agreement to which a Seller (or any representative thereof) and the Company are parties to, or (C) the
D&amp;O Tail Insurance, or (iii) relating to or arising from any commercial relationship such Grantor may have with the Company or any
of its respective Affiliates independently from its role as a shareholder of the Company.</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Covenant Not to Sue</U>. With effect as of the Option Closing, each Grantor, on behalf of itself and the Grantor Releasing Parties,
agrees that it shall not, in its own capacity, or as successor, assignor or assignee, or otherwise, assert, commence, join in, or assist
or encourage any third party in asserting, any claim against any Company Released Party with respect to any of the matters released under
Section &#8206;8.5.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Conditions
                                            to the Option Closing</U></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The respective obligation of each Party to consummate the Option Closing shall be subject to the satisfaction (or waiver in writing by
the Investor, the Company and the Representative) of each of the following conditions as of the Option Closing Date:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Legal Impediment</U>. There shall not be in effect any order, law, rule or regulation restraining, enjoining or otherwise prohibiting
the consummation of the Option Closing (including, any anti-trust filing or approval if and to the extent legally required), and no action
or proceeding by any governmental authority shall be pending or threatened before any court or administrative body seeking to restrain
or prohibit or impose any material condition on the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 The obligations of the Investor to consummate the Option Closing shall be subject to the satisfaction (or waiver in writing by the Investor)
of each of the following conditions as of the Option Closing Date:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Warranties</U>. The representations and warranties of the Grantors set forth in Section &#8206;6 shall be true
and correct in all material respects as of the Option Closing Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Covenants</U>. The Grantors and the Company shall have duly performed and complied in all material respects with all covenants and
obligations to be performed by them under this Agreement prior to or at the Option Closing.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Legal Impediment</U>. There shall not be in effect any order, law, rule or regulation restraining, enjoining or otherwise prohibiting
the consummation of the Option Closing, and no action or proceeding by any governmental authority shall be pending or threatened before
any court or administrative body seeking to restrain or prohibit or impose any material condition on the consummation of the transactions
contemplated hereby.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Material Adverse Change</U>. Since the date of the Exercise Notice, there shall not have occurred any Material Adverse Change.
</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Company Acquisition</U>. If the Investor consummates the acquisition of 100% of the Shares of the Company by way of a Company Acquisition
(as defined in Section 5.2), all necessary resolutions of the Company&rsquo;s board of directors and shareholders to authorize such Company
Acquisition shall have been duly adopted, all documentation required to implement the Company Acquisition shall have been duly executed
and delivered by the parties thereto (other than the Investor or its affiliates), and all statutory or other waiting periods required
under applicable law shall have expired or been waived.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Third-Party Consents</U>. All consents, approvals, waivers or authorizations required to be obtained from any third party (including
lenders, lessors, or counterparties to material contracts) or from any governmental or regulatory authority in connection with the transactions
contemplated by this Agreement (including any Company Acquisition, if applicable) shall have been obtained and shall be in full force
and effect.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Deliver</U>y. Each of the documents and deliveries set forth in Section &#8206;2.2.4 shall have been duly and timely delivered to
the Investor, and all such documents shall be in full force and effect as of the Option Closing.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The obligations of the Grantors to consummate the Option Closing with respect to the Option Purchased Securities Shares shall be subject
to the satisfaction (or waiver in writing by the Representative) of each of the following conditions as of the Option Closing Date:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Purchase Price</U>. The Investor (or its designated Affiliate) shall have paid the Closing Purchase Price in accordance with Section
&#8206;2.2.1, including any partial payment in shares if elected by the Investor pursuant to Section &#8206;1.3.3.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Escrow Deposit</U>. The Investor shall have deposited the Adjustment Escrow Amount with the Paying Agent pursuant to Section &#8206;3.5.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Warranties</U>. The representations and warranties of the Investor set forth in Section &#8206;7 shall be true
and correct in all respects as of the Option Closing Date. The Representatives shall have received a certificate dated the Option Closing
Date and signed on behalf of Buyer by an authorized signatory of Buyer, confirming the foregoing.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Covenants</U>. The Investor shall have duly performed and complied in all material respects with all covenants and obligations to
be performed by it under this Agreement prior to or at the Option Closing. The Representative shall have received a certificate dated
the Option Closing Date and signed on behalf of Buyer by an authorized signatory of Buyer, confirming the foregoing.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Legal Impediment</U>. There shall not be in effect any order, law, rule or regulation restraining, enjoining or otherwise prohibiting
the consummation of the Option Closing, and no action or proceeding by any governmental authority shall be pending or threatened before
any court or administrative body seeking to restrain or prohibit or impose any material condition on the consummation of the transactions
contemplated hereby.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Termination</U>.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Call Option shall automatically terminate upon the <U>earliest</U> of (such date, the &ldquo;<B>Call Option Termination Date</B>&rdquo;):</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.1.&nbsp;&nbsp;
The consummation of the Option Closing (provided, however, that all provisions relating to the period following the Option Closing shall
remain in effect);</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.2.&nbsp;&nbsp;
11:59 PM and 59 seconds (Israel time) on the Call Option Expiry Date, if no Exercise Notice has been provided by the Investor prior to
such time; or</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.3.&nbsp;&nbsp;
Following the repayment in full of the Loan Amount when it becomes due and payable in accordance with the Investment Agreement. </FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.4.&nbsp;&nbsp;
The date (if any) upon which the Investor constitutes a &ldquo;Defaulting Investor&rdquo; as defined and in accordance with the provisions
of the Investment Agreement.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.5.&nbsp;&nbsp;
Pursuant to section 2.4.6.2 of the Investment Agreement, , where Investor elects not to proceed to invest in the Company due to the occurrence
of a Material Adverse Change, upon the date of the applicable Officer&rsquo;s Certificate (as defined in the Investment Agreement).</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1.6.&nbsp;&nbsp;
Immediately prior to the consummation of the Acquisition Transaction (as defined in the Amended Articles) pursuant to Article 143 of
the Amended Articles (Call Option Carveout). </FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For the avoidance of any doubt, except as expressly provided in this Section &#8206;10, the Call Option shall remain in full force and
effect until and including the Call Option Expiry Date and may not be terminated by the Company, the Grantors, or the Representative
for any reason whatsoever.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Mutual
                                            Covenants </U></B></FONT></TD></TR></TABLE>




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 Solely to the extent that the payment of the Exercise Price includes Equity Consideration, then the Buyer undertakes as follows: Buyer
shall use commercially reasonable efforts to file as soon as practicable following the Option Closing a resale registration statement
on Form F-3 or other applicable form (each, a &ldquo;<B>Registration Statement</B>&rdquo;) providing for the resale of the shares issued
as Equity Consideration by the Grantors and use commercially reasonable efforts to cause the Registration Statement to be declared effective
as soon as practicable, and to take all commercially reasonable efforts to ensure that such Registration Statement remains effective
until the earlier of: (i) twelve (12) months after the Option Closing and (ii) the date that all of such Buyer&rsquo;s shares, as the
case may be, have been sold. Buyer shall cause any such Registration Statement to materially comply with all applicable requirements
of federal and state securities laws of the United States. Each relevant Grantor to be issued such shares, hereby (i) consents to the
use of its name and to the inclusion of business information relating to it in any such Registration Statement; (ii) agrees to provide
promptly to Buyer such information concerning its business and affairs as may reasonably be requested by Buyer for inclusion in any such
Registration Statement, or in any amendments or supplements thereto; and (iii) agrees to cause its counsel to cooperate with Buyer&rsquo;s
counsel in the preparation of any such Registration Statement. Each such Grantor shall promptly advise Buyer, in writing, if at any time
prior to the effectiveness of any such Registration Statement, Grantor shall obtain knowledge of any facts that might make it necessary
or appropriate to amend or supplement any such Registration Statement in order to make the statements contained or incorporated by reference
therein not misleading or to comply with applicable Legal Requirements. The Buyer shall bear the expenses of one counsel for the Grantors
in connection with such Registration Statement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>D&amp;O Insurance; Indemnification and Exculpation</U></B>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
                                            of the Option Closing Date, each of the Company and its Subsidiaries shall maintain, for
                                            a period of seven (7) years after the Option Closing Date, the Company&rsquo;s and its Subsidiaries&rsquo;
                                            current directors&rsquo; and officers&rsquo; liability insurance in respect of acts or omissions
                                            occurring at or prior to the Option Closing, covering each Person currently covered by the
                                            Company&rsquo;s and its Subsidiaries&rsquo; directors&rsquo; and officers&rsquo; liability
                                            insurance policy, on terms with respect to such coverage and amount no less favorable than
                                            those of such policy in effect on the date hereof (&ldquo;<B>D&amp;O Tail Insurance</B>&rdquo;).
                                            </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
                                            Buyer shall not, and shall cause the Company and its Subsidiaries not to, amend, repeal,
                                            or otherwise modify the obligations with respect to all rights to indemnification and exculpation
                                            from liabilities for acts or omissions occurring at or prior to the Option Closing now existing
                                            in favor of the current or former directors or officers of the Company and its Subsidiaries
                                            as provided in the Company&rsquo;s and its Subsidiaries&rsquo; Articles of Association or
                                            organizational documents, as in effect on the date hereof, without further action, as of
                                            the Option Closing, and such obligations shall survive the Option Closing and shall continue
                                            in full force and effect (except as otherwise required by applicable Law) in accordance with
                                            their terms. </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
                                            the event that the Company or any of its Subsidiaries or any of their successors or assignees
                                            (i) consolidates with or merges into any other Person and is not the continuing or Company
                                            or any of its Subsidiaries or entity of such consolidation or merger or (ii) transfers or
                                            conveys all or substantially all its properties and assets to any Person, then, and in each
                                            case, Buyer and the Company or any of its Subsidiaries, as the case may be, shall cause provision
                                            to be made so that successors and assignees of the Company or any of its Subsidiaries, as
                                            the case may be, assume the obligations
set forth in this Section 11.2. The provisions of this Section 11.2 are (x) intended to be for the benefit of, and will be enforceable
by, each current or former director or officer of the Company or any of its Subsidiaries, as the case may be, his or her heirs and his
or her representatives and (y) are in addition to, and not in substitution for, any other rights to indemnification or contribution that
any such Person may have by contract or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 32.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Publicity. No Party shall issue a press release or public announcement or otherwise make any public disclosure (nor shall the Company
communicate with any of its employees or permit any Company personnel to do so, except for communications with such employees, representatives,
agents, shareholders, partners, Affiliates and/or agencies necessary for the Company to satisfy its obligations hereunder), concerning
the subject matter of this Agreement (including its existence) without the prior written approval of the Representative or the Buyer,
as applicable; provided that the Parties shall be permitted to issue a press release in agreed form on the date hereof; provided further
that any Party may make any public disclosure it believes based upon opinion of counsel is required by applicable law or stock market
rule and in such case (other than disclosure pursuant to stock market rule or securities laws) such Party must, prior to making such
disclosure, (a) use commercially reasonable efforts to advise the other Parties of such disclosure (including a copy thereof) as far
in advance of such disclosure as is reasonably practicable and (b) consult with the other Parties with respect to the content of such
disclosure.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"><B><U>Miscellaneous</U></B>.</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"></FONT></P></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law.</U> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Israel, without
regard to conflict of law principles that would result in the application of the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Jurisdiction.</U> The competent courts located in Tel Aviv, Israel shall have exclusive jurisdiction over any disputes arising out
of or relating to this Agreement, and each of the Parties hereby submits irrevocably to the jurisdiction of such courts.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment and Waiver.</U> No amendment, modification or waiver of any provision of this Agreement shall be effective unless in writing
and signed by the Investor and the Representative (on behalf of the Grantors); provided, however, that a waiver by a Party of any breach
or failure to comply with any provision hereof shall not operate as or be construed to be a waiver of any other breach or failure.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Entire Agreement.</U> This Agreement (including the preamble, recitals, Exhibits, and Schedules hereto), together with any joinders
(including Optionee/ Warrantholder Joinders) and the Paying Agent &amp; Escrow Agreement, constitutes the entire agreement and understanding
between the Parties with respect to the subject matter hereof and supersedes all prior written or oral agreements or understandings relating
thereto. In the event of any conflict or inconsistency between the terms of this Agreement and the Investment Agreement, the terms of
this Agreement shall govern and control.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices.</U> All notices and other communications required or permitted under this Agreement shall be in writing and shall be deemed
given: (a) when delivered personally; (b) when sent by email with confirmation of delivery if sent during normal business hours, and
otherwise on the next Business Day; (c) ten (10) days after being mailed by registered or certified mail, postage prepaid, return receipt
requested; or (d) two (2) Business Days after being sent via an internationally recognized overnight courier with written
confirmation of delivery. Notices shall be sent to the addresses (or email addresses) specified below, or to such other address as a
Party may from time to time notify in writing:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-top: 0pt; padding-bottom: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Company</FONT></TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Neurolief
    Ltd.</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12
    Giborei Israel, Netanya, Israel, 4250412</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Attn: Chief Executive Officer</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">E-mail:
    scott.drees@neurolief.com</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">With
    a copy (which shall not constitute service of process) to:</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amit,
    Polak, Matalon &amp; Co.</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">18
    Raoul Wallenberg St.</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Building
    D</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6th
    floor<BR>
    Tel Aviv 6971915</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Attn:
    James Raanan, Adv.</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">E-mail:
    jamesr@apm.law</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Representative</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Sabban
    Law Offices</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Beit
    Manzur</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7th
    Floor<BR>
    2 HaNofar Street</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Ra&rsquo;anana
    4366402, Israel</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Attn:
    Behir Sabban, Adv.</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">E-mail:
    behir@sabbanlaw.com</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Investor</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BrainsWay
                                            Ltd.</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">16
    Hartum Street, 3rd Floor, RAD Tower,</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Jerusalem, 9777516, Israel</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Attn:
    Menachem Klein, General Counsel</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">E-mail:
    MKlein@brainsway.com</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-top: 0pt; padding-bottom: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">With
    a copy (which shall not constitute service of process) to:</FONT></TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">S.
    Friedman, Abramson &amp; Co,</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Azrieli
    Town, 146 Menachem Begin Road,</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Tel Aviv-Jaffa, Israel</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Attn:
    Sarit Molcho and Simon Synett</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">E-mail:
    Saritm@sfa.law; Simons@sfa.law</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement,
which shall remain enforceable, to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of
this Agreement (including, without limitation, the portion of this Agreement containing any provision held to be invalid, illegal or
unenforceable that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested
by the provision held invalid, illegal or unenforceable.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Expenses</U>. Except as expressly set forth herein, each Party shall bear its own costs and expenses in connection with the negotiation,
preparation, execution and performance of this Agreement and the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Specific Performance</U>. Each of the Parties acknowledges and agrees that the rights of each Party to consummate the transactions
contemplated by this Agreement are unique and that any breach of this Agreement may cause irreparable harm to the non-breaching Party
for which monetary damages would not be an adequate remedy. Accordingly, each Party shall be entitled to seek specific performance of
the terms and provisions of this Agreement and to obtain injunctive or other equitable relief to prevent any breach, or to enforce the
observance and performance of any covenant, obligation, agreement, term or condition hereof, in addition to any other remedy to which
it may be entitled at law or in equity. The Parties hereby waive (a) any requirement for the securing or posting of any bond in connection
with any such remedy, and (b) any defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts (including counterparts transmitted by electronic mail
in PDF format), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.10.&nbsp;&nbsp;&nbsp;&nbsp; <U>Successors
and Assigns</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, in whole or in
part, by operation of Law or otherwise by any of the Parties without the prior written consent of the other Parties. Notwithstanding
the foregoing, Buyer shall have the right to assign this Agreement without the prior written consent of the other Parties (i) to any
of its Affiliates, <I>provided, however</I>, that that no such assignment or transfer shall become effective unless each such
Affiliate has provided the Company and the Representative with a confirmation in writing that it is bound by all terms and
conditions of this Agreement and each of the Transaction Documents (as defined in the Investment Agreement) as if it were an
original party to it; and <I>provided further</I>, that Buyer shall agree to guarantee the obligations of such Affiliate hereunder
and under the Transaction Documents; or (ii) to an acquiror in connection with a sale of all or substantially all of its assets or
business (whether by merger, asset sale, share sale or otherwise), provided that such acquiror has provided the Company and the
Representative with a confirmation in writing that it is bound by all terms and conditions of this Agreement and each of the
Transaction Documents as if it were an original party to it. For avoidance of doubt, any payment of the Exercise Price in <FONT STYLE="line-height: 115%">Equity
Consideration, if made according to the provisions of this Agreement, shall solely relate to tradable shares of the Buyer itself
(and not shares of any other entity) regardless of whether or not the Buyer assigned its rights and obligations herein pursuant to
this Section 12.10. Subject to the preceding sentence, the provisions hereof shall inure to the benefit of, and be binding upon, the
successors and assigns of the parties hereto.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="line-height: 115%">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="line-height: 115%"></FONT></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="line-height: 115%"></FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.11.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Titles and Subtitles</U>. The titles of the sections and subsections of this Agreement are for convenience of reference only and are
not to be considered in construing this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12.12.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Further Assurances</U>. Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably
be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]</I></B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I></I></B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[EXECUTION
PAGE 1 TO CALL OPTION AGREEMENT]</I></B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IN
WITNESS WHEREOF, the Company, the Investor and the Representative have executed this Call Option Agreement as of the date set forth in
the first paragraph hereof.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Neurolief
    Ltd.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: ____________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Brainsway
    Ltd.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: ____________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Behir
    Sabban, Adv.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: ____________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD>
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[EXECUTION
PAGE __ TO CALL OPTION AGREEMENT]</I></B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IN
WITNESS WHEREOF, the Grantors have executed this Call Option Agreement as of the date set forth in the first paragraph hereof.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Terralab
    Ventures L.P.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Astorre Modena; Harold Weiner</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Terra
    Ventures Partners II (Cayman) L.P.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Astorre Modena; Harold Weiner</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Terra
    Ventures Partners II SCA SICAR</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Astorre Modena; Harold Weiner</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Amit
    Dar</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Amit Dar</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Shmuel
    Shany</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Shmuel Shany</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Jonathan
    Bar-Or</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Jonathan Bar-Or</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Efrat
    Kantor</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Efrat Kantor</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>KT
    Squared LLC</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Gabriel Merkin</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Mont
    Pelerin Capital Limited </B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Amir Weitmann; Arie Benguigui</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Deborah
    Edelstein Weiss</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Deborah Edelstein Weiss</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Izba
    S.A</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Sergio Fogel</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Sergio
    Fogel</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Sergio Fogel</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
________________________</B></FONT>&nbsp;</P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Shevet
    5G LLC</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Baruch Glaubach</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Esther
    Muschel Holdings LLC </B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Esther Muschel</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>MLS
    Properties LLC</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Shlomo Spetner</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Michael
    Deouell </B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Michael Deouell</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Marc
    Epstein</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Marc Epstein</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Eaton
    Associates</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Marc Epstein</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Mark
    Hetterley</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Mark Hetterley</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Keren
    Keshet - The Rainbow Foundation</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Yehuda Novick</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Michael
    Steinhardt</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Michael Steinhardt</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>David
    Steinhardt</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: David Steinhardt</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Drakanea
    Management Ltd.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Mark Vickers; Matthew Toussaint</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Thomas
    Hook</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Thomas Hook</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Scott
    Drees</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Scott Drees</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Anthony
    Borowicz</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Anthony Borowicz</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0pt; font: 12pt Arial, Helvetica, Sans-Serif; padding-top: 0pt; padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Sawai
    Group Holdings Co. Ltd.</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: ___________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Avinoam
    Rosenzweig</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>By
    (sign name): _________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Print
    Name: </B>Avinoam Rosenzweig</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Title:
    _______________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Date:
    ________________________</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Uriel
    Rosenzweig</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: Uriel Rosenzweig</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 0pt"><P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>James
    Rosenzweig</B></FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
    (sign name): _________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Print
    Name: James Rosenzweig</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    _______________________</FONT></P>
    <P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Date:
    ________________________</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">EXHIBIT
A</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">OPTIONEE/
WARRANTHOLDER JOINDER AGREEMENT</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
Joinder Agreement (this &ldquo;<B>Joinder</B>&ldquo;) is entered into as of _________, 2025, by and between [OPTION/ WARRANT HOLDER NAME],
an individual/entity (the &ldquo;<B>Option Holder</B>&ldquo;), and the parties to that certain Call Option Agreement dated as of _________,
2025 (the &ldquo;<B>Call Option Agreement</B>&ldquo;), by and among BrainsWay Ltd., an Israeli public company (the &ldquo;<B>Buyer</B>&ldquo;),
Neurolief Ltd., a company organized under the laws of the State of Israel (the &ldquo;<B>Company</B>&ldquo;), and the securities holders
of the Company listed in Schedule A thereto (the &ldquo;<B>Grantors</B>&ldquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>1.
RECITALS</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
the Option Holder is a holder of certain securities of the Company as set forth in Section 4 below; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
pursuant to Section [&#9679;] of the Call Option Agreement, the Option Holder desires to become bound by the Call Option Agreement as
a Grantor thereunder with respect to such securities; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
the execution and delivery of this Joinder by the Option Holder is a condition precedent to the Option Holder becoming bound as a Grantor
under the Call Option Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Option Holder hereby agrees as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>2.
Joinder and Binding Effect</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
executing and delivering this Joinder, the Option Holder hereby agrees to become bound by, and shall become a party to, the Call Option
Agreement as a &ldquo;Grantor&rdquo; thereunder, and shall be bound by and comply with all of the terms, conditions, obligations, covenants,
representations, warranties and agreements set forth in the Call Option Agreement that are applicable to the Grantors thereunder with
respect to the Option Purchased Securities, with the same force and effect as if the Option Holder had been an original signatory thereto.
The Option Holder acknowledges and agrees that upon execution of this Joinder, all references to &ldquo;Grantor&rdquo; or &ldquo;Grantors&rdquo;
in the Call Option Agreement shall be deemed to include the Option Holder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
purposes of the Call Option Agreement, the Option Holder&rsquo;s &ldquo;Option Purchased Securities&rdquo; shall consist of those Company
securities identified in Section 4 of this Joinder. The parties to the Call Option Agreement shall treat the Option Holder as a Grantor
for all purposes under the Call Option Agreement, and the Option Holder shall be entitled to all rights, and subject to all obligations,
of a Grantor thereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>3.
Representations and Warranties</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Without
derogating from the Representations and Warranties set forth in Section 6 of the Call Option Agreement, all of which are deemed made
by the Option Holder, the Option Holder hereby represents and warrants to the Buyer and the Company as follows:</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.1
The Option Holder is the sole legal and beneficial owner of the Option Purchased Securities, free and clear of any liens, charges, pledges,
security interests, encumbrances or other third-party rights of any nature whatsoever (collectively, &ldquo;<B>Encumbrances</B>&rdquo;),
and upon exercise of the Call Option by the Buyer, the Option Holder will transfer to the Buyer good and valid title to the Option Purchased
Securities, free and clear of any Encumbrances.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2
The Option Holder has full legal capacity and authority to execute and deliver this Joinder and to perform its obligations hereunder.
This Joinder has been duly executed and delivered by the Option Holder and constitutes the legal, valid and binding obligation of the
Option Holder, enforceable against the Option Holder in accordance with its terms.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.3
The execution, delivery and performance by the Option Holder of this Joinder and the consummation of the transactions contemplated hereby
do not and will not: (i) violate or conflict with any law, statute, rule, regulation, judgment, order, writ or decree of any governmental
authority applicable to the Option Holder; (ii) violate or conflict with any agreement, arrangement or understanding to which the Option
Holder is a party or by which the Option Holder or the Option Purchased Securities may be bound; or (iii) require any consent, approval
or authorization of any person or entity.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>4.
Option Securities Coverage</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Option Holder hereby confirms and agrees that all of their Vested Company Options and Option Purchased Securities, as defined in the
Call Option Agreement, shall be subject to the terms and conditions of the Call Option Agreement. As of the date hereof, the Option Holder&rsquo;s
securities that are subject to the Call Option Agreement consist of:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
_______ [Vested Company Options / Warrants] to purchase _______ [Ordinary Shares/Preferred __] of the Company at an exercise price of
NIS _______ per share; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
_______ Option Purchased Securities consisting of _______ [specify type] shares of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Option Holder acknowledges and agrees that any additional Company securities that the Option Holder may acquire after the date hereof,
whether through exercise of options, warrants, conversion of convertible securities, or otherwise, shall automatically become subject
to the Call Option Agreement without need for further action or documentation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>5.
Acknowledgment of Terms</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Option Holder hereby acknowledges and confirms that it has received, carefully reviewed and fully understands all terms, conditions and
provisions of the Call Option Agreement. The Option Holder further acknowledges that it has had the opportunity to consult with legal
counsel of its choice regarding the Call Option Agreement and this Joinder. The Option Holder enters into this Joinder freely and voluntarily,
with full knowledge of its significance, and with the intent to be legally bound by all terms and conditions contained in the Call Option
Agreement.</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>6.
Governing Law and Jurisdiction</B></FONT></P>




<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
Joinder Agreement shall be governed by and construed in accordance with the laws of the State of Israel, without giving effect to principles
of conflicts of law. The parties hereby irrevocably submit to the exclusive jurisdiction of the competent courts located in Tel Aviv-Jaffa,
Israel in respect of any dispute or matter arising out of or connected with this Joinder Agreement. Each party hereby irrevocably waives
any objection it may have to the venue of any action or proceeding brought in such court or to the convenience of such forum.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"><B>7.&nbsp;
Miscellaneous</B></FONT></P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This Joinder may be executed in any number of counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument. Delivery of an executed counterpart of this Joinder by electronic transmission (including PDF
or any electronic signature complying with applicable law) shall be equally effective as delivery of a manually executed counterpart
of this Joinder. Any party delivering an executed counterpart of this Joinder by electronic transmission shall also deliver a manually
executed counterpart of this Joinder, but failure to do so shall not affect the validity, enforceability or binding effect of this Joinder.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 45%; border: black 1pt solid; font: 12pt Arial, Helvetica, Sans-Serif; padding: 15pt 15pt 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">IN
    WITNESS WHEREOF, the Option Holder has executed this Joinder Agreement as of the date first written above. <BR>
    <BR>
    OPTION HOLDER:<BR>
    <BR>
    By: _______________________<BR>
    Name: [OPTION HOLDER NAME]<BR>
    Title: ______________________<BR>
    Date: ______________________ </FONT></TD>
    <TD STYLE="width: 10%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 12pt Arial, Helvetica, Sans-Serif; padding: 15pt 15pt 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">ACCEPTED
    AND AGREED:<BR>
    <BR>
    BRAINSWAY LTD.<BR>
    <BR>
    By: _______________________<BR>
    Name: ____________________<BR>
    Title: _____________________<BR>
    Date: _____________________ </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">EXHIBIT
B</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">SHAREHOLDER
REGISTER</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">EXHIBIT
C</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">SHARE
TRANSFER DEED</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
undersigned _________________ (the &quot;<B>Transferor</B>&quot;) does hereby transfer for due consideration to <FONT STYLE="background-color: yellow">____________</FONT>.,
a company incorporated under the laws of the State of Israel, (the &quot;<B>Transferee</B>&quot;), [<FONT STYLE="background-color: yellow">Number</FONT>]
[<FONT STYLE="background-color: yellow">Type</FONT>] Shares of Neurolief Ltd. (the &quot;<B>Company</B>&quot;), par value NIS 0.01 each
(the &quot;<B>Shares</B>&quot;) subject to the same terms and conditions on which the Transferor held the Shares at the time of the execution
of this share transfer deed, and the Transferee hereby agrees to accept the Shares subject to the aforesaid terms and conditions.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Transferor hereby assigns and transfers, and the Transferee hereby accepts and assumes, any and all of the rights, liabilities and obligations
of the Transferor with respect to the Shares.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Transferor and the Transferee hereby authorize and grant full power and authority to any of the officers of the Company to register the
sale and transfer of the Shares, and the acceptance thereof, in the shareholders&rsquo; register of the Company.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
Share Transfer Deed may be executed in counterparts, each of which when executed and delivered shall be deemed to be an original and
all of which counterparts taken together shall constitute but one and the same instrument.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
witness whereof, the Transferor and the Transferee have executed and delivered this share transfer deed as of ______________, 202__.</FONT>&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>The
Transferor:</B></FONT></P></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Transferee:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 12pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Name:</FONT></TD>
    <TD STYLE="font: 12pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-bottom: 0pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">EXHIBIT
D</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WRITTEN
RESIGNATION</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Neurolief
Ltd.</U></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(the
&ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt/14pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Dear
Sirs,</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Re:
<B><U>Resignation Letter</U></B></FONT></P>

<P STYLE="font: 11pt/15pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">I,
the undersigned, _________, Israeli ID number _________, hereby resign from my position as a member of the board of directors of the
Company (the &ldquo;<B>Board</B>&rdquo;) and from any and all committees of the Board, if any, effective as of date hereof.</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Sincerely,</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;&ndash;</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">[Name]</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>EXHIBIT
E</B></FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">CAP
TABLE ADJUSTMENT EXAMPLE</FONT></P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">&nbsp;<IMG SRC="exhibitf.jpg" ALT=""></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%">&nbsp;43</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; line-height: 115%"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>exh_994.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">- 1 -</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 0.35pt"><B>THE COMPANIES LAW, 5759-<FONT STYLE="letter-spacing: -0.2pt">1999</FONT></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 45.75pt 0pt 45.9pt"><B>A PRIVATE COMPANY LIMITED BY <FONT STYLE="letter-spacing: -0.1pt">SHARES</FONT></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0.25pt 0pt 0.35pt"><B>Amended and Restated Articles of <FONT STYLE="font-size: 10pt">Association</FONT>
<FONT STYLE="letter-spacing: -0.25pt">of</FONT></B></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0.3pt 0pt 0.35pt"><FONT STYLE="font-variant: small-caps"><B>Neurolief <FONT STYLE="letter-spacing: -0.2pt">LTD.</FONT></B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 7.15pt"><FONT STYLE="letter-spacing: -0.1pt"><B><U>General</U></B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.3pt"></TD><TD STYLE="width: 9pt">1.</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">1.1.</FONT></TD><TD STYLE="text-align: justify">The name of the Company is &ldquo;Neurolief <FONT STYLE="letter-spacing: -0.1pt">Ltd.&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">1.2.</FONT></TD><TD STYLE="text-align: justify">The object of the Company is to engage in any lawful activity or <FONT STYLE="letter-spacing: -0.1pt">business.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">1.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">The liability of each Shareholder is limited to the unpaid portion of the par value
of each share held by such Shareholder.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Interpretation; <FONT STYLE="letter-spacing: -0.1pt">General</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.3pt"></TD><TD STYLE="width: 30.25pt">2.</TD><TD STYLE="text-align: justify">In these Articles, unless the context otherwise <FONT STYLE="letter-spacing: -0.1pt">requires:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">&ldquo;<B>Affiliate</B>&rdquo; means (i) with respect to a natural person, any member
of such Person's immediate family (including any child, step child, parent, step parent, in-laws, spouse, sibling, stepson or stepdaughter
or the lineal descendants of any of the foregoing); or (ii) with respect to a Person or entity,
any Person or entity which directly or indirectly Controls, is Controlled by, or is under common Control with such Person or entity.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.95pt 0pt 113.95pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Articles</B>&rdquo; means these Amended and Restated Articles of Association
of the Company, as shall be further amended from time to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">&ldquo;<B>Board</B>&rdquo; means the Company&rsquo;s board of directors designated
or elected in accordance with the Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Bonus Shares</B>&rdquo; means Shares issued by the Company for no consideration
to Shareholders entitled to receive them on a pro rata basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">&ldquo;<B>Business Day</B>&rdquo; means a day on which customer services are provided
by a majority of the major commercial banks in Israel and the United States (including for the avoidance of doubt, Fridays).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.1pt">&ldquo;<B>BWAY</B>&rdquo; means Brainsway Ltd., a company organized under the laws
of the State of Israel and/or any Affiliate thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.7.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.1pt">&ldquo;<B>BWAY Investment Agreement</B>&rdquo; means the Investment Agreement made
between BWAY and the Company dated August 18, 2025.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.8.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.1pt">&ldquo;<B>Call Option</B>&rdquo; means the Call Option granted to BWAY pursuant
to the Call Option Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.9.</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.1pt">&ldquo;<B>Call Option Agreement</B>&rdquo; mean the Call Option Agreement entered
by and among the Company, BWAY and the Sellers (as defined therein) dated August 18, 2025
for the acquisition of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.10.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Companies Law</B>&rdquo; means the Companies Law, 5759-1999 and all the
regulations promulgated under it.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.11.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">&ldquo;<B>Companies Ordinance</B>&rdquo; means the Companies Ordinance [New Version],
5743- 1983 and all the regulations promulgated under it.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.12.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Company</B>&rdquo; means the company whose name is set forth <FONT STYLE="letter-spacing: -0.1pt">above.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.13.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt"><B>&ldquo;Control</B>&rdquo; means the holding directly or indirectly of at least
50% of the voting power in a corporation or of the right to appoint at least half of the directors or members of a similar body having
a similar function in a corporation.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.14.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Deemed Liquidation</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="letter-spacing: -0.1pt">8.1.2.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.15.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="letter-spacing: -0.1pt"><B>&ldquo;Defaulting Investor&rdquo; </B>shall have the meaning set
forth in the BWAY Investment Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.16.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Distribution</B>&rdquo; means the grant of a Dividend or an obligation
for such grant, directly or indirectly, and a Repurchase.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.17.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Dividend</B>&rdquo; means any asset transferred by the Company to a Shareholder
in respect of such Shareholder&rsquo;s Shares, whether in cash or in any other way, including a transfer without valuable consideration,
but excluding Bonus Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">2.18.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">&ldquo;<B>Prior CLA</B>&rdquo; means that certain Amended and Restated Convertible
Bridge Loan Agreement by and between the Company and certain lenders listed therein dated July 10, 2024, as amended on November 7, 2024,
and as further amended on or about the date hereof, which shall be converted into Preferred B-2 Shares immediately prior and subject to
the initial Closing of the BWAY Investment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.19.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Founders</B>&rdquo; means Amit Dar and Shmuel <FONT STYLE="letter-spacing: -0.1pt">Shany.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.20.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>General Meeting</B>&rdquo; means an annual or special general meeting of the <FONT STYLE="letter-spacing: -0.1pt">Shareholders.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.21.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>IPO</B>&rdquo; means a firmly underwritten initial public offering of
the Company&rsquo;s Ordinary Shares pursuant to an effective registration statement under the United States Securities Act of 1933, as
amended, or equivalent law of another jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.22.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">&ldquo;<B>Key Employee</B>&rdquo; has such meaning set forth in the Preferred B
Investment <FONT STYLE="letter-spacing: -0.1pt">Agreement.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.23.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>KT</B>&rdquo; means KT Squared, LLC, a Delaware limited liability <FONT STYLE="letter-spacing: -0.1pt">company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.24.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Law</B>&rdquo; means the Companies Law, the Companies Ordinance and any
other law that shall be in effect from time to time with respect to companies and that shall apply to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">2.25.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>M&amp;A Transaction</B>&rdquo; means any of the following transactions:
(i) the sale, lease or other disposal of all or substantially all of the assets or Shares of the Company or repurchase by the Company
of the Company&rsquo;s Shares; (ii) the consolidation, merger or reorganization of the Company with or into any other Person or any other
transaction made by the Company, as a result of which the Shareholders prior to such event do not own, by virtue of their shareholdings
in the Company prior to such event, a majority of the Shares of the surviving entity (which surviving entity may be the Company); (iii)
any transfer or a grant of an exclusive license of material intellectual property of the Company, other than in the Company&rsquo;s ordinary
course of business; or (iv) any other transaction or series of related transactions in which Control of the Company is acquired by any
Person (other than an IPO). Notwithstanding anything in the foregoing to the contrary, to the extent the Call Option is exercised such
transaction shall be deemed an M&amp;A Transaction which shall trigger the liquidation preference distribution pursuant to Article 8.1.1,
excluding, however, any distribution to the Preferred S Shares under sub-article 8.1.1.1.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.26.</FONT></TD><TD STYLE="text-align: justify"><B>&ldquo;Office</B>&rdquo; means the registered office of the <FONT STYLE="letter-spacing: -0.1pt">Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.27.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Office Holders</B>&rdquo; as defined in the Companies <FONT STYLE="letter-spacing: -0.2pt">Law.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.28.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Ordinary Shares</B>&rdquo; means Ordinary Shares of the Company par value NIS 0.01 <FONT STYLE="letter-spacing: -0.1pt">each.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.29.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Original Issue Date</B>&rdquo; means with respect to each Preferred Share
the date on which such Preferred Share was issued by the Company, which, in the case of Preferred Shares received upon conversion of any
&ldquo;SAFE&rdquo;, convertible loans (including without limitation, the New CLA, and the Principal Amount extended under the BWAY Investment
Agreement) or other convertible instruments shall mean the conversion date thereof; Notwithstanding the foregoing, the &ldquo;<B>Original
Issue Date</B>&rdquo; with respect to each of the outstanding Preferred A/A-1/B/B-1 Shares, shall mean the original date upon which such
shares were originally first issued prior to the effectuation of the 2025 Conversion (i.e. therefore no change shall apply to the Original
Issue Date of such shares by virtue of the 2025 Conversion and subsequent reclassification).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.30.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>Original Issue Price</B>&rdquo; means, each as applicable, the Preferred
A Original Issue Price, the Preferred A-1 Original Issue Price, the Preferred B Original Issue Price, the Preferred B-1 Original Issue
Price, the Preferred B-2 Original Issue Price, the Preferred B-3 Original Issue Price, the Preferred B-4 Original Issue Price, the Preferred
S-1 Original Issue Price, the Preferred S-2 Original Issue Price and the Preferred S-3 Original Issue Price.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">2.31.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>New CLA</B>&rdquo; means that certain convertible loan agreement by and
between the Company and certain lenders listed therein dated February, 2025, as amended immediately prior to the initial Closing of the
BWAY Investment Agreement (such agreement constituting the &ldquo;<I>Second Company CLA</I>&rdquo; as defined in the BWAY Investment Agreement).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.32.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">&ldquo;<B>Non</B>-<B>Qualifying Investor(s)</B>&rdquo; means the party defined
in the New CLA as a Non-Qualifying Lender, who did not previously invest its Pro Rata Share (as defined in the New CLA prior to its amendment)
in the New CLA, resulting in the conversion of its previous held preferred shares into Ordinary Shares following the effectuation of the
2025 Recap. The Capitalization Table (as defined in the BWAY Investment Agreement) identifies any Non-Qualifying Investor.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">2.33.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.6pt">&ldquo;<B>Permitted Transferee</B>&rdquo; means, <I><U>provided</U></I> that any
of the following (including any of their Affiliates) are not a competitor of the Company: (1) in relation to any Preferred Shareholder:
(i) a transferee by operation of law; (ii) in the case of an individual Preferred Shareholder - a spouse, child, brother, sister or trustee
of the Preferred Shareholder and any entity which is controlled by or under common control with the Preferred Shareholder; (iii) in the
case of any incorporated Preferred Shareholder (whether a company or a partnership or any other legal entity) - a Person who is an Affiliate
of such Preferred Shareholder, or any of its shareholders, directors, officers, co-investors, limited partners, general partners or the
shareholders, limited or general partners of such shareholders or limited or general partners, or entities that manage or co-manage, or
are managed or whose account is managed by, directly or indirectly, such Preferred Shareholder or any of its shareholders, members, limited
partners, general partners or the shareholders, members, limited or general partners of such shareholders limited or general partners
or management company; (iv) transferees in the framework of a transfer which is part of a transfer of a significant portion of the Preferred
Shareholder&rsquo;s portfolio of investments; (2) in relation to any Shareholder who is not a Preferred Shareholder: (a) a transferee
by operation of law; (b) a Person who is an Affiliate of such Shareholder; (c) in the case of an individual Shareholder - a parent, spouse,
child, brother or sister, or a wholly owned corporation (by it and its parent, spouse, child, brother or sister) of such Shareholder,
and (d) a trust which does not permit any of the settled property or the income therefrom to be applied otherwise than for the benefit
of the relevant Shareholder and no power or control over the voting powers conferred by any Shares are subject to the consent of any person
other than the trustees of such Shareholder. In addition, Deborah Edelstein Weiss and KT shall be deemed Permitted Transferees of each
other.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.34.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">&ldquo;<B>Person</B>&rdquo; means an individual, corporation, partnership, joint
venture, trust, any other corporate entity and any unincorporated association or organization.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">2.35.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Preferred B Investment Agreement</B>&rdquo; means that certain Series
B Preferred Share Purchase Agreement by and between the Company and the Investors (as defined therein), dated October 7, 2022.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.36.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred A Original Issue Price</B>&rdquo; means with respect to each Preferred
A Share, US$4.480 as such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.37.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Preferred A-1 Original Issue Price</B>&rdquo; means with respect to each
Preferred A-1 Share, US$3.584 as such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.38.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred B Original Issue Price</B>&rdquo; means with respect to each Preferred
B Share, US$4.5381 as such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.39.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Preferred B-1 Original Issue Price</B>&rdquo; means with respect to each
Preferred B-1 Share, US$3.4036 as such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.40.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Preferred B-2 Original Issue Price</B>&rdquo; means with respect to each
Preferred B-2 Share, US$3.08, reflecting the conversion price per share pursuant to which the Prior CLA is actually converted into Preferred
B-2 Shares (if and to the extent so converted), as such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.41.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>Preferred B-3 Original Issue Price</B>&rdquo; means with respect to each
Preferred B-3 Share, a price identical to the Preferred B-4 Original Issue Price.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.42.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Preferred B-4 Original Issue Price</B>&rdquo; means with respect to each
Preferred B-4 Share, the conversion price per share pursuant to which the New CLA, is actually converted into Preferred B-4 Shares (if
and to the extent so converted), as such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.43.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Preferred S-1 Original Issue Price</B>&rdquo; means with respect to each
Preferred S-1 Share, the conversion price per share pursuant to which the Initial Principal Amount (as defined in the BWAY Investment
Agreement) is actually converted into Preferred S-1 Shares (if and to the extent so converted) as per the BWAY Investment Agreement, as
such price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.44.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Preferred S-2 Original Issue Price</B>&rdquo; means with respect to each
Preferred S-2 Share, the conversion price per share pursuant to which the Second Principal Amount (as defined in the BWAY Investment Agreement)
is actually converted into Preferred S-2 Shares (if and to the extent so converted) as per the BWAY Investment Agreement, as such price
may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.45.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Preferred S-3 Original Issue Price</B>&rdquo; means with respect to each
Preferred S-3 Share, the actual Third Investment PPS (as defined in the BWAY Investment Agreement) paid by BWAY for its Preferred S-3
Shares at the Third Closing (as defined in the BWAY Investment Agreement) (if and to the extent the Third Closing takes place), as such
price may be adjusted as set forth in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.46.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Preferred A Shares</B>&rdquo; means the New Series A Preferred Shares,
par value NIS 0.01 each, of the Company, as created by the Company following the 2025 Recap.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.47.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Preferred A-1 Shares</B>&rdquo; means the New Series A-1 Preferred Shares,
par value <FONT STYLE="letter-spacing: -0.25pt">NIS</FONT> 0.01 each, of the Company, as created by the Company following the 2025 <FONT STYLE="letter-spacing: -0.1pt">Recap.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.48.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Preferred B Shares</B>&rdquo; means the New Series B Preferred Shares,
par value NIS 0.01 each, of the Company, as created by the Company following the 2025 Recap.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.49.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Preferred B-1 Shares</B>&rdquo; means the New Series B-1 Preferred Shares,
par value <FONT STYLE="letter-spacing: -0.25pt">NIS </FONT>0.01 each, of the Company, as created by the Company following the 2025 <FONT STYLE="letter-spacing: -0.1pt">Recap.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.50.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred B-2 Shares</B>&rdquo; means the Series B-2 Preferred Shares, par
value NIS 0.01 each, of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.51.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>Preferred B-3 Shares</B>&rdquo; means the Series B-3 Preferred Shares,
par value NIS 0.01 each, of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.52.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred B-4 Shares</B>&rdquo; means the Series B-4 Preferred Shares, par
value NIS 0.01 each, of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.53.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred S Shares</B>&rdquo; means the Preferred S-1 Shares, the Preferred
S-2 Shares and the Preferred S-3 Shares, constituting the shares issuable to the Investor (or its nominee) pursuant to the BWAY Investment
Agreement. It is clarified that the Preferred S Shares shall constitute as a single class for all purposes under these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.54.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred S-1 Shares</B>&rdquo; means sub-Series 1 of the Preferred S Shares,
par value NIS 0.01 each, of the Company, to be issued to the Investor upon conversion of the Initial Principal Amount (as defined in the
BWAY Investment Agreement), to the extent converted.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.55.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred S-2 Shares</B>&rdquo; means sub-Series 2 of the Preferred S Shares,
par value NIS 0.01 each, of the Company, to be issued to the Investor upon conversion of the Second Principal Amount (as defined in the
BWAY Investment Agreement), to the extent converted.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.56.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred S-3 Shares</B>&rdquo; means sub-Series 3 of the Preferred S Shares,
par value NIS 0.01 each, of the Company, to be issued to the Investor upon the Third Closing (as defined in the BWAY Investment Agreement),
to the extent the Third Closing takes place.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.57.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">&ldquo;<B>Preferred S Majority</B>&rdquo; means the holder(s) of the majority of the
issued and outstanding Preferred S-1 Shares, Preferred S-2 Shares and Preferred S-3 Shares, voting together as a single class, provided
that such majority shall in all cases include BWAY (alone or together with an Affiliate under its Control) as the holder of such majority.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.58.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>Preferred B Majority</B>&rdquo; means the holders of the majority of the
issued and outstanding Preferred B Shares, Preferred B-1 Shares, Preferred B-2 Shares, Preferred B-3 Shares and Preferred B-4 Shares,
voting together as a single class.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.59.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Ordinary Shareholder</B>&rdquo; means a holder of Ordinary Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.60.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Preferred B Shareholder</B>&rdquo; means a holder of Preferred B <FONT STYLE="letter-spacing: -0.1pt">Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.61.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Preferred B-1 Shareholder</B>&rdquo; means a holder of Preferred B-1 <FONT STYLE="letter-spacing: -0.1pt">Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.62.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Preferred B-2 Shareholder</B>&rdquo; means a holder of Preferred B-2 <FONT STYLE="letter-spacing: -0.1pt">Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.63.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Preferred B-3 Shareholder</B>&rdquo; means a holder of Preferred B-3 <FONT STYLE="letter-spacing: -0.1pt">Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.64.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Preferred B-4 Shareholder</B>&rdquo; means a holder of Preferred B-4 <FONT STYLE="letter-spacing: -0.1pt">Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.65.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Preferred Shareholder</B>&rdquo; means a holder of Preferred <FONT STYLE="letter-spacing: -0.1pt">Shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.66.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">&ldquo;<B>Preferred Shares</B>&quot; means, collectively, the Preferred A Shares,
the Preferred A-1 Shares, the Preferred B Shares, the Preferred B-1 Shares, the Preferred B-2 Shares, the Preferred B-3 Shares, the Preferred
B-4 Shares and the Preferred S Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.67.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">&ldquo;<B>QIPO</B>&rdquo; means the closing of an IPO of with net proceeds to the
Company of at <FONT STYLE="letter-spacing: -0.1pt">least $50,000,000.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.68.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">&ldquo;<B>Qualifying <FONT STYLE="letter-spacing: -0.5pt">Preferred B-4 Investor</FONT>
Pro-Rata Share</B>&rdquo; shall mean the ratio of the <FONT STYLE="letter-spacing: -0.6pt">principal </FONT>amount invested by a Qualifying
Preferred B-4 Investor to the total principal amount invested by all Qualifying Preferred B-4 Investors under the New CLA; all in accordance
with the Company&rsquo;s records.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-size: 10pt">2.69.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">&ldquo;<B>Qualifying Preferred B-4 Investor</B>&rdquo; shall mean a holder of Preferred
B-4 Shares that is/was a party to the New CLA and constituted thereunder a &ldquo;Qualifying Lender&rdquo; (as defined therein).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-size: 10pt">2.70.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">&ldquo;<B>Re-Allocated Preference</B>&rdquo; means the Re-Allocated A Preference
and the Re-Allocated B Preference.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.71.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.65pt"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT>&ldquo;<B>Re-Allocated
A Preference</B>&rdquo; means an aggregate amount of US$737,190 (constituting the accrued liquidation and dividend preference under Article
8.1 of these Articles attributable to the Preferred A-1 Shares and Preferred A Shares previously held by the Non-Qualifying Investor(s)
converted into Ordinary Shares as of the initial Closing of the BWAY Investment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.72.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT>&ldquo;<B>Re-Allocated
B Preference</B>&rdquo; means an aggregate amount of US$ 445,205 (constituting the accrued liquidation and dividend preference under Article
8.1 of these Articles attributable to the Preferred B-1 Shares and Preferred B Shares held by the Non-Qualifying Investor(s) converted
into Ordinary Shares as of the initial Closing of the BWAY Investment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.73.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">&ldquo;<B>2025 Recap</B>&rdquo; means the recapitalization carried out by the Company
as part of the closing of the New CLA, which included, among other actions, the conversion of all previous outstanding preferred shares
of the Company into Ordinary Shares, on a 1:1 basis (the &ldquo;<B>2025 Conversion</B>&rdquo;), and the immediate reclassification of
the previous Preferred B-1/B/A/A-1 Shares held by Qualifying Investors into new Preferred B-1/B/A/A-1 Shares, respectively, on a 1:1 basis,
conferring to the holders thereof the rights, privileges, and preferences provided under these Articles; all to become effective immediately
prior to, and subject to, the consummation of the initial Closing of the BWAY Investment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.74.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">&ldquo;<B>Recapitalization Event</B>&rdquo; means any event of share combination
or subdivision, share split, reverse share split, share dividend, distribution of Bonus Shares or any other reclassification, reorganization
or recapitalization of the Company&rsquo;s share capital or other similar events on the basis of a Shareholder&rsquo;s pro-rata share
of all outstanding Shares of the Company on an as-if-converted to Ordinary Shares basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.75.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">&ldquo;<B>Register</B>&rdquo; means the Register of Shareholders that is to be kept
pursuant to Section 127 of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.76.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Repurchase</B>&rdquo; means the acquiring or the financing of the acquiring,
directly or <FONT STYLE="letter-spacing: -0.1pt">indirectly, by the Company or by a subsidiary of the Company or other corporate entity
</FONT>under the Company&rsquo;s control, of Shares of the Company or securities convertible into or exercisable for Shares of the Company,
or the redemption of redeemable securities that are part of the Company&rsquo;s share capital pursuant to Section 312(d) of the Companies
Law, including an obligation to do any of the same, and all provided that the seller is not the Company itself or another corporate entity
fully owned by the <FONT STYLE="letter-spacing: -0.1pt">Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.77.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Securities Law</B>&rdquo; means the Israeli Securities Law, 1968, as <FONT STYLE="letter-spacing: -0.1pt">amended.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.78.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&ldquo;<B>Shares</B>&rdquo; means any Ordinary Shares, any Preferred Shares or
any other equity security issued by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.79.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Shareholder</B>&rdquo; means a shareholder of the <FONT STYLE="letter-spacing: -0.1pt">Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">2.80.</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Special Share</B>&rdquo; means the Special Share, par value NIS 0.01 each, of the Company, as
created by the Company pursuant to the BWAY Investment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.25pt"></TD><TD STYLE="width: 30.3pt">3.</TD><TD STYLE="text-align: justify; padding-right: 6.9pt">All terms used herein and not otherwise defined herein shall have the meanings defined
in the Law, as in effect on the day on which these Articles become binding on the Company; words and expressions importing the singular
shall include the plural and vice versa if the context so requires; words and expressions importing the masculine gender shall include
the feminine gender. Headings to Articles herein are for convenience only and shall not affect the meaning or interpretation of any provision
hereof. In the event of any discrepancy or inconsistency between these Articles (in their current English form) and their Hebrew translation
(if any), the Articles drafted in the English language shall prevail and the Hebrew translation shall be disregarded.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.25pt"></TD><TD STYLE="width: 30.3pt">4.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">For purposes of computing minimum shareholdings required for any purposes under
these Articles, each Shareholder shall be entitled to aggregate its holdings in the Company with the holdings of any of its Permitted
Transferees, and the aggregate holdings shall be considered to be held by such Shareholder and its Permitted Transferees, and such rights
&ndash; to the extent they are determined to be available at such time - may be exercised with the consent of the other Permitted Transferees
(up to the maximum extent so determined to be available in the aggregate to all such shareholders) by any, some or all of such shareholders
who are Permitted Transferees of each other.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt"><U>Limitations</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.3pt"></TD><TD STYLE="width: 30.25pt">5.</TD><TD STYLE="text-align: left">The following limitations shall apply to the <FONT STYLE="letter-spacing: -0.1pt">Company:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">5.1.</FONT></TD><TD STYLE="text-align: justify">the right to transfer Shares is restricted in the manner hereinafter <FONT STYLE="letter-spacing: -0.1pt">provided;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">5.2.</FONT></TD><TD STYLE="text-align: justify">the number of Shareholders at any time (excluding employees and former employees of the Company who have
been Shareholders during their employment and remain Shareholders after termination of their employment with the Company) shall not exceed
50; <U>provided</U>, <U>however</U>, that if two or more individuals hold a share or Shares of the Company jointly, they shall be deemed
to be one Shareholder for purposes of these Articles; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">5.3.</FONT></TD><TD STYLE="text-align: justify">an offer to the public to subscribe for Shares or debentures of the Company is <FONT STYLE="letter-spacing: -0.1pt">prohibited.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt">Capital</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.25pt"></TD><TD STYLE="width: 30.3pt">6.</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">The authorized share capital of the Company is 391,648 New Israeli Shekels (NIS)
divided into 21,062,619 Ordinary Shares, 1,400,000 Preferred A Shares and 100,000 Preferred A-1 Shares, 2,500,000 Preferred B Shares,
2,200,000 Preferred B-1 Shares, 1,621,000 Preferred B-2 Shares, 1,000,000 Preferred B-3 Shares, 3,042,000 Preferred B-4 Shares, 2,212,524
Preferred S-1 Shares, 2,271,458 Preferred S-2 Shares, 1,755,219 Preferred S-3 Shares, and one (1) Special Share.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 6.75pt 0pt 42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.25pt"></TD><TD STYLE="width: 30.3pt">7.</TD><TD STYLE="text-align: justify; padding-right: 7pt"><U>The Ordinary Shares</U>. Subject to the rights and privileges of the Preferred
Shares and the Special Share, the Ordinary Shares shall rank pari passu between them and shall entitle their holders:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">7.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">to receive notices of, and to attend, General Meetings where each Ordinary Share shall
have one vote for all purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">7.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">to share, on a per share pro rata basis, in Bonus Shares, bonuses, profits or Distributions
as may be declared by the Board and approved by the Shareholders, if required, out of funds legally available therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">7.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">upon liquidation or dissolution &ndash; to participate in the distribution of the
assets of the Company legally available for distribution to Shareholders after payment of all debts and other liabilities of the Company
(in each case, proportionally to the number of Ordinary Shares outstanding and the amounts paid by Shareholders on account of their Shares,
if not paid in full, before calls for payment were made); and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">7.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">to appoint, dismiss, and replace directors of the Company pursuant to the provisions
of these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.25pt"></TD><TD STYLE="width: 30.3pt">7A.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt"><U>The Special Share</U>.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -70.85pt; margin: 0pt 7.1pt 0pt 113.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt">&nbsp;</TD><TD STYLE="width: 70.85pt">7A.1.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">Except as set forth
in this Article 7A, the Special Share shall not confer upon its holder any economic or participation rights whatsoever, including without
limitation rights to dividends or other distributions, except that upon a liquidation of the Company, the holder thereof shall be entitled
to receive an amount equal to the nominal value of the Special Share, in priority to any distribution to holders of Ordinary Shares, but
following payment of any liquidation preferences to the holders of Preferred Shares pursuant to Article 8.1.</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
                                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.85pt">7A.2</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">As of the initial Closing under the BWAY Investment Agreement, the Company has issued
to BWAY one (1) Special Share, which shall confer upon BWAY the rights and privileges granted to BWAY under these Articles in respect
of the appointment of director(s) and all other approvals, rights and consents set forth in Articles 12, 17, 39 through 42B (inclusive),
59, 75, 91, 140 through 143 (inclusive), and any other provision referring to the Special Share or the holder thereof; in each case subject
to Article 144 (&ldquo;<I>Defaulting Investor</I>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.85pt">7A.3.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">The rights and privileges attached to the Special Share shall be exercisable by
BWAY from and after its issuance until the earlier of the following events (i) the Special Share becoming a Deferred Share according to
Section 7.A.4 below; or (ii) the full repayment of the outstanding Loan Amount (as defined in the BWAY Investment Agreement) by the Company
in accordance with and subject to provisions of the BWAY Investment Agreement, whichever occurs first. For the avoidance of doubt, such
rights shall apply regardless of whether BWAY holds any other Shares of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.85pt">7A.4.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">The Special Share shall automatically become a Deferred Share, with no rights or
privileges (other than the right to receive its nominal value upon liquidation following payment of any liquidation preferences to the
holders of Preferred Shares pursuant to Article 8.1) upon the earlier of: (i) issuance to BWAY of any Preferred S Shares pursuant to the
conversion of any portion of the Principal Amount (in which case, the rights and privileges conferred upon BWAY under this Article 7A.
and otherwise under these Articles by virtue of its holding the Special Share shall automatically attach to and be exercised by virtue
of BWAY&rsquo;s holdings of Preferred S Shares); or (ii) BWAY is a Defaulting Investor.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.25pt"></TD><TD STYLE="width: 30.3pt">8.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt"><U>The Preferred Shares</U>. The Preferred Shares confer on the holders thereof
all rights accruing to holders of Ordinary Shares in the Company, and in addition are entitled to the following rights:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.1.</FONT></TD><TD STYLE="text-align: justify"><U>Liquidation and Distribution <FONT STYLE="letter-spacing: -0.1pt">Preference</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.8pt 0pt 184.45pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>8.1.1.</TD><TD STYLE="text-align: justify; padding-right: 6.7pt">In the event of (i) any liquidation, dissolution, or winding-up of the Company, either voluntary or non-voluntary; (ii) any bankruptcy,
insolvency or reorganization proceeding under any bankruptcy or insolvency or similar law, whether voluntary or involuntary, is properly
commenced by or against the Company; or (iii) a receiver or liquidator is appointed to all or substantially all of the Company&rsquo;s
assets; collectively, a &ldquo;<B>Liquidation</B>&rdquo;; then in each such event, the assets or proceeds available for distribution or
payment to the Shareholders (the &ldquo;<B>Distributable Proceeds</B>&rdquo;) shall be distributed among the Shareholders according to
the following order of preference:</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 6.7pt">&nbsp;</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="width: 178.2pt"></TD><TD STYLE="width: 36pt">8.1.1.1</TD><TD STYLE="text-align: justify; padding-right: 6.7pt">First, the holders of Preferred S Shares shall be entitled, prior and in preference
to the holders of any other class of Shares, to receive, out of the Distributable Proceeds, an amount per Preferred S Share equal to the
greater of: (i) the Original Issue Price of such Preferred S Share; and&nbsp;(ii) the amount that would be distributed in respect of such
Preferred S Share had all Shares of the Company been converted into Ordinary Shares immediately prior to such Deemed Liquidation and the
entire Distributable Proceeds distributed among the Shareholders on a pro-rata, as-converted basis (without taking into account any liquidation
preferences under this Article 8.1), in US$ (in cash, cash equivalents or, if applicable, securities), and less the aggregate of all amounts
of Preferred S Dividend Preference and/or Distributable Proceeds previously paid in preference with respect to each such Preferred S Share
(the &ldquo;<B>Preferred S Preference</B>&rdquo;). In the event that the Distributable Proceeds shall be insufficient for the distribution
of the Preferred S Preference in full to all of the holders of Preferred S Shares, the Distributable Proceeds shall be distributed among
the holders of Preferred S Shares on a pro rata and pari passu basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 178.2pt"></TD><TD STYLE="width: 36pt">8.1.1.2</TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Second, after payment in full of the Preferred S Preference but prior and in preference
to the holders of Preferred B-2 Shares, Preferred B-1 Shares, Preferred B Shares, Preferred A Shares, Preferred A-1 Shares and Ordinary
Shares of the Company: the holders of Preferred B-4 Shares and Preferred B-3 Shares shall be entitled to receive for each Preferred B-4
Share and Preferred B-3 Share held by them, prior and in preference to the holders of any other Shares of the Company, an amount equal
to two (2) times the applicable Original Issue Price of each such Preferred B-4 Share and Preferred B-3 Share, respectively, in US$ (in
cash, cash equivalents or, if applicable, securities), plus any accrued and unpaid undeclared dividends on behalf of the Preferred B-3/B-4
Dividend Preference, plus an amount equal to all other declared but unpaid Dividends on each Preferred B-4 Share and Preferred B-3 Share
and less the aggregate of all amounts of Preferred B-3/B-4 Dividend Preference and/or Distributable Proceeds previously paid in preference
with respect to each such Preferred B-4 Share and Preferred B-3 Share (the &ldquo;<B>Preferred B-3/B-4 Preference</B>&rdquo;). In the
event that the Distributable Proceeds shall be insufficient for the distribution of the Preferred B-3/B-4 Preference in full to all of
the holders of Preferred B-4 Shares and Preferred B-3 Shares, the Distributable Proceeds shall be distributed among the holders of Preferred
B-4 Shares and Preferred B-3 Shares on a pro rata and pari passu basis (based on the total Preferred B-3/B-4 Preference owed thereto and
not based on the number of Preferred B-4 Shares and Preferred B-3 Shares held).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.3pt"></TD><TD STYLE="width: 36pt">8.1.1.3</TD><TD STYLE="text-align: justify; padding-right: 6.8pt">Third, after payment in full of the Preferred S Preference and the Preferred B-3/B-4
Preference but prior and in preference to the holders of Preferred A Shares, Preferred A-1 Shares and Ordinary Shares of the Company:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.75pt; margin: 0pt 6.65pt 0pt 220.3pt"><FONT STYLE="letter-spacing: -0.1pt">(A)<FONT STYLE="font-size: 10pt">&nbsp;
</FONT></FONT>the holders of Preferred B-2 Shares, Preferred B-1 Shares and Preferred B Shares shall be entitled to receive for each Preferred
B-2 Share, Preferred B-1 Share and Preferred B Share held by them, an amount equal to two (2) times the applicable Original Issue Price
of each such Preferred B-2 Share, Preferred B-1 Share and Preferred B Share, respectively, in US$ (in cash, cash equivalents or, if applicable,
securities), plus any accrued and unpaid undeclared dividends on behalf of the Preferred B/B-1/B-2 Dividend Preference, plus an amount
equal to all other declared but unpaid Dividends on each Preferred B-2 Share, Preferred B-1 Share and Preferred B Share and less the aggregate
of all amounts of Preferred B/B-1/B-2 Dividend Preference and/or Distributable Proceeds previously paid in preference with respect to
each such Preferred B-2 Share, Preferred B-1 Share and Preferred B Share (the &ldquo;<B>Preferred B/B-1/B-2 Preference)</B>; and</P>

<P STYLE="margin: 0pt 6.65pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 2.75pt">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 6.65pt 0pt 220.3pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.7pt 0pt 220.3pt"><FONT STYLE="letter-spacing: -0.1pt">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT></FONT>each Qualifying Preferred B-4 Investor shall be entitled to receive, an amount equal to its Qualifying Preferred B-4 Investor
Pro-Rata Share of the Re-Allocated B Preference (&ldquo;<B>Qualifying Preferred B-4 Investor Re-Allocated B Preference</B>&rdquo;). The
entitlement for the Re-Allocated B Preference shall be tied to the Preferred B-4 Shares issued to each Qualifying Preferred B-4 Investor,
such that for each Preferred B-4 Share held any Qualifying Preferred B-4 Investor by virtue of the conversion of its investment pursuant
to the New CLA, such Qualifying Preferred B-4 Investor shall be entitled to receive, in addition to the Preferred B-4 Preference as per
article 8.1.1, an amount equal to such Qualifying Preferred B-4 Investor Re-Allocated B Preference divided by the number of Preferred
B-4 Shares issued to such Qualifying Preferred B-4 Investor upon conversion of the New CLA.</P>

<P STYLE="margin: 0pt 6.7pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 178.2pt"></TD><TD STYLE="width: 36pt">8.1.1.4</TD><TD STYLE="text-align: justify; padding-right: 6.7pt">In the event that the Distributable Proceeds shall be insufficient for the distribution
of the Preferred B/B-1/B-2 Preference and the Re-Allocated B Preference in full, the Distributable Proceeds shall be distributed among
the applicable holders on a pro rata and pari passu basis (based on the total Preferred B/B-1/B-2 Preference and Re-Allocated B Preference
owed thereto and not based on the number of Preferred B-2 Shares, Preferred B-1 Shares and Preferred B Shares held).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.3pt"></TD><TD STYLE="width: 36pt">8.1.1.5</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Fourth, after payment in full of the Preferred S Preference, the Preferred B-3/B-4
Preference, the Preferred B/B-1/B-2 Preference and the Re-Allocated B Preference, but prior and in preference to the holders of Ordinary
Shares of the Company:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.8pt 0pt 220.3pt"><FONT STYLE="letter-spacing: -0.1pt">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT></FONT>the holders of Preferred A-1 Shares and Preferred A Shares shall be entitled to receive for each Preferred A-1 Share and
Preferred A Share held by them, an amount equal to the higher of: (i) one (1) times the applicable Original Issue Price of each such Preferred
A-1 Share and Preferred A Share, respectively, in US$ (in cash, cash equivalents or, if applicable, securities), plus any accrued and
unpaid undeclared dividends on behalf of the Preferred A/A-1 Dividend Preference, plus an amount equal to all other declared but unpaid
Dividends on each Preferred A-1 Share and Preferred A Share and less the aggregate of all amounts of Preferred A/A-1 Dividend Preference
and/or Distributable Proceeds previously paid in preference with respect to each such Preferred A-1 Share and Preferred A Share (the &ldquo;<B>Preferred
A/A-1 Preference&rdquo;)</B>, and (ii) the amount per share such holder would have received for such Preferred A Share or Preferred A-1
Share had all Preferred A Shares and Preferred A-1 Shares been converted into Ordinary <FONT STYLE="letter-spacing: -0.1pt">Shares </FONT>immediately
prior to such Liquidation (taking into account the aggregate amount of Distributable Proceeds previously paid in preference pursuant to
this Article 8.1 and any Dividend Preference paid pursuant to these Articles below with respect to such Preferred A Share and Preferred
A-1 Shares) (the &ldquo;<B>Preferred A Pro-Rata Distribution</B>&rdquo;).</P>

<P STYLE="margin: 0pt 6.8pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 6.8pt 0pt 220.3pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.75pt; margin: 0pt 6.65pt 0pt 220.3pt"><FONT STYLE="letter-spacing: -0.1pt">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;
</FONT></FONT>each Qualifying Preferred B-4 Investor shall be entitled to receive, an amount equal to its Qualifying Preferred B-4 Investor
Pro-Rata Share of the Re-Allocated A Preference (&ldquo;<B>Qualifying Preferred B-4 Investor Re-Allocated A Preference</B>&rdquo;). The
entitlement for the Re- Allocated A Preference shall be tied to the Preferred B-4 Shares issued to each Qualifying Preferred B-4 Investor,
such that for each Preferred B-4 Share held by any Qualifying Preferred B-4 Investor by virtue of the conversion of its investment pursuant
to the New CLA, such Qualifying Preferred B-4 Investor shall be entitled to receive, in addition to the Preferred B-4 Preference as per
articles 8.1.1 and 8.1.2, an amount equal to such Qualifying Preferred B-4 Investor Re-Allocated A Preference divided by the number of
Preferred B-4 Shares issued to such Qualified Preferred B-4 Investor upon conversion of the New CLA.</P>

<P STYLE="margin: 0pt 6.65pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 2.75pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.75pt 0pt 220.3pt">(In the event that the Distributable
Proceeds shall be insufficient for the distribution of the Preferred A/A-1 Preference and the Re-Allocated A Preference, in full, the
Distributable Proceeds shall be distributed among the applicable holders on a pro rata and pari passu basis (based on the total Preferred
A/A-1 Preference and Re-Allocated A Preference owed thereto).</P>

<P STYLE="margin: 0pt 6.75pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.3pt"></TD><TD STYLE="width: 36pt">8.1.1.6</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Lastly, after payment in full of the Preferred S Preference, the Preferred B-3/B-4
Preference, the Preferred B/B-1/B-2 Preference, the Re- Allocated B Preference, the Preferred A/A-1 Preference or the Preferred A Pro-Rata
Distribution (as applicable) and the Re- Allocated A Preference (collectively: the &ldquo;<B>Liquidation Preference</B>&rdquo;), the Preferred
B-4 Shareholders, Preferred B-3 Shareholders, Preferred B-2 Shareholders, Preferred B-1 Shareholders and the Ordinary Shareholders, in
respect of their Preferred B-4 Shares, Preferred B-3 Shares, Preferred B-2 Shares, Preferred B-1 Shares, Preferred B Shares and Ordinary
Shares, respectively, then outstanding, the remaining Distributable Proceeds available for distribution, if any, shall be distributed
on a pro-rata, pari passu and as-converted basis (without, for the avoidance of doubt, such Preferred B-4 Shares, Preferred B-3 Shares,
Preferred B-2 Shares, Preferred B-1 Shares and Preferred B Shares actually being <FONT STYLE="letter-spacing: -0.1pt">converted </FONT>into
Ordinary Shares). For clarity, receipt of their respective portion of the Liquidation Preference by the applicable Preferred Shareholders
shall not derogate from the right of such Preferred Shareholders to receive the distribution in the prior <FONT STYLE="letter-spacing: -0.1pt">sentence.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.1.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.6pt">Unless otherwise approved by the Preferred B Majority and (except in the event of
an exercise of the Call Option) the Preferred S Majority, any M&amp;A Transaction shall be treated as a Liquidation pursuant to the above
provisions of this Article 8.1 (a &ldquo;<B>Deemed Liquidation</B>&rdquo;), and the provisions of Articles 8.1.1.1 through 8.1.1.6 shall
apply to a distribution of the Distributable Proceeds received by the Company and/or the Shareholders in connection with such Deemed Liquidation.
In the event of a Deemed Liquidation resulting from the transfer of outstanding Shares of the Company, no such transfer shall be valid
and the Company shall not register it in the Register, unless measures determined by the Board that are satisfactory to the Preferred
B Majority and (except in the event of an exercise of the Call Option) the Preferred S Majority are taken for the distribution of the
consideration received for such transfer in accordance with Articles 8.1.1.1 through 8.1.1.6 above; where in the case of the Call Option,
the measures set forth in the Call Option Agreement shall apply and are deemed to fully satisfy the requirements set forth in this Article
8.1.2.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.6pt 0pt 184.45pt">Notwithstanding anything to the contrary
<FONT STYLE="letter-spacing: -0.1pt">in these Articles (and in particular Article 8.1.2 above), in connection with a transaction in which
BWAY (or any Affiliate, transferee or assignee thereof) (a <B>&ldquo;BWAY Party&rdquo;</B>) is exercising the Call Option in such transaction,
(i) No BWAY Party shall be entitled to receive any Distributable Assets from such transaction, (ii) Articles 8.1.1.1 (i.e., the Preferred
S Preference) and 8.1.1.6 (to the extent relating to pro-rata participation by a BWAY Party) above shall not apply, and (ii) the Distributable
Assets shall be solely and exclusively allocated between the Company&rsquo;s security holders (excluding any BWAY Party) selling their
securities in such transaction according the distribution waterfall set forth in Article 8.1.1 (after disregarding the items set forth
above).</FONT></P>

<P STYLE="margin: 0pt 6.6pt 0pt 184.45pt; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.1.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.6pt">In the event of a Deemed Liquidation if any portion of the consideration payable
or distributable to the Shareholders is placed into escrow or is payable or distributable to the Shareholders subject to contingencies
(the &ldquo;<B>Deferred Payments</B>&rdquo;), the purchase agreement or plan of merger or consolidation for such transaction shall provide
that (and in the absence of such provision, including with respect to the Call Option Agreement, the following shall in any event apply):
that (a) the portion of such consideration that is not placed in escrow and not subject to any contingencies (the &ldquo;<B>Initial Consideration</B>&rdquo;)
shall be allocated among the Shareholders in accordance with Articles 8.1.1.1, 8.1.1.2 8.1.1.3, 8.1.1.4, 8.1.1.5 and 8.1.1.6 as if the
<FONT STYLE="letter-spacing: -0.1pt">Initial </FONT>Consideration were the only consideration payable in connection with such Deemed Liquidation
and (b) any additional consideration which becomes payable or distributable to the shareholders of the Company upon release from escrow
or satisfaction of contingencies shall be allocated among the shareholders in accordance with Articles <FONT STYLE="letter-spacing: -0.1pt">8.1.1.1,
</FONT>8.1.1.2 8.1.1.3, 8.1.1.4, 8.1.1.5 and 8.1.1.6 after taking into account the previous payment of the Initial Consideration and Deferred
Payments (if any) as part of the same transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.1.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">The Company shall give each holder of record of Preferred Shares written notice
of such Liquidation, Distribution of Dividends or Deemed Liquidation (other than pursuant to the exercise of the Call Option, where if
the Call Option is exercised the Company shall provide each such holder with notice as soon as possible following its receipt of the Exercise
Notice (as defined in the Call Option Agreement) impending transaction not later than ten (10) Business Days prior to the Shareholders&rsquo;
meeting called to approve such transaction, or ten (10) Business Days prior to the closing of such transaction, whichever is earlier,
and shall also notify such holders in writing of the final approval of such transaction. The first of such notices shall describe the
material terms and conditions of the impending transaction and the provisions of this Article 8.1, and the Company shall thereafter give
such holders prompt notice of any material changes. The transaction shall in no event take place sooner than ten (10) Business Days after
the Company has given the first notice provided for herein or sooner than ten (10) Business Days after the Company has given notice of
any material changes to the information provided in a notice provided for herein; <U>provided</U>, <U>however</U>, that such periods may
be shortened upon the written consent of the holders of the Preferred B Majority and (except in the event of an exercise of the Call Option)
the Preferred S Majority.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.1.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt"><FONT STYLE="letter-spacing: -0.1pt">If the amount deemed paid or distributed under
this Article 8.1 is</FONT> <FONT STYLE="letter-spacing: -0.2pt">made </FONT>in property other than in cash, the value of such distribution
shall be the fair market value of such property, determined as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.3pt"></TD><TD STYLE="width: 36pt">8.1.5.1</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">For securities not subject to investment letters or other similar restrictions
on free marketability,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 7pt 0pt 220.3pt">&nbsp;</P>

<P STYLE="margin: 0pt 7pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">(1)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if traded on a securities exchange or the NASDAQ Stock Market, the value shall be deemed to be the average of the closing prices
of the securities on such exchange or market over the thirty (30) day period ending three (3) days prior to the closing of such transaction;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.8pt 0pt 220.3pt">&nbsp;</P>

<P STYLE="margin: 0pt 6.8pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">(2)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if actively traded over-the-counter, the value shall be deemed to be the average of the closing bid prices over the thirty (30)
day period ending three (3) days prior to the closing of such transaction; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.9pt 0pt 220.3pt">&nbsp;</P>

<P STYLE="margin: 0pt 6.9pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">(3)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Board
and approved by the Preferred B Majority and (except in the event of an exercise of the Call Option) the Preferred S Majority; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.9pt 0pt 220.3pt">&nbsp;</P>

<P STYLE="margin: 0pt 6.9pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">(4)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if securities to be issued pursuant to the exercise of the Call Option, the price attributed to such securities pursuant to the
terms of the Call Option Agreement.</P>

<P STYLE="margin: 0pt 6.9pt 0pt 220.3pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.3pt"></TD><TD STYLE="width: 36pt">8.1.5.2</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">The method of valuation of securities subject to investment letters or other similar
restrictions on free marketability (other than restrictions arising solely by virtue of a shareholder&rsquo;s status as an affiliate or
former affiliate) shall take into account an appropriate discount (as determined in good faith by the Board) from the market value as
determined pursuant to Article 8.1.5.1 above so as to reflect the approximate fair market value thereof.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 6.75pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 43.15pt; text-align: left">8.1A <U>Dividend <FONT STYLE="letter-spacing: -0.1pt">Rights</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 43.15pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 115.15pt"><FONT STYLE="letter-spacing: -0.1pt">8.1A1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preferred
<FONT STYLE="letter-spacing: -0.1pt">Shares</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 115.15pt; font-size: 10pt; text-align: left; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.7pt 0pt 2.6in"><I><U>first</U></I><U>,</U> the holders
of the then outstanding Preferred S Shares shall be entitled to receive, prior and in preference to the payment of any dividends on any
other class or series of Shares (including, without limitation, all other Preferred Shares and the Ordinary Shares), when, as and if declared
by the Board, out of any funds and assets of the Company legally available therefor, cumulative and compounding dividends in an amount
per share equal to eight percent (8%) of the applicable Original Issue Price of each such Preferred S Share, per annum, from the applicable
Original Issue Date (the &ldquo;<B>Preferred S Dividend Preference</B>&rdquo;) (<FONT STYLE="letter-spacing: -0.1pt">provided, however,
that the holders of Preferred S Shares shall not be entitled to the Preferred S Dividend Preference in a Deemed Liquidation in which a
BWAY Party is exercising the Call Option in such transaction)</FONT>;</P>

<P STYLE="margin: 0pt 6.7pt 0pt 2.6in; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 6.7pt 0pt 2.6in; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.7pt 0pt 2.6in"><I><U>second, </U></I>after payment in
full of the Preferred S Dividend Preference, the holders of the then outstanding Preferred B-4 Shares and Preferred B-3 Shares shall be
entitled to receive, prior and in preference to the payment of any dividends on the Preferred B-2 Shares, Preferred B-1 Shares, Preferred
B Shares, Preferred A-1 Shares, Preferred A Shares and Ordinary Shares, when, as and if declared by the Board, out of any funds and assets
of the Company legally available therefor, cumulative and compounding dividends at the rate of eight percent (8%) of the applicable Original
Issue Price per each Preferred B-4 Share and Preferred B-3 Share, per annum from the Original Issue Date (the &ldquo;<B>Preferred B-3/B-4
Dividend <FONT STYLE="letter-spacing: -0.1pt">Preference</FONT></B><FONT STYLE="letter-spacing: -0.1pt">&rdquo;);</FONT></P>

<P STYLE="margin: 0pt 6.7pt 0pt 2.6in; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.65pt 0pt 2.6in"><I><U>third</U></I><U>,</U> after payment
in full of the Preferred B-3/B-4 Dividend Preference in respect of all Preferred B-4 Shares and Preferred B-3 Shares then outstanding,
the holders of the then outstanding Preferred B-2 Shares, Preferred B-1 Shares and Preferred B Shares, shall be entitled to receive, prior
and in preference to the payment of any dividends on the Preferred A-1 Shares, Preferred A Shares and Ordinary Shares, when, as and if
declared by the Board, out of any funds and assets of the Company legally available therefor, cumulative and compounding dividends at
the rate of eight <FONT STYLE="letter-spacing: -0.1pt">percent </FONT>(8%) of the applicable Original Issue Price per each Preferred B-2
Share, Preferred B-1 Share and Preferred B Share, per annum from the Original Issue Date (the &ldquo;<B>Preferred B/B-1/B-2 Dividend Preference</B>&rdquo;);
and</P>

<P STYLE="margin: 0pt 6.65pt 0pt 2.6in; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.7pt 0pt 2.6in"><I><U>fourth</U></I><U>,</U> after payment
in full of the Preferred B/B-1/B-2 Dividend Preference in respect of all Preferred B-2 Shares, Preferred B-1 Shares and Preferred B Shares
then outstanding, the holders of the then outstanding Preferred A-1 Shares and Preferred A Shares, shall be entitled to receive, prior
and in preference to the payment of any other dividends, when, as and if declared by the Board, out of any funds and assets of the Company
legally available therefor, cumulative and compounding dividends at the rate of six percent (6%) of the applicable Original Issue Price
per each Preferred A-1 Share and Preferred A Share, per annum from the Original Issue Date (the &ldquo;<B>Preferred A/A-1 Dividend Preference</B>&rdquo;,
and collectively with the Preferred S Dividend Preference, the Preferred B-3/B-4 Dividend Preference and Preferred B/B-1/B-2 Dividend
Preference, the &ldquo;<B>Dividend Preference</B>&rdquo;).</P>

<P STYLE="margin: 0pt 6.7pt 0pt 2.6in; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 115.15pt"></TD><TD STYLE="width: 72.05pt"><FONT STYLE="letter-spacing: -0.1pt">8.1A2</FONT></TD><TD STYLE="text-align: justify; padding-right: 2.25pt"><U>Ordinary Shares</U>. If, after payment in full of the Dividend Preference as
specified in Section 8.1A1 for the Preferred Shares, the Board shall declare additional dividends out of funds legally available therefor,
then such additional dividends shall be paid pro rata on the Preferred Shares and Ordinary Shares on a pro-rata, pari passu and as-converted
basis according to the number of Ordinary Shares held by each holder, where each holder of Preferred Shares is to be treated for this
purpose as holding the greatest whole number of Ordinary Shares then issuable upon conversion of all Preferred Shares held by such holder
(without, for the avoidance of doubt, such Preferred Shares actually being converted into Ordinary Shares).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 114.55pt"></TD><TD STYLE="width: 72.65pt"><FONT STYLE="letter-spacing: -0.1pt">8.1A3</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt"><U>Non-Cash Dividends</U>. Whenever a dividend provided for in this Section 8.1A
shall be payable in property other than cash, the value of such dividend shall be determined in accordance with Article 8.1.5 above which
shall apply <I>mutatis mutandis </I>hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt"><U>Conversion</U>. The Preferred Shareholders shall have conversion rights as follows
(the &ldquo;<B>Conversion Rights</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.9pt"><FONT STYLE="font-size: 10pt">8.2.1.</FONT></TD><TD STYLE="text-align: justify"><U>Right to <FONT STYLE="letter-spacing: -0.1pt">Convert</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.1.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Each Preferred Share shall be convertible at the option of the holder of such share,
at any time after the Original Issue Date of such share, into such number of fully paid and nonassessable Ordinary Shares of the Company
as is determined by dividing the applicable Original Issue Price for such share by the Conversion Price (as defined below) at the time
in effect for such share. The initial conversion price per each Preferred Share shall be the Original Issue Price for such share (the
&ldquo;<B>Conversion Price</B>&rdquo;); <U>provided</U>, <U>however</U>, that the Conversion Price for each Preferred Share shall be adjusted
in accordance with any Recapitalization Event and pursuant to the anti- dilution and other adjustment provisions set forth <FONT STYLE="letter-spacing: -0.1pt">herein.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.1.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Notwithstanding anything to the contrary herein, each Preferred Share (including
the applicable accrued Dividend Preference, subject to applicable law and required tax withholding, if any) shall automatically be converted
into fully paid and nonassessable Ordinary Shares by dividing the applicable Original Issue Price by the Conversion Price at the time
in effect for such Preferred Share, immediately upon: (i) a QIPO; or (ii) upon the written consent of (A) the Preferred B Majority and
(B) the holder of the Special Share or the Preferred S Majority. For the avoidance of doubt, in the event of a conversion under subsection
(ii) above for an IPO (excluding a QIPO), the liquidation preference provisions described in Article 8.1 shall apply and any deviation
therefrom shall be subject to the written consent of (A) the Preferred B Majority and (B) the holder of the Special Share or the Preferred
S Majority.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.1.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt"><U>Mechanics of Conversion</U>. Before any Preferred Shareholder shall be entitled
to convert any Preferred Share into Ordinary Shares, the Preferred Shareholder shall surrender the certificate or certificates thereof,
or an affidavit of loss of the certificate or certificates therefor in a form reasonably acceptable to the Company, duly executed, at
the Office and shall give written notice by registered mail, postage prepaid, to the Company of the election to convert the same. The
Company shall, as soon as practicable thereafter, issue and deliver to such Preferred Shareholder a certificate or certificates for the
number of Ordinary Shares to which such Preferred Shareholder shall be entitled as aforesaid. Such conversion shall be deemed to have
been made immediately prior to the close of business on the date of the surrender of the certificate or submission of the affidavit of
loss of the certificate representing the Preferred Shares to be converted, and the Person or Persons entitled to receive the Ordinary
Shares issuable upon such conversion shall be treated for all purposes as the record holder of such Ordinary Shares as of such date. In
the case of conversion pursuant to Article 8.2.1.2, such conversion shall be deemed to have been made immediately prior to the close of
business on the date of the occurrence of any of the events listed in <FONT STYLE="letter-spacing: -0.1pt">Article </FONT>8.2.1.2 and
subject to the actual occurrence of such event, and the Person or Persons entitled to receive the Ordinary Shares issuable upon such conversion
shall be treated for all purposes as the record holder of such Ordinary Shares as of such date; once again provided that the event does
actually occur.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.9pt"><FONT STYLE="font-size: 10pt">8.2.2.</FONT></TD><TD STYLE="text-align: justify"><U>Conversion Price Adjustments of Preferred <FONT STYLE="letter-spacing: -0.1pt">Shares</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.65pt">In the event that the Company issues any Additional Securities (as defined below)
at a price per share lower than the Conversion Price of Preferred Shares in effect immediately prior to such issuance (the &ldquo;<B>Reduced
Price</B>&rdquo;), then the Conversion Price of <FONT STYLE="letter-spacing: -0.2pt">such </FONT>series of Preferred Shares shall be reduced,
for no additional consideration, in accordance with the following broad based weighted average formula:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 294.95pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.6pt 0pt 255.35pt"><IMG SRC="formula.jpg" ALT="" STYLE="height: 78px; width: 175px"></P>

<P STYLE="margin: 0pt 6.6pt 0pt 255.35pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0pt 6.6pt 0pt 255.35pt; font-size: 10pt; text-align: justify; text-indent: 0in">where <B>CP </B>is the reduced Conversion
Price; <B>A </B>is the number of Ordinary Shares, on an as-converted fully diluted basis (treating for this purpose as outstanding all
Ordinary Shares issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of convertible
securities (including the Preferred Shares), outstanding immediately prior to the relevant issuance of Additional Securities; but excluding
Ordinary Shares reserved for Options that were not allocated prior to the relevant issuance of Additional Securities); <B>P</B>' is the
Conversion Price applicable to the Preferred Shares of the applicable series in effect immediately prior to such issuance; <B>C</B> is
the number of Additional Securities; and <B>P</B>'' is the Reduced Price.</P>

<P STYLE="margin: 0pt 6.6pt 0pt 255.35pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 6.6pt 0pt 255.35pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.65pt">No adjustment to the Conversion Price pursuant to Article 8.2.3.1 shall be made
if it has the effect of increasing the Conversion Price of such Preferred Share above the Conversion Price of such Preferred Share in
effect immediately prior to such <FONT STYLE="letter-spacing: -0.1pt">adjustment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">In the case of the issuance of Additional Securities for cash, the consideration
shall be deemed to be the amount of cash received therefor after deducting from such cash amount any discounts, finder&rsquo;s fees or
underwriting commissions paid or incurred by the Company in connection with the issuance and sale <FONT STYLE="letter-spacing: -0.1pt">thereof.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">In the case of the issuance of Additional Securities for a consideration in whole
or in part other than cash, the consideration other than cash shall be deemed to be the fair value thereof, as shall be determined in
accordance with Article 8.1.4 above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">In the case of the issuance of warrants or options to purchase, or rights to subscribe
for, Additional Securities, or securities which by their terms are convertible into or exchangeable for Additional Securities or options
to purchase or rights to subscribe for such convertible or exchangeable securities (collectively, &ldquo;<B>Options</B>&rdquo;), the Additional
Securities deliverable upon exercise (assuming the satisfaction of any conditions to exercisability, including without limitation the
passage of time, but without taking into account potential anti-dilution adjustments), conversion or exchange, as the case may be, of
such Options, shall be deemed to have been issued at <FONT STYLE="letter-spacing: -0.25pt">the </FONT>time of issuance of such Options
at a consideration equal to the consideration (determined in the manner provided in Articles 8.2.3.3 and 8.2.3.4), if any, received by
the Company for such Options upon the issuance of such Options plus any additional consideration payable to the Company pursuant to the
terms of such Options (without taking into account potential anti-dilution adjustments) for the Additional Securities covered thereby;
<U>provided</U>, <U>however</U>, that if any Options as to which an adjustment to the Conversion Price has been made pursuant to this
Article 8.2.3.5 expire without having been exercised, then the Conversion Price shall be readjusted as if such Options had not been issued
(without any effect, however, on adjustments to the Conversion Price as a result of other events described in this Article); <U>provided</U>
that no such readjustment shall have the effect of increasing the applicable Conversion Price to an amount which exceeds the applicable
Conversion Price that would have resulted from other issuances of Additional Securities after the time of issuance of such Options had
such Options not been <FONT STYLE="letter-spacing: -0.1pt">issued.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">For purposes of this Article 8.2.2, the consideration for any Additional Securities
shall be taken into account at the U.S. dollar equivalent thereof, on the day such Additional Securities are issued or deemed to be issued
pursuant to Article 8.2.3.5.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.2.7.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">&ldquo;<B>Additional Securities</B>&rdquo; means any shares, warrants, convertible
deeds or any other security or right exercisable or convertible into shares of the Company, other than the Excluded Securities. The &ldquo;<B>Excluded
Securities</B>&rdquo; means any of the <FONT STYLE="letter-spacing: -0.1pt">following: </FONT>(i) options or shares issued to employees,
directors or consultants, pursuant to an employee stock option plan or any incentive plan approved by the <FONT STYLE="letter-spacing: -0.1pt">Board;
</FONT>(ii) securities issued upon conversion of the Preferred Shares; (iii) securities issued to the public in an <FONT STYLE="letter-spacing: -0.2pt">IPO;
</FONT>(iv) securities issued in the framework of a Recapitalization Event; (v) issuance of securities of the Company pursuant to (A)
the BWAY Investment Agreement (including all of the Preferred S Shares), and (B) the New CLA, including without limitation, the warrants
issuable thereunder and the shares issued upon exercise thereof (including, Preferred B-3 Shares or Preferred B-4 Shares issuable upon
conversion thereof or otherwise thereunder), as well as the warrants issued thereunder and shares issued upon exercise thereof; (vi) securities
issued pursuant to Article 141.6.1 below; and (vi) securities issued in any other issuance with respect to which (A) the holders of the
Preferred B Majority and (B) the holder of the Special Share or the Preferred S Majority, agreed, in writing, qualify from the definition
of &ldquo;Additional Securities&rdquo; for the purpose of waiver of anti-dilution and/or pre-<FONT STYLE="letter-spacing: -0.1pt">emptive
</FONT>rights with respect to such issuance, as the case may <FONT STYLE="letter-spacing: -0.2pt">be.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.2.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt"><U>Recapitalization Event</U>. If at any time or from time to time there shall
be a Recapitalization Event (other than any actions under Article 8.2.2), and other than a Liquidation, Distribution of Dividends or Deemed
Liquidation under Article 8.1), provision shall be made so that the Preferred Shareholders shall thereafter be entitled to receive upon
conversion of the Preferred Shares the number of Ordinary Shares or other securities or property of the Company or otherwise, to which
a holder of Ordinary Shares deliverable upon conversion of the Preferred Shares would have become entitled to as a result of the Recapitalization
Event had the Preferred Shares been converted to Ordinary Shares immediately prior to such Recapitalization Event. In any such case, appropriate
adjustment shall be made in the application of the provisions of these Articles with respect to the rights of the Preferred Shareholders
after the recapitalization to the end that the provisions of these Articles (including adjustment, if necessary, of the Original Issue
Price and the Conversion Price then in effect and the number of shares issuable upon conversion of the Preferred Shares) shall be applicable
after that event as equivalent to the manner in which they were applicable prior to such event as may be <FONT STYLE="letter-spacing: -0.1pt">practicable.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.9pt"><FONT STYLE="font-size: 10pt">8.2.4.</FONT></TD><TD STYLE="text-align: justify"><U>No Fractional Shares and Certificates as to <FONT STYLE="letter-spacing: -0.1pt">Adjustments</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.4.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">No fractional shares shall be issued upon conversion of the Preferred Shares, and
the number of Ordinary Shares to be issued shall be rounded to the nearest whole share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 184.45pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.2.4.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Upon the occurrence of each adjustment of the Conversion Price of a series of Preferred
Shares pursuant to this Article 8, the Company, at its expense, shall promptly compute such adjustment in accordance with the terms hereof
and prepare and furnish to each Preferred Shareholder a certificate setting forth each adjustment and showing in detail the facts upon
which such adjustment is based. The Company shall furnish or cause to be furnished to such holder a like certificate setting forth (i)
such adjustment, (ii) the Conversion Price at the time in effect, and (iii) the number of Ordinary Shares and the amount, if any, of other
property which at the time would be received upon the conversion of a Preferred <FONT STYLE="letter-spacing: -0.1pt">Share.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.2.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt"><U>Notices of Record Date</U>. In the event of any taking by the Company of a record
of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any Dividend
or other Distribution, any right to subscribe for, purchase or otherwise acquire any shares of any class or any other securities or property,
or to receive any other right, the Company shall mail to each holder of shares, at least ten (10) Business Days prior to the date specified
therein, a notice specifying the date on which any such record is to be taken for the purpose of such Dividend, Distribution or other
right, and the amount and character of such Dividend, Distribution or other right.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.2.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt"><U>Reservation of Shares Issuable Upon Conversion</U>. The Company shall at all
times reserve and keep available out of its authorized but unissued Ordinary Shares, solely for the purpose of effecting the conversion
of the Preferred Shares, such number of its Ordinary Shares as shall from time to time be sufficient to effect the conversion of all outstanding
Preferred Shares; and if at any time the number of authorized but unissued Ordinary Shares shall not be sufficient to effect the conversion
of all then outstanding Preferred Shares, then the Company will take such corporate action as may be necessary to increase its authorized
but unissued Ordinary Shares to such number of shares as shall be sufficient for such purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt"><U>No Impairment</U>. The Company will not through any reorganization, recapitalization,
transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good
faith assist in the carrying out of all the provisions of this Section 8.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">8.4.</FONT></TD><TD STYLE="text-align: justify"><U>Voting <FONT STYLE="letter-spacing: -0.1pt">Rights</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.4.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">Except with respect to election of directors or as required by law and subject to
Articles 140 through 142, the Preferred Shares shall vote together with the other shares of the Company, and not as a separate class,
in all Shareholders meetings, except as required herein or by law, with each Preferred Share having votes in such number as if then converted
into Ordinary Shares (&ldquo;on an as-converted basis&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.4.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Except as set forth herein, the Preferred S-1 Shares, the Preferred S-2 Shares and
the Preferred S-3 Shares shall vote together, as a single class, including for purposes of approving a merger pursuant to Chapter 8 of
the Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.4.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Except as set forth herein, the Preferred B Shares, Preferred B-1 Shares, Preferred
B-2 Shares, Preferred B-3 Shares and Preferred B-4 Shares shall vote together, as a single class, including for purposes of approving
a merger pursuant to Chapter 8 of the Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">8.4.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">Except as set forth herein, the Preferred A Shares and Preferred A-1 Shares shall
vote together, as a single class, including for purposes of approving a merger pursuant to Chapter 8 of the Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Shares; Pre-emptive <FONT STYLE="letter-spacing: -0.1pt">Rights</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">9.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Subject to the provisions of these Articles, including for the avoidance of any
doubt, Articles 140 and 141, the unissued shares of the Company shall be at the disposal of the Board who may offer, allot, grant options
or otherwise dispose of shares to such Persons, at such times and upon such terms and conditions as the Company may by resolution of the
Board determine.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">10.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Subject to the provisions of these Articles, including for the avoidance of any
doubt, Articles 140 and 141, the Company may issue shares having the same rights as the existing shares, or having preferred or deferred
rights, or rights of redemption, or restricted rights, or any other special right in respect of dividend distributions, voting, appointment
or dismissal of directors, return of share capital, distribution of Company&rsquo;s property, or otherwise, all as determined by the Company
from time to time, subject to the provisions of these Articles. The Company may convert any part of the issued shares to deferred shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">11.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Subject to the provisions of the Companies Law and these Articles, the Company
may issue redeemable shares and redeem them, <U>provided</U>, <U>however</U>, that the Preferred Shares shall enjoy similar redemption
rights (if granted), unless otherwise agreed by (A) the Preferred B Majority and (B) the Preferred S Majority.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">12.</TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Until an IPO, each Shareholder who holds at least 3% of the issued and outstanding
share capital of the Company on an as-converted basis (each a &ldquo;<B>Major Holder</B>&rdquo;) and BWAY (so long as it holds the Special
Share or any Shares issued under the BWAY Investment Agreement or issuable upon conversion of the Principal Amount), who shall be deemed
a Major Holder for all purposes of these Articles; <I>(provided, however</I>, that BWAY (and any of its Affiliates or transferees) shall
not be considered a Major Holder under these Articles for any purpose, if it is a Defaulting Investor with respect to the Second Principal
Amount) (an &ldquo;<B>Offeree</B>&rdquo;) shall have a preemptive right with respect to any issuance of Additional Securities by the Company
at the offering price, in accordance with the following terms:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.7pt 0pt 113.95pt"><FONT STYLE="font-size: 10pt">12.1.&nbsp;&nbsp;&nbsp;
</FONT>Each Major Holder shall have the pre-emptive right to purchase up to its Pro Rata Portion (calculated as of the date of the Pre-emption
Notice) of any issuance of Additional Securities. &quot;Pro Rata Portion&quot; shall mean the ratio of (a) the number of outstanding shares
of the Company which such Offeree holds immediately prior to the issuance of such Additional Securities (including, in the case of BWAY,
all Shares issuable upon conversion of the portion of the outstanding Principal Amount then invested under the BWAY Investment Agreement
(the <B>&ldquo;Invested Principal Amount&rdquo;</B>)), on an as converted basis, to (b) the total number of all outstanding shares of
the Company held by all Shareholders (including all Shares issuable upon conversion of the Invested Principal Amount), on an as converted
basis, immediately prior to the issuance of the New Securities (the &ldquo;<B>Pro Rata Portion</B>&rdquo;). Each Major Holder (other than
BWAY to the extent it is a Defaulting Investor) shall have a right of over-allotment, such that if any Major Holder does not elect to
exercise its pre-emptive rights hereunder to purchase its Pro Rata Portion of the Additional Securities, each Major exercising its preemptive
rights hereunder may purchase such non-purchasing Major Holder&rsquo;s portion (the &quot;<B>Major Holder Over-Allotment</B>&quot;). If
the Major Holder Over-Allotment is oversubscribed by the Major Holder exercising their pre-emptive rights hereunder, then any such Major
Holder Over-Allotment to be made among the Major Holders shall be made on a pro rata basis such that an exercising Major Holder's pro
rata portion of the Major Holder Over-Allotment shall be the ratio of the total number of shares of the Company then held by such exercising
Major Holder, to the sum of the total number of shares held by all of the Major Holders exercising their Major Holder Over-Allotment rights
hereunder.</P>

<P STYLE="margin: 0pt 6.7pt 0pt 113.95pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 6.7pt 0pt 113.95pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">12.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">If the Company proposes to issue Additional Securities, it shall give each Major
Holder a written notice thereof of its intention to do so, describing the Additional Securities it proposes to issue, the price of each
Additional Security, the general terms upon which the Company proposes to issue them, and the number of Additional Securities that each
Major Holder has the right to purchase (the &quot;<B>Pre-emption Notice</B>&quot;). Each Major Holder shall have seven (7) Business Days
from the date of delivery of the Pre-emption Notice to it (the &quot;<B>Pre-emption Period</B>&quot;), to agree to purchase all or any
part of its Pro Rata Portion of such Additional Securities, including any such Additional Securities in the Major Holder Over-Allotment,
by giving written notice to the Company setting forth the quantity of the Additional Securities to be purchased by <FONT STYLE="letter-spacing: -0.2pt">it.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">12.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Following the consummation of the preemptive procedure detailed above, the Additional
Securities shall be sold under the terms specified in the Pre-emption Notices, pursuant to the acceptances and the allocations detailed
above. To the extent the Major Holders fail to exercise in full the pre-emptive right, together with any Major Holder Over-Allotment,
within the Pre-emption Period, then the Company shall have one hundred (100) days after the delivery of the Pre-emption Notice to sell
the un-sold Additional Securities at a price and upon general terms no more favorable to the purchasers thereof than specified in the
Pre-emption Notices. If the Company has not sold the un-sold Additional Securities within said one hundred (100) day period, the Company
shall not thereafter issue or sell such un-sold Additional Securities without first re-offering them to the Major Holders in the manner
provided above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">12.4.</FONT></TD><TD STYLE="text-align: justify">An Offeree may assign its right under this Article 12 to a Permitted <FONT STYLE="letter-spacing: -0.1pt">Transferee.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">12.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">If the offer to Shareholders under this Article 12 may constitute an offer to the
public under applicable laws which is subject to prospectus requirements then such offer shall be limited to (i) the type of offerees
the offering to which is exempted from such prospectus requirement, and (ii) to such limited number of Shareholders with the highest holdings
in the Company (aggregating holdings of Permitted Transferees for the purpose of calculating the Shareholders with the highest holdings;
<I>provided that </I>such Permitted Transferees shall be considered as separate entities to the extent viewed as such by applicable law;
and <I>further provided </I>that the transfers to such Permitted Transferees were not made for the purpose of increasing the number of
entities that are Permitted Transferees of the original transferring Shareholder(s) eligible to participate in the offer to Shareholders
under this Article 12), not including and in addition to the offerees under paragraph (i), the offering to which is exempted from such
prospectus requirement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>13.</TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Subject to Articles 8.2, 12 and 140, the Company may issue from time to time options, warrants, other rights to subscribe for instruments
convertible into, or exchangeable for shares of the Company, the terms and conditions of which shall be determined by the Board in accordance
with these Articles.</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 7.15pt">&nbsp;</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">14.</TD><TD STYLE="text-align: justify; padding-right: 7.15pt">The Company shall not be bound to recognize any equitable, contingent, future or
partial interest in any share or any other right whatsoever in any share other than an absolute right to the entirety thereof in the registered
holder.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.3pt"></TD><TD STYLE="width: 36.25pt">15.</TD><TD STYLE="text-align: justify">If two or more Persons are registered as joint holders of a <FONT STYLE="letter-spacing: -0.1pt">share:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">15.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">They shall be jointly and severally liable for any calls or any other liability
with respect to such share. However, with respect to voting, powers of attorney and furnishing of notices, the one registered first in
the Register shall be deemed to be the sole owner of the share unless all the registered joint holders notify the Company in writing to
treat another one of them as the sole owner of the share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">15.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Each one of them shall be permitted to give receipts binding all the joint holders
for dividends or other moneys or property received from the Company in connection with the share and the Company shall be permitted to
pay all the dividend or other moneys or property due with respect to the share to one or more of the joint holders, as it shall <FONT STYLE="letter-spacing: -0.1pt">choose.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">16.</TD><TD STYLE="text-align: justify; padding-right: 7pt">Share certificates shall bear the signature of one director, or of any other person
or persons authorized thereto by the Board. Each Shareholder shall be entitled to one numbered certificate for all the shares of any series
registered in his or its name, and if the Board so approves, to several certificates, each for one or more of such shares. Each certificate
shall specify the serial numbers of the shares represented thereby. A share certificate registered in the names of two or more persons
shall be delivered to the person first named in the Register. If a share certificate is defaced, lost or destroyed, it may be replaced,
upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the Board may deem fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Drag <FONT STYLE="letter-spacing: -0.1pt">Along</FONT></U></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">17.</TD><TD STYLE="text-align: justify; padding-right: 7pt">Subject to the provisions of the Companies Law and Articles 140, 141, and 142, until the consummation of a QIPO, if (i) a <I>bona
fide </I>offer from any Person (including, BWAY (its successors and assigns) pursuant to the exercise of the Call Option) (the &ldquo;<B>Third
Party</B>&rdquo;) is made to effect a Deemed Liquidation (a &ldquo;<B>Proposed Transaction</B>&rdquo;), and (ii) (A) the Preferred B Majority,
and (B) subject to Article 143 below <I>(Call-option Carveout)</I> the holder of the Special Share or the Preferred S Majority, provide
their affirmative consent to such Proposed Transaction (the &ldquo;<B>Proposing Shareholders</B>&rdquo;), then such decision shall be
binding upon the Company and all remaining Shareholders (the &ldquo;<B>Remaining Shareholders</B>&rdquo;) will be required, if so demanded
in writing by the Proposing Shareholders (the &ldquo;<B>Drag Along Notice</B>&rdquo;), to sell all of their Shares to such Third Party,
or vote to approve the terms and conditions of the Proposed Transaction.</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">At every meeting of the Shareholders of the Company called with respect to any of
the following, and at every adjournment or postponement thereof, and on every action or approval by written consent of the shareholders
of the Company with respect to any of the following, the Remaining Shareholders shall vote all Shares of the Company that such Remaining
Shareholders then hold or for which such Remaining Shareholders otherwise then have voting power: (A) in favor of approval of the Proposed
Transaction and any matter that could reasonably be expected to facilitate the Proposed Transaction; and (B) against any proposal for
any recapitalization, merger, sale of assets or other business combination (other than the Proposed Transaction) between the Company and
any Person other than the party or parties to the Proposed Transaction or any other action or agreement that would result in a breach
of any covenant, representation or warranty or any other obligation or agreement of the Company under the definitive agreement(s) related
to the Proposed Transaction or which could result in any of the conditions to the Company's obligations under such agreement(s) not being
fulfilled, in each case unless otherwise determined by the Proposing Shareholders. In any event the Proposed Transaction <FONT STYLE="letter-spacing: -0.25pt">is
</FONT>brought to a vote at a shareholders meeting, any Shareholder who shall have failed to vote in favor of such Proposed Transaction,
shall be deemed to have given an irrevocable proxy to such person as shall be designated by the Board to vote for the acceptance of such
Proposed Transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Each Remaining Shareholder shall take all necessary actions in connection with the
consummation of the Proposed Transaction as requested by the Company or the Proposing Shareholders and shall, if requested by the Proposing
Shareholders, execute and deliver any agreements and instruments prepared in connection with such Proposed Transaction which agreements
are executed by the Proposing Shareholders and shall waive any dissenting minority or similar rights in connection with such Proposed
Transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Upon receipt of the Drag Along Notice, each Remaining Shareholder shall be obligated
to sell all of its shares, or vote to approve such Proposed Transaction, notwithstanding any other no sale right, first refusal rights
or other rights, and the proceeds of such Proposed Transaction shall be distributed among all Shareholders in accordance with the liquidation
preference provisions set forth in Article 8.1 above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">At the closing of the Proposed Transaction (which place, date and time shall be
designated by the Proposing Shareholders and provided to each of the Remaining Shareholders at least 5 days in advance), each such Remaining
Shareholder shall deliver certificates evidencing all of its shares, duly endorsed or accompanied by written instruments of transfer in
form satisfactory to the Third Party, duly executed by such Remaining Shareholder, against delivery of the purchase price therefore.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">In the event that a Remaining Shareholder fails to surrender its certificate or
an affidavit of a lost certificate, in a form acceptable to the Board, in connection with the consummation of a Proposed Transaction,
such certificate shall be deemed cancelled and the Company shall be authorized to issue a new certificate in the name of the Remaining
Shareholder and the Board of Directors shall be authorized to establish an escrow account, for the benefit of such Remaining Shareholder
into which the consideration for such securities represented by such cancelled certificate shall be deposited and to appoint a trustee
to administer such account.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Anything in these Articles to the contrary notwithstanding, the General Meeting shall,
if requested by the Proposing Shareholders, assume the power and authority of the Board to discuss and approve, for all intents and purposes,
the Proposed Transaction on behalf of the Company, effective as of the time on which the written consent of the Proposing Shareholders
shall have been received by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.7.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">In the event that the Proposing Shareholders consent to the Proposed Transaction,
any sale or other transfer, assignment or conveyance of shares by the Shareholders, other than pursuant to the Proposed Transaction, shall
be absolutely prohibited.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.8.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Each Shareholder recognizes and accepts that the powers granted to the Company
or the Board as set forth in this Article 17 are granted in order to ensure and protect the rights of the other Shareholders and that
therefore, such powers, upon the use thereof shall be irrevocable with respect to such matter or action with respect to which the Board
has exercised such powers.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.9.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">With respect to Section 341 of the Companies Law, the Shareholders specifically
agree to amend the provisions set forth therein in the following manner:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.9.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">the threshold set forth in Section 341 shall mean the Proposing Shareholders threshold
set forth in Article 17 (ii).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.9.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">the parties acknowledge that the application of the distribution preference provisions
set forth in Article 8.1 shall not be deemed to mean that the Shareholders are offered different treatment or terms in the Proposed Transaction
(even if certain Proposing Shareholders will receive consideration and benefits that other Shareholders will not <FONT STYLE="letter-spacing: -0.1pt">receive).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.9.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">the parties agree that the timeframe set forth in Section 341(a) for accepting the
Proposed Transaction by the Proposing Shareholders shall not be limited to the time frame specified in the aforementioned <FONT STYLE="letter-spacing: -0.1pt">provision.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.9.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">the parties agree that the notices that should be sent by the Third Party according
to the provisions set forth in Section 341(a) and 341(c) (each a &ldquo;<B>341 Notice</B>&rdquo;) may be sent by either the Third Party
or the Company and the time frame set forth in the aforementioned provisions for sending each of the 341 Notices shall not be limited
to the time frame specified therein.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.9.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">the parties agree that Section 341(d) should not be interpreted or construed in
a manner which limits the Shareholders' power only to the amendment of the threshold set forth in Section 341(a), by allowing to lower
the eighty percent (80%) threshold required by the Companies Law to the threshold contemplated in these Articles, but also to amend any
procedural and other terms set forth under Section 341, and therefore the terms set forth herein are to supersede the provisions of Section
341.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.9.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">For the purposes of this Article 17, if the Proposed Transaction is in the form
of a: (i) merger, when computing the Proposing Shareholders threshold, the provisions of Section 320(c) of the Companies Law shall apply;
and (ii) share purchase agreement, in the event the Third Party is a Shareholder, or is a Person, which, directly or indirectly, controls,
or is under common control with a Shareholder, the said Shareholder shall be considered to be an &quot;Interested Shareholder&quot; and
as such, shall not be included in calculating the Proposing Shareholders threshold.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.10.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Notwithstanding the foregoing, a Remaining Shareholder will not be required to comply
with the requirements of this Article 17 in connection with any Proposed Transaction unless:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.10.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">any representations and warranties to be made by such Remaining Shareholder in connection
with the Proposed Transaction are limited to representations and warranties related to authority, ownership and the ability to convey
title to such Shares, including but not limited to representations and warranties that (i) the Remaining Shareholder holds all right,
title and interest in and to the Shares such Remaining Shareholder purports to hold, free and clear of all liens and encumbrances, (ii)
the obligations of the Remaining Shareholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents
to be entered into by the Remaining Shareholder have been duly executed by the Remaining Shareholder and delivered to the acquirer and
are enforceable against the Remaining Shareholder in accordance with their respective terms <FONT STYLE="letter-spacing: -0.25pt">and
</FONT>(iv) neither the execution and delivery of documents to be entered into in connection with the transaction, nor the performance
of the Remaining Shareholder&rsquo;s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment,
order or decree of any court or governmental agency;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.10.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">the Remaining Shareholder shall not be liable for the inaccuracy of any representation
or warranty made by any other Person in connection with the Proposed Transaction, other than the Company (except to the extent that funds
may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach
by any Remaining Shareholder of any of identical representations, warranties and covenants provided by all Shareholders);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.10.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">the liability for indemnification, if any, of such Remaining Shareholder in the
Proposed Transaction and for the inaccuracy of any representations and warranties made by the Company in connection <FONT STYLE="letter-spacing: -0.1pt">with
such Proposed Transaction, is several and not joint with any other </FONT>Person (except to the extent that funds may be paid out of an
escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any Shareholder of
any of identical representations, warranties and covenants provided by all Shareholders), and is pro rata in proportion to the amount
of consideration paid to such Remaining Shareholder in connection with such Proposed Transaction (in accordance with the provisions of
the Articles); and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">17.10.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">liability of such Remaining Shareholder shall be limited to such Remaining Shareholder's
applicable share (determined based on the respective proceeds payable to each Shareholder in connection with such Proposed Transaction
in accordance with the provisions of the Articles) of a negotiated aggregate indemnification amount that applies equally to all Shareholders
but that in no event exceeds the amount of consideration otherwise payable to such Remaining Shareholder in connection with such Proposed
Transaction, except with respect to claims related to fraud by such Remaining Shareholder, the liability for which need not be limited
as to such Remaining Shareholder.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.11.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Notwithstanding anything to the contrary herein, if BWAY exercises the Call Option
pursuant to the Call Option Agreement and elects, in accordance with such agreement, to consummate a Company Acquisition (as defined therein),
then such Company Acquisition shall be deemed a Proposed Transaction for purposes of this Article 17. In such event, the execution of
the Call Option Agreement by the Grantors (as defined therein) shall be deemed to constitute the affirmative consent required under Article
17 (ii), and each such Grantor shall be deemed a Proposing Shareholder for purposes of this Article 17, without any further action or
consent required. The provisions of this Article 17 shall apply mutatis mutandis to effect the transfer of all Shares to BWAY, and each
Shareholder shall take all actions required to facilitate the consummation of such Company Acquisition, including voting in favor thereof
and executing all relevant agreements and instruments, as further provided in the Call Option Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">17.12.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Without derogating from Article 17.11 above, to the fullest extent permissible under
applicable law, each Shareholder hereby (i) irrevocably waives and agrees not to assert any appraisal rights, dissenters&rsquo; rights,
or similar claims under applicable law in connection with any Proposed Transaction that constitutes a Company Acquisition pursuant to
the Call Option Agreement, (ii) agrees that any and all costs, expenses or liabilities incurred by the Investor or the Company, in accordance
with the Call Option Agreement and in connection with any such rights asserted by non-signing Shareholders (including legal fees, settlement
payments, or judgment amounts) may be deducted from the consideration payable to such Shareholders in accordance with the provisions of
the Call Option Agreement, and (iii) acknowledges and agrees that no such event shall give rise to any claim for increased consideration
or other compensation from the Investor or the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 6.7pt 0pt 113.95pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: left"><FONT STYLE="letter-spacing: -0.2pt"><U>Lien</U></FONT></P>

<P STYLE="font-size: 10pt; text-indent: -42.55pt; margin: 0pt 6.85pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">18.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">The Company shall have a lien and first pledge on every Share that was not paid
up in full, in respect of money due to the Company on calls for payment or payable at fixed times, whether or not presently payable, or
the fulfillment and performance of the obligations and commitments to which the Company is entitled in respect of the Share. The lien
on a Share shall also apply to Dividends and other distributions payable on it. The directors may exempt any Share, in full or in part,
temporarily or permanently, from the provisions of this Article.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">19.</TD><TD STYLE="text-align: justify; padding-right: 6.8pt">The Company may sell any Share on which it has a lien in any manner the Board sees
fit, but such Share shall not be sold before the date of payment of the amount in respect of which the lien exists, or the date of fulfillment
and performance of the obligations and commitments in consideration of which the lien exists, has arrived, and until fourteen (14) days
have passed after written notice has been given to the registered holder at that time of the Share, or to whoever is entitled to it upon
the registered owner&rsquo;s death or bankruptcy, demanding payment of the amount against which the lien exists, or the fulfillment and
performance of the obligations and commitments in consideration of which the lien exists, and such payment or fulfillment and performance
have not been made.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">20.</TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The net proceeds of the sale shall be applied in payment of the amount due to the
Company for the fulfillment and performance of the obligations and commitments as aforesaid in the preceding Article, and the remainder,
if any, shall be paid to whoever is entitled to the Share on the day of the sale, subject to a lien on amounts the date of payment of
which has not yet arrived, similar to the lien on the Share before its sale.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">21.</TD><TD STYLE="text-align: justify; padding-right: 6.7pt">After the execution of a sale of pledged Shares as aforesaid, the Board shall be
permitted to sign or to appoint someone to sign a deed of transfer of the sold Shares and to register the purchaser&rsquo;s name in the
Register as the owner of the Shares so sold, and it shall not be the obligation of the buyer to supervise the application of the purchase
price nor will his right in the Shares be affected by any fault or error in the procedure of sale. The sole remedy of one who has been
aggrieved by the sale shall be in damages only and against the Company exclusively.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Calls for <FONT STYLE="letter-spacing: -0.1pt">Payment</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">22.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">With respect to Shares not fully paid for according to their terms of issuance,
a Shareholder, whether he is the sole holder of Shares or holds the Shares together with another Person, shall not be entitled to receive
Dividends nor any other right a Shareholder has unless he has paid all the calls by the Company which shall have been made from time to
time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">23.</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Subject to any contractual undertakings of the Company, the Board may make calls
for payment from Shareholders of the amount not yet paid up on their Shares as the Board shall see fit, <U>provided</U> that the Company
gives the Shareholders prior notice of at least fourteen (14) days on every call and that the date for payment set forth in such notice
be not less than one month after the last call for payment. Each Shareholder shall pay the amount called to the Company on the date and
at the place prescribed in the Company&rsquo;s notice.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">24.</TD><TD STYLE="text-align: justify; padding-right: 0.1in">The joint holders of a Share shall be jointly and severally liable to pay the calls
for payment on such Share in full.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">25.</TD><TD STYLE="text-align: justify; padding-right: 7pt">If the amount called is not paid by the prescribed date, the Person from whom it is
due shall be liable to pay such index linkage differentials and interest as the Board shall determine, from the date on which payment
was prescribed until the day on which it is paid, but the Board may forego the payment of such linkage differentials or interest, in whole
or in part.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">26.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Any amount that, according to the conditions of issuance of a Share, must be paid
at the time of issuance or at a fixed date, whether on account of the par value of the Share or premium, shall be deemed for the purposes
of these Articles to be a call for payment that was duly made. In the event of non-payment of such amount all the provisions of these
Articles shall apply in respect of such amount as if a proper call for its payment had been made and an appropriate notice thereof given.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36.3pt; margin: 0pt 0.1in 0pt 42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>27.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">At the time of issuance of Shares the Board may make arrangements that differentiate between Shareholders, in respect of the amounts
of calls for payment, their dates of payment or the rate of interest.</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">&nbsp;</TD></TR>
                                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">28.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">The Board may, if it thinks fit, accept from any Shareholder for his Shares any
amount of money the payment of which has not yet been called and paid, and to pay him (i) interest for that advance until the day on which
payment of that amount would have been due had he not paid it in advance, at a rate agreed between the Company and such Shareholder, and
(ii) any Dividends that may be paid for that part of the Shares for which the Shareholder has paid in advance.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Forfeiture of <FONT STYLE="letter-spacing: -0.1pt">Shares</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">29.</TD><TD STYLE="text-align: justify; padding-right: 7pt">If a Shareholder fails to pay any call or installment of a call on the day appointed
for payment thereof, the Board may, at any time thereafter during such time as any part of such call or installment remains unpaid, serve
a notice on him requiring payment of so much of the call or installment as is unpaid, together with any interest which may have accrued
and any expenses that were incurred as a result of such non-payment.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">30.</TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The notice shall specify a date not less than seven (7) days from the date of the
notice, on or before which the payment of the call or installment or part thereof is to be made together with interest and any expenses
incurred as a result of such non-payment. The notice shall also state the place the payment is to be made and that in the event of non-payment
at or before the time appointed, the Share in respect of which the call was made will be liable to forfeiture.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">31.</TD><TD STYLE="text-align: justify; padding-right: 6.9pt"><FONT STYLE="letter-spacing: -0.1pt">If the requirements of any such notice as aforesaid
are not complied with, any Share in respect of which </FONT>the notice has been given may at any time thereafter, before the payment required
by the notice has been made, be forfeited by a resolution of the Board to that effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">32.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">The forfeiture shall apply to those Dividends that were declared but not yet distributed
with respect to the forfeited Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">33.</TD><TD STYLE="text-align: justify; padding-right: 7.1pt">A Share so forfeited shall be deemed to be the property of the Company and can be
sold or otherwise disposed of, on such terms and in such manner as the Board thinks fit. At any time before a sale or disposition the
forfeiture may be canceled on such terms as the Board thinks fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">34.</TD><TD STYLE="text-align: justify; padding-right: 7.05pt">A Person whose Shares have been forfeited shall cease to be a Shareholder in respect
of the forfeited Shares, but shall nevertheless remain liable to pay to the Company all moneys which, at the date of forfeiture, were
presently payable by him to the Company in respect of the Shares, but his liability shall cease if and when the Company receives payment
in full of the nominal amount of the Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">35.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">The forfeiture of a Share shall cause, at the time of forfeiture, the cancellation
of all rights in the Company and of any claim or demand against the Company with respect to that Share, and of other rights and obligations
between the Share owner and the Company accompanying the Share, except for those rights and obligations which these Articles exclude from
such a cancellation or which the Law imposes upon former Shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">36.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">The Person to whom the Share is sold or disposed of shall be registered as the
holder of the Share and shall not be bound to see to the application of the purchase money, if any, nor shall his title to the Share be
affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale or disposal of the Share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">37.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">The provisions of these Articles as to forfeiture shall apply in the case of non-payment
of any sum which, by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the par value of the Share
or by way of premium, as if the same had been payable by virtue of a call duly made and notified.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Transfer of <FONT STYLE="letter-spacing: -0.1pt">Shares</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">38.</TD><TD STYLE="text-align: justify; padding-right: 6.95pt">No Transfer of Shares shall be effective unless the Transfer is not in violation
of Articles 39, 40 and 41 and has been approved by the Board, which consent shall not be unreasonably withheld or delayed, provided that
such consent shall not be required for a transfer to a Permitted Transferee or from a Permitted Transferee back to the original Shareholder;
provided, that with respect to any Grantor, any Transfer to a Permitted Transferee shall, until the Call Option terminates or expires,
be expressly conditioned upon such Permitted Transferee becoming a party to the Call Option Agreement by executing and delivering a joinder
or counterpart thereto in form and substance satisfactory to BWAY, thereby becoming subject to the terms and conditions of the Call Option
Agreement as a &ldquo;Grantor&rdquo; with respect to the Shares so Transferred. The Board may refuse to register a Transfer in the event
that such a Transfer is to a competitor of the Company, or in the event that such a Transfer would result in the Company having more than
50 shareholders. In the event that the Board does not notify the transferor of its refusal to allow a Transfer together with a detailed
reasoning for such refusal within fourteen (14) days of receipt by the Company of a request for Transfer which includes the identity of
the transferor then the Board shall be deemed to have approved such Transfer, provided that such agreement by the Board will be deemed
to be subject to compliance by the transferor and the transferee with the terms of these Articles related to a Transfer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -36.25pt; margin: 0pt 0 0pt 42.4pt">39.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No <FONT STYLE="letter-spacing: -0.1pt">Sale</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">39.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Until a QIPO, and subject in any event to Article 39.3 below, the Founders shall
be entitled to sell, transfer, assign, pledge or otherwise dispose of (each, a &quot;<B>Transfer</B>&quot;) up to 10% of his securities
in the Company, calculated on the date of adoption of these Articles, per year, but neither Founder shall Transfer in the aggregate more
than 25% of his securities in the Company, calculated on the date of adoption of these Articles, other than to his Permitted Transferees,
without the approval of (A) the Preferred B Majority and (B) the holder of the Special Share or the Preferred S Majority, except in connection
with a sale of all or substantially all of the Shares of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">39.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">Until the expiration of a three (3) year period as of the Initial Closing of the
Preferred B Investment Agreement as such term is defined therein, and subject in any event to Article 39.3 below, no Key Employee shall
be entitled to Transfer any of its securities in the Company, other than to his Permitted Transferees, without the approval of (A) the
Preferred B Majority and (B) the holder of the Special Share or the Preferred S Majority, except in connection with a sale of all or substantially
all of the Shares of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">39.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">Unless and until the Call Option expires or is terminated, except as may be required
to give effect to the transactions contemplated by the Call Option or with the prior written consent of BWAY (and subject to the conditions
determined by BWAY) and the Preferred B Majority (if other than pursuant to and in accordance with the terms of the Call Option Agreement),
each of the Grantors shall not, directly or indirectly, Transfer any of its Shares or any interest therein, nor create any Encumbrance
thereon, nor enter into any agreement to do any of the foregoing, prior to the earlier of the Option Closing or 11:59 PM and 59 seconds
(Israel time) on the Expiry Date, if no Exercise Notice has been provided by the Investor prior to such time. In this Article 39.3, capitalized
terms not defined elsewhere in these Articles carry the meanings given to them in the Call Option Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.9pt 0pt 42.45pt">For purposes of this Article 39, any
Transfer of securities in any corporate Shareholder controlled by a Key Employee or Founder (alone or with others), which is not considered
a transfer to a Permitted Transferee, as well as any Transfer of securities which would result in a change of control in any corporate
Shareholder controlled by a Grantor, shall be deemed to be a Transfer of securities in the Company and therefore limited as <FONT STYLE="letter-spacing: -0.1pt">aforesaid.</FONT></P>

<P STYLE="margin: 0pt 6.9pt 0pt 42.45pt; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">40.</TD><TD STYLE="text-align: justify; padding-right: 6.7pt"><U>Right of First Refusal</U>. Subject to the provisions of Article 39, and without
derogating therefrom, until a QIPO, each Major Holder (an &ldquo;<B>Entitled Shareholder</B>&rdquo;), shall have a right of first refusal
with respect to any Transfer of all or any of the securities of the Company by any other Shareholder (the &ldquo;<B>Transferor</B>&rdquo;)
other than to a Permitted Transferee of such Transferor or pursuant to the Call Option Agreement, in accordance with the following provisions:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">40.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Any Transferor proposing to Transfer all or any of its Shares (the &ldquo;<B>Offered
Shares</B>&rdquo;) shall first provide the Entitled Shareholders with an offer stating the identity of the Transferor and of the transferee
and the terms of the proposed Transfer (the &ldquo;<B>Offer</B>&rdquo;). Each of the Entitled Shareholders may accept such Offer in respect
of any portion of the Offered Shares (&ldquo;<B>Accepting Entitled Shareholders</B>&rdquo;) by giving the Company notice to that effect
within fourteen (14) days after being served with the Offer (an <FONT STYLE="letter-spacing: -0.1pt">&ldquo;<B>Acceptance</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.55pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">40.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">If the Acceptances, in the aggregate, are in respect of all of, or more than, the
Offered Shares, then the Accepting Entitled Shareholders shall acquire the Offered Shares, on the terms aforementioned, in proportion
to their respective holdings of the Company&rsquo;s issued and outstanding share capital (calculated on an as-converted basis), <U>provided</U>,
<U>however</U>, that no Accepting Entitled Shareholders shall be entitled or shall be forced to acquire under the provisions of this Article
40 more than the number of Offered Shares initially accepted by such Accepting Entitled Shareholder under the Acceptance, and upon the
allocation to it of the full number of Offered Shares so accepted, such Accepting Entitled Shareholder shall be disregarded in any subsequent
computations and allocations hereunder. Any Offered Shares remaining after the computation of such respective entitlements shall be re-allocated
among the remaining Accepting Entitled Shareholders (other than those to be disregarded as aforesaid), in the same manner, until one hundred
percent (100%) of the Offered Shares have been allocated as aforesaid.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">40.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">If the Acceptances are in respect of less than the full number of Offered Shares,
then the Accepting Entitled Shareholders shall not be entitled to acquire the Offered Shares, and the Transferor, at the expiration of
the aforementioned fourteen (14) day period, shall be entitled to Transfer all (but not less than all) of the Offered Shares to the proposed
transferee(s) identified in the Offer, <U>provided</U>, <U>however</U>, that in no event shall the Transferor Transfer any of the Offered
Shares to any transferee other than such proposed transferee(s) or Transfer the same on terms more favorable to the transferee(s) than
those stated in the Offer, and <U>provided</U>, <U>further</U>, that any Offered Shares not Transferred within ninety (90) days after
the expiration of such fourteen</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 113.95pt">(14) day period, shall again be subject
to the provisions of this Article <FONT STYLE="letter-spacing: -0.25pt">40.</FONT></P>

<P STYLE="margin: 0pt 0 0pt 113.95pt; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">40.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt"><P STYLE="margin-top: 0; margin-bottom: 0">The
Transferor shall be bound, upon payment of the offer price, to Transfer to the Accepting Entitled Shareholders the Offered Shares which
have been allocated to the Accepting Entitled Shareholders pursuant to this Article 40. If, after becoming so bound, the Transferor defaults
in Transferring the Offered Shares, the Company may receive the purchase price therefor and the Transferor shall be deemed to have appointed
any member of the Board as his agent to execute a Transfer of the Offered Shares to the Accepting Entitled Shareholders and, upon execution
of such Transfer, the Company shall hold the purchase price therefor in trust for the Transferor.</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">40.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">For purposes of this Article 40, any Transfer of securities in any corporate Transferor
by a shareholder thereof, which is not considered a transfer to a Permitted Transferee, shall be deemed to be a Transfer of securities
in the Company and therefore limited as <FONT STYLE="letter-spacing: -0.1pt">aforesaid.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">40.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">The right of first refusal set forth in this Exhibit C shall not apply to: (a) a
Transfer which is part of a Drag Along and (b) a Transfer which is part of an IPO.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -70.8pt; margin: 0pt 0 0pt 42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">41.</TD><TD STYLE="text-align: justify; padding-right: 6.7pt"><U>Co-Sale</U></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">41.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Until a QIPO, in the event of a Transfer of Ordinary Shares by an Ordinary Shareholder,
such Ordinary Shareholder proposing to make the Transfer (the &ldquo;<B>Co-Sale Transferor</B>&rdquo;) shall promptly notify each Major
Holder that holds Preferred Shares (a &ldquo;<B>Co-Sale Entitled Shareholder</B>&rdquo;) in writing describing in such notification the
identity of the proposed transferee, the number and type of securities being Transferred and the terms of the proposed Transfer (the &ldquo;<B>Co-Sale
Transferor's Notice</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">41.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Upon receipt of the Co-Sale Transferor's Notice, each Co-Sale Entitled Shareholder
shall have the option, exercisable by written notice to the Co-Sale Transferor, within 14 days after receipt of the Co-Sale Transferor's
Notice, to require the Co-Sale Transferor to provide as part of its proposed Transfer that such Co-Sale Entitled Shareholder be given
the right to participate in the Transfer and (i) to Transfer up to such amount of securities in the Company owned by such Co-Sale Entitled
Shareholder determined by multiplying the total number of securities being Transferred times a fraction, the numerator of which is the
number of issued and outstanding shares held by such Co-Sale Entitled Shareholder (assuming for purposes of this section, the conversion
into Ordinary Shares of all Preferred Shares) and the denominator of which is the total number of issued and outstanding shares held by
all of the Co-Sale Entitled Shareholders and the Co-Sale Transferor (assuming, for purposes of this section, the conversion into Ordinary
Shares of all Preferred Shares) (the &ldquo;<B>Pro Rata Shares</B>&rdquo;), or (ii) in the event that the Transfer results in an M&amp;A
Transaction, to Transfer up to all of the Shares then held by such Co-Sale Entitled Shareholder in the Company (the &ldquo;Total Shares&rdquo;;
the Pro Rata Shares together with the Total Shares, the &ldquo;Co-Sale Participating Shares&rdquo;); by including the Co-Sale Participating
Shares held by such Co-Sale Entitled Shareholder with the securities being Transferred to any proposed purchaser thereof. The Transfer
by any such Co-Sale Entitled Shareholder in accordance with this Article 41.2, shall be on the same terms and conditions under which the
securities of the Co-Sale Transferor are being Transferred, provided that if the Transfer transaction qualifies as a Deemed Liquidation,
pursuant to Article 8.1 above, then the proceeds obtained from such Transfer transaction shall be allocated in accordance with the provisions
of Article 8.1.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">41.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">In the event that Co-Sale Entitled Shareholders choose to exercise their rights
hereunder (&ldquo;Exercising Co-Sale Entitled Shareholders&rdquo;), the Co-Sale Transferor must reduce the number of securities it desires
to Transfer from the total amount of securities to be purchased by the proposed transferee and the Exercising Co-Sale Entitled Shareholders
will contribute all of their Co-Sale Participating Shares and the Transferor will contribute the remaining number of securities up to
the total number of securities to be purchased by the proposed transferee.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">41.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">For purposes of this Article 41, any Transfer of securities in any corporate Co-Sale
Transferor by a Co-Sale Transferor thereof, which is not considered a transfer to a Permitted Transferee, shall be deemed to be a Transfer
of securities in the Company and therefore limited as aforesaid.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">42.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">The rights of first refusal and rights of co-sale set forth in Articles 40 and
41 respectively shall not apply to a Transfer of securities from a Shareholder to a Permitted Transferee of a Shareholder, back to the
original Shareholder and/or to a Permitted Transferee of such Permitted Transferee, <U>provided</U>, that such Permitted Transferee remains
within the definition of a Permitted Transferee of the Transferor or Co-Sale Transferor, as <FONT STYLE="letter-spacing: -0.1pt">applicable.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">42A.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Notwithstanding anything to the contrary in these Articles (including, without
limitation, Articles 39 through 42), any Transfer of Shares in connection with the exercise of the Call Option under the Call Option Agreement,
including any Transfer effected pursuant to a Drag Along transaction initiated as part of a Company Acquisition in accordance with Article
17.11, shall be exempt from all transfer restrictions set forth in these Articles, including but not limited to restrictions under the
&ldquo;No Sale&rdquo; provisions of Article 39, the Right of First Refusal under Article 40, and the Co-Sale rights under Article 41.
Without derogating from the foregoing or from Article 17.11, each Shareholder expressly and irrevocably (i) waives any rights of first
refusal, co-sale rights, or other similar rights (contractual or statutory) that might otherwise apply in connection with any such Transfer
of Shares, including a Proposed Transaction effected pursuant to the Drag Along provisions of Article 17.11 in furtherance of the Call
Option Agreement, and (ii) agrees that the execution of the Call Option Agreement and approval of the transactions contemplated thereby
shall constitute all approvals necessary under these Articles for purposes of compliance with any such Transfer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt">42B.</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">For the avoidance of doubt, no Transfer of Shares by a Shareholder to BWAY pursuant
to the Call Option Agreement shall require any further approval, notice, waiver, offer or other action under Articles 39&ndash;42, and
shall be deemed fully approved by the Board and all Shareholders (including by each class thereof) in accordance with these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">43.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Each Transfer of securities shall be made in writing in such form as shall be approved
by the Board from time to time, in which, inter alia, the transferee agrees to be subject to these Articles of Association (as may be
amended), and which shall be executed by both the transferor and transferee, and delivered to the Office together with the transferred
share certificates, if share certificates have been issued with respect to the shares to be transferred, and any other proof of the transferor&rsquo;s
title that the Board may require. The share transfer deed with respect to a share that has been fully paid may be signed by the transferor
only. A deed of transfer that has been registered, or a copy thereof, as shall be decided by the Board, shall remain with the Company;
any deed of transfer that the Board shall refuse to register shall be returned, upon demand, to the Person who furnished it to the Company,
together with the share certificate, if furnished.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">44.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">The transferor shall be deemed to remain a holder of the shares until the name
of the transferee is entered into the Register in respect thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">45.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">The Company may impose a fee for registration of a share transfer, at a reasonable
rate as may be determined by the Board from time to time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">46.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Upon the death of a Shareholder, the remaining partners, in the event that the deceased
was a partner in a share, or the administrators or executors or heirs of the deceased, in the event the deceased was the sole holder of
the share or was the only one of the joint holders of the share to remain alive, shall be recognized by the Company as the sole holders
of any title to the shares of the deceased. However, nothing aforesaid shall release the estate of a joint holder of a share from any
obligation to the Company with respect to the share that he held in partnership.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">47.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">Any Person becoming entitled to a share as a consequence of the death or bankruptcy
or liquidation of a Shareholder shall, upon such evidence being produced as may from time to time be required by the Board, have the right
either to be registered as a Shareholder in respect of the share, or, instead of being registered himself, to transfer such share to another
Person, in either instance subject to the Board&rsquo;s power hereunder to refuse or delay registration as they would have been entitled
to do if the deceased or the bankrupt had transferred his share before his death or before his bankruptcy, and subject to all other provisions
hereof relating to transfers of shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">48.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">A Person becoming entitled to a share because of the death of a Shareholder shall
be entitled to receive, and to give receipts for, dividends or other payments paid or distributions made, with respect to the share, but
shall not be entitled to receive notices with respect to General Meetings or to participate or vote therein with respect to that share,
or to use any other right of a Shareholder, until he has been registered as a Shareholder with respect to that share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Changing Share <FONT STYLE="letter-spacing: -0.1pt">Rights</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">49.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">Subject to the provisions of these Articles, if at any time the share capital is
divided into different classes of shares, the Company may change, convert, broaden, add or vary in any other manner the rights, preferences
or privileges attached to such classes by resolution of the General Meeting of the <FONT STYLE="letter-spacing: -0.1pt">Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">50.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">Without derogating from the foregoing, only a direct change to the rights attached
to a certain class of shares under these Articles shall require an approval obtained at a meeting of the holders of such class of shares
or the written consent of the holders of more than fifty percent (50%) of the issued shares of such class. It is hereby clarified that
any resolution required to be adopted pursuant to these Articles by the consent of a separate class of shares, whether by way of a separate
General Meeting of such class or by way of written consent, shall be given by the holders of shares of such class entitled to vote or
give consent thereon and no holder of shares of a certain class shall be banned from voting or consenting by virtue of being a holder
of more than one class of shares of the Company, irrespective of any conflicting interests that may exist between such different classes
of shares. A Shareholder shall not be required to refrain from participating in the discussion, voting and/or consenting on any resolution
concerning an amendment to any class of shares held by such Shareholder, due to the fact that such Shareholder may benefit in one way
or another from the outcome of such resolution.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">51.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">For the avoidance of doubt, it is hereby clarified and agreed that (i) an increase
of the authorized or issued share capital of an existing class of shares; (ii) the creation of a new class of shares or the issuance of
shares thereof; (iii) a change of the conversion price of any class of shares; (iv) a waiver or a change, in whole or in part, to a right,
preference or privilege of a class of shares (such as liquidation rights, registration rights, pre-emptive rights, etc, whether set forth
in these Articles or in any agreement), whether applied on a one-time or permanent basis and whether applied in connection with a current
or a future event, which waiver or change is applied in the same manner to all classes of shares to which such wavier or change is applicable,
regardless whether the economic effect of such change affects classes of shares differently, shall not be deemed to be a direct change
to the rights attached to any one (1) class of shares. Furthermore, any waiver or change to the rights attached to a class of shares shall
not be deemed to be a direct change to the rights attached to another class of shares if such other class of shares was not entitled to
the relevant rights prior to such waiver or change.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.3pt"></TD><TD STYLE="width: 36.25pt"><FONT STYLE="font-size: 10pt">52.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">[Reserved]</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Modification of <FONT STYLE="letter-spacing: -0.1pt">Capital</FONT></U></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">53.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">The Company may, from time to time, by a resolution in a General Meeting, and subject
to the provisions of these Articles:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">53.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">consolidate and divide its share capital or a part thereof into shares of greater
value than its existing shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">53.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">cancel any shares which have not been purchased or agreed to be purchased by any
<FONT STYLE="letter-spacing: -0.1pt">Person;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">53.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">by subdivision of its existing shares, or any of them, divide the whole, or any
part, of its share capital into shares of lesser value than is fixed by these Articles, and in a manner so that with respect to the shares
created as a result of the division it will be possible to grant to one or more shares a right of priority, preference or advantage with
respect to dividend, capital, voting or otherwise over the remaining or similar share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">53.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">reduce its share capital, and any fund reserved for capital redemption, in the
manner that it shall deem to be desirable under the provisions of Section 287 of the Companies <FONT STYLE="letter-spacing: -0.2pt">Law;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">53.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">increase its share capital, regardless of whether or not all of its shares have
been issued, or whether the shares issued have been paid in full, by the creation of new shares, divided into shares in such par value,
and with such preferred or deferred or other special rights (subject always to the provisions of these Articles), and subject to any conditions
and restrictions with respect to Dividends, return of capital, voting or otherwise, as shall be directed by the resolution; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">53.6.</FONT></TD><TD STYLE="text-align: justify">convert part of its issued and paid-up shares into deferred <FONT STYLE="letter-spacing: -0.1pt">shares.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>General <FONT STYLE="letter-spacing: -0.1pt">Meetings</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">54.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">A General Meeting shall be held at least once every year, at such place and time
as may be prescribed by the Board but in any event not more than fifteen (15) months after the preceding General Meeting. The annual General
Meetings shall be called Annual General Meetings; all other General Meetings shall be called Special General Meetings.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">55.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The Board, whenever it thinks fit, may, and upon a demand in writing by: (i) a director;
or (ii) one or more Shareholders holding (on an as-converted basis) at least ten percent (10%) of the issued and outstanding share capital
and at least one percent (1%) of the voting rights; or (iii) one or more Shareholders holding at least ten percent (10%) of the voting
rights in the Company, shall, be entitled to convene a Special General Meeting. Any such demand shall include the objects for which the
meeting should be convened, shall be signed by those making the demand (the &ldquo;<B>Petitioners</B>&rdquo;) and shall be delivered to
the Office. The demand may contain a number of documents similarly worded each of which are signed by one or more of the Petitioners.
If the directors do not convene a meeting, the Petitioners may convene by themselves a Special General Meeting as provided in Section
64 of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.3pt"></TD><TD STYLE="width: 36.25pt"><FONT STYLE="font-size: 10pt">56.</FONT></TD><TD STYLE="text-align: justify">Notices of General Meetings shall be given as <FONT STYLE="letter-spacing: -0.1pt">follows:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">56.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">A prior notice of at least seven (7) days and no more than thirty (30) days (not
including the day of delivery but including the day of the meeting) of any General Meeting shall be given with respect to the place, date
and hour of the meeting and the nature of every subject on its agenda.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">56.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">The notice shall be given to Shareholders entitled pursuant to these Articles to
receive notices from the Company, as hereinafter provided.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">56.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">Non-receipt of a notice, given as aforesaid, shall not invalidate the resolution
passed or the proceedings held at the relevant Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">56.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">With the consent of all the Shareholders who are entitled at such time to receive
notices, the Company shall be permitted to convene Meetings and to resolve any resolution, upon shorter notice or without any notice and
in such manner, generally, as shall be approved by the Shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">57.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Notwithstanding anything to the contrary herein or to applicable law, the holders
of the Preferred Shares shall vote together with the holders of all other shares of the Company, and not as a separate class, in all Shareholders
meetings. Each Preferred Share shall entitle the holder thereof to such number of votes as if such shares had been converted into Ordinary
Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Proceedings of General <FONT STYLE="letter-spacing: -0.1pt">Meetings</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">58.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Subject to the provisions of these Articles, the function of the General Meeting
shall be to receive and to deliberate with respect to the profit and loss statements, the balance sheets, the ordinary reports and the
accounts of the directors and auditors; to declare Dividends, to appoint accountants-auditors and to fix their salaries, to amend these
Articles, to approve certain actions and transactions under the provisions of Section 255 and Section 268 through Section 275 of the Companies
Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">59.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">No matter shall be discussed at a General Meeting unless a quorum is present at
the time when the General Meeting starts its discussions. Subject to the provisions of these Articles, two or more Shareholders present,
personally or by proxy, who hold or represent the majority of the voting rights in the Company, including (A) the Preferred B Majority
and (B) the holder of the Special Share or the Preferred S Majority, shall constitute a quorum for General Meetings (it being understood
that without derogating from the requirement to obtain the consent of the holder of the Special Share with respect to the specific matters
for which its consent is required, the Special Share does not vote, and any written consent can be obtained without requiring the signature
of the holder of the Special Share).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">60.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">If within half an hour from the time appointed for the meeting a quorum is not
present, the meeting, shall stand adjourned to the same place and time one week from the date of the original meeting. If a notice of
the adjourned meeting has been given to the Shareholders, and a quorum is not present at the adjourned meeting within half an hour from
the time appointed for the meeting, two or more Shareholders present personally or by proxy, shall be a quorum, and shall be entitled
to deliberate and to resolve in respect of the matters for which the meeting was convened.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">61.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">The chairman of the Board or a director appointed by the Board for such purpose
shall open all General Meetings and shall preside as chairman at the meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">62.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The provisions of these Articles relating to General Meetings shall, mutatis mutandis,
apply to any General Meeting of the holders of a particular class of shares (a &ldquo;<B>Class Meeting</B>&rdquo;), provided, however,
that the requisite quorum at any such Class Meeting shall be one or more members present in person or by proxy and holding not less than
a majority (50%) of the issued and outstanding shares of such <FONT STYLE="letter-spacing: -0.1pt">class.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Vote by <FONT STYLE="letter-spacing: -0.1pt">Shareholders</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">63.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Every resolution put to the vote at a General Meeting shall be decided by a count
of votes. Subject to any provision in the Law or in these Articles requiring a higher majority, all resolutions shall be passed by majority
vote of the shares held by shareholders present at the meeting (on an as-converted basis).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">64.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">Subject to the provisions of these Articles, in a count of votes, each Shareholder
present at a <FONT STYLE="letter-spacing: -0.1pt">General </FONT>Meeting, personally or by proxy, shall be entitled to one vote for each
share held by it; <U>provided</U> that no Shareholder shall be permitted to vote at a General Meeting or to appoint a proxy to vote thereat
unless he has paid all calls for payment and all moneys then due to the Company from him with respect to his shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">65.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">If the number of votes for and against is equal the chairman of the meeting shall
have no casting vote, and the resolution proposed shall be deemed rejected.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">66.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">In the case of joint holders of a share, the vote of the senior holder who tenders
a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. The appointment of
a proxy to vote on behalf of a share held by joint holders shall be executed by the signature of the senior of the joint holders. For
the purposes of this Article, seniority shall be determined by the order in which the names of the joint holders stand in the Register.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">67.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">An objection to the right of a Shareholder or a proxy to vote in a General Meeting
must be raised at such meeting or at such adjourned meeting wherein that Person was supposed to vote, and every vote not disqualified
at such a meeting shall be valid for each and every matter. The chairman of the meeting shall decide whether to accept or reject any objection
raised at the appointed time with regard to the vote of a Shareholder or proxy, and his decision shall be final.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">68.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">A Shareholder of unsound mind, or in respect of whom an order to that effect has
been made by any court having jurisdiction, may vote, whether on a show of hands or by a count of votes, only through his legal guardian
or such other Person, appointed by the aforesaid court, who performs the function of a representative or guardian. Such representative,
guardian, or other Person may vote by proxy.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">69.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">A Shareholder which is a corporation shall be entitled, by a decision of its board
of directors, or by a decision of a person or other body according to a resolution of its board of directors, to appoint a person who
it shall deem fit to be its representative at every meeting of the Company. The representative appointed as aforesaid shall be entitled
to perform on behalf of the corporation he represents all the powers that the corporation itself might perform as if it were a person.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">70.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">In every vote, a Shareholder shall be entitled to vote either personally or by
proxy. A proxy need not be a Shareholder. Shareholders may participate in a General Meeting by means of a conference telephone call or
similar communications equipment by means of which all persons participating in the meeting can hear each other and participation in a
meeting pursuant to this Article shall constitute presence in person at such meeting. Shareholders may also vote in writing, by delivery
to the Company, prior to a General Meeting, of a written notice stating their affirmative or negative vote on an issue to be considered
by such meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">71.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">A letter of appointment of a proxy, power of attorney or other instrument pursuant
to which the appointee is acting shall be in writing. An instrument appointing a proxy, whether for a specific meeting or otherwise, may
be in the following form or in any other similar form prescribed by the <FONT STYLE="letter-spacing: -0.1pt">Board:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 78.1pt">&ldquo;I, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
</U>a Shareholder holding shares <FONT STYLE="letter-spacing: -0.25pt">in <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>hereby appoint &nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> as my proxy to vote
in my name and place at the [annual, special, adjourned - as the case may be] General Meeting of Neurolief Ltd. to be held on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
and at any adjournment thereof.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 78.1pt">In witness whereof signed by me this day of
, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="letter-spacing: -0.5pt">.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 5.1in"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="margin: 0pt 0 0pt 5.1in; font-size: 10pt; text-align: justify; text-indent: 0in">Appointor&rsquo;s <FONT STYLE="letter-spacing: -0.1pt">Signature&rdquo;</FONT></P>

<P STYLE="margin: 0pt 0 0pt 5.1in; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 6.9pt 0pt 43.15pt">Such instrument or a copy thereof shall
be deposited at the Office, or at such other place as the Board may direct from time to time, before the time appointed for the meeting
or adjourned meeting wherein the person referred to in the instrument is appointed to vote, or presented to the chairman at the meeting
in which such person shall vote that share. An instrument appointing a proxy which is not limited <FONT STYLE="letter-spacing: -0.25pt">in
</FONT>time shall expire twelve (12) months after the date of its execution; if the appointment shall be for a limited period (whether
limited by time or until the occurrence of a certain event), whether in excess of twelve (12) months or not, the instrument shall be for
the period stated therein.</P>

<P STYLE="margin: 0pt 6.9pt 0pt 43.15pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 6.9pt 0pt 43.15pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">72.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">A vote pursuant to an instrument appointing a proxy shall be valid notwithstanding
the death of the appointor, or the appointor becoming of unsound mind, or the cancellation of the proxy or its expiration in accordance
with any law, or the transfer of the shares with respect to which the proxy was given, unless a notice in writing of any such event was
received at the Office before the meeting took place.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">73.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">A Shareholder is entitled to vote by a separate proxy with respect to each share
held by him, <U>provided</U> that each proxy shall have a separate letter of appointment containing the serial number of share(s) with
respect to which such proxy is entitled to vote. If a specific share is included by the holder in more than one letter of appointment,
that share shall not entitle any of the proxy holders to a vote.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">74.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Subject to the provisions of any law, a resolution in writing signed by all the holders
of shares, entitled to vote with respect to such shares at General Meetings, or a resolution as aforesaid agreed upon by telex, telegram
facsimile or email (with signatures attached), shall have the same validity as any resolution, carried in a General Meeting of the Company
duly convened and conducted for the purpose of passing such a resolution. If all the Shareholders shall consent in writing, or by facsimile,
to any action to be taken by the Shareholders, such action shall be as valid as though it had been unanimously authorized at a duly convened
General Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt"><U>Board</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.3pt"></TD><TD STYLE="width: 36.25pt"><FONT STYLE="font-size: 10pt">75.</FONT></TD><TD STYLE="text-align: left"><U>Board <FONT STYLE="letter-spacing: -0.1pt">Composition</FONT></U><FONT STYLE="letter-spacing: -0.1pt">.
Subject to Article 144 below:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 36pt">75.1</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">As of the Closing under the BWAY Investment Agreement (and subject thereto), the
Board shall initially consist of up to five (5) directors, to be designated, appointed and removed as follows: (a) two (2) by KT (each,
a &ldquo;<B>KT Director</B>&rdquo;); (b) one (1) by KT (the <B>&ldquo;Preferred B Director&rdquo;</B>) (who shall not be an employee or
affiliate of KT), whose appointment shall be subject to the prior written approval of BWAY, not to be unreasonably withheld, delayed or
conditioned); (c) one (1) by BWAY (a &ldquo;<B>BWAY Director</B>&rdquo;); and (d) one (1) shall be Amit Dar.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">&nbsp;</TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>75.2</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">As of the Second Closing under the BWAY Investment Agreement (and subject thereto), the Board shall consist of up to five (5) directors,
to be designated, appointed and removed as follows: (a) two (2) KT Directors; <FONT STYLE="letter-spacing: -0.3pt">(b) the Preferred B
Director (where any of the KT Directors and the Preferred B Director may be Amit Dar at KT&rsquo;s election); and </FONT>(c) <FONT STYLE="letter-spacing: -0.3pt">two
(2) by </FONT>BWAY, one of whose appointment shall be subject to the prior written approval of KT, not to be unreasonably withheld, delayed
or conditioned; and</TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">&nbsp;</TD></TR>
                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>75.3</TD><TD STYLE="text-align: justify; padding-right: 6.75pt">As of the Third Closing under the BWAY Investment Agreement (and subject thereto), the Board shall consist of up to five (5) directors,
to be designated, appointed and removed as follows: (a) two (2) KT Directors; <FONT STYLE="letter-spacing: -0.3pt">(b) the Preferred B
Director; and </FONT>(c) <FONT STYLE="letter-spacing: -0.3pt">two (2) </FONT>BWAY Directors.</TD></TR>
                                                                                                                      </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 36pt">75.4</TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Each non-employee director shall be entitled in such person&rsquo;s discretion
to be a member of any Board committee.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 36pt">75.5</TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Subject to the provisions set forth in Article 75.1 above, the appointment or removal
of a director may be effected at any time, including during an initial or extended term of service of a director, by the delivery of a
notice to the Company at its principal office, signed by the Shareholders or directors entitled to effect such appointment or removal.
A director cannot be removed or replaced except by the Shareholders or directors who were entitled to appoint such director in accordance
with Article 75.1.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">76.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">If any member of the Board is not designated or appointed, or if the office of
any member of the Board is vacated, the other members of the Board may act in every way and manner provided for under these Articles and
the law as long as their number does not fall below the quorum required by these Articles for a Board meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">77.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Except as set forth herein, any person may be an alternate member of the Board
(an &ldquo;<B>Alternate Director</B>&rdquo;) if such person is qualified to serve as a director of the Company. Any Alternate Director
shall have a vote equal to the vote of the Board member that he substitutes. An Alternate Director shall have, subject to his letter of
appointment, all authorities vested to the member of the Board he substitutes. The tenure of office of an Alternate Director shall automatically
be terminated upon the dismissal of such member, or upon the office of the member of the Board he substitutes being vacated for any reason,
or upon the occurrence of one of the situations stated in Article 80 below in relation with such Alternate Director. In the event that
a member of the Board is precluded by law or otherwise from participating in a meeting or a vote of the Board, such member shall be entitled
to appoint an Alternate Director to so participate and/or vote in his place.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.3pt"></TD><TD STYLE="width: 36.25pt"><FONT STYLE="font-size: 10pt">78.</FONT></TD><TD STYLE="text-align: justify">A director shall not be required to hold qualifying shares in the <FONT STYLE="letter-spacing: -0.1pt">Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.3pt"></TD><TD STYLE="width: 36.25pt"><FONT STYLE="font-size: 10pt">79.</FONT></TD><TD STYLE="text-align: justify">A director may hold another paid position or function, except as accountant-auditor, in the <FONT STYLE="letter-spacing: -0.1pt">Company,
</FONT>or in any other company of which the Company is a Shareholder or in which the Company has some other interest, or that has an interest
in the Company, together with his position as a director, upon such conditions with respect to salary and other matters as determined
by the Board and approved by the General Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">80.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">Subject to the provisions of the Law, of these Articles, or to the provisions of
an existing contract, the tenure of office of a director shall automatically be terminated upon the occurrence of one of the <FONT STYLE="letter-spacing: -0.1pt">following:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">80.1.</FONT></TD><TD STYLE="text-align: justify">if he becomes <FONT STYLE="letter-spacing: -0.1pt">bankrupt;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">80.2.</FONT></TD><TD STYLE="text-align: justify">if he is declared insane, becomes of unsound mind or legally <FONT STYLE="letter-spacing: -0.1pt">incompetent;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">80.3.</FONT></TD><TD STYLE="text-align: justify">if he resigns by an instrument in writing delivered to the Company; <FONT STYLE="letter-spacing: -0.25pt">or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">80.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.35pt">with his death and if it is a corporation or other entity, with the liquidation
of such corporation or other entity.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">81.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Members of the Board shall not receive any remuneration for their services as a
Board member from the Company&rsquo;s funds, unless otherwise resolved by the General Meeting, and at a rate decided by such resolution.
The members of the Board shall be entitled to reimbursement of their expenses in the course of their performance of their duties as directors,
including expenses in relation of participating in Board meetings, according to a reasonable reimbursement policy of the Company and subject
to the prior approval of Board. The foregoing shall not be construed to apply to remuneration paid to any Board member who is also an
employee (or service provider) of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Powers and Duties of <FONT STYLE="letter-spacing: -0.1pt">Directors</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">82.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The Board shall determine and direct the Company&rsquo;s policy and shall supervise
and inspect the performance of the Company&rsquo;s CEO or General Manager and his or her actions and responsibilities, and it may pay
all expenses incurred in connection with the establishment and registration of the Company as it shall see fit. The Board shall be entitled
to perform the Company&rsquo;s powers and authorities pursuant to Section 92 of the Companies Law and subject to any provision in Law,
in these Articles, or the regulations that the Company shall adopt by a resolution in its General Meeting (insofar as they do not contradict
the Law or these Articles). However, any regulation adopted by the Company in its General Meeting as aforesaid shall not affect the legality
of any prior act of the Board that would be legal and valid but for that regulation.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">83.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Without limiting the generality of the preceding provision, but subject to the provisions
of these Articles, the Board may from time to time, in its discretion, borrow or secure the payment of any sum of money for the purposes
of the Company, and it may raise or secure the repayment of such sum in such manner, at such times and upon such terms and conditions
in all respects as it thinks fit, and, in particular, by the issue of bonds, perpetual or redeemable debentures, debenture stock, or any
mortgages, charges, or other securities on the whole or any part of the property of the Company, both present and future, including its
uncalled capital for the time being and its called but unpaid capital.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Functions of the <FONT STYLE="letter-spacing: -0.1pt">Directors</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">84.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">The Board may meet in order to transact business, to adjourn its meetings or to
organize them otherwise as it shall deem fit, in accordance with the Articles herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">85.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The directors shall select a chairman of the Board. Such chairman shall not have
any additional or casting vote but, to the extent appointed, shall have the authority to conduct meetings of the Board, call meetings
of the Board and determine the agenda for meetings of the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">86.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The presence of a majority of the directors then in office (which must include at
least one BWAY Director and one KT Director, for as long as BWAY and KT, respectively, each has the right to appoint a Director) at the
opening of a meeting, shall constitute a quorum for meetings of the Board. Notwithstanding the aforesaid, if within half an hour of the
time arranged for the Board meeting no quorum is present, such meeting shall stand adjourned to the same day of the following week, at
the same hour and in the same place, or in the event that such a day is not a Business Day, then to the first Business Day thereafter,
and in such adjourned meeting if no quorum is present within half an hour of the time arranged, at least a majority of the directors,
who are present at such adjourned meeting, shall be deemed a <FONT STYLE="letter-spacing: -0.1pt">quorum.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">87.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The Board may delegate any of its powers to committees and may from time to time
revoke such delegation; provided that no committee of the Board will be established unless a majority of the directors then serving on
the Board, approved its constitution, composition and authorities; and further provided that such delegation does not contradict Section
112 of the Companies Law. Any such committee shall, to the extent reasonably practicable, reflect the composition of the Board as set
out in Article 75, in terms of the relative representation of Shareholders. The individuals appointed to any such committee need not be
the same individuals serving on the Board, provided, however, that any nomination or appointment to a committee that would have required
the approval of any Shareholder if made to the Board pursuant to Article 75 shall require the same approval when made to a committee.
Each committee to which any powers of the Board have been delegated shall abide by any regulations enacted by the Board with respect to
the exercise of such delegated powers. In the absence of such regulations or if such regulations are incomplete in any respect, the committee
shall conduct its business in accordance with these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">88.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Members of the Board or a committee thereof may participate in a meeting of the Board
or the committee by means of a conference telephone call or similar communications equipment by means of which all persons participating
in the meeting can hear each other, and participation in a meeting pursuant to this Article shall constitute presence in person at such
meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">89.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">Every director may at any time request that a Board meeting be called and the Chairman
shall call such a meeting upon such request.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">90.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">Any notice of a Board meeting can be given in writing, or by telegram, facsimile
or telex and shall include reasonable detail of the issues of such meeting. Notice shall be given at least three (3) Business Days before
the time appointed for the meeting, unless all of the members of the Board at that time agree to a shorter notice, or waive notice altogether.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">91.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Subject to the other provisions of these Articles, issues raised before all meetings
of the Board shall be decided by the majority of the voting power of the directors present at the meeting of the Board, with each director
having one vote; provided, however, that if not all BWAY Directors are appointed by BWAY or not all KT Directors are appointed by KT (for
the avoidance of doubt, not including for such purpose the Preferred B Director), the then-appointed BWAY Director(s) and KT Directors
(for the avoidance of doubt, not including for such purpose the Preferred B Director), as the case may be shall have the voting power
of the respective non-appointed <FONT STYLE="letter-spacing: -0.1pt">directors. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">92.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">A resolution in writing signed or approved in writing (including by facsimile)
by all of the directors entitled to participate and vote on the issue at stake shall be valid for any purpose as a resolution adopted
at a Board meeting that was duly convened and held. In place of a director the aforesaid resolution may be signed and delivered by an
Alternate Director.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">93.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">All actions performed bona fide by the Board or by any person acting as a director
or as an Alternate Director shall be as valid as if each and every such person were duly and validly appointed and fit to serve as a director
or an Alternate Director, as the case may be, even if at a later date a flaw shall be discovered in the appointment of such a director
or such a person acting as aforesaid, or in his qualifications to so serve.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">94.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The Board shall cause minutes to be taken of all General Meetings of the Company,
of the appointments of officers of the Company, and of Board&rsquo;s meetings, which minutes shall include the following items, if applicable:
the names of the persons present; the matters discussed at the meeting; the results of votes taken; resolutions adopted at the meeting;
and directives given by the meeting. The minutes of any meeting, signed or appearing to be signed by the chairman of the meeting, shall
serve as prima facie proof of the truth of the contents of the minutes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">95.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">The directors shall comply with all provisions of the Companies Law, and especially
with the provisions in respect of -</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">95.1.</FONT></TD><TD STYLE="text-align: justify">registration in the Company&rsquo;s books of all liens that affect the Company&rsquo;s <FONT STYLE="letter-spacing: -0.1pt">assets;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">95.2.</FONT></TD><TD STYLE="text-align: justify">keeping a register of <FONT STYLE="letter-spacing: -0.1pt">Shareholders;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">95.3.</FONT></TD><TD STYLE="text-align: justify">keeping a register of directors; <FONT STYLE="letter-spacing: -0.25pt">and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">95.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">delivery to the Registrar of Companies of all notices and reports that are required
to be so delivered.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Personal <FONT STYLE="letter-spacing: -0.1pt">Interest</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">96.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">All transactions and actions in which an Office Holder (as such term is defined
in the Companies Law) in the Company has a personal interest shall be approved in accordance with the provisions of the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">97.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">The Company may approve an action of an Office Holder of the type listed in Section
254(a) of the Companies Law if the Board determines that all of the conditions for such approval, as set forth in the Companies Law, have
been fulfilled and approves such action.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 7.15pt; text-align: justify"><U>Local <FONT STYLE="letter-spacing: -0.1pt">Management</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">98.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">The Board may organize from time to time arrangements for the management of the
Company&rsquo;s business in any particular place, whether in Israel or abroad, as they shall see fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6.25pt"></TD><TD STYLE="width: 36.3pt"><FONT STYLE="font-size: 10pt">99.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">Without derogating from the general powers granted to the Board pursuant to the
preceding Article, the Board may from time to time convene any local management or agency to conduct the business of the Company in any
particular place, whether in Israel or abroad, and may appoint any person to be a member of such local management, or to be a director
or agent, and may decide his manner of compensation. The Board may from time to time grant a person so appointed any power, authority,
or discretion that the Board may have at that time, and may authorize any person acting at that time as a member of a local management
to continue in his position notwithstanding that some position has been vacated there, and any such appointment or authorization may be
made upon such conditions as the Board deems fit. The Board may from time to time relieve any person so appointed or revoke or change
any such authorization.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>CEO, General Manager, President, Secretary,
Other Officers and <FONT STYLE="letter-spacing: -0.1pt">Attorneys</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">100.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Subject to the provisions of these Articles, the Board may from time to time appoint
one or more persons, whether or not he is a member of the Board, as the Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;) of the Company.
The appointment may be either for a fixed period of time or without limiting the time that the CEO will stay in office. The Board may,
from time to time, subject to any provision in any contract between the CEO and the Company, release him from his office and appoint another
or others in his or their place. The CEO shall be responsible for the current operation of the Company&rsquo;s affairs within the bounds
of the policy determined by the Board and subject to its directions. In addition, the Board may from time to time grant and bestow upon
the CEO those powers and authorities that it exercises pursuant to these Articles and under the provisions of Section 92 of the Companies
Law, as it shall deem fit, and may grant those powers and authorities for such period, and to be exercised for such objectives and purposes,
in such time and conditions, and on such restrictions, as it shall decide; and it can from time to time revoke, repeal, or change any
one or all of those powers or authorities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">101.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">Subject to the provisions of these Articles, the Board may from time to time appoint
a Secretary to the Company, a Treasurer and/or Comptroller or Chief Financial Officer as well as other officers, personnel, agents and
servants, including management companies, for fixed, provisional or special duties, as the Board may from time to time deem fit, and may
from time to time, in its discretion, suspend and/or dismiss any one or more of such persons. The Board may determine the powers and duties
of such persons, and may demand security in such cases and in such amounts as it deems fit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">102.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Subject to the provisions of these Articles, the wages and any other compensation
of the CEO and other managers, officers or personnel shall be determined from time to time by the Board, and it may be paid by way of
a fixed salary or commission, or a percentage of profits or of the Company&rsquo;s turnover or of any other company that the Company has
an interest in, or by participation in such profits, or in any combination of the aforementioned methods, or such other method as the
Board shall determine.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">103.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">The Board may from time to time directly or indirectly authorize any company, firm,
person or group of people to be the attorneys in fact of the Company for purposes and with powers and discretion which shall not exceed
those conferred upon the Board or which the Board can exercise pursuant to these Articles, and for such a period of time and upon such
conditions as the Board may deem proper. Every such authorization may contain such directives as the Board deems proper for the protection
and benefit of the persons dealing with such attorneys. The Board may also grant such an attorney the right to transfer to others, in
part or in whole, the powers, authorities and discretions granted to him, and may terminate and revoke the appointments or revoke all
or any part of the powers granted to them.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt"><U>Dividends</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">104.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Subject to these Articles and the provisions of Sections 301 through 311 (inclusive)
of the Companies Law, the Company, at a General Meeting and upon the recommendation of the directors, may, subject to the approval of
the <FONT STYLE="letter-spacing: -0.15pt">(A) </FONT>Preferred B Majority and the (B) holder of the Special Share or Preferred S Majority,
declare a Dividend to be paid to the Shareholders, subject to their preferences and according to their rights and benefits under these
Articles (including, without limitation, Article 8.1A (<I><U>Dividend Rights</U></I><U>)</U>, and to decide the time of payment. A Dividend
may not be declared in excess of that recommended by the Board. Without derogating from the foregoing, the Company will not declare or
pay any dividends on the Preferred Shares or the Ordinary Shares unless and until each of the accrued and unpaid amount of <FONT STYLE="letter-spacing: -0.15pt">(i)
the Preferred S Dividend Preference, </FONT>(ii) the Preferred B-3/B-4 Dividend Preference (iii) the Preferred B/B-1/B-2 Dividend Preference,
and (iv) the Preferred A/A-1 Dividend Preference, have been paid in full.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">105.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">A notice of the declaration of a Dividend shall be given to the Shareholders registered
in the Register, in the manner provided for in these Articles.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">106.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">Subject to the provisions of these Articles, and subject to any rights or conditions
attached at that time to any share in the capital of the Company granting preferential, special or deferred rights or not granting any
rights with respect to Dividends, the profits of the Company which shall be declared as Dividends shall be distributed according to the
proportion of the nominal value paid up to account of the shares held at the record date fixed by the Company, without regard to premium
paid in excess of the nominal value, if any. No amount paid or credited as paid on a share in advance of calls shall be treated for purposes
of this Article as paid on a share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">107.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">The Board may issue any share upon the condition that a Dividend shall be paid
at a certain date, or that a portion of the declared Dividend for a certain period shall be paid, or that the period for which a Dividend
shall be paid shall commence at a certain date, or any similar condition; in any such case, subject to the Law and these Articles, the
Dividend shall be paid in respect of such a share in accordance with such a condition.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">108.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">At the time of declaration of a Dividend the Company may decide that such a Dividend
shall be paid in whole or in part by way of distribution of certain properties, including by means of distribution of fully paid up shares
or debentures or debenture stock of the Company, or by means of distribution of fully paid up shares or debentures or debenture stock
of any other company, or in one or more of the aforesaid ways.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">109.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">The Company shall have a lien on any Dividend paid in respect of a share on which
the Company has a charge, and may use it to pay any debts, obligations or commitments to which the charge applies.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">110.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">The persons registered in the Register as Shareholders on the record date for declaration
of the Dividend shall be entitled to receive the Dividend. A transfer of shares shall not transfer the right to a Dividend, which has
been declared after the transfer but before the registration of the transfer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">111.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">A Dividend may be paid by, inter alia, check or payment order to be mailed to the
address of a Shareholder or person entitled thereto as registered in the Register, or in the case of joint owners - to the address of
one of the joint owners as registered in the Register. Every such check shall be made out to the person to whom it is sent. The receipt
of the person who on the record date in respect of the Dividend is registered as the holder of any share or, in the case of joint holders,
of one of the joint holders, shall serve as a release with respect to payments made in connection with that share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">112.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">If at any time the share capital is divided into different classes of shares, the
distribution by way of Dividend, of fully paid up shares, or from funds, shall be made in one of the two following manners as to be determined
by the Board:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">112.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">all holders of shares entitled to fully paid up shares shall receive one uniform
class of shares; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">112.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">each holder of shares entitled to fully paid up shares shall receive shares of
the class of shares held by him and entitling him to fully paid up shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">113.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">In order to give effect to any resolution in connection with a Distribution, the
Board may resolve any difficulty that shall arise with respect to such Distribution in such way as it shall deem proper, including the
issuance of certificates for fractional shares, and the determination of the value of certain property for purposes of Distribution. The
Board may further decide that payment in cash shall be made to a Shareholder on the basis of value decided for that purpose, or that fractions
the value of which is less than one New Israeli Shekel shall not be taken into account for the purpose of adjusting the rights of all
the parties. The Board shall be permitted in this regard to grant cash or property to trustees in escrow for the benefit of persons entitled
thereto, as the Board shall see fit. Wherever required, an agreement shall be submitted to the Registrar of Companies and the Board may
appoint a person to execute such an agreement in the name of the persons entitled to any Dividend, property, fully paid-up shares or debentures
as aforesaid, and such an appointment shall be valid and binding on the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">114.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">The Board may, with respect to all Dividends not demanded within thirty (30) days
after their declaration, invest or use them in another way for the benefit of the Company, until they shall be <FONT STYLE="letter-spacing: -0.1pt">demanded.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">115.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">All Articles in these Articles of Association relating to Dividends, shall apply,
<I>mutatis mutandis</I>, to a Distribution by the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt"><U>Reserves</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">116.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.8pt">The Board may set aside from the profits of the Company the sums they deem proper,
as a reserve fund or reserve funds for extraordinary uses, or for special dividends or other funds or for the purpose of preparing, improving
or maintaining any property of the Company, and for such other purposes as shall in the discretion of the Board be beneficial to the Company,
and the Board may invest the various sums so set aside in such investments as they deem proper, and from time to time deal in, change,
or transfer such investments, in part or in whole, for the benefit of the Company. The Board may also divide any reserve liability fund
to special funds as it shall deem proper, transfer moneys from fund to fund and use every fund or any part thereof in the business of
the Company, without being required to keep such sums separate from the rest of the Company&rsquo;s property. The Board may, from time
to time, also transfer to the next year profits out of such sums which are, in their discretion, beneficial to the Company. The Board
may generally create funds as they deem necessary, either those resulting from profits of the Company or from re-evaluation of property,
or from premiums paid for shares or from any other source and use them in their discretion as they deem fit so long as the creation, changes
or uses of such funds do not exceed any provision of the Law or accepted accounting principles and <FONT STYLE="letter-spacing: -0.1pt">practices.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">117.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">All premiums received from the issue of shares shall be capital funds, and they
shall be treated for every purpose as capital and not as profits distributable as Dividends. The Board may organize a reserve capital
liability account and transfer from time to time all such premiums to the reserve capital liability account or use such premiums and moneys
to cover depreciation or doubtful loss. All losses from sale of investments or other property of the Company shall be debited to the reserve
account, unless the Board decides to cover such losses from other funds of the Company. The Board may use moneys credited to the capital
reserve liability account in any manner that these Articles or the Law <FONT STYLE="letter-spacing: -0.1pt">permit.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">118.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Any amounts transferred and credited to the account of income and expense fund or
general reserve liability account or capital liability reserve account, may, until otherwise used in accordance with these Articles, be
invested together with such other moneys of the Company in the day to day business of the Company, without having to differentiate between
these investments and the investment of other moneys of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>Capitalization of Reserve <FONT STYLE="letter-spacing: -0.2pt">Funds</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">119.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">The Company may from time to time resolve at a General Meeting that any amount,
investment or property not required as a source for payment of fixed preferential Dividends and (i) standing credited at that time to
any fund or to any reserve liability account of the Company, including also premiums received from issuance of shares, debentures, or
debenture stock of the Company, or (ii) being net profits not distributed and remaining in the Company, shall be capitalized, and that
such amount shall be distributed as Bonus Shares, in the manner so directed by such resolution. The Board shall use such investment, sum
or property, according to such a resolution, for full payment of such shares of the Company&rsquo;s capital not issued to the Shareholders,
and to issue such shares and to distribute them as fully paid shares among the Shareholders according to their pro rata right for payment
of the value of the shares and their rights in the amount capitalized. The directors may also use such investment, sum or property, or
any part thereof, for the full payment of the Company&rsquo;s capital issued and held by such Shareholders, or such investment, sum or
property in any other manner permitted by such a resolution. If any difficulty shall arise with respect to such a distribution, the Board
may act, and shall have all the powers and authorities, as set forth in Article 113 above, <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt"><U>Office</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3pt"></TD><TD STYLE="width: 42.25pt"><FONT STYLE="font-size: 10pt">120.</FONT></TD><TD STYLE="text-align: left">The Board shall determine the location of the <FONT STYLE="letter-spacing: -0.1pt">Office.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: left"><U>Stamp and <FONT STYLE="letter-spacing: -0.1pt">Signatures</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">121.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">The Board shall cause the Company&rsquo;s stamp, of which the Company shall have
at least one, to be kept in safekeeping, and it shall be forbidden to use the stamp in violation of any instructions the Board may give
in connection with the use thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">122.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Subject to the provisions of these Articles, the Board may designate any Person
or Persons (even if they are not members of the Board) to act and to sign in the name of the Company, and to apply the Company&rsquo;s
stamp; the acts and signature of such a person or persons shall bind the Company, insofar as such person or persons have acted and signed
within the limits of their authority.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">123.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">The printed or typed name of the Company by any means next to the signatures of
the authorized signatories of the Company, as aforesaid, shall be valid as if the stamp of the Company was affixed.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>Accounts and <FONT STYLE="letter-spacing: -0.2pt">Audit</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3pt"></TD><TD STYLE="width: 42.25pt"><FONT STYLE="font-size: 10pt">124.</FONT></TD><TD STYLE="text-align: justify">The Board shall cause correct accounts to be <FONT STYLE="letter-spacing: -0.2pt">kept:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">124.1.</FONT></TD><TD STYLE="text-align: justify">of the assets and liabilities of the <FONT STYLE="letter-spacing: -0.1pt">Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">124.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">of moneys received or expended by the Company and the matters for which such moneys
are expended or received; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">124.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">of all purchases and sales made by the Company. The account books shall be kept
in the Office or at such other place as the Board deems fit, and they shall be open for inspection by the directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">125.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The Board shall determine from time to time, in any specific case or type of cases,
or generally, whether and to what extent, and at what times and places, and under what conditions or regulations, the accounts and books
of the Company, or any of them, shall be open for inspection by the Shareholders. No Shareholder other than a director shall have any
right to inspect any account book or document of the Company except as conferred by Law or authorized by the Board or by the Company in
a General Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">126.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">Accountants-Auditors shall be appointed and their function shall be set out in
accordance with the <FONT STYLE="letter-spacing: -0.2pt">Law.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">127.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.25pt">Not less than once a year, the directors shall submit before the Company at a General
Meeting a balance sheet and profit and loss statement for the period after the previous statement. The statement shall be prepared in
accordance with the relevant provisions of the Companies Law. A report of the auditor shall be attached to the statements, and it shall
be accompanied by a report from the Board with respect to the condition of the Company&rsquo;s business, the amount (if any) they propose
as a Dividend, and the amount (if any) that they propose to set aside for the fund <FONT STYLE="letter-spacing: -0.1pt">accounts.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: left"><FONT STYLE="letter-spacing: -0.1pt"><U>Notices</U></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">128.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">A notice or any other document may be served by the Company upon any Shareholder
either personally or by sending it by mail, telegram, facsimile, electronic mail or telex addressed to such Shareholder at his registered
address as appearing in the Register. If the address of a Shareholder is outside of Israel, then any notice sent by mail shall be sent
by airmail.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">129.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">All notices with respect to any share to which persons are jointly entitled may
be given to one of the joint holders, and any notice so given shall be sufficient notice to all the holders of such share.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">130.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">A Shareholder registered in the Register who shall from time to time furnish the
Company with an address at which notices may be served, shall be entitled to receive all notices he is entitled to receive according to
these Articles at that address. However, except for the aforesaid, no Shareholder whose address is not registered in the Register shall
be entitled to receive any notice from the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">131.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.95pt">A notice may be given by the Company to the persons entitled to a share in consequence
of the death or bankruptcy of a Shareholder by sending it through the mail in a prepaid airmail letter or telegram or telex or facsimile
addressed to them by name, at the address, if any, furnished for the purpose by the persons claiming to be so entitled or, until such
an address has been so furnished, by giving the notice in any manner in which the same might have been given if the death or bankruptcy
have not <FONT STYLE="letter-spacing: -0.1pt">occurred.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">132.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Any notice or other document, (i) if delivered personally, shall be deemed to have
been served upon delivery, (ii) if sent by mail, shall be deemed to have been served seven (7) Business Days after the delivery thereof
to the post office; if sent by airmail, shall be deemed to have been served five (5) Business Days after the delivery thereof to the post
office; and (iii) if sent by email or confirmed facsimile, shall be deemed to have been served twenty four (24) hours after the time such
email or facsimile was sent. In proving such service, it shall be sufficient to prove that the letter containing the notice was properly
addressed and delivered at the post office, or if sent by email or confirmed facsimile, to provide a delivery receipt, as the case may
be.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>Office Holders<FONT STYLE="font-weight: normal">&rsquo;</FONT>
Indemnity, Insurance and <FONT STYLE="letter-spacing: -0.1pt">Exemption</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">133.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">The Company may indemnify its Office Holders to the fullest extent permitted by
the Law. Subject to the provisions of the Law including the receipt of all approvals as required therein or under any applicable law,
and the provisions of Article 133.7 below, the Company may indemnify an Office Holder with respect to the following liabilities and expenses,
provided that such liabilities or expenses were incurred by such Office Holder in such Office Holder&rsquo;s capacity as an Office Holder
of the <FONT STYLE="letter-spacing: -0.1pt">Company:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">a monetary liability imposed on him/her in favor of a third party in any judgment,
including any settlement confirmed as judgment and an arbitrator's award which has been confirmed by the court;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">reasonable litigation expenses, including legal fees, paid for by the Office Holder,
in an investigation or proceeding conducted against such Office Holder by an agency authorized to conduct such investigation or proceeding,
and which investigation or proceeding (i) concluded without the filing of an indictment against such Office Holder and without there having
been a financial obligation imposed against such Office Holder in lieu of a criminal proceeding, or (ii) concluded without the filing
of an indictment against such Office Holder but with there having been a financial obligation imposed against such Office Holder in lieu
of a criminal proceeding for an offense that does not require proof of criminal intent;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">reasonable litigation expenses, including legal fees paid for by the Office Holder,
or which the Office Holder is obligated to pay under a court order, in a proceeding brought against the Office Holder by the Company,
or on its behalf, or by a third party, or in a criminal proceeding in which the Office Holder is found innocent, or in a criminal proceeding
in which the Office Holder was convicted of an offense that does not require proof of criminal intent.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">Payment to a victim as set forth in Section 52ND(a)(1)(a) in the Israeli Securities
Law, 1968 (the &ldquo;<B>Securities Law</B>&rdquo;); or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Expenses incurred by the Office Holders in connection with any proceeding against
him pursuant to Chapter H3, H4, I1 of the Securities Law, including all reasonable <FONT STYLE="letter-spacing: -0.1pt">expenses.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.6.</FONT></TD><TD STYLE="text-align: justify">For purposes of Article 131.2 <FONT STYLE="letter-spacing: -0.1pt">above:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">133.6.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">the &quot;<I>conclusion of a proceeding without the filing of an indictment</I>&quot;
regarding a matter in which a criminal proceeding was initiated, means the closing of a file pursuant to Section 62 of the Criminal Procedure
Law [Consolidated Version], 5742-1982 (the &ldquo;<B>Criminal Procedure Law</B>&rdquo;) or a stay of process by the Attorney General pursuant
to Section 231 of the Criminal Procedure Law; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">133.6.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">a &quot;<I>financial obligation imposed in lieu of a criminal proceeding</I>&quot;
means a financial obligation imposed by law as an alternative to a criminal proceeding, including an administrative fine pursuant to the
Administrative Offenses Law, 5746-1982, a fine for committing an offense categorized as a finable offense pursuant to the provisions of
the Criminal Procedure Law or a penalty.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">133.7.</FONT></TD><TD STYLE="text-align: justify">The Company may undertake to indemnify an Office Holder as aforesaid in <FONT STYLE="letter-spacing: -0.1pt">Articles
</FONT>133.1 through 133.5 above: (i) prospectively, provided that, in respect of Article 133.1, the undertaking is limited to categories
of events which in the opinion of the Board can be foreseen when the undertaking to indemnify is given, and to an amount set by the Board
as reasonable under the circumstances, and (ii) retroactively.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">134.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">Subject to the provisions of any Law, the Company may procure, for the benefit of
any of its Office Holders, office holders&rsquo; liability insurance with respect to any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">134.1.</FONT></TD><TD STYLE="text-align: justify">a breach of the duty of care owed to the Company or any other <FONT STYLE="letter-spacing: -0.1pt">person;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">134.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">a breach of the fiduciary duty owed to the Company, <U>provided</U> that the Office
Holder acted in good faith and had reasonable grounds to assume that the action would not injure the Company; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">134.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">a monetary liability imposed on an Office Holder in favor of a third party, in respect
of an act performed by the Office Holder by virtue of the Office Holder being an Office Holder of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">135.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.85pt">Subject to the provisions of any Law, the Company may exempt in advance, by a Board
resolution, Office Holders from all or part of their responsibilities for damages due to their violation of their duty of care to the
Company. Notwithstanding the foregoing, the Company may not exempt Office Holders in advance from their responsibilities for damages due
to their violation of their duty of care to the Company with respect to Distributions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">136.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt"><FONT STYLE="letter-spacing: -0.2pt">The provisions of Articles 134, 135 and 136
above are not intended, and shall not be interpreted, to restrict </FONT>the Company in any manner in respect of the procurement of insurance
and/or in respect of indemnification (i) in connection with any person who is not an Office Holder, including, without limitation, any
employee, agent, consultant or contractor of the Company who is not an Office Holder, <FONT STYLE="letter-spacing: -0.1pt">and/or (ii)
in connection with any Office Holder to the extent that such insurance and/or indemnification </FONT>is not specifically prohibited under
law; provided that the procurement of any such insurance and/or the provision of any such indemnification shall be approved by the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>Winding <FONT STYLE="letter-spacing: -0.25pt">Up</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">137.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Subject to the provisions of these Articles to the contrary, and subject to any
rights or conditions attached at that time to any share in the capital of the Company granting preferential, special or deferred rights
or not granting any rights with respect to winding up or liquidation, in the event of a winding up of the Company, the Company&rsquo;s
property distributable among the Shareholders shall be distributed in proportion to the sum paid on account of the nominal value of the
shares held by them, of any class, without taking into account premiums paid in excess of the nominal value.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">138.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.9pt">Subject to provisions of these Articles to the contrary, if the Company is voluntarily
wound up, the liquidators may, with the approval of a resolution in a General Meeting, divide the property as is among the Shareholders,
or deposit any part of the Company&rsquo;s property with trustees in escrow for the benefit of Shareholders, as they deem proper.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">139.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.75pt">Subject to provisions of these Articles to the contrary, if, at the time of liquidation,
the Company&rsquo;s property available for distribution among the Shareholders shall not suffice to return all the paid up capital, and
subject to, and without derogating from, any rights or surplus rights or existing restrictions at that time of any special class of shares
forming part of the capital of the Company, such property shall be divided so that the losses shall as much as possible be borne by the
Shareholders in proportion to the paid up capital or that which shall have been paid at the commencement of the liquidation on the shares
held by each of them. If, at the time of liquidation, the Company&rsquo;s property designated for distribution among the Shareholders
is in excess of the amount necessary for the return of capital paid up at the beginning of the liquidation, it shall belong and be delivered
to the Shareholders pro rata to the amount paid on the nominal value of each share held by each of them at the commencement of the <FONT STYLE="letter-spacing: -0.1pt">liquidation.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>Protective <FONT STYLE="letter-spacing: -0.1pt">Provisions</FONT></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">140.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">Notwithstanding anything to the contrary in these Articles, until the earlier of
(a) the Third Closing (except as specified in Article 140.5) or (b) an IPO or Deemed Liquidation, the consent of at least the Preferred
B Majority will be required for any of the following actions (whether taken directly or indirectly, by merger, consolidation or otherwise),
other than the actions listed in Articles 140.9, 140.10, 140.11, and 140.16 which will require the consent of the KT Directors:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.1.</FONT></TD><TD STYLE="text-align: justify">any M&amp;A <FONT STYLE="letter-spacing: -0.1pt">Transaction (but not, for the avoidance of any doubt,
any transaction pursuant to the exercise of the Call Option);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">any sale by the Company of all or substantially all of its assets (including any
exclusive license of material intellectual property, except for any such license outside of the United States), any merger of the Company
with another entity or any sale of more than 50% of the voting power of the Company <FONT STYLE="letter-spacing: -0.1pt">(other than any
transaction pursuant to the exercise of the Call Option)</FONT>;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">any sale, mortgage, pledge of, or placement of a security interest on, any material
asset (including material intellectual property rights) of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any liquidation, dissolution or winding up of the Company (including any Deemed
Liquidation or IPO or consenting to any of the foregoing), other than the consummation of the Call Option;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">any amendment, alteration or repeal of the Articles that adversely affects the rights,
preferences or privileges of the Preferred Shares, including to increase or decrease of the share capital of the Company or to change
any right attached to any share, or to create any new class or series of shares having rights, preferences or privileges equal or senior
to the Preferred Shares (other than the Preferred S Shares); but not including an amendment for the purpose of increasing an existing
class or series of shares (provided, however, that following the Third Closing the Preferred B Majority shall still be required pursuant
to this Article 140.5 but the creation of any new class or series of shares having rights, preferences or privileges equal or senior to
such Preferred Shares shall not be considered adverse thereto);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.1in">creating or authorizing the creation of any security senior to or on parity with
the Preferred Shares (including any security convertible into or exercisable for such series) or reclassifying, altering or amending any
existing security that is junior to or on parity with the Preferred Shares, if such reclassification, alteration or amendment would render
such other security senior to or on parity with the Preferred Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.7.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">reserved;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.8.</FONT></TD><TD STYLE="text-align: justify">purchasing, redeeming or paying any dividend on any share <FONT STYLE="letter-spacing: -0.1pt">capital;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.9.</FONT></TD><TD STYLE="text-align: justify">any increase in the number of shares reserved by the Company for issuance to <FONT STYLE="letter-spacing: -0.25pt">any
</FONT>employee, officer, director, consultant or advisor of the Company or any of its subsidiaries under the Company&rsquo;s incentive
equity based plans or other arrangements approved by the Board and any grant of option or other equity based award in excess of the number
of shares reserved for such purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.10.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7pt">creating or authorizing the creation of any debt security (including negative pledges)
or any borrowings of any assets of the Company or any subsidiary, which are not in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.11.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.05pt">make any loan or advance to any person, including, any employee or director, except
advances and similar expenditures in the ordinary course of business or under the terms of an employee shares or option plan approved
by the Board;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.12.</FONT></TD><TD STYLE="text-align: justify; padding-right: 6.7pt">creating or holding share capital in any subsidiary that is not a wholly-owned subsidiary
or disposing of any subsidiary shares or all or substantially all of any subsidiary assets;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.13.</FONT></TD><TD STYLE="text-align: justify">any increase or decrease in the authorized size of the <FONT STYLE="letter-spacing: -0.1pt">Board or otherwise
change the composition of the Board;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.14.</FONT></TD><TD STYLE="text-align: justify">any acquisition of, or material interest in, another <FONT STYLE="letter-spacing: -0.1pt">entity;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.15.</FONT></TD><TD STYLE="text-align: justify">effecting any <FONT STYLE="letter-spacing: -0.2pt">IPO;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.16.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">approving the annual budget, or authorising or incurring any aggregate expenditure
in excess of the greater of fifteen percent (15%) above the expenses set forth in the approved budget or 50% of any cash received by the
Company in excess of the cash projected to be received by the Company under the budget;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.17.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">changing the principal business of the Company, entering new lines of business
materially different than the current business, or exiting the current <FONT STYLE="letter-spacing: -0.1pt">depression </FONT>line of
business; <FONT STYLE="letter-spacing: -0.3pt">or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">140.18.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">entering into or becoming a party to any transaction with any Founder, director,
officer, or shareholder of the Company, member of their immediate family, or any Affiliate of any such person or any other &ldquo;related
or interested party&rdquo; transaction, including the granting of incentives (including shares or options), except pursuant to a transaction
for the equity (including via SAFE of convertible debt) related financing of the Company that is otherwise permitted under these Articles
and is offered to all shareholders with preemptive rights.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"></P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">141.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.1pt">Notwithstanding anything to the contrary in these Articles, but subject to Article
144, none of the following actions shall be taken, approved or effected by the Company, its Board or any Shareholder, unless approved
in writing in advance by BWAY, or with respect to the actions referenced in Articles 140.9, 140.10, 140.11, and 140.16, at least one BWAY
Director:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 7.1pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">subject to Article 143 below, the actions referenced in Article 140.1, 140.2 and
140.4 above;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.15pt 0pt 118.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any of the actions referenced in Article 140.3, 140.8, 140.12-15, and 140.17-18;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any amendment, alteration or repeal of the Articles that adversely affects the
rights, preferences or privileges of the holders of either (i) the Preferred S Shares or (ii) the Special Share, including to increase
or decrease of the share capital of the Company or to change any right attached to any share, or to create any new class or series of
shares having rights, preferences or privileges equal or senior to either the Preferred S Shares or the Special Share (provided, however,
that the foregoing shall not preclude the increase of the number of authorized Preferred S Shares in order to issue any Preferred S Shares
as expressly permitted under Article 141.6.1);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">creating or authorizing the creation of any security senior to or on parity with
either (i) the Preferred S Shares or (ii) the Special Share (including any security convertible into or exercisable for such series) or
reclassifying, altering or amending any existing security that is junior to or on parity with either the Preferred S Shares or the Special
Share, if such reclassification, alteration or amendment would render such other security senior to or on parity with either (provided,
however, that the foregoing shall not preclude the increase of the number of authorized Preferred S Shares in order to issue any Preferred
S Shares as expressly permitted under Article 141.6.1);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any issuance of any Special Share or Preferred S Share (except as expressly permitted
under Article 141.6.1) to any Person other than BWAY.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any issuance of Additional Securities, except as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 118.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">141.6.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Additional Securities consisting of Preferred S Shares, Preferred B-3 or Preferred
B-4 Shares, or Shares of any other class that is junior or on par to the Preferred B-3 or Preferred B-4 Shares, issued to existing Shareholders
or new investors at a price per share that is equal to or greater than the Conversion Price applicable to the most recently funded Principal
Amount under the BWAY Investment Agreement, or if after the Third Closing, the Third Investment PPS; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 118.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">141.6.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Additional Securities consisting of Preferred B-3 or Preferred B-4 Shares or Shares
of any other class that is junior to the Preferred B-3 or Preferred B-4 Shares, issued at a price per share that is not more than five
percent (5%) below the Conversion Price applicable to the most recently funded Principal Amount under the BWAY Investment Agreement, or
if after the Third Closing, the Third Investment PPS; provided that the total aggregate consideration received by the Company from all
such issuances, whether in one or multiple transactions, does not exceed US$2,000,000 (two million USD); and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.7.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Any creation or incurrence of indebtedness by the Company or any subsidiary, except
for indebtedness that meets all of the following conditions: (i) the aggregate principal amount outstanding at any time does not exceed
US$2,000,000 (two million USD), (ii) such indebtedness is not convertible into or exchangeable for any securities of the Company and does
not provide any rights to acquire securities of the Company (except for an instrument convertible or exchangeable for Additional Securities
referenced in Article 141.6.1 above and on the terms set forth therein), and (iii) such indebtedness is subordinate to the outstanding
Loan Amount (if any) and unsecured.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 47.7pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">141.8.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">as long as the Call Option has not expired:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">141.8.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any issuance of Additional Securities (<B>including</B> Excluded Securities) that
is not conditioned upon the recipient becoming a party to the Call Option Agreement in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">141.8.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">any Transfer by any Grantor or other Shareholder in violation of Section 8.2 of
the Call Option Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">141.8.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.15pt">Any amendment to, or waiver under, these Articles if such amendment or waiver would
reasonably be expected to modify or limit the enforceability or effect of the Call Option Agreement or the rights of BWAY thereunder.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 7.15pt 0pt 47.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">142.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">The veto rights listed above in Articles 140 and 141 shall apply with respect to
any action or resolution listed above in Articles 140 and 141 proposed to be taken or adopted by any subsidiary of the Company.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 42.55pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt"><U>Call-option
Carveout</U></FONT></P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">143.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">Capitalized terms used but not defined in this Article 143 shall carry the meanings
given to them in the Call Option Agreement. If at any time prior to the exercise of the Call Option the Company or the Preferred B Majority
receives a bona fide offer (the <B>&ldquo;Third-Party Offer&rdquo;</B>) from an unaffiliated third party (the <B>&ldquo;Third-Party Offeror&rdquo;</B>)
to acquire all of the issued and outstanding shares or substantially all assets of the Company (an <B>&ldquo;Acquisition Transaction&rdquo;</B>),
the Investor shall not unreasonably withhold, condition, or delay its consent to such Acquisition Transaction, <B>provided that</B>:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 113.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">143.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Third-Party Offer constitutes an arm&rsquo;s-length transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">143.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the purchase price payable under the Third-Party Offer (the &ldquo;<B>Third-Party
Purchase Price</B>&rdquo;) is greater than 1.75 times the Company&rsquo;s Equity Value determined based on the Minimum Call Option Price
in effect on the date the Third-Party Offer is received, in accordance with the Call Option Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">143.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Company provides the Investor with written notice of the material terms and
conditions of the Third-Party Offer, including price, payment terms, and identity of the Third-Party Offeror, promptly after receipt of
such offer;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">143.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Investor is given a period of thirty (30) calendar days from receipt of such
written notice (the <B>&ldquo;Election Period&rdquo;</B>) to exercise the Call Option for an Exercise Price determined based on the Minimum
Call Option Price in effect on the date the Third-Party Offer is received, in accordance with the Call Option Agreement; <B>provided</B>
that if the Third-Party Offer is received during the Non-Exercise Period, then notwithstanding any limitation in the Call Option Agreement
regarding the exercise during such period, the Investor shall be entitled to exercise the Call Option and the following shall apply:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">143.4.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">if the Third-Party Purchase Price is greater than 1.75x the Company&rsquo;s Equity
Value determined based on the First Minimum Call Option Price, but less than 1.75x the Company&rsquo;s Equity Value based on the Second
Minimum Call Option Price, the Investor shall be entitled to exercise the Call Option for an Exercise Price determined based on the First
Minimum Call Option Price; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">143.4.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">if the Third-Party Purchase Price is greater than 1.75x the Company&rsquo;s Equity
Value determined based on the Second Minimum Call Option Price, the Investor shall be entitled to exercise the Call Option for an Exercise
Price determined based on the Second Minimum Call Option Price;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">143.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Investor does not exercise the Call Option within the Election Period; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">143.6.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">In the event that the Investor exercises the Call Option pursuant to the foregoing,
the Investor undertakes that, for a period of 12 months following the completion of the closing of the Call Option Agreement, it shall
not, directly or indirectly, sell, assign, transfer or otherwise dispose of (whether in a single transaction or a series of related transactions)
all or substantially all of the shares in the Company or all or substantially all of the assets of the Company to the Third Party Offeror
(or any of its Affiliates), or enter into any binding agreement to do so.<BR>
For the avoidance of doubt, nothing in this Article 143 shall preclude the Investor: (i) from entering into any broader corporate transaction,
merger, consolidation, reorganization, financing, or strategic partnership, provided that such transaction does not constitute a standalone
sale of all or substantially all of the shares or assets of the Company to the Third Party Offeror (or any of its affiliates or related
parties); or (ii) if pursuant to such transaction the Shareholders would receive proceeds from such sale, as if (together with any proceeds
paid to them under the Call Option Agreement) such sale had occurred immediately prior to the Call Option exercise.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 113.95pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -42.55pt; margin: 0pt 7.3pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.05pt; text-align: justify"><U>Defaulting Investor</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 7.3pt 0pt 42.55pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 7.3pt 0pt 42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25pt"></TD><TD STYLE="width: 42.3pt"><FONT STYLE="font-size: 10pt">144.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">In the event BWAY is a Defaulting Investor the following provisions shall apply
and supersede any other provisions in these Articles to the contrary:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 113.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">144.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">for as long as the Loan Amount (as defined in the BWAY Investment Agreement) is
outstanding under the terms of the BWAY Investment Agreement, the Special Share shall not have any rights under these Articles and its
consent shall not be required for any matter (including its presence in any quorum), except that;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 113.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">144.1.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Company may not incur any indebtedness senior to the Loan Amount, or agree to
the placement of any lien on its assets, without the consent of the holder of the Special Share.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 7.3pt 0pt 184.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">144.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">if following BWAY becoming a Defaulting Investor, the Loan Amount is converted in
accordance with the terms of the BWAY Investment Agreement:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 184.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">144.2.1.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Loan Amount will be converted into the applicable series of Preferred S Shares
pursuant to the BWAY Investment Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">144.2.2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">Article 8.1.1.1 shall be deemed deleted in its entirety and by the following which
shall apply in the event of any Liquidation or Deemed Liquidation: <B><U>(A)</U></B> the Preferred S Shares shall entitle their holders
to receive for each Preferred S Share held by them, an amount equal to the higher of: (i) one (1) times the Preferred S-1 Original Issue
Price (in cash, cash equivalents or, if applicable, securities) (the <B>&ldquo;Preferred S Preference&rdquo;</B>), and (ii) the amount
per share such holder would have received for such Preferred S Share had all Preferred S Shares been converted into Ordinary <FONT STYLE="letter-spacing: -0.1pt">Shares
</FONT>immediately prior to such Liquidation (taking into account the aggregate amount of Distributable Proceeds previously paid in preference
pursuant to Article 8.1); and <B>(B) </B>the Preferred S-1 Preference shall be paid pari passu with the Preferred B-3/B-4 Preference (or,
if shares other than Preferred B-4 or B-3 Shares are issued upon conversion of the New CLAs, pari passu with the liquidation preference
paid to the holders of such shares).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">144.2.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">the Preferred S Shares shall not be entitled to receive the Preferred S Dividend
Preference; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 113.5pt"></TD><TD STYLE="width: 70.95pt"><FONT STYLE="font-size: 10pt">144.2.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">any matter requiring the consent or vote of the Preferred S Majority (including
any class vote), or mandatory presence in any quorum, shall no longer be required, except for: any amendment, alteration or repeal of
the Articles that adversely affects the rights, preferences or privileges of the holders of the Preferred S Shares or to change any right
attached to any Preferred S Share (provided, however, that the creation of any new class or series of shares having rights, preferences
or privileges equal or senior to the Preferred S Shares shall not be considered adverse to thereto).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 113.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">144.3.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">if the Loan Amount is converted prior to BWAY becoming a Defaulting Investor, then
upon BWAY becoming a Defaulting Investor, with respect to the portion of the Loan Amount already converted, the provisions of Article
144.2 shall apply mutatis mutandis and the Preferred S-1 Original Issue Price shall be equal to the conversion price applied to such conversion.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: right; text-indent: 0in; margin: 0pt 7.3pt 0pt 273.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">144.4.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">BWAY shall no longer have the right to appoint a director, and any BWAY Director
then serving maybe removed and replaced by the Preferred B Majority.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -70.8pt; margin: 0pt 0 0pt 42.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 70.8pt"><FONT STYLE="font-size: 10pt">144.5.</FONT></TD><TD STYLE="text-align: justify; padding-right: 7.3pt">BWAY, or the holder of the Special Share or Preferred S Share, shall (i) no longer
be entitled to any rights under Articles 12 (Preemptive Rights) if it is a Defaulting Investor with respect to the Second Principal Amount,
(ii) Article 40 (Rights of First Refusal), (iii) Article 41 (Co-sale rights) if it is a Defaulting Investor with respect to the Second
Principal Amount, and (iv) any restrictions on the transferability of any Shares that are subject to the approval of BWAY, the holder
of the Special Share or the Preferred S Majority shall expire.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 7.3pt 0pt 42.55pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 7.3pt 0pt 42.55pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">*****</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>6
<FILENAME>exh_995.htm
<DESCRIPTION>EXHIBIT 99.5
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Exhibit 99.5</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>SECOND
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">THIS
SECOND AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT (the &ldquo;<U>Agreement</U>&rdquo;) is made as of the 18th day of
August 2025, by and <FONT STYLE="font-weight: normal">among</FONT> Neurolief Ltd., an Israeli company (the
&ldquo;<U>Company</U>&rdquo;), BrainsWay Ltd., an Israeli company (&ldquo;<U>BWAY</U>&rdquo;) and certain holders of Preferred
Shares listed on <B><U>Schedule A</U></B> hereto (the &ldquo;<U>Investors</U>&rdquo;) and signatory hereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>RECITALS</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
the Company and certain shareholders of the Company are parties to that certain Amended and Restated Investors` Rights Agreement made
as of the 22<SUP>nd</SUP> day of October, 2022 (the &ldquo;<U>Prior Investors` Rights Agreement</U>&rdquo;); and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
concurrently with the execution and delivery of this Agreement, the Company is entering into that certain Investment Agreement dated
of even date herewith (the &ldquo;<U>Investment Agreement</U>&rdquo;) with BWAY, which provides that as a condition to the Closing under
the Investment Agreement, this Agreement must be executed and delivered by the Company, BWAY and the requisite majority of Investors;
and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
as of the date hereof, BWAY has not converted the Principal Amount (as defined in the Investment Agreement) into Preferred S Shares,
but holds the right to do so pursuant to the Investment Agreement, and the Company and the Investors acknowledge and agree that, regardless
of whether such conversion has occurred, BWAY shall be entitled to all rights granted to BWAY personally or Investors or Holders generally
under this Agreement from and as of the date hereof, for so long as the Principal Amount remains outstanding, or as long as it holds
any securities convertible into or exercisable for Preferred Shares or any Preferred S Shares themselves.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">WHEREAS,
the requisite parties to the Prior Investors` Rights Agreement wish to amend and restate in its entirety the Prior Investors` Rights
Agreement by entering into this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>NOW,
THEREFORE</B>, the parties hereby agree to amend and restate the Prior Investors` Rights Agreement in its entirety as follows:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Definitions</U></B><FONT STYLE="letter-spacing: 0pt">.</FONT>
                                            For purposes of this Agreement:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Affiliate</B>&rdquo; means (i) with respect to a natural person, any member of such Person's immediate family (including any
child, step child, parent, step parent, in-laws, spouse, sibling, stepson or stepdaughter or the lineal descendants of any of the foregoing);
or (ii) with respect to a Person or entity (including a natural person), any Person or entity which directly or indirectly Controls,
is Controlled by, or is under common Control with such Person or entity.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Control</B>&rdquo; means the holding directly or indirectly of at least 50% of the voting power in a corporation or of the
right to appoint at least half of the directors or members of a similar body having a similar function in a corporation.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &ldquo;<B>Damages</B>&rdquo; means any loss, damage, or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect
thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration
statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto; (ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make
the statements therein not misleading; or (iii) any violation or alleged violation by <FONT STYLE="font-weight: normal">the indemnifying</FONT>
party <FONT STYLE="font-weight: normal">(or any of its agents or Affiliates)</FONT> of the Securities Act, the Exchange Act, any state
securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Exchange Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">&ldquo;</FONT>Excluded Registration<FONT STYLE="font-weight: normal">&rdquo; means (i) a registration
relatingto the sale of securities to employees of the Company or a subsidiary pursuant to a share option, share purchase, or similar
plan; (ii) a registration relating to SEC Rule 145 transaction; or (iii) a registration on any form that does not include substantially
the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">&ldquo;</FONT>Form F&#45;1<FONT STYLE="font-weight: normal">&rdquo; means such form under the Securities
Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &ldquo;<B>Form F&#45;3</B>&rdquo; means such form under the Securities Act as in effect on the date hereof or any registration form
under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other
documents filed by the Company with the SEC.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>GAAP</B>&rdquo; means generally accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Holder</B>&rdquo; means any holder of Registrable Securities who is a party to this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>&ldquo;Inactive Investor&rdquo;</B> shall mean either: (i) BWAY meeting the criteria of a Defaulting Investor, as defined under the
Investment Agreement; (ii) BWAY&rsquo;s exercise of its right not to consummate the Second or Third Closing due to the occurrence of
a Material Adverse Change (as such terms are defined in the Investment Agreement); or (iii) the Loan Amount (as defined in the Investment
Agreement) being repaid in full in accordance with the terms of the Investment Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Initiating Holders</B>&rdquo; means, collectively, Holders who properly initiate a registration request under this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">1.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IPO<FONT STYLE="font-weight: normal">&rdquo;
means the Company&rsquo;s first underwritten public offering of its Ordinary Shares under the Securities Act.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Ordinary Shares</B>&rdquo; means Ordinary Shares of the Company, nominal value NIS 0.01 each.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Permitted Transferee</B>&rdquo; shall have the meaning set forth in the Company&rsquo;s Articles of Association, as may be
amended from time to time (&ldquo;<U>Articles</U>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">1.15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Person<FONT STYLE="font-weight: normal">&rdquo;
means any individual, corporation, partnership, trust, limited liability company, association </FONT>or other <FONT STYLE="font-weight: normal">entity.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>&ldquo;Preferred Shares&rdquo; </B>means, collectively, the Series A Preferred Shares of the Company, nominal value NIS 0.01 each,
the Series A-1 Preferred Shares of the Company, nominal value NIS 0.01 each, the Series B Preferred Shares of the Company, nominal value
NIS 0.01 each, the Series B-1 Preferred Shares of the Company, nominal value NIS 0.01 each, the Series B-2 Preferred Shares of the Company,
nominal value NIS 0.01 each, the Series B-3 Preferred Shares of the Company, nominal value NIS 0.01 each, the Series B-4 Preferred Shares
of the Company, nominal value NIS 0.01 each, and the Preferred S Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>&ldquo;Preferred S Shares&rdquo;</B> means, collectively, the Series S-1 Preferred Shares of the Company, nominal value NIS 0.01 each,
the Series S-2 Preferred Shares of the Company, nominal value NIS 0.01 each, and the Series S-3 Preferred Shares of the Company, nominal
value NIS 0.01 each.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Registrable Securities</B>&rdquo; means (i) the Ordinary Shares issuable or issued upon conversion of the Preferred Shares;
(ii) <FONT STYLE="font-weight: normal">any Ordinary Shares </FONT>acquired by the Investors after the date hereof; and (iii) any Ordinary
Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause <U>(i) and (ii)</U> above;
<U>excluding</U>, however, in all cases, any Registrable Securities sold by a Person in a transaction in which the <FONT STYLE="font-weight: normal">applicable
</FONT>rights under <FONT STYLE="font-weight: normal">this Agreement</FONT> are not assigned <FONT STYLE="font-weight: normal">pursuant
to <U>Section 4.1</U>, and excluding for purposes of <U>Section </U>2</FONT> any shares for which registration rights have terminated
pursuant to <U>Section <FONT STYLE="font-weight: normal">2.13</FONT></U> of this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Registrable Securities then outstanding</B>&rdquo; means the number of shares determined by adding the <FONT STYLE="font-weight: normal">number
of outstanding Ordinary Shares that are Registrable Securities</FONT> and the <FONT STYLE="font-weight: normal">number of Ordinary Shares
</FONT>issuable <FONT STYLE="font-weight: normal">(directly or indirectly) </FONT>pursuant to then exercisable <FONT STYLE="font-weight: normal">and/</FONT>or
convertible securities that upon exercise of such convertible securities will be Registrable Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>SEC</B>&rdquo; means the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>SEC Rule 144</B>&rdquo; means Rule 144 promulgated by the SEC under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>SEC Rule 145</B>&rdquo; means Rule 145 promulgated by the SEC under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Securities Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;<B>Selling Expenses</B>&rdquo; means all underwriting discounts, selling commissions, and <FONT STYLE="font-weight: normal">share</FONT>
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except <FONT STYLE="font-weight: normal">for
the fees and disbursements of the Selling Holder Counsel borne and paid by the Company </FONT>as provided in <U>Section <FONT STYLE="font-weight: normal">2.6.</FONT></U></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Registration
                                            Rights</U></B><FONT STYLE="letter-spacing: 0pt">.</FONT> The Company covenants and agrees
                                            as follows:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Demand Registration</U><FONT STYLE="letter-spacing: 0pt">.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="letter-spacing: 0pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="font-weight: normal"><U>Form
F-1 Demand</U>. </FONT>If at any time after one hundred eighty (180) days after the effective date of the registration statement for
the IPO (the &ldquo;<U>Commencement Date</U>&rdquo;), the Company receives a request from Holders of a majority of the Registrable
Securities then outstanding, which majority includes BWAY (provided it is not an Inactive Investor), that the Company <FONT STYLE="font-weight: normal">file</FONT>
a <FONT STYLE="font-weight: normal">Form F-1 </FONT>registration <FONT STYLE="font-weight: normal">statement</FONT> with an
anticipated aggregate offering price of at least $5 million, then the Company shall (i) within ten (10) days after the date such
request is given, give notice thereof (the &ldquo;<U>Demand Notice</U>&rdquo;) to all Holders other than the Initiating Holders; and
(ii) as soon as practicable, following expiration of the twenty (20) day period mentioned below, use commercially reasonable efforts
to file a <FONT STYLE="font-weight: normal">Form F-1</FONT> registration statement under the Securities Act covering all Registrable
Securities that the I<FONT STYLE="font-weight: normal">nitiating </FONT>Holders <FONT STYLE="font-weight: normal">requested</FONT>
to be registered and <FONT STYLE="font-weight: normal">any additional Registrable Securities requested to be included in such
registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the
date the Demand Notice is given, and in each case, </FONT>subject to the limitations of <U>Section&nbsp;2.1(<FONT STYLE="font-weight: normal">c</FONT>)</U> <FONT STYLE="font-weight: normal">and <U>Section
2.3.</U></FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal"><U>Form F-3 Demand</U>. If at any time when it is eligible to use a Form&nbsp;F-3 registration statement,
the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding, among them
BWAY </FONT>(provided it is not an Inactive Investor)<FONT STYLE="font-weight: normal">, that the Company file a Form F-3 registration
statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling
Expenses, of at least $3 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand
Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable</FONT> following expiration of the twenty (20)
day period mentioned below<FONT STYLE="font-weight: normal">, file a Form F-3 registration statement under the Securities Act covering
all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such
Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
<U>Section 2.1(c)</U> and <U>Section&nbsp;2.3</U>.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the foregoing obligations,
if the Company furnishes to Holders requesting a registration pursuant to this <U>Section 2.1,</U> a certificate signed by the Company&rsquo;s
chief executive officer stating that in the good faith judgment of the Company&rsquo;s Board of Directors, it would be materially detrimental
to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such
registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material
information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render the Company unable
to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with
respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period
of not more than one hundred eighty (180) days after the request of the Initiating Holders is given; <U>provided, however</U>, that the
Company shall not register any securities for its own account or that of any other shareholder during such one hundred eighty (180) day
period other than <FONT STYLE="font-weight: normal">an Excluded Registration.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal"></FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section 2.1<FONT STYLE="font-weight: normal">(a)</FONT></U>
(i) during the period that is sixty (60) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on
a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, <U>provided</U>, that
the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; (ii) after the Company has effected two (2) registrations <FONT STYLE="font-weight: normal">pursuant to <U>Section
2.1(a)</U></FONT>; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form F-3 pursuant to a request made pursuant to <U>Section <FONT STYLE="font-weight: normal">2.1(b)</FONT></U><FONT STYLE="font-weight: normal">.
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Section 2.1(b)</U>
(i) during the period that is forty five (45) days before the Company&rsquo;s good faith estimate of the date of filing of, and
ending on a date that is </FONT>one ninety <FONT STYLE="font-weight: normal">(90) days after the effective date of, a
Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to
cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to <U>Section
2.1(b)</U> within the twelve (12) month period immediately preceding the date of such request.</FONT> A registration shall not be
counted as &ldquo;effected&rdquo; for purposes of this <U>Section 2.1<FONT STYLE="font-weight: normal">(d)</FONT></U> until such
time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, <FONT STYLE="font-weight: normal">and forfeit
their right to one demand registration statement </FONT>pursuant to <U>Section <FONT STYLE="font-weight: normal">2.6,</FONT></U><FONT STYLE="font-weight: normal">
in which case such withdrawn registration statement shall be counted as &ldquo;effected&rdquo; for purposes of this <U>Section&nbsp;2.1(d).</U></FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Company Registration</U>. If the Company proposes to register (including, for this purpose, a registration effected by the Company
for shareholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such
securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice
of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company
shall, subject to the provisions of <U>Section 2.3</U>, cause to be registered all of the Registrable Securities, that each such Holder
has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated
by it under this <U>Section 2.2</U> before the effective date of such registration, whether or not any Holder has elected to include
Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne
by the Company in accordance with <U>Section 2.6</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Underwriting Requirements</U><FONT STYLE="letter-spacing: 0pt">.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="letter-spacing: 0pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If, pursuant to <U>Section <FONT STYLE="font-weight: normal">2.1</FONT></U><FONT STYLE="font-weight: normal">,</FONT> the Initiating
Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise
the Company as a part of their request made pursuant to <U>Section <FONT STYLE="font-weight: normal">2.1,</FONT></U> and the Company
shall include such information in the Demand Notice. The underwriter<FONT STYLE="font-weight: normal">(s)</FONT> will be selected by
the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders, which majority includes BWAY
(provided it is not an Inactive Investor). In such event, the right of any Holder to include such Holder&rsquo;s Registrable
Securities in such registration shall be conditioned upon such Holder&rsquo;s participation in such underwriting and the inclusion
of such Holder&rsquo;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall (together with the Company as provided in <U>Section <FONT STYLE="font-weight: normal">2.4</FONT>(e))</U>
enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any
other provision of this <U>Section <FONT STYLE="font-weight: normal">2.3,</FONT></U> if the managing underwriter(s) advise(s) the
Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the
Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and
the number of Registrable Securities that may be included in the underwriting shall be allocated among <FONT STYLE="font-weight: normal">such</FONT>
Holders of other Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of
Registrable Securities owned by each Holder <FONT STYLE="font-weight: normal">or in such other proportion as shall mutually be
agreed to by all such selling Holders</FONT>; <U>provided</U>, <U>however</U>, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the
underwriting.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In connection with any offering involving an underwriting of shares of the Company&rsquo;s share capital pursuant to <U>Section 2.2</U>,
the Company shall not be required to include any of the Registrable Securities of any Holder in such underwriting unless such Holder
accepts the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the
underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of
securities, including Registrable Securities, requested by shareholders to be included in such offering exceeds the number of securities
to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable
Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering
providing the preference to the Holders of Preferred Shares as outlined in Section 2.3(a). If the managing underwriter advises the Company
in writing that marketing factors require a limitation of the number of shares to be underwritten, then subject to such underwriter&rsquo;s
limitations the Holders shall be entitled to register Registrable Securities pursuant to the following registration priority: first,
the Company shall be entitled to register the Company's Shares; second, the Holders of other Registrable Securities shall be entitled
to register such number of Registrable Securities required to be registered by them (pro rata to the respective number of Registrable
Securities required by each Holder of Registerable Securities to be included in the registration); and third, to the extent possible,
any other securities of the Company. The above notwithstanding, the Holders of Registrable Securities shall be entitled to register such
a number of Registrable Securities in any registration pursuant to this Section 2.3 (other than in the IPO) constituting at least 30%
(thirty percent) of all the shares registered under such registration (pro rata to the respective number of Registrable Securities required
by each Holder of Registrable Securities to be included in the registration). For purposes of the provision in this <U>Section <FONT STYLE="font-weight: normal">2.3</FONT>(b)</U>
concerning apportionment, for any selling <FONT STYLE="font-weight: normal">Holder</FONT>, such Holder and the Permitted Transferees
of such Holder shall be deemed to be a single &ldquo;selling Holder&rdquo;.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of <U>Section <FONT STYLE="font-weight: normal">2.1</FONT></U><FONT STYLE="font-weight: normal">,</FONT> a registration
shall not be counted as &ldquo;effected&rdquo; if, as a result of an exercise of the underwriter&rsquo;s cutback provisions in <U>Section
<FONT STYLE="font-weight: normal">2.3</FONT>(a)</U>, the total number of Registrable Securities that Holders have requested to be included
in such registration statement that are actually included constitute less than thirty percent (30%) of the total number of shares included
in such registration.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Obligations of the Company</U><FONT STYLE="letter-spacing: 0pt">.</FONT> Whenever required under this <U>Section 2</U> to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially
reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of
the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred and
eighty (180) days (and in the case of registration on Form F-3, two years) or, if earlier, until the distribution contemplated in
the registration statement has been completed; <U>provided, however</U>, that such period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Ordinary Shares (or other securities) of the Company,
from selling any securities included in such registration;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions
as shall be reasonably requested by the selling Holders; <U>provided that</U> the Company shall not be required to qualify to do business
or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service
in such jurisdiction and except as may be required by the Securities Act;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter<FONT STYLE="font-weight: normal">(s)</FONT> of such offering;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading
system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
promptly make available for inspection by the selling Holders, any managing underwriter<FONT STYLE="font-weight: normal">(s)</FONT> participating
in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter
or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and
cause the Company&rsquo;s officers, directors, employees, and independent accountants to supply all information reasonably requested
by any such seller, underwriter, attorney, accountant, or agent<FONT STYLE="font-weight: normal">, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence</FONT> in connection
<FONT STYLE="font-weight: normal">therewith</FONT>;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
furnish, at the request of any </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">selling
Holder <FONT STYLE="font-weight: normal">requesting registration of Registrable Securities, on the date that such Registrable
Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Agreement, if such
securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the
registration statement with respect to such securities becomes effective (i) an opinion, dated such date, of counsel representing
the Company for the purposes of such registration, in form and </FONT>substance as is customarily given to underwriters in an
underwritten public offering, addressed to the selling <FONT STYLE="font-weight: normal">Holders and to the underwriters, if any,
and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is
customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the
selling Holders and the underwriters, if any;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed, or the happening of
any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading
in the light of the circumstances then existing; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Furnish Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this <U>Section
2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information
regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required
to effect the registration of such Holder&rsquo;s Registrable Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#9;<U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to <U>Section&nbsp;2</U>, including all registration, filing, and qualification fees; printers&rsquo; and accounting
fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders
selected by Holders wishing to participate in such registration holding the majority of the Registrable Securities then held by Holders
<FONT STYLE="font-weight: normal">(&ldquo;<U>Selling Holder Counsel</U>&rdquo;)</FONT>, shall be borne and paid by the Company; <U>provided,
however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Section
2.1</U> if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities
then held by Holders to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable
Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities then
held by Holders agree to forfeit their right to one registration pursuant to <U>Section 2.1<FONT STYLE="font-weight: normal">(a)</FONT></U>
or <U>Section <FONT STYLE="font-weight: normal">2.1(b)</FONT></U><FONT STYLE="font-weight: normal">,</FONT> as the case may be; <U>provided
further</U> that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business,
or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit
their right to one registration pursuant to <U>Section 2.1<FONT STYLE="font-weight: normal">(a)</FONT></U> or <U>Section <FONT STYLE="font-weight: normal">2.1(b)</FONT></U>.
All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section 2</U> shall be borne and paid by the Holders
pro rata on the basis of the number of Registrable Securities registered on their behalf.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of
this <U>Section 2</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 <U>Indemnification</U>. If any Registrable Securities are included in a registration statement under this <U>Section 2</U>:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and <FONT STYLE="font-weight: normal">share</FONT>holders of each such Holder; legal counsel and accountants for each such
Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such
Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any <FONT STYLE="font-weight: normal">claim or</FONT> proceeding from which Damages may result, as such
expenses are incurred; <U>provided, however</U>, that the indemnity agreement contained in this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT>(a)</U>
shall not apply to amounts paid in settlement of any such <FONT STYLE="font-weight: normal">claim</FONT> or proceeding if such settlement
is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for
any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with
written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly
for use in connection with such registration.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each
of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within
the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act),
any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder,
against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with
such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any <FONT STYLE="font-weight: normal">claim or</FONT> proceeding
from which Damages may result, as such expenses are incurred; <U>provided, however</U>, that the indemnity agreement contained in this
<U>Section <FONT STYLE="font-weight: normal">2.8</FONT>(b)</U> shall not apply to amounts paid in settlement of any such <FONT STYLE="font-weight: normal">claim</FONT>
or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and
<U>provided further</U> that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under
<U>Sections 2.8(b)</U> and <U>2.8(d)</U> exceed the proceeds from the offering <FONT STYLE="font-weight: normal">received by such Holder
</FONT>(net of any Selling Expenses <FONT STYLE="font-weight: normal">paid by such Holder</FONT>), except in the case of fraud or willful
misconduct by such Holder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Promptly after receipt by an indemnified party under this <U>Section&nbsp;<FONT STYLE="font-weight: normal">2.8</FONT></U> of notice
of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification
hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT></U><FONT STYLE="font-weight: normal">,</FONT>
give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such
action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice
has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided, however</U>, that
an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of
such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice
to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of
any liability to the indemnified party under this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT></U><FONT STYLE="font-weight: normal">,</FONT>
to the extent that such failure materially prejudices the indemnifying party&rsquo;s ability to defend such action. The failure to
give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than
under this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT></U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT></U>
but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of
time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT></U> provides for indemnification in such case, or (ii) contribution
under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this <U>Section&nbsp;<FONT STYLE="font-weight: normal">2.8</FONT></U><FONT STYLE="font-weight: normal">,</FONT>
then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which
they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of <FONT STYLE="font-weight: normal">the</FONT>
indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss,
claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying
party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement
of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party
or by the indemnified party and the parties&rsquo; relative intent, knowledge, access to information, and opportunity to correct or prevent
such statement or omission; <U>provided, however</U>, that, in any such case, (x) no Holder will be required to contribute any amount
in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration
statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will
be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided further</U> that
in no event shall a Holder&rsquo;s liability pursuant to this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT>(d)</U>, when combined
with the amounts paid or payable by such Holder pursuant to <U>Section <FONT STYLE="font-weight: normal">2.8</FONT>(b)</U>, exceed the
proceeds from the offering <FONT STYLE="font-weight: normal">received by such Holder </FONT>(net of any Selling Expenses <FONT STYLE="font-weight: normal">paid</FONT>
by such Holder), except in the case of willful misconduct or fraud by such Holder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement
entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this <U>Section <FONT STYLE="font-weight: normal">2.8</FONT></U> shall survive the completion of any
offering of Registrable Securities in a registration under this <U>Section 2</U>, and otherwise shall survive the termination of this
Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Reports
Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation
of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to
a registration on Form F&#45;3, the Company shall:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
make and keep <FONT STYLE="font-weight: normal">available adequate current </FONT>public information, as those terms are understood and
defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act (at any time after the Company has become subject to such reporting requirements); and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company
that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of
the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company
has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
F&#45;3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such
other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the
Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form F&#45;3 (at any time after the Company
so qualifies to use such form).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">2.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><U>Limitations on Subsequent Registration
Rights</U>. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority
of the Registrable Securities then outstanding which are held by Holders, which majority includes BWAY (provided it is not an Inactive
Investor), enter into any agreement with any holder or prospective holder of any securities of the Company that would provide to such
holder registration rights on a basis equal to or more favorable than the registration rights granted to the Holders herein<FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>&ldquo;Market
Stand&#45;off&rdquo; Agreement</U><FONT STYLE="letter-spacing: 0pt">.</FONT> In connection with the IPO, each Holder hereby agrees
that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the <FONT STYLE="font-weight: normal">registration by the Company for its own behalf of Ordinary Shares
or any other equity securities under</FONT> the <FONT STYLE="font-weight: normal">Securities Act on a</FONT> registration statement <FONT STYLE="font-weight: normal">in
such IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty
(180) days),</FONT> which period may be extended upon the request of the managing underwriter for an additional period of up to
seventeen (17) days if the Company issues or proposes to issue an earnings or other public release within seventeen (17) days of the
expiration of the 180-day period (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase
any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or
indirectly, any Ordinary Shares or any securities convertible into or exercisable or exchangeable <FONT STYLE="font-weight: normal">(directly
or indirectly) </FONT>for Ordinary Shares (whether such shares or any such securities are then owned by the Holder or are thereafter
acquired) or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of <FONT STYLE="font-weight: normal">such securities</FONT>, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Ordinary Shares or other securities, in cash, or otherwise. The foregoing
provisions of this <U>Section <FONT STYLE="font-weight: normal">2.11</FONT></U> shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers, directors and
shareholders individually owning more than one percent (1%) of the Company&rsquo;s outstanding Ordinary Shares (after giving effect
to conversion into Ordinary Shares of all outstanding Preferred Shares) agree to the same restrictions. The underwriters in
connection with <FONT STYLE="font-weight: normal">such registration</FONT> are intended third&#45;party beneficiaries of this <U>Section <FONT STYLE="font-weight: normal">2.11</FONT></U>
and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder
agrees to execute such agreements as may be reasonably requested by the underwriter(s) in connection with such registration that are
consistent with this <U>Section 2.11</U> or that are necessary to give further effect thereto. Any discretionary waiver or
termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all
Holders subject to such agreements, based on the number of shares subject to such agreements. In the event that the managing
underwriter(s) grant(s) a release of these market standoff requirements for securities greater than $10,000 in value in the
aggregate, all Holders of securities subject to market standoff shall be entitled to participate in such release on a pro rata basis
based on the relative number of Registrable Securities then outstanding held by such Holders.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Transfer of Registration Rights.</U> Subject as further provided in Section 5.1, the registration rights granted under the provisions
of this <U>Section 2</U> may be transferred by a Holder to (i) any partner or retired partner of such Holder which is a partnership,
(ii) any member or former member of such Holder which is a limited liability company, (iii) any family member or trust for the benefit
of such individual Holder, (iv) a Permitted Transferee (as such term is defined in the Articles) of such Holder; or (v) any transferee
who acquires Registrable Securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Registration Outside the U.S</U>.&#9; The provisions of Section 2 hereof shall apply also, <I>mutatis mutandis</I>, to any registration
of shares of the Company in any jurisdiction other than the U.S. and all references to U.S. laws and regulations shall be deemed as made
to the applicable relevant laws.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in
any registration pursuant to <U>Section <FONT STYLE="font-weight: normal">2.1</FONT></U> or <U>Section <FONT STYLE="font-weight: normal">2.2</FONT></U>
shall terminate upon the <FONT STYLE="font-weight: normal">earliest to occur</FONT> of:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the closing of a Deemed Liquidation Event, as such term is defined in the Company&rsquo;s Articles; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-weight: normal">the fifth anniversary of the Commencement Date.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; letter-spacing: 0pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Information
                                            Rights</U></B><FONT STYLE="letter-spacing: 0pt">.</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Financial Statements</U>. The Company shall deliver to BWAY and to each holder of Preferred Shares who holds at least
2% of the issued and outstanding share capital of the Company on an as converted basis:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as soon as practicable, but in any event within sixty (60) days after the end of each fiscal year of the Company (or within
forty-five (45) days after the end of each fiscal year once BWAY holds twenty percent (20%) or more of the issued and outstanding
share capital of the Company on an as converted basis), financial statement for such year, including (i) a consolidated balance
sheet as of the end of such year, (ii) statements of income and of cash flows for such year, (iii) a comparison between (x) the
actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as
defined below) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources
and applications of funds for such year, and (iv) a statement of shareholders&rsquo; equity as of the end of such year, setting
forth in each case in comparative form the figure for the previous fiscal year, all in reasonable detail, in NIS with United State
dollar- convenience translation, prepared in accordance with GAAP, audited by an accounting firm of international standing, and in a
form reasonably acceptable to BWAY and KT Squared, LLC (&ldquo;<U>KT</U>&rdquo;);</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as soon as practicable, but in any event within thirty (30) days after the end of each of the first three (3) quarters of each fiscal
year of the Company, unaudited financial statements for such quarter, including an unaudited consolidated balance sheet of the Company
as at the end of each such period and unaudited consolidated statements of income and cash flow of the Company for the period from the
beginning of the current fiscal year to the end of such quarterly period, setting forth in each case in comparative form the figures
for the corresponding period of the previous fiscal year, all in reasonable detail, in NIS with United States dollar convenience translation
and signed by the chief financial officer (or if none, by the chief executive officer) of the Company<FONT STYLE="font-weight: normal">,
and </FONT>in a form reasonably acceptable to BWAY and KT <FONT STYLE="font-weight: normal">(except that such financial statements may
(i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP)</FONT>;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
as soon as available, but in any event within twenty one (21) days of the end of each fiscal quarter of the Company, if any changes have
occurred within said quarter, a statement showing the number of shares of each class and series of share capital and securities convertible
into or exercisable for share capital outstanding at the end of the period, the Ordinary Shares issuable upon conversion or exercise
of any outstanding securities convertible or exercisable for Ordinary Shares and the exchange ratio or exercise price applicable thereto,
and the number of options (issued and not yet issued but reserved for issuance, if any), all in sufficient detail as to permit the Investors
to calculate their respective percentage equity ownership in the Company on both issued and fully-diluted bases, and certified by the
chief financial officer or chief executive officer of the Company as being true, complete, and correct;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
such other information as any Investor may from time to time reasonably request that is customary to provide to a shareholder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company shall deliver to the Board of Directors:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; color: Black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">as soon as practicable, but in any event
until December 1st of each year, a budget and business plan for the next fiscal year (the &ldquo;<U>Budget</U>&rdquo;) prepared in accordance
with the guidelines of <FONT STYLE="font-weight: normal">the Board of Directors;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 as soon as available, but in any event within fourteen (14) days of the end of each month, a monthly business report and bank statements
in a form agreed by the Board.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If,
for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated financial statements of the Company and
the subsidiaries.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Notwithstanding
anything else in this <U>Section 3</U> to the contrary, the Company may cease providing the information set forth in this <U>Section
3</U> during the period starting with the date thirty (30) days before the Company&rsquo;s good-faith estimate of the date of filing <FONT STYLE="font-weight: normal">of
a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration </FONT>statement
and related offering; provided that the Company&rsquo;s covenants under this <U>Section 3</U> shall be reinstated at such time as
the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become
effective.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Notwithstanding
anything to the contrary herein, the Company shall deliver to BWAY, upon its reasonable written request and with reasonable advance notice,
such information as may be reasonably necessary for BWAY to comply with any applicable law, including without limitation, securities
laws, stock exchange rules and regulations and/or any request of any stock exchange, the SEC, the Israeli Securities Authority, Ministry
of Finance or any other governmental authority. The Company hereby undertakes, upon BWAY&rsquo;s reasonable written request, to use commercially
reasonable efforts to assist BWAY to fulfill the aforementioned legal obligations.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Inspection</U>. The Company shall permit BWAY (provided it is not an Inactive Investor) and each Investor holding at least 5% of the
outstanding share capital of the Company on a fully-diluted basis (provided that the Board of Directors has not reasonably determined
that such Investor is a competitor of the Company) or its authorized representatives and upon Investor&rsquo;s reasonable notice, to
visit and inspect the Company&rsquo;s properties, including its corporate and financial records; examine its books of account and records;
and discuss the Company&rsquo;s affairs, finances, and accounts with its officers, during normal business hours of the Company as may
be reasonably requested by the Investor; <U>provided, however</U>, that the Company shall not be obligated pursuant to this <U>Section
3.3</U> to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information
or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination of Information Rights</U><FONT STYLE="letter-spacing: 0pt">.</FONT> The covenants set forth in <U>Section 3</U> shall
terminate and be of no further force or effect immediately before the consummation of the QIPO, as such term is defined in Articles.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;
<U>General Disclosure Covenant</U>. In addition, and not as a limitation on any of the foregoing, the Company covenants that it will
provide full disclosure and information regarding all of the Company&rsquo;s material affairs at meetings of the Board and, to the extent
required under applicable law, at annual general meetings of the shareholders, and extraordinary general meetings of the shareholders.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Confidentiality</U>.
Each Investor acknowledges that the information received by such Investor from the Company pursuant to Section 3 is confidential,
and it will not use such confidential information or reproduce, disclose or disseminate such information to any other person (other
than its employees or agents having a need to know the contents of such information, and its attorneys) unless the Company has made
such information available to the public generally, except (a) in connection with the exercise of rights under this Agreement, (b)
as may be required by law, (c) to its members, limited partners, general partners or management company or to the attorneys thereof
in order to protect and monitor their investment in the Company, or in connection with periodic reports or general statements to
such persons, (d) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser is
under a written obligation to the Company to keep such information confidential as provided herein, provided that such prospective
purchaser is not a competitor of the Company, (e) information that was known to the Investor prior to the disclosure thereof, (f)
information that is legally transmitted or disclosed to the Investor by a third party which owes no obligation of confidentiality to
the Company, or (g) information that is developed by such Investor or its agents independently of and without reference to any
confidential information of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0 0; text-align: justify; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>ESOP;
                                            Directors and Officers Insurance</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unless
otherwise approved by the Board of Directors, all future employees and consultants of the Company or its Affiliates who purchase, receive
options to purchase, or receive awards of shares of the Company&rsquo;s share capital after the date hereof, such options and awards
shall vest as follows: vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting
following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over
the following thirty-six (36) months.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company shall obtain and continue to maintain in full force and effect, a valid Directors and Officers insurance policy of financially
sound and reputable insurers, covering the directors in the Company (including the newly designated directors) in an amount of at least
US$ 2,000,000.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Miscellaneous</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#9;<U>Successors and Assigns</U>. <FONT STYLE="font-weight: normal">The rights under this Agreement</FONT> may <FONT STYLE="font-weight: normal">be</FONT>
assigned (<FONT STYLE="font-weight: normal">but only with all related obligations</FONT>) <FONT STYLE="font-weight: normal">by a Holder
to a transferee of</FONT> Registrable Securities <FONT STYLE="font-weight: normal">that (i) is a Permitted Transferee (as such term is
defined under the Articles) of a Holder (other than a competitor of the Company) or (ii)</FONT> with respect to registration rights,
if the transferee (other than a competitor of the Company) acquires at least 80% of the shares of the original purchaser&rsquo;s Registrable
Securities<FONT STYLE="font-weight: normal">); <U>provided</U>, however, that (x) the Company is, within a reasonable time after such
transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities</FONT> with respect
to <FONT STYLE="font-weight: normal">which such</FONT> rights <FONT STYLE="font-weight: normal">are being transferred; and (y)&nbsp;such
transferee agrees in</FONT> a written instrument <FONT STYLE="font-weight: normal">delivered </FONT>to the Company to be bound by <FONT STYLE="font-weight: normal">and
subject to </FONT>the terms <FONT STYLE="font-weight: normal">and conditions </FONT>of this <FONT STYLE="font-weight: normal">Agreement,
including the provisions of <U>Section 2.11</U>. </FONT>The terms and conditions of this Agreement inure to the benefit of and are binding
upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided herein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Governing Law</U>. This Agreement and any controversy arising out of or relating to this <FONT STYLE="font-weight: normal">Agreement</FONT>
shall be governed by and construed in accordance with the internal laws of the State of Israel, without regard to conflict of law principles
that would result in the application of any law other than the law of the State of Israel. Any dispute arising under or in relation to
this Agreement shall be resolved exclusively in the competent court located in Tel Aviv, Israel, and each of the parties hereby irrevocably
submits to the exclusive jurisdiction of such court.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts; Facsimile</U><FONT STYLE="letter-spacing: 0pt">.</FONT> This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may
also be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#9;<U>Notices</U>. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent,
if sent by electronic mail or <FONT STYLE="font-weight: normal">facsimile</FONT> during the recipient&rsquo;s normal business hours,
and if not sent during normal business hours, then on the recipient&rsquo;s next business day; (iii) five (5) days after having been
sent by registered or certified mail, postage prepaid; or (iv) one (1) <FONT STYLE="font-weight: normal">business </FONT>day after <FONT STYLE="font-weight: normal">the
business day of</FONT> deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with
written verification of receipt. All communications shall be sent to the respective parties at their addresses as documented in the
Company&rsquo;s records, or to <FONT STYLE="font-weight: normal">the principal office of the Company and to the attention of the
Chief Executive Officer, in the case of the Company, or to </FONT>such email address, facsimile number, or address as subsequently
modified by written notice given in accordance with this <U>Section 6.5</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendments and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and <FONT STYLE="font-weight: normal">either</FONT> retroactively or prospectively) only
with the written consent of the Company and the holders of at least 60% of the Registrable Securities then outstanding, including KT
and BWAY (provided it is not an Inactive Investor); <U>provided </U><FONT STYLE="font-weight: normal">that any provision hereof may be
waived by any waiving party on such party&rsquo;s own behalf, without the consent of any other party</FONT>. Notwithstanding the foregoing,
this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor
without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion.
The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent
in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this <U>Section
<FONT STYLE="font-weight: normal">5.6</FONT></U> shall be binding on all parties hereto, regardless of whether any such party has consented
thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed
to be or construed as a further or continuing waiver of any such term, condition, or provision. In the event the Loan Amount is repaid
in full in accordance with the Investment Agreement, all of BWAY&rsquo;s rights under this Agreement shall immediately cease.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement,
and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable
to the maximum extent permitted by law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Aggregation of Shares</U>. All Registrable Securities held or acquired by Permitted Transferees shall be aggregated together for the
purpose of determining the availability of any rights under <FONT STYLE="font-weight: normal">this</FONT> Agreement and such Permitted
Transferees may apportion such rights as among themselves in <FONT STYLE="font-weight: normal">any</FONT> manner they deem appropriate.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Entire Agreement</U>. This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement
<FONT STYLE="font-weight: normal">among</FONT> the parties with respect to the subject matter hereof, and any other written or oral agreement
relating to the subject matter hereof existing between the parties is expressly terminated.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8239;&#9;<U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching
or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar
breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party,
shall be cumulative and not alternative.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;
<U>Further Action</U>. Each of the parties shall take such actions, including the execution and delivery of further instruments and voting
its shares in the Company, as may be necessary to give full effect to the provisions hereof and to the intent of the parties hereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>[Remainder
of Page Intentionally Left Blank]</I></FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investors' Rights Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-right: 4pt; padding-left: 0pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Company:</U></B></FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>NEUROLIEF
    LTD.</B></FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
    &#9;_______________________<BR>
    Name:&#9;_______________________</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
    &#9;_______________________</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 15%; padding-right: 4pt; padding-left: 4pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%; padding-right: 4pt; padding-left: 4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[Neurolief
Ltd./ Signature Page to Investors' Rights Agreement - Company]</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[Neurolief
Ltd./ Signature Page to Investors' Rights Agreement &ndash; Investors (1/4)]</I></B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>BrainsWay
Ltd.</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>KT
Squared, LLC</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Terra
Ventures Partners II (Cayman) L.P.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Terra
Ventures Partners II SCA SICAR</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Deborah
Edelstein Weiss</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Sergio
Fogel</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Mark
Hetterley</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[Neurolief
Ltd./ Signature Page to Investors' Rights Agreement &ndash; Investors (2/4)]</I></B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Drakanea
Management Ltd.</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Keren
Keshet - The Rainbow Foundation</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>David
Steinhardt</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Michael
Steinhardt</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Izba
S.A.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Shevet
5G LLC</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[Neurolief
Ltd./ Signature Page to Investors' Rights Agreement &ndash; Investors (3/4)]</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>MLS
Properties LLC</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Michael
Deouell</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Marc
Epstein</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Eaton
Associates</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Efrat
Kantor </B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________<BR>
<BR></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Jonathan
Bar-Or</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Esther
Muschel Holding LLC</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By:
&#9;_______________________<BR>
Name:&#9;_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Title:
&#9;_______________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Scott
Drees</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Anthony
Borowicz</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>[Neurolief
Ltd./ Signature Page to Investors' Rights Agreement &ndash; Investors (4/4)]</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Thomas
Hook</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Avinoam
Rosenzweig</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>James
Rosenzweig</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Uriel
Rosenzweig</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">_______________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;<BR STYLE="clear: both"></FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Schedule
A</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Holders
of Preferred Shares</U></B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">KT
Squared, LLC</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Terra
Ventures Partners II (Cayman) L.P.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Terra
Ventures Partners II SCA SICAR</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deborah
Edelstein Weiss</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Efrat
Kantor</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Jonathan
Bar-Or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Thomas
Hook</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Sergio
Fogel</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Izba
S.A.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">David
Steinhardt</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Michael
Steinhardt</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Keren
Keshet - The Rainbow Foundation</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Drakanea
Management Ltd.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">MLS
Properties LLC</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Michael
Deouell</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Marc
Epstein</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Eaton
Associates</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mark
Hetterley</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Scott
Drees</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Anthony
Borowicz</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shevet
5G LLC</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Esther
Muschel Holding LLC</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Avinoam
Rosenzweig</FONT></P>




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">James
Rosenzweig</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Uriel
Rosenzweig</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">22</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  %<# 2(  A$! Q$!_\0
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MO]][?@?D,N#L;[7EC*/+WN]O2V_]7/GCPYX(\8^,2#HWAR:XC/'G.^V,?5L
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??0VAZ-:>'-%L-*L(A#96,"6T$8_A1%"J/R HH)/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>formula.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 formula.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !? -0# 2(  A$! Q$!_\0
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METNYU.]UB>/87FC@BN;98(</@%G=B1R%Y"@'U'17R%^T?^T?\:/@M\!O&_Q
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M!&#C85ZG.>,5/!OP]U[POJ[7FI?$WQ5XOMS$T8T_6;;28X Q(P^;6Q@DW#!
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D[CCFE8YSN">6 #\^X;:[BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>exhibitf.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibitf.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $R KH# 2(  A$! Q$!_\0
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MJ:FU7X:^&M5@T:"_\/Z--#I.V/38Y+<;;8#;A(QV7Y%^4<':..*$K??^&O\
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MUA4@B&,$=PHJ;66@:.USPGQMX:^)VI_##PE:Z%>./$4A-YJEQ)J3Q26\[_O
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MYH+2V6*!GO$U$"&S=#=;U\K;F0.9(&('!"G/*@'Z%^R0?\\8_P#O@4?9(/\
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MRK58.FU?4S>+J)VT,"/]H/XPQM(?^%):1\[;O^1[A] /^?7VI_\ PT1\8?\
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M'_X4EI'R@C'_  G</?'_ $Z^U=!L;^Z?RHV-_=/Y4?7JOD'MYF%_PT+\8O\
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MW_/L?^^Q5BB@"OY\W_/L?^^Q4-U-,43-N1^\3^,?WA5ZH+S_ %:?]=$_]"%
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M5K60>7*..\9J;[8O_/.;_OV: #[)_P!-IO\ ONC[)_TVF_[[H^V+_P \YO\
MOV:/MB_\\YO^_9H /LG_ $VF_P"^ZANK7")^^E/[Q!]__:%3?;%_YYS?]^S4
M-U=J43]W+_K$/^K/]X4 3?9/^FTW_?='V3_IM-_WW1]L7_GG-_W[-'VQ?^><
MW_?LT 'V3_IM-_WW1]D_Z;3?]]T?;%_YYS?]^S1]L7_GG-_W[- $,]KB2W_?
M2\O_ '_]EJF^R?\ 3:;_ +[J*>[4R6_[N7A_^>9_NM4OVQ?^><W_ '[- !]D
M_P"FTW_?='V3_IM-_P!]T?;%_P"><W_?LT?;%_YYS?\ ?LT 'V3_ *;3?]]T
M?9/^FTW_ 'W1]L7_ )YS?]^S1]L7_GG-_P!^S0!8KQ#]MW_DT;XM?]B]=?\
MH%>T?9Y/^?F7\E_PKQ+]MJ%U_9(^+1,\C?\ %/77!"_W?I0!X;??$_5]%\5W
M.GS+9R6#:U_9\33C$JQ_9K=D"(&5F4O(^Z4!]@QE2,D4+'X\W)TRUEO;6P6[
MN1Y42P[S%+<BZBA>*)U9Q*%23?O4X.,D+@@;-]JUCI-U=6=Y\4M8MKJSC5IH
MGM;3< 2BX3_1/WAW2(NU-QRX&,FH7\3Z3"H9OBSJJH;4WJO]FM-K0@ EE(M,
M,0&!*#+#/(I1TLW_ %_7]=0?5&)9_'?6[N.\:?2=-T:);U+3[5J$V4L-S3#%
MU&DA<'$2@,1&-T@&..;*^/-<L/"_PTU&[U0_Z?;Q-J5I&B?;;MW:-5:-)$_>
M*"S;HUV288,#\I%='?L-+TFWU2\^(^O6UG<L$A:2RM1)*QS\JQ?9/,)P"<;<
M@ GIS39YX;70=0UR;XH:M'I-ADW=XT5ELAP%)W?Z-GHR_F*:T6H/78XEOC3X
MD\(^"6N-6MK2]OOLR7-I.8I3YFZ2X'ES$LBA\0#!!4?,  QP&N:K\</$MCI+
M:DFA:>EK-J$EE;F=F01!+=9<SO))&H+LX1<$8VL?F/RUVEY92Z=]F-S\2=8@
M^U0R7$)>*QQ)'&GF.P/V;H$^;Z5#8!-52%[7XH:G.D]O#=1.%L LD4V3"P)M
M@#OVG ZG'2A::?U_6C'=;EGP1X[O?$WB37=+OK:UM'L$AECBM9//(1Q_RTE5
MBN_((V;5(QGY@0:[:N-.AW(D,1^)&IB0-L,9.G;@V,XQ]GSG';K0F@W,@@*_
M$?4V$_\ J2/[.(E_W?\ 1_FZ'IZ&@1V5%<)I5F-<M;:YT[XFZC>P76[R'A_L
MYO-VDAMH^SY."#G'2M'_ (0[5_\ H>=>_P"_%A_\C4 =57,?$[_DGVO?]>X_
M]#6F?\(=J_\ T/.O?]^+#_Y&KF_B1X2U6+P'K;MXUUN91!RCP60#?,O7%N#^
MM 'V]17$_P#" Z[_ -%'\2_^ ^F__(='_" Z[_T4?Q+_ . ^F_\ R'0!VU>"
MZ;\9=0LOCQX@TC6=76#PS:"2*.%X$'E./LJQ[@%$B;GF8+(S,DN\! I0Y]$_
MX0'7?^BC^)?_  'TW_Y#K"CT%/$&OWWA\?%#6K_5=+$-U<636NF.UN6),3D&
MSP#E"1W!&?2A;_U_6@/8\NU?XR^*=)\(^+I!XKM]0U+3KQ9++4[)[9K.<.)F
M6S56MU)F18U+P M(VY L@+''H'A?XM>?XW\>Z+>^*=/EEMKBS@TF">)8_L\T
MT1Q"ZK\S8D !R<@Y'%0ZGXIT;1[O4K6[^-6LQW&FW0L[N);?3G:"4Q>;M8+9
M'&(_G8]%&2Q%7+*WL?$NLWEA%\5M9N]0T4?:I%FM--!@'S)YR,UD 5&'4NI(
M'(S22TL-O6YY9H_QH\>1PVEQJ&O6M[#:ZI';FWL);9YM=#);"1;)UMV258Y7
ME&U0C8.&DRI->S_!OQS+XMO/&]E<Z_:Z]+I&NR6L+VZ1IY<!BB95*IU 8R+N
M.2=IYXXP;#Q'IFJ6EM<6?QA\0W:7-P+6%(;"Q>1W*JXQ&+'=MVLK;\;=K*<X
M(-:_ARU?Q=+J,6D_%;Q%=RZ?-Y%U&+33T:-L9'#60)4CHPRIP<$XJNM_ZZ?U
M\Q=/Z\_Z^1I_ 7_DCGA+_KQ3^9KOJ\0^!_@;6KCX2>%I(_B#XBMT:R0B*.WT
MXJO7@;K4G\R:[G_A ==_Z*/XE_\  ?3?_D.D!U>K3BVTJ\F-W'8".%W-W* 4
MAPI.]@2!@=3D]J^</"_QUNM:L/AC_P 5[9OK.HLSZG;2Q6T=M/;1RNLTCMMR
MLA&Q42,@[CD@J#CV3_A ==_Z*/XE_P# ;3?_ )#K$U;1O(UJQ\-:C\4]<_M+
M5XI?L^G36VF,UQ&JDR?+]CZ;<YSUYI;.X=#B/&OQ>O\ 4?&=[9^"_'NF+#'I
M"W]S!J1MH(($D$+PF"1TW&5HS*^Y]\:ADW+V-+P=\<M2GUCP@NN^*H].F:SN
M=0UC3=1BMXD&GK]H%O<!PBLTT@2.3$>$V)(=B@KGM=<NM/\ !FH'1]2^+^LZ
M;>0V!OQ9&WTW>MLKK$&519]-[*@4<DD  U7ANM(\4W.GZ,/BSK>H-K$1>WMI
MK'3RDX 8E#NLMN\"-R8VPPV-D<&FO+^M_P"OD'J8?Q'\>^,M(\0>*)?"FJ:Q
MJ^G6FGK&8X]*ANH[*[N%\R*1%2)9'6&%"Q4L^6GB!P,X;\)OBAXW\3?$+P]9
MZC<I?:9J.C+?W5NL<<<E@#;6[(9X@@DAE>5Y>&;:RD;5&TFNAFU[3;>[U>V?
MXR:Z)]*XND6UT]BIW!"J8LOWC!V5"J;B&8*0"0*O:81K&N+HUM\5O$IU1K87
M:VLMC81.T1"G(WV0R0'3*]5W#(&:(Z?UZ_U\@?\ 7X?U\S>^&_\ R,'Q%_[&
M+_VPLZB^._BB\\%_";Q)K>GZS#H5]96KS074T22 R 96,*_!+'"C@]>AKD_A
M]X&UN77?'X7XA>(HBFO[69;?3LR'[#:'<<VAYY XP, <9R3VG_" Z[_T4?Q+
M_P" VF__ "'2:NK(:=F>>Z9\<-1?XRF#4GNM/\"MH\CVUS)IQ^RW$JRVZK<K
M= $%9#.41 >P)&6 '$^(_C?XTT.VU:UM]=M-52/5"TGB"VFA6TMK<QW4D=FK
M?96\NY)ABC*R+-S(OS L,>Y77PTU6^14N?B!X@N$5UE59;33& =2&5@#9]00
M"#V(%9WB;3I?!ME!=ZW\6->TVWFN([6*2:#30'ED8*B#_0^22:+;?UU_I?U8
M2TO?^M/Z_K4Y'X=?&W6M:^).M6WB>VU3PQHL]A9-IECK.E&W:&:2:2$!IL8D
MDD*JVT'  P.C&N&D^.WB2]@N+K1/&Z:EHS2W+Z3=M8V[7&H7$:VZQ64B*@"+
M,[7#1C"RLB [N"3Z]XKT>#PY/HJ^(?BGK%I+>7RV^FB\MM,R]R48@1YL^&VA
M^>PSSS6*OC30GL8KT?&G7?LDMPML)C9V 4,P4J6/V'Y48.A$C80AE(/(IK7;
M^O\ @BV_K^M B\>ZQHEW\0+VX\37EYIEHLNG:-%>Z?%(SZA%!+//Y:PQ(TB(
M J!23DQ/\V:XOP?\;M=U1?"5G=^,XH]>O-:: VLR6C6MU9(\7G.;E8U67 <I
M&80A,C!2&V.:],U.2'1O$4.A7WQ>URUU26/S!!)!IH"J0[#<WV/:I(CD(#$$
MA&QG!JI;:S97;Z2J?%SQ*O\ :TIALFETZRC69N  "UB  Q("DX#'[N:(Z-/T
M_KY_EH.6UO7^OZ]3I$_Y+Y-_V+*?^E35W]>'IX&UK_A>,L7_  L'Q#YG_".(
MWG?9].W8^TL-O_'KC'?IGWKNO^$!UW_HH_B7_P !]-_^0Z .VHKB?^$!UW_H
MH_B7_P !]-_^0Z/^$!UW_HH_B7_P'TW_ .0Z .VK@?"O_)8?'W_7II?_ *#<
M58_X0'7?^BC^)?\ P'TW_P"0ZX;PQX&UI_BSXYC'Q!\1(Z6NFEI1;Z=N?*SX
M!S:XXQQ@#KSF@#V^BN)_X0'7?^BC^)?_  'TW_Y#H_X0'7?^BC^)?_ ?3?\
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M+_A0!/14'V>3_GYE_)?\*/L\G_/S+^2_X4 %Q_K;?_KI_P"RM4]4IX'$EO\
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MK7;MMX%Q&"/)!;!S@[N1P*]L^'WCF?QK8:A+<016-W9W;6LMI#.9C%@ KN?
M5B5(.4++@CFNI\U_[[?G3\_ZZ?U_PX'@$?AWP=;$SV^KM#J @U98[P^%[EW6
M:]G$OG<PG+(%V<\D'J.E5- \)>$]+A1KO7I;V\CD$D4Y\.7I,'^G?:V$9:,E
M0?N=>G)]*^BO-?\ OM^='FO_ 'V_.DM+6Z ]59GA'A>U\/>&=:T&\AUB.*/2
MTG@8VGAJ^CDN87DD=(V!0HI4R9+JH8D=0#BO2?\ A:?AG_G\O?\ P47O_P 9
MKKO-?^^WYT>:_P#?;\Z.E@.1_P"%I^&?^?R]_P#!1>__ !FN<^)'Q-\-W'@/
M6XX[N\+M   =*O%'WE[F'%>H^:_]]OSKF/B?*_\ PKW7OG;_ (]QW_VUH ]X
M_P"%X>$?^?C5/_!'??\ QFC_ (7AX1_Y^-4_\$=]_P#&:[VB@#@O^%X>$?\
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M\-\@C,8VQC*_)$,80AM^]UC1[U-:LW\2:FMKXDO+FXUK4+?0+Z*[$.P1VUO
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MZ*&G_@BA_P#BZXCPUX4\;/\ %7QM&GCY$F2UTWS)/[$A^<$3X&-_;G\Z[O\
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M1O\ P+3_ !H_X7M\//\ H<]&_P# M/\ &@#-;X9>*F-X3XSLB;P 7.?#EO\
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M9_>)_ /[PJ;[?;_\]D_.H;N]MRB8F0_O$/7_ &A0!-Y,_P#S\?\ C@H\F?\
MY^/_ !P4?;[?_GLGYT?;[?\ Y[)^= !Y,_\ S\?^."CR9_\ GX_\<%'V^W_Y
M[)^='V^W_P">R?G0!#/%.)+?-Q_'_<']UJF\F?\ Y^/_ !P5%/>VYDM\3)P^
M3S_LM4OV^W_Y[)^= !Y,_P#S\?\ C@H\F?\ Y^/_ !P4?;[?_GLGYT?;[?\
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M^"_4_P#X_7&^'K;]HG_A9WC'R-0^%WV_[+I_VDO8ZEY>W$VS:/.SG[V<GTH
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M#$UOXDNHK+[.\=JMQ;RM(RN H@*R!$C>0G<O"&DDKKY(;;L_FS-TGP'XBL?
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M_P FD?%G_L7[K_T&@#A;KP]KFHZ?JUO/\.])D@UQE>^(\1,&N& 0#+"VR/\
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M>:?'#;) B0GQ9,R'R9FGB+*8,,RR.YW')^8@\<5SGCKP3>Z#\/\ 6IH/ =C
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M$K\3_P#1/M0_\&UA_P#':/\ A*_$_P#T3[4/_!M8?_': (O^%.>"?^A>A_\
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M+;Q-\*F=8K?X?ZQ=7-RDEU801SX:]M(_.,ERA-P J@6\GROM8Y3"_,*Z[6M
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MWADGVB=DB PSX)98]WS @%CZWK6@7FO1WZ^/_%-JOAG3#_H5C>VQNKY782B
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M_P#G^\2_^%1J7_R10!VU<#X5_P"2P^/O^O32_P#T&XJQ_P *AT/_ )_O$O\
MX5&I?_)%<-X8^%.BR?%GQS";WQ$$CM=-(*^)-1#'*SYRPGR>G&2<=J /;Z\E
M\<>*IO!OQ=T[4KA_$3^'H=!O9+]+>TGET])%:)H>539YI"S 9.>@XW#/2?\
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M#9Z_V9JN<?6TKS&S\:_#>_T9=5AN/'+60N+>&23^W]1_=1SA3!.P^U9V.'7
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M;Z_J30-.4D=(=QN1\[")L<8'&2,BN>TS7_!&HW]O:36OQ!TYYM5_L5GO->U
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MZL18L IDP7PIQ7HWC+2/"7@CPU%K]XWC:ZTLIY\TUEK^I2?9H=NYI9/])&%
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M_P#/1O[K>]3?8X_[TO\ W];_ !H GHJ#[''_ 'I?^_K?XT?8X_[TO_?UO\:
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MAI:(ZFPLTL=(T'2/^$/^($^D:)>6]W9V,R6)11!"(X8F(F!9%91* 3GS #G
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MNK7_  [)O 'Q*O8-=\>LO@/Q7+YNO!RJP6N4/V&T&TYN.O&>.Q%=E_PM*_\
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M<^(-2U:TOF\1V"WKQ64K0W*2(INK<QM!NB6!B5)4[<X^;@@%ME_6KM]W5_\
M!#S_ *T7]+_ACJO!.@IX U5KW2O"GQ C&5B2W,&G>6MJIG9+8XDRR*]P[AB2
M^54%B 08F\*V,MMX7M;CP/XWO+70KDWP%S9Z<\MW=&;SS-),9/,!,OSL$90Q
MX((XJY\,O&GB/3[[Q?;^*]9OM0TQ<0VVL6=I-*/M86YDG\E/LZF-5BCBPA$B
M!\*'=FVUP^A?$?QC=ZQX/^PZSX@O=)N=1+I%<V;"Z-N]U$JQ3'R0LDJQ%V=6
M,?EH^0SLF"UK)+^OZZ_B)Z)O^OZZ?@>@I\2;W_A=TMQ_P@?BO=_PCJ1^3Y%K
MNQ]I8[O^/C&.W6NX_P"%I7__ $3WQ=_WXM/_ )(IJ?\ )?)O^Q93_P!*FKOZ
M0S@O^%I7_P#T3WQ=_P!^+3_Y(H_X6E?_ /1/?%W_ 'XM/_DBN]HH X+_ (6E
M?_\ 1/?%W_?BT_\ DBN(\-?$F]C^*WC>8> _%;M+:Z:#$(+7<F%GY/\ I&.<
M\8]#7NE<#X5_Y+#X^_Z]-+_]!N* %_X6E?\ _1/?%W_?BT_^2*X7QA<Z]XC\
M46_B#3]'\=Z)?VNG7.GVT<>GZ;+!'YVW=(0TN\L#'&1\X'R=,$Y]7^(%XVG^
M"-<N4U"?2I(K21EO+6(2RQ-C@JI5LG/^R?I7@VC?%[Q:FM?#C5]5AURW\&Q:
M.S:OJ'V*/[/<RBQ,DTUP3B6,QRH4"!%RV_&[*BINK^GZW';3U_2QHW.C7M_?
M>++B\TCXD7(\1VHLI]UOIBR6\  'EPR!PR+C?QD\RNW7!#]5TN[G\4CQ!I7A
MKQOHM_#:K8VBV^GZ<([:#=%O08E#/\L9"B1F5"[$#M7.>(?&_C?_ (2J^4:O
MX@M-*?5)8];\BP.W2M.%Q&+26V/E$[I(BQ8C><%B0I7BS\-OBOXTTWQE;R>/
MS>PZ<MDD;*UO+$(8S#!Y5S*JQ['>::1H]@(=6XVX!Q<=D_Z_K7\_,E]5_7]?
M\#N6=2\$1:GK.I:PWAOXAVVK7DYD6ZM;73(O)0I-&R[%?:[-'<2*9'#28"?-
M\@K1\-:5>^%=<O+^QT7XBB.<VR);/:Z8P@MX"OEVJ.7WB$*&&TG)\QSG<<UC
M>,/''BBT@^)":?K6L[+6:)M(F2.4@7/^D;X WV3.<I&1"%*'"#SOWAQUW@KX
MARS_ !3UR.XUC7&TV.""TFT[4M.?Y+]W09@"1?+$@8(S[F4L2<X0L9CW7]:?
MU]_F.7G_ %_7Z>1R,_PXL+FPO+=O"'CF)]0OTO[Z:WT[286F9 %0(%8"$J <
M21!9,LQW9/'5^(/B3>R?%KP;,? ?BM6CT[4P(C!:[GRUKR/](Q@8Y^HK@O\
MA8FOWEM)J6B^)]?U.TBUK=8Z%?6,\-]J,01$,1D6 "+=)O=$<8"D;BHX7W/Q
M)S\9/ W;_B6ZK_.TI]/Z[('N'_"TK_\ Z)[XN_[\6G_R17)_$#5=0\>1:.@\
M+^.M'&FW\6HK]CM-.?S9(VW(&\R5OE!],$YZU[0W0\X]Z^6C\1O$5UI=M/8^
M)-8UB\L/$M[$NF-836\VKV_G*(8UD2 (@"DD9 4@\G ) M7;Y_B@V5_E^#.E
MMH]?D\4Z%X@U33_'^I7NEQRHML=/TP6K-)([,ZH92R-L81[@^=B 9^9BU67P
MPAL_#5M%X4\>*NAW#7R236NG22W-T9?.::27S1("TF2XC9 ZDJ>.*G\3_$/6
M/$GQA\-V_A[4]5/A6\18':QMF57RUU'-(A,95U4QIN<NI3"%!().,C3M?\5Z
M+)X/OCKWB*:/5M=:XCT[4T+2QZ476,>8OV< G8IF;S)$,0<D!R M*.MK=_U_
MI_+R&]+^GZ?TB;6_![^++FSN_$/A_P ?ZEJ%OIRV?VF*STVW=I0%_?%EDWGY
MUWB-F:,-SM-2V?AJ\L-<M-4@TOXD+/!%<Y5K32G4W%P[O/=*"WR2L7QE< *H
M4  L&M?%/Q'K>JW2Z_X)USQ)'IZZ$VKR-;6Y>TD60>5;(D;1YR29)F(^95B!
MP=P!YWPEXX^($7B+PG<W.JW^H:<S2O>V302LT5C&UWYDY_T8>>C!(/+D)CD;
M"_NB7-4M=_ZU_K^DA/;^OZ_KS-[4_#::MK>I:S<>$/&LFJW=D+!;I]*TARD1
M,9D#J6Q,7\E,^:&P,A=N:/$_B)_"?P]\(:!:>"?&9M-,UC2(HIKY+6220)=Q
M8#,)_O'&!P!D@<#HSQ?\3H[;QCXLFC\1>+(M%LM-0W%E;6#B:6Y=H3"MD#;Y
M554E9')(S+U'EL5ZG4+G4+SX/_#^;5M235]3;5]$^TWT<919I!>0AFP57OWV
MC/7 SBA?#_7G_7S%U_KR.G_X6E?_ /1/?%W_ 'XM/_DBL+QSXIOO&_A'5M ;
MP;XVTN+4K=[66ZM+:Q:58W&UPOF3,N2I(R0<9XYKUJO#/$/C&XC\9?$W3I=;
M\0W5II^EVE_:6FEVS1RQS*TOF06\BPX<M^X!!+'YQT&<1*VS+7=&-K&E^(/$
M&E6NG:A;?$*2SM+J"XAABT[2PDBQ1*JQS(TC+(/,!E. HW;>,+@VO$VC+XGT
M[Q);3^$O':3>(+F.:]N6L],F;8D0C2%!)(RJB@%E(&Y78L#DU%XS\4:_X9^%
M&FZ9;>)=3U+QWH\UO#?R6\3.\]T\8F,'R6[),=K@*A,8;Y=SK6/XY^)/BNWN
M?&MCH^MZA+!;>(8(WN9["4?8[,V;,T<310Y*FY18=ZAR"QR><U4GJ[_UL3'9
M6_K<UM4T6\\0VFG6>L>'_'EY9:??"YMH4L]/#)$AC\J+SFF:48$>&=75GWR
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M_C5BB@"O]D_Z;S?]]5XG^VS;;/V2?BR?-E;_ (IZZX+?[->V?;X/[Y_[Y/\
MA7B?[;-Y%)^R3\60K$G_ (1ZZ_A/]V@#AQ!I,>L2Z9_PG?C99K0!;BY^WL+6
MWDV!O+>?R?+5]I!VEL\CUJU?V&BZ/*J7WQ1U^PD>1D"W/B2*-F=>&&"HY'<=
M17):C?\ A.^M_$EC#XYN;30]?:2ZN-/&A7$CQW+H@,B2F/.S<BOL(Z@C< <5
MG1Z9X$N&O)]5\8S:I?7DC33SMH$T:EC>171VIY1VC=$JXR>.2210MU<'HG8]
M#BT+3+JV2ZA^(WB6XA=%DCDAU^-PX?.PJ0G.XJ0,=2#BL(ZUX4M_#":W<_$_
MQ-I]B]@FJ-%=:XB3I;/C;(T6S<!\P'3J:Y>#2_!%G?V\MMXYO(;1;M;RXM3H
M<[>>R74]S&H?RLHJFX93@'(53D<YRF\&>!G:)7^(>IR06^D/I-O$^CW)$0:W
M2$R ;-I_U8?;MSDD%B, "V=P>]D>F/X;\/:VY:;Q]XBN/[-F%RKSZW'B)P!B
M9"4Z?O5 <<9?&<FK+Z9I*:?J]S'\1_%%S;:2KO?K:ZXDS6^P$L'1(R0P"GY<
M9XKAKNP^'^HZY;:M=^++F6Z&K'5+M8]&N$CO%*0!K9U\HXB,EM#+U)!7'2F^
M$M,^'OA'1O$&FP^*KF=-5L6TY+F32[XSP0$R$*68,K8,K'Y509SQS2=[:;_J
M"WU_I'5Z;>^&=3TR/5(/B?XGCT][."_%Y<:T((Q#,66-BSQ@ DHPVGD$8(%:
MYT+38DWGXD^)$0!WW'Q#&  JAG;.SH%96)[!@3P17E>H^$/AU<W^H75IXSU"
MR\^XM;RWMETR\\FUFB259&4(J,5E,[N5##:Y)'4BGS^$?AI+<V[1>*;JTM8H
M[2,V-OI%T(2L2A)@-T;,!/&D2,"3@1CDY-5I<2O;4]!U:+2M'U,Z;<>./'4E
MPD0N)Q;7DD\=M&V2KS.D)6,-M;&XC.#275MHEE-X;BG^('B^.3Q&^S2P=3/^
MD'9Y@_Y9?+\I'+8Y('4XK,U3Q-X7NO$>KZG8>-9],M]:MX[?4[/^P[B83;$:
M-6C=HP8CL?:>&!P,8/-<G=Z'X3UF"S_M;XF:M+=:;8V]CILNG:-<6D=N(94E
M5WC\MQ*Q>.,G) PF.YI+?7^OZT&_(Z_4-0T33/%5UX=E\8^.WU6".-A%%J*M
MYSR%=D48V99R'4] ,9YX.,WXP:59Z7X:UK1F\4^.;S49-/\ M'E1W+SP1QF0
M*&F=8MJ*6!'S$=*/B3+X!^),KSW'B:2PNA"L4$T6B7#&,A\LS'R@SY'R@%@%
M&2.2:R?BQKGP]N- U;Q#+JDVI:G8:$+"T\W3+IY%V2;S(K>5DR-DC'?ZFA=+
M@_(^I/\ A43?]#OXP_\ !F/_ (BC_A43?]#OXP_\&8_^(KC_ /ALCX=?\\/&
M?_A"ZU_\B4?\-D?#K_GAXS_\(76O_D2@#KQ\'\,6'C7Q<&. 6&I+D^F3Y=+_
M ,*B;_H=_&'_ (,Q_P#$5Q__  V1\.O^>'C/_P (76O_ )$H_P"&R/AU_P \
M/&?_ (0NM?\ R)0!UZ_"#:6*^-?%RECEB-24%CC&3^[YX 'X5S.E:9H&M^*K
MSP[9_$3QE+J=J9%=3>,L;-'L\U4D,6QV3S(]P4DKO&:K?\-D?#K_ )X>,_\
MPA=:_P#D2O-9OC#\-3\1[[QI:W/BO3M6EB$$#6GPTU92J,\33&8FU/G.ZPA
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M^AW\8?\ @S'_ ,17'_\ #9'PZ_YX>,__  A=:_\ D2C_ (;(^'7_ #P\9_\
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M/_A43?\ 0[^,/_!F/_B*/^%1-_T._C#_ ,&8_P#B*X__ (;(^'7_ #P\9_\
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M!];'V3X2@,OA317::7+64!.&_P"F:UK?9/\ IO-_WU63X2NXH?"FBH[$,MC
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M3_IO-_WU1]D_Z;S?]]4?;X/[Y_[Y/^%'V^#^^?\ OD_X4 0SVN)+?]]+R_\
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M>"[G:!$'"8']H<??;/)[=* /HBBO#_\ A#_VAO\ HIW@+_PBKK_Y94?\(?\
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MNWB%K,1$F=C?PCTH E6>/:/WB=/[PI?/C_YZ)_WT*1;:':/W2=/[HH^S0_\
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M*//C_P">B?\ ?0I/LT/_ #R3_OD4?9H?^>2?]\B@!?/C_P">B?\ ?0H\^/\
MYZ)_WT*3[-#_ ,\D_P"^11]FA_YY)_WR* %\^/\ YZ)_WT*//C_YZ)_WT*3[
M-#_SR3_OD4?9H?\ GDG_ 'R* (K>:,27'[Q?]9_>']T5-Y\?_/1/^^A4%O;Q
M&2XS$G$G]T?W14WV:'_GDG_?(H 7SX_^>B?]]"CSX_\ GHG_ 'T*3[-#_P \
MD_[Y%'V:'_GDG_?(H 7SX_\ GHG_ 'T*//C_ .>B?]]"D^S0_P#/)/\ OD4?
M9H?^>2?]\B@!?/C_ .>B?]]"CSX_^>B?]]"D^S0_\\D_[Y%'V:'_ )Y)_P!\
MB@"'SH_MQ/F+CR_[P]:G\^/_ )Z)_P!]"J_V>+[<1Y28\O\ NCUJ?[-#_P \
MD_[Y% "^?'_ST3_OH4>?'_ST3_OH4GV:'_GDG_?(H^S0_P#/)/\ OD4 +Y\?
M_/1/^^A4$4T?VN<^8O1?XA[U-]FA_P">2?\ ?(J"*WB-W./*3 "_PCWH L>?
M'_ST3_OH4>?'_P ]$_[Z%)]FA_YY)_WR*/LT/_/)/^^10 OGQ_\ /1/^^A1Y
M\?\ ST3_ +Z%)]FA_P">2?\ ?(H^S0_\\D_[Y% "^?'_ ,]$_P"^A1Y\?_/1
M/^^A2?9H?^>2?]\BC[-#_P \D_[Y% "^?'_ST3_OH5#)-']KA/F+]UOXA[5+
M]FA_YY)_WR*ADMXOM<(\I,%6_A'M0!/Y\?\ ST3_ +Z%'GQ_\]$_[Z%)]FA_
MYY)_WR*/LT/_ #R3_OD4 +Y\?_/1/^^A1Y\?_/1/^^A2?9H?^>2?]\BC[-#_
M ,\D_P"^10 OGQ_\]$_[Z%'GQ_\ /1/^^A2?9H?^>2?]\BC[-#_SR3_OD4 +
MY\?_ #T3_OH5!=S1E(_WB_ZQ/XA_>%3?9H?^>2?]\BH;NWB"1XB3_6)_"/[P
MH G\^/\ YZ)_WT*//C_YZ)_WT*3[-#_SR3_OD4?9H?\ GDG_ 'R* %\^/_GH
MG_?0H\^/_GHG_?0I/LT/_/)/^^11]FA_YY)_WR* %\^/_GHG_?0H\^/_ )Z)
M_P!]"D^S0_\ /)/^^11]FA_YY)_WR* %\^/_ )Z)_P!]"H[F>,VTO[Q?N'^(
M>E/^S0_\\D_[Y%1W-O$+:4B)/N'^$>E #X9XQ"G[Q?NC^(4[SX_^>B?]]"F0
MVT1B3]TGW1_"*=]FA_YY)_WR* %\^/\ YZ)_WT*//C_YZ)_WT*3[-#_SR3_O
MD4?9H?\ GDG_ 'R* (;Z:,VD@$B]/[PJ?SX_^>B?]]"J]];Q"TD(B0'']T5/
M]FA_YY)_WR* %\^/_GHG_?0H\^/_ )Z)_P!]"D^S0_\ /)/^^11]FA_YY)_W
MR* %\^/_ )Z)_P!]"H;N:,HG[Q?]8G\0_O"I?LT/_/)/^^14-W;Q!$Q$G^L3
M^$?WA0!/Y\?_ #T3_OH4>?'_ ,]$_P"^A2?9H?\ GDG_ 'R*/LT/_/)/^^10
M OGQ_P#/1/\ OH4>?'_ST3_OH4GV:'_GDG_?(H^S0_\ /)/^^10!%/-&9+?]
MXO\ K/[P_NM4WGQ_\]$_[Z%03V\0DM_W2<R?W1_=:IOLT/\ SR3_ +Y% "^?
M'_ST3_OH4>?'_P ]$_[Z%)]FA_YY)_WR*/LT/_/)/^^10 OGQ_\ /1/^^A1Y
M\?\ ST3_ +Z%)]FA_P">2?\ ?(H^S0_\\D_[Y% #=US_ '(O^^S_ (5!>O<+
M9SDI%@1L3ASZ?2KU5]1_Y!]S_P!<F_D: .63X@AOE%CE@ 2HFY ]<8]C^5*?
MB!@X-@?^_O\ ]:OG[Q]\&](U9M?UNUMM5FUO5H[>*<65Q&<K'(KC$4Q6)URH
MW(Q =<C/-<O%X>^+ZW48@N8-&C32ECM+2QV/8PR"U=?+<--\K><58.(Y-N%
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M_P!]G_"IZ* (-US_ '(O^^S_ (5!=M<;$RD7^L3^,^H]JO57O/N1_P#71/\
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M*** *]A_QYP_[M6*KV'_ !YP_P"[5B@ HHHH **** "BBB@""V_UEQ_UT_\
M914]06W^LN/^NG_LHJ>@ HHHH **** "BBB@"O\ \OY_ZY?UJQ5?_E_/_7+^
MM6* "BBB@ JO%_Q^7'T7^M6*KQ?\?EQ]%_K0!8HHHH **** "BBB@ J"3_C\
M@_W7_I4]02?\?D'^Z_\ 2@">BBB@ HHHH **** "J]Y]R/\ ZZ)_Z$*L57O/
MN1_]=$_]"% %BBBB@ HHHH **** "HKK_CVF_P!P_P JEJ*Z_P"/:;_</\J
M'0_ZF/\ W13Z9#_J8_\ =%/H **** *]_P#\><OTJQ5>_P#^/.7Z58H ****
M "H+S_5I_P!=$_\ 0A4]07G^K3_KHG_H0H GHHHH **** (+C_6V_P#UT_\
M96J>H+C_ %MO_P!=/_96J>@ HHHH **** "J^H_\@^Y_ZY-_(T?8(?[I_P"^
MC_C45W8PBTF^4_<;^(^GUH ^./&4'Q)N?&=[>Z/:ZA)<:<-0&F"6*$::(GMH
MU@=6^^\Q/FY5L@,!P!C-2X\._$;45LO$(:ZO/$.F:5J::<E[;I$L<LDT(B$B
MO&I,OE>;AE50VU1CDAOLQ?#>E[1_H,/_ 'S2_P#"-Z7_ ,^,/_?-&WW6_/\
MS!Z_>?'<B_%NZT>ZD@U'489XM,E>S46$*227+7:JBS"6,%F2 NPPJ*V%)R1R
MOB.S^(NL>*=5T;[%JEUX:MY[,V]U=&',S0WMJPF5D1/O1>>S#)^[T4\'[#_X
M1O2_^?&'_OFC_A&]+_Y\8?\ OFFG9H'JFCRC3[]M3M$NGL[G3VD+$VUVJK*F
M&(^8*2.<9'/0BK->G?\ "-Z7_P ^,/\ WS1_PC>E_P#/C#_WS2 \QHKT[_A&
M]+_Y\8?^^:/^$;TO_GQA_P"^: /,:*]._P"$;TO_ )\8?^^:/^$;TO\ Y\8?
M^^: /,:DM?\ CZ@_ZZ+_ #%>E?\ "-Z7_P ^,/\ WS4-WX?TV*VD=+*)749!
M"\@T ;%>:?M#:>-3^&MS!(=3-L;F SPZ99M>&>/> 8I84='DB;.U@C!L'K@&
MO0_L$/\ =/\ WT?\:464(.0K ^SG_&DU<:=CY]\&7OB7PKXSTW5]4\,ZUI]D
M=$@L+W3H)9;B-;MWMDA"/).XFP"_(6,Q@2%RY(-<MJG@[QJO]J0VFG^*;_PV
MU_<3[WF>VU.6ZDAN/*!VS?-!%*T)#C:,GD,J9KZK%E".BL/^!G_&D^P0_P!T
M_P#?1_QIO7\?Q=Q+W?P_!6/G3P%!XY\(ZS=G6H-;EUR_@GTZYO'E:>UNK^2=
MFM)X5+%4BB@4[V"J%& 0S5R=CX(^(H@MP+#Q5';&V2.SBFU%S);ZV([8/>3'
MS<FW++.>24Y8[/G6OK@64(SA6&?]L_XTGV"'^Z?^^C_C2MI_7]=?R[#_ *_K
M^N_<^=/">C?$+2O"OBRSAL=?BUW4M+-G]JNKL.G]KA+IY;N-GD/EPN/(160
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MG[Q]?K4_V"'^Z?\ OH_XT 6**K_8(?[I_P"^C_C1]@A_NG_OH_XT 6*KQ?\
M'Y<?1?ZT?8(?[I_[Z/\ C4$5E";N<;3@!?XC[^] %^BJ_P!@A_NG_OH_XT?8
M(?[I_P"^C_C0!8HJO]@A_NG_ +Z/^-'V"'^Z?^^C_C0!8HJO]@A_NG_OH_XT
M?8(?[I_[Z/\ C0!8J"3_ (_(?]U_Z4GV"'^Z?^^C_C4,EE"+N$;3@JW\1]O>
M@"]15?[!#_=/_?1_QH^P0_W3_P!]'_&@"Q15?[!#_=/_ 'T?\:/L$/\ =/\
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M51,*?]8@^\?[P]Z +U%5_L$/]T_]]'_&C[!#_=/_ 'T?\: +%%5_L$/]T_\
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
